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The formation of DNA triple helices offers the possibility of selectively targeting 
specific genes to control their expression in vivo. This anti-gene strategy provides 
powerful tools for the development of therapeutics (anti-cancer drugs, drugs for viral 
infections) at the transcriptional level.  
 
DNA triplexes are formed when an oligonucleotide binds to the major groove of double 
helical DNA; the third strand can bind in either a parallel motif, or an anti-parallel 
motif. The requirement of low pH for the protonation of cytosine in the parallel binding 
motif makes the formation of triple helices difficult under physiological conditions.  
 
Described in this thesis is a novel method for the synthesis of the deoxycytidine 
analogue, 2-amino-3-methyl-5-(2’-deoxy-β-D-ribofuranosyl)pyridine (
MeP). The 
phosphoramidite monomer of 
MeP was synthesised and incorporated as a “protonated” 
cytidine analogue into triplex forming oligonucleotides (TFOs). It was compared with 




MePOMe), and 2’-O-aminoethyl 
MeC  (
MeCAE). Triplex stability studies 
indicate that over the pH range 6.2-8.0, the general trend observed in terms of melting 




MeCAE. DNase I footprinting 
studies indicate that at pH 7.5, 
MeP, when incorporated into the TFO, enhances the 
stability of the triplex by three-fold relative to 
MeC. In addition, UV melting, DNase I 
footprinting, and gel electrophoresis studies were carried out on a triplex formed by the 
binding of a TFO containing 
MeP and a 5’-Psoralen to a target duplex. This revealed the 
benefits of the combined modifications on the stability of the resultant triplex. 
“Soaking” experiments (in vivo) were also performed with this TFO on the organism C. 
elegans (the worms were soaked in solutions of the TFO for TFO delivery), to observe 
whether the TFO would induce loss-of-function phenotypes. Tm measurements 
indicated that in the pH range 6.6-8.0, photo-crosslinking of the TFO to the duplex 
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In all organisms, the biological information that is needed to construct and maintain that 
organism is stored within the genome. Most genomes (human genome and those of 
other cellular life forms), are made up of DNA (deoxyribonucleic acid), however, a few 
viruses have RNA (ribonucleic acid) genomes. Nucleotides are the monomeric subunits 
that make up the long thread-like polymeric chains of DNA and RNA molecules. 
The human genome consists of two distinct parts: 
 
(i)  The nuclear genome/nuclear DNA – located in the nucleus of a cell, and is 
made up of approximately 3,200,000,000 nucleotides of DNA, which are distributed 
amongst 23 pairs of chromosomes; These 23 pairs of chromosomes consist of 22 
autosomal pairs and the sex chromosome pair, XX for females and XY for males. In 
each pair, one chromosome is paternally inherited, the other maternally inherited. 
 
(ii)  The mitochondrial genome/mitochondrial DNA (mtDNA) - is a circular DNA 
molecule of 16,569 nucleotides, multiple copies of which are located in the 
mitochondria. They are located within the cell, surrounding the nucleus. In humans, 
100-10,000 separate copies of mitochondrial DNA are usually present per cell. In most 
multicellular organisms, mtDNA is maternally inherited (inherited from the mother).  
 
Each of the cells (approximately 10
13)
 in the adult human body has its own copy or 
copies of the genome, the only exceptions being those few cell types that lack a nucleus 
in their fully differentiated state (red blood cells). 
 
1.2  THE HISTORY OF DNA DISCOVERY
1,2 
 
It has been more than 200 years since DNA was first discovered. During this time, 
many dedicated scientists and geneticists have contributed to the current knowledge on 
the human genome. 4 
 
In 1866, Gregor Mendel established the basic laws of inheritance. He discovered that 
genes govern hereditary traits. They exist in pairs, and undergo separation, independent 




DNA was first discovered in 1869 by Johann Friedrich Miescher.
1 His initial research 
focused on determining the fundamentals governing human leukocyte cells (white blood 
cells) which were obtained from human pus. Miescher had obtained the first 
comparatively clean preparation of DNA/‘nuclein’ (as he had originally named it). 
Using elemental analysis, he detected various elements typically found in organic 
molecules: carbon, hydrogen, oxygen, nitrogen. Meischer’s analyses also revealed that 
nuclein contained a large proportion of phosphorus.
2  
 
In 1889, Richard Altmann succeeded in the complete separation of DNA from proteins. 
As a result of its acidic behaviour, he named the substance ‘nucleic acid’. ‘Nucleic acid’ 
was in fact the same substance Meischer had isolated and first described as ‘nuclein’.
2 
 
Albrecht Kossel confirmed that nuclein/DNA is restricted to the nucleus. He also 
confirmed that the purine and pyrimidine bases, one pentose sugar, and phosphoric acid, 
are the fundamental building blocks. He also deduced from his research that nucleic 
acids are involved in the synthesis of new protoplasm during growth and replacement. 
In 1910 Kossel was awarded the Nobel Prize in Physiology or Medicine, in recognition 
of his groundbreaking work on the chemistry of proteins and nucleic acids. Despite 
these early breakthroughs, the full importance and impact of nucleic acids remained 
unclear for several decades.
2 
 
1.3  DNA AND RNA STRUCTURE
3 
 
1.3.1 Primary  Structure
3 
 
Nucleic acids are made up of a linear array of nucleotides. ‘Nucleotides’, a term that 
was introduced by Levene
4 and Jacobs in 1909, are the phosphate esters of nucleosides. 
Both RNA (ribonucleic acid) and DNA (deoxyribonucleic acid) are composed of 5 
 
nucleotides. Whilst conducting hydrolysis studies of nucleic acids they discovered that 
the carbohydrate component of DNA was 2’-deoxyribose, and that of RNA was D-
ribose.




As determined by Kossel, all nucleotides consist of three major components: (1) a 
nitrogen heterocyclic base; (2) a pentose sugar; and (3) a phosphate residue. The major 
bases are monocyclic pyrimidines or bicyclic purines. Adenine (A) and guanine (G) are 
the major purine derivatives, and are found to be present in both DNA and RNA. 
Cytosine (C), Thymidine (T) and uracil (U) are the major pyrimidine derivatives. Both 
C and T are present in DNA while in RNA, T is replaced by its non-methylated 
pyrimidine derivative, U (fig. 1.1).
3 
 
Nucleosides are the condensation products of a pentose sugar and a nitrogenous base. In 
RNA, the nucleobase is joined from either the N-1 of the pyrimidine or the N-9 of the 
purine, to the C-1’ position of the D-ribose sugar (fig. 1.2). This bond locks the D-ribose 
(which can mutarotate under certain conditions, adopting furanose, acyclic or pyranose 
forms; fig. 1.3) into a five-membered furanose ring and resides on the same side of the 
sugar ring as the C-5’ hydroxymethyl, forming a β-glycosidic linkage. In DNA, the 
condensation reaction occurs between the same nucleobase nitrogen as in RNA, 





Fig. 1.1: Structures of the five major purine and pyrimidine bases of nucleic acids in their dominant 







































deoxyadenosine deoxyguanosine deoxycytidine deoxythymidine  
 
Fig. 1.4: Structures of the four deoxyribonucleosides. 
 
Rotation about the glycosidic bond allows the nucleobase to occupy either of two 
principal orientations, giving rise to two conformers. The nucleoside is referred to as the 
anti conformer when the smaller H-6 atom in pyrimidines, or H-8 atom in purines 
resides above the sugar ring. Whereas, when the larger O-2 atom from pyrimidines or 
the N-3 atom from purines resides above the sugar ring, the nucleoside is referred to as 
the syn conformer (fig. 1.5). In DNA, to enable base pairing, the anti conformation is 






Fig. 1.5: Anti and syn conformers for a purine nucleoside (A) and a pyrimidine nucleoside (C). 
 
The 1’-position of the furanose ring is an anomeric centre. When the nucleobase resides 
on the same face of the sugar ring as the 5’-hydroxyl group it is known as the β-anomer, 
when it resides on the opposite face it is known the α-anomer (fig. 1.6). In both DNA 
and RNA, it was deduced from respective x-ray crystallography studies that the 





Fig. 1.6: The structures of α- and β-deoxyguanosine. 
 
The furanose rings encounter a phenomenon described as ‘puckering’. Puckering is the 
twisting of the sugar ring out of plane to minimise non-bonded steric and electronic 
interactions between the substituents. It identifies the displacement of carbons 2’ and 3’ 
from the plane C
1’-O
4’-C
4’. The sugar pucker is described as C
2’-endo (south, S) when 
the  endo displacement of C
2’ is greater than the exo displacement of C
3’ ( fig. 1.7). 
Whereas the sugar pucker is described as C
3’-endo (north, N) when the endo 
displacement of C
3’ is greater than the exo displacement of C
2’. The endo face of the 
furanose is on the same side as C
5’ and the base; the exo is on the opposite face to the 
base.
7,8 In solution the N and S conformations are in dynamic equilibrium. There exists 
a number of influential factors that give preference for a specific conformation: (1) the 8 
 
preference of electronegative substituents at C
2’ and C
3’ for axial orientation; (2) the 
orientation of the base (syn goes with C
2’-endo); (3) the formation of an intra-strand 
hydrogen bond from exocyclic OH
2’ in one RNA residue to endocyclic O
4’ in the next, 
which favours C
3’-endo  pucker. DNA adopts an S-type conformation, while RNA 





Fig. 1.7: The structures of the sugar puckers in β-nucleosides; C
2’-endo (S) and C
3’-endo (N). Where B = 
nucleobase; X = OH (RNA, N-type) or H (DNA, S-type). 
 
Within a nucleotide, the phosphate group can be found at either the 3’- or 5’-position of 
the sugar, depending on the method used to break down the DNA to produce the 
nucleotide (fig. 1.8). It was P. A. Levene
9 that also discovered during hydrolysis studies 
on nucleic acids, the order in which the three major components of a single nucleotide 













Fig. 1.8: The structure of the C nucleotide, 2’-deoxycytidine-5’-monophosphate. 
 
DNA and RNA are linear polynucleotides in which each nucleoside is linked to the next 
by means of a 3’-5’-phosphodiester (fig. 1.9). Klein and Thannhauser established that 
each DNA nucleoside is joined by a phosphodiester linkage, from its 5’-hydroxyl group 
to the 3’-hydroxyl group of one neighbour, and by a second phosphodiester linkage 
from its 3’-hydroxyl group to the 5’ hydroxyl of its other neighbour. The chain 9 
 
possesses directionality (the order of a nucleic acid sequence is always written in the 5’ 
to 3’ direction). These phosphodiester residues are stable towards chemical hydrolysis, 
and are deprotonated at physiological pH resulting in nucleic acid chains being highly 
negatively charged, and consequently forming salts.
3 The primary structure of DNA is 
given by the sequence of bases within a single strand. It is this sequence that gives DNA 















































































































































1.3.2 Secondary  Structure 
 
It was the combination of ideas and discoveries by Erwin Chargaff
10-13, Rosalind 
Franklin




17, and many other scientists of that time that led to the breakthrough of the 
secondary structure of DNA. 
 
Erwin Chargaff
10-13 analysed the base composition of DNA in a number of organisms. 
He reported that DNA composition varies from one species to another. He developed a 
method to separate the individual products of hydrolysis of DNA by means of paper 
chromatography and by use of ultraviolet spectroscopy, to quantify their relative 
abundance. He noticed regularity in the ratios of the bases. The ratio of the amounts of 
adenine to thymidine, and the ratio of guanine to cytosine, is always very close to unity. 
Hence the proportion of purines, (A + G), is always equal to the proportion of 
pyrimidines, (C + T). Although the ratio of (G + C)/(A + T) varies from species to 
species, different tissues from a single species give DNA of the same composition. 
 
Sven Furberg
16 reported in 1952 the possibility of the structure of nucleic acids adopting 
one of the two proposed models. In model I, ‘the pyrimidine and purine rings are piled 
in a central column directly on top of each other, 3.4 Å apart, with the ribose rings and 
the phosphate groups in a spiral enclosing the column. The structure is held together by 
Van der Waals attraction between the flat rings in the column’. In model II, ‘the ribose 
rings and phosphate groups form a flattish central column, from which the purines and 
the pyrimidines stand out perpendicularly. Successive bases are pointing outwards in 
opposite directions, all the N-C
1’ bonds being roughly parallel, and there is one base 
directly above another at a distance of 6.8 Å. No forces are acting between the 
pyrimidine and purine bases, therefore, the whole molecule must be held together by 
interactions between atoms in the pentose rings and the phosphate groups, which are 
packed very efficiently in a compact sheet’. It was suggested that the available evidence 
from x-ray crystallography studies favoured model I.     
 
Pauling and Corey
18,19 using x-ray crystallographic studies and other principles of the 
molecular structure, proposed the structure of nucleic acids to be three intertwined 11 
 
helical polynucleotide chains in a right-handed nature. The phosphate groups form the 
dense core and the bases project radially on the outside with their planes being 
approximately perpendicular to the molecular axis. 
 
Rosalind Franklin and R. Gosling
14,15, using x-ray diffraction studies on DNA fibres, 
identified that the hydrophilic phosphate backbones of the nucleotide chains of DNA 
should be positioned so as to interact with water molecules on the outside of the 
molecule while the hydrophobic bases should be packed into the core. This conclusion 
was reached from the studies by Gulland et al.
20, they showed that in aqueous solution 
the CO and NH2 groups of the bases are inaccessible and cannot be titrated, whereas the 
phosphate groups are fully accessible. Also, the ready availability of the phosphate 
groups for interaction with proteins can most easily be explained in this way.  
 
James Watson and Francis Crick
17 were the first scientists to formulate an accurate 
description of DNA. Their work was directly dependent on the research of numerous 
scientists before them that have been discussed above. The structure they suggested 
contained two helical chains each coiled round the same axis (fig. 1.10)
21. Each chain 
consists of phosphodiester groups joining β-D-deoxyribofuranose residues with 3’,5’ 
linkages. Both chains follow right-handed helices, the sequence of residues in the two 
chains run in opposite directions; one strand runs 3’ to 5’ and the other 5’ to 3’. Each 
chain loosely resembles Furberg’s model I
16 discussed above: the bases are on the inside 
of the helix and the phosphates on the outside. The sugar is roughly perpendicular to the 
attached base. There is a residue on each chain every 3.4 Å, in the z-direction (i.e. the 
bases stack one upon another). An angle of 36 ° exists between adjacent residues, hence 
the structure repeats after ~10 residues on each chain or after 34 Å vertically. The radius 
of the helix is 10 Å. The phosphates located on the outside are easily accessed by 
cations. DNA is an open structure with a high water content. The two chains are held 
together by hydrogen bonds that exist between the purine and pyrimidine bases; a single 
base from one chain is hydrogen-bonded to single base from the other chain, the two lie 
side-by-side with identical z-coordinates with their planes being perpendicular to the 
fibre axis. Hence, when the sequence of bases on one chain is given, the sequence on 
the opposite chain is automatically determined; the two strands are complementary. The 
stability of the duplex is derived from both base stacking (π-π interactions of the stacked 
aromatic bases) and hydrogen bonding.  12 
 
The bases are present in their amino-keto rather than enol tautomeric forms. Adenine 
hydrogen bonds to thymidine, and guanine hydrogen bonds to cytosine (fig. 1.11); 
known as Watson-Crick base pairing and agrees with Erwin Chargaff’s base abundance 
findings
13. The NH groups of the bases are good hydrogen bond donors (d), while the 
sp
2-hybridised electron pairs on the oxygens of the base C=O groups and on the ring 
nitrogens are good hydrogen bond acceptors (a). The a·d hydrogen bonds are largely 
electrostatic in character. There exist two hydrogen bonds in an A·T base pair and three 
in a G·C base pair. The formation of hydrogen bonds between the base pairs gives a C
1’-
C
1’ distance of 10.60 ± 0.15 Å, with an angle of 68 ± 2 ° between the two glycosidic 
bonds. As a result of this, the base pairs are pseudosymmetric, so when one base pair is 
overlaid by the other base pairs the phosphodiester backbones fall on top of each other, 




















































Fig. 1.11: Structures of the Watson-Crick base pairs; A·T and G·C respectively, indicated are the regions 
of the major and minor grooves along with the hydrogen bond donors (d) and acceptors (a). In each case 
dR indicates the deoxyribose sugar. 
 
Watson-Crick base-pairing is the dominant kind of interaction between bases; however, 
other pairings, such as Hoogsteen pairs exist (fig. 1.12). Hoogsteen pairs have an angle 
of 80 ° between the glycosidic bonds and an 8.6 Å separation of the anomeric carbons; 
hence they are not pseudosymmetric with Watson-Crick pairs. Reversed Hoogsteen 
pairs and reversed Watson-Crick pairs also exist, they occur when one base is rotated 


















Fig. 1.12: Hoogsteen base pair A·T. 
 
On further studies of heterogeneous DNA fibres, Franklin and Gosling
14,15 identified 2 
distinct conformations for the DNA double helix which can interconvert. The highly 
crystalline A-DNA (fig. 1.13)
21 is the favoured form at low humidity (and high salt), 
while the less-ordered B-DNA, for which the properties were reported by Watson and 
Crick and are discussed above, is the dominant structure at high humidity (and low salt). 14 
 
In the A-form DNA, two co-axial helical chains run in opposite directions in a right-
handed manner, the number of residues per helical turn increases from ten (in B-DNA) 
to eleven, hence the pitch of the helix decreases from 34 Å to 28 Å. The vertical 
component of the inter-base distance is therefore decreased from 3.4 Å in B-DNA to 
2.55 Å in A-DNA. The planes of the base pairs are displaced off-axis towards the minor 
grove and are tilted at ~ 25 °. In A-DNA the phosphate groups lie on a helix of radius 
9  Å. The furanose ring has C
3’-endo pucker and the glycosidic bond is in the anti 
conformation. The major groove of A-DNA is extremely deep and the minor groove is 
extremely shallow. The sugars of B-DNA (the principal form) have C2’-endo pucker, 
with all the glycosides having anti conformation. B-DNA has a wide major groove and 
a narrow minor groove, of equal depth, running around the helix along the entire length 
of the molecule. Proteins interact with DNA principally in the major groove, and some 
small drug molecules (e.g. netropsin, distamycin) bind in the minor groove. 
 
RNA can also form right-handed duplexes, which exist in the A-form. The same base 
pairing rules apply; A·U and G·C. There are a number of other conformations of RNA 
and DNA, most of which are subtle variations on the A- and B- form; they are classed 
according to their sugar pucker; C
3’-endo for the A-form, and C
2’-endo for the B-form.
3 
 
Z-DNA was discovered from x-ray crystal structures on the chemically synthesised 
strand d(CGCGCG) which spontaneously forms a duplex in aqueous buffer, and exists 
when the helix strands run antiparallel, but left-handed in nature. There are 11.6 base 
pairs per helical turn, the major groove is completely flattened out on the surface of the 
molecule and the minor groove is very deep. The base pairs are displaced off-axis. 
There exists an alternation of syn  and  anti conformations at guanine and cytosine 
respectively which produces a zig-zag chain path and hence a dinucleotide unit repeat.
21 
 
In DNA and RNA, the structure conformation and properties are governed by the 
sequence of base pairs within. It is the π-π stacking interactions between successive 
base-pairs that provide this crucial link between sequence, structure and properties. 
There are four interactions that contribute towards the energy of π-π interactions: (1) 
van der Waal’s interactions; (2) electrostatic interactions between partial atom charges; 
(3) electrostatic interactions between the negatively charged π-electron clouds out of the 15 
 
planes of the aromatic molecules with the positively charged σ-nuclei framework; and 
(4) electrostatic interactions between the π-electron clouds and partial atomic charges.
22 
Furthermore, the stability of the DNA or RNA structure is also governed by van der 
Waals’ interactions, electrostatic interactions, solvent interactions, and hydrogen 




Fig. 1.13: The major nucleic acid duplex conformations in DNA (A-form, B-form, and Z-form) and RNA 
(A-form). The sugar-phosphate backbone is represented by the ribbon.
21 
 
1.4  DNA FUNCTION AND THE GENETIC CODE 
 
Watson and Crick observed that the specific base-pairing within DNA could provide a 
mechanism for heredity. Genetic information is encoded in the sequence of bases that 
are attached to the C
1’ of deoxyribose sugars along a DNA chain. This specific sequence 
determines the structure of proteins and represents genetic inheritance. Overall, DNA 






1.4.1 DNA  Replication
23-25 
 
An exact copy of DNA is created prior to cell division; the enzyme topoisomerase 
unwinds the DNA at the origin, and helicase splits the strands of the DNA molecule 
apart by breaking the hydrogen bonds between base-pairs, forming a ‘bubble’ within the 
‘mother’ duplex (fig.1.14). Origins tend to be where there are A.T-rich regions due to 
there existing two hydrogen bonds between the base pairs rather than three, which exist 
between G.C base pairs, hence a positive relationship between the number of hydrogen 
bonds and the difficulty in breaking these bonds. RNA primase creates RNA primer 
nucleotides at the initiation point on each template strand; the leading strand receives 
one RNA primer per active origin of replication while the lagging strand receives 
several. DNA polymerase catalyses the polymerisation of the deoxyribonucleotides into 
a complementary DNA strand at the 3’-end of the RNA primer, by adding new 
deoxyribonucleotide triphosphates (dNTP) complementary to the template strand by 
Watson-Crick pairing, one at a time via the creation of phosphodiester bonds. Extension 
of the leading strand occurs in one continuous motion along the template in a 3’ to 5’ 
manner, while the lagging strand is extended in a discontinuous motion due to Okazaki 
fragments
26 (relatively short fragments of DNA with no RNA primer at the 5’-end) in a 
5’ to 3’ direction. Due to its orientation, opposite to the working orientation of DNA 
polymerase, which moves on a template in a 3’ to 5’ manner, replication of the lagging 
strand is more complicated than that of the leading strand. RNA primase attaches more 
RNA primer in the remaining gaps on the lagging strand and DNA polymerase extends 
the primed segments, yielding a series of Okazaki fragments. RNA primers are then 
removed by 5’-3’ exonucleases (RNase), which DNA polymerase replaces with DNA 
nucleotides. A single gap in the sugar-phosphate backbone (nick) on the leading strand 
and several gaps in the sugar-phosphate backbone on the lagging strand can be found. 
DNA ligase fills these gaps in by forming a phosphodiester bond between a 5’-
phosphate and a 3’-hydroxyl group, thus completing the newly replicated ‘daughter’ 
strands of DNA. Cell division can now occur.
23-25  
 
Overall, replication has a proofreading mechanism; DNA polymerases are in general 
extremely accurate, they can remove nucleotides from the end of a strand in order to 
correct mismatched bases. However, mismatches can persist; hence creating genetic 





Fig. 1.14: DNA replication within the nucleus of a cell. 
 
1.4.2  DNA Transcription
27 
 
Transcription, or RNA synthesis, is the process of creating an equivalent RNA copy of a 
sequence of DNA, and is the first step leading to gene expression. The existence of base 
pairs provides a complementary language that can be converted back and forth between 
RNA and DNA in the presence of the correct enzymes. 
 
The DNA helix unwinds and transcription starts at the promoter region. The promoter 
region is a particular location where the enzyme RNA polymerase initiates RNA 
synthesis. RNA polymerase reads the sequence of only the ‘template strand’ of the 
DNA duplex in a 3’ to 5’ manner, producing a complementary antiparallel RNA strand 
(where T is replaced by U). Transcription continues until one entire gene has been 
created where the RNA sequence (same sequence as the ‘coding strand’ of DNA) has 
been transcribed from the DNA sequence (transcription unit). The new RNA strand 
separates from the DNA. If the gene transcribed encodes for a protein, messenger RNA 
(mRNA) is created from pre-messenger RNA, which has been chopped by a process 
called RNA splicing to remove the introns (RNA that does not code for proteins). It is 
then used to create a protein via translation (see below). Alternatively, the transcribed 
gene may encode for ribosomal RNA (rRNA) or transfer RNA (tRNA), other 
components of the protein assembly process, or other ribozymes.  18 
 
A DNA transcription unit encoding for a protein contains not only the sequence that 
will eventually be directly translated into the protein (‘coding sequence’), but also 
‘regulatory sequences’ that direct and regulate the synthesis of a particular protein. The 
‘regulatory sequences’ upstream from the coding sequence is called the ‘5’-untranslated 
region’ (5’-UTR), and the sequence downstream from the coding sequence is called the 
‘3’-untranslated region’ (3’-UTR). Transcription has some proof reading mechanisms, 
however, they are not as efficient as the controls for DNA replication.
27  
 
1.4.3  RNA Translation
28 
 
RNA translation is the process by which proteins are expressed. There exists 20 
different amino acids, and these are the building blocks of proteins. 
 
During translation, mRNA leaves the cell nucleus to enter the cytoplasm, and tRNA is 
replenished from the nucleus as it is depleted. Translation proceeds in four stages: (1) 
activation; (2) initiation; (3) elongation; and (4) termination. During activation, a 
condensation reaction occurs, and the correct amino acid is covalently bound at its 
carboxyl group to the 3’-hydroxyl group of the correct tRNA, forming an ester, with the 
elimination of water. Initiation involves the subunits of the ribosome binding to the 5’-
end of mRNA with the help of initiation factors. The mRNA is decoded by the 
ribosome to produce a specific amino acid chain. The ribosome facilitates decoding by 
inducing the binding of tRNAs with complementary mRNAs. tRNAs are made up of 
anticodon sequences. Using Watson-Crick base pairing, the triplet of tRNA bases form 
hydrogen bonds to the complementary triplet of bases that make up the codon sequences 
in mRNA. The tRNAs carry specific amino acids that are chained together one at a 
time, into a polypeptide as the mRNA passes through and is ‘read’ by the ribosome. The 
ester at the 3’-end of the tRNA carrying the amino acid for extension of the protein 
chain, reacts with the α-amino group of the terminal amino acid of the growing protein 
chain to form a new peptide bond. The tRNAs one by one are then expelled from the 
ribosome. Termination of the polypeptide chain occurs when the A site (tRNA-binding 
site) of the ribosome faces a stop codon (UAA, UAG or UGA). No tRNA can recognise 
or bind to this codon; the stop codon has no anticodon. The stop codon induces the 
binding of a release factor protein that prompts the termination of protein synthesis, and 
disassembly of the entire ribosome/mRNA complex.
28 19 
 
1.4.4  The Genetic Code and the Wobble Hypothesis 
 
The genetic code is universal. There are 4 bases in RNA (A, G, C, U), Crick and 
Brenner et al.
29 proposed that there are 64 (4
3) possible triplet codes. Theoretically only 
22 codes are required, one for each of the 20 naturally occurring amino acids, in 
addition to a start codon and a stop codon to indicate the beginning and end of a protein 
sequence. Many amino acids have several codes (degeneracy) hence all 64 possible 
triplet codes are used. No two amino acids have the same code, however, similar codon 




30 proposed that the first two base pairs of the codon-anticodon pairing triplet, that 
codes for a specific amino acid, uses the standard base pairing (G·C, A·U and vice 
versa) rather strictly. However, there exists some ‘wobble’ (flexibility) in the pairing of 
the third base, in that there exists some variation (I·A, U·G, U·I etc; I represents inosine 
which is an analogue of guanosine, and lacks an amino group on the 2-position of the 
purine ring, see fig. 1.15). This existence of ‘wobble’ base pairs (fig. 1.16) means that a  
single base in the 5’-anticodon position of tRNA is able to recognise either of the 
pyrimidines or purines in mRNA as its 3’-codon base pair. This explains the degeneracy 
of the genetic code (e.g. the codons for the amino acid threonine are ACU, ACC, ACA 
and  ACG). Not all triplet base combinations are possible. Wobble base pairs have 
different geometries to Watson-Crick pairs and are not as stable. 
 
 




Fig. 1.16: The structures of a few ‘wobble῾ base pairs; U·G, U·I and A·I respectively. 
 
1.4.5  DNA Mutations and Repair
31 
 
It is estimated that without external influences, base pairing in DNA would allow more 
than 1 % incorporation of incorrect nucleotides. This is due to competition between the 
correct GC/AT base pairs and eight possible base mismatches; AA, GG, AG, CC, TT, 
CT, AC, GT. The first three of these are purine-purine mismatches, the second three are 
pyrimidine-pyrimidine mismatches and the final two are purine-pyrimidine mismatches. 
After a cycle of replication, purine-purine and pyrimidine-pyrimidine mismatches give 
rise to ‘transversion mutations’ and purine-pyrimidine mismatches produce ‘transition 
mutations’. DNA polymerase with their proofreading activity check for the 
incorporation of incorrect nucleotides, remove them and insert the correct nucleotide. 
However, the DNA polymerases cannot solely provide sufficient control and requires 
the aid of other proofreading and repair enzymes seeking out mismatches and 
effectively correcting them as the new DNA duplex is formed. These proof reading and 
repair enzymes that are used during DNA replication, work extensively with high 
efficiency, however, some mismatches do go uncorrected (1 in 10
9) forming mutations. 
Mutations are changes in the DNA sequence of a cell’s genome. As well as occuring 
during DNA replication, mutations can arise from radiation, viruses, transposons 
(sequences of DNA that can move around to different positions within the genome of a 
single cell; process called transposition), and mutagenic chemicals. A single mismatch 
has the effect of providing an incorrect sequence for gene formation which in turn gives 
an incorrect RNA sequence by altering the code of the codon triplet. This then leads to 
the incorporation of one incorrect amino acid residue.Which in turn can lead to the 
expression of an incorrect protein, or a protein that posseses different functions to that 
of the protein that should have been expressed. In many cases when mismatches have 21 
 
not been identified during replication, there are no disasterous consequences; some have 
no effect. However, if the DNA sequence is coding for a regulatory gene that controls 
the expression of an important protein, the presence of a mismatch can decrease the 
efficiency of regulation. This can lead to over production/under production of the 
specific protein, causing tissue to eventually degenerate, malfunction or develop cancers 
which can then lead to cell death. Occasionally however, the presence of a mismatch 
can be beneficial for example, by enhancing the region of the genome responsible for 
disease defense, hence making the host more resistant to attack from bacteria and 
viruses. Or, the mutation could produce a protein that works better than the original or 
performs a new function, hence the mutant organism will have a competitive advantage 




The post-replicative DNA repair enzymes are able to distinguish the newly synthesised 
strand of the DNA duplex that requires repairing (the daughter strand) from the template 
strand (parental strand). Normally in the parental strands, the 5-position of some of the 
cytosine bases are methylated while the daughter strands are not. It is only after the 
proofreading and repair enzymes have checked that the daughter strand is a faithful 
reverse complementary copy of the parent, methylation of the specific cytosine bases in 
the daughter strand is carried out by an enzyme. The exact location within the DNA 
duplex that requires repairing is determined by considering the stability of the duplex 
from hydrogen bonding and base stacking interactions. It is these interactions that are 
important in the driving force for the formation of duplex DNA, which is an 
entropically unfavourable process. Prior to DNA duplex formation, the complex 
network of hydrogen bonds formed from the polar groups (amido, amidino, guanidino, 
carbonyl) of the heterocyclic bases in the single strands of DNA with the surrounding 
water molecules have to be broken. Overall, for duplex formation, the stability from the 
formation of the inter-base hydrogen bonds and base stacking interactions must be 
greater than the instability obtained from the loss of entropy and the energy required in 
breaking hydrogen bonds (endothermic process) from the DNA single strands to water. 
Mismatches (see fig. 1.17, fig. 1.18 and fig. 1.19 for a few of the various kinds of 
mismatches) can form wobble base pairs (these types of base pairs are formed in the 
ribosome and partly responsible for the degeneracy of the genetic code), or they can 
involve the base mispairs to be present in their tautomeric forms (some of these are 22 
 
almost perfect mimics of Watson-Crick base pairs in overall shape), they an also 
involve ionized bases, or the pairing schemes can involve anti-syn isomerisation about 
the glycosidic bond. These various forms of mismatches generally destabilise the DNA 
duplex thermodynamically, due to the change in the shape and geometry of the 
mismatched pair, from that of Watson-Crick base pairs. The ‘‘mis-shapen’’ base pairs 
are unlikely to form stable stacking interactions within the DNA double helix, and in 
some cases hydrogen bonding of the heteroatoms to the surrounding water molecules is 
also inhibited, hence further destabilising the base pair. This destabilisation gives local 
melting and enhanced rates of the double helix opening. It is this phenomenon that is 
usually recognised by DNA repair enzymes. Some mismatches, however are harder to 
detect, and these can sometimes persist due to being unrecognised by the DNA repair 
enzymes.
31 Aboul-Ela et al.
32 observed a hierarchy of mismatch stabilities that can be 
expressed as G·T > G·G > G·A > C·T > A·A = T·T > A·C = C·C. It has been well 
documented
33,34 however, that this hierarchy does not correlate with the efficiencies of 
correction of the different mismatches. G·T and A·C transition mismatches are usually 
well repaired due to these mismatches enhancing the rate of helix opening; while G·A 








Fig. 1.18: The structure of the A




Fig. 1.20: The structures of the G·A anti-anti mismatch (left) and the G·A anti-syn mismatch (right).  
 
1.4.6  Reverse Transcription 
 
Reverse transcription was discovered independently by David Baltimore
35, Howard 
Temin
36 and Satoshi Mizutani
36. Reverse transcription occurs after an RNA retrovirus 
enters a host cell and with the aid of reverse transcriptase (an RNA-dependent DNA 
polymerase enzyme), single-stranded RNA of the retrovirus is transcribed into double 
stranded DNA. This is then integrated into the host chromosomal DNA and replicated 
along with it to produce the virus, reversing the direction of genetic transcription. 
Reverse transcription is extremely error-prone, due to reverse transcriptase enzyme 
having no proofreading ability, and it is during this step that mutations may occur; such 
mutations may cause drug resistance. HIV-1 is a well studied reverse transcriptase from 
human immunodeficiency virus (HIV) type 1.  
 
Antiretroviral drugs
37,38 such as zidovudine (AZT) (fig. 1.21) have been designed to 
block the HIV reverse transcriptase’s enzymatic function and prevent completion of 
synthesis of the double-stranded viral DNA. Thereby preventing HIV from multiplying. 
Drugs like these are known as reverse transcriptase inhibitors (RTIs). RTIs are also used 
to treat tumours and cancer. RTIs can be subdivided into three groups: (1) Nucleoside 
analogue reverse transcriptase inhibitors (NRTIs); (2) Nucleotide analogue reverse 
transcriptase inhibitors (NtRTIs); and (3) Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). NRTIs and NtRTIs have essentially the same mode of action; they 
are analogues of the naturally occurring deoxynucleotides needed to synthesise the viral 
DNA, and they compete with the natural deoxynucleotides for incorporation into the 
growing viral DNA chain. However, unlike the natural deoxynucleotide substrates, 
NRTIs and NtRTIs lack a 3’-hydroxyl group on the deoxyribose moiety. As a result, 
following incorporation of an NRTI or an NtRTI, the next incoming 24 
 
deoxyribonucleotide cannot form the next 5’-3’ phosphodiester bond needed to extend 
the chain. Hence, the synthesis of the viral DNA is terminated. All NRTIs and NtRTIs 
are classified as competitive substrate inhibitors. In contrast, NNRTIs block reverse 
transcriptase by binding at a different site on the enzyme (a specific ‘pocket’ binding 
site) compared to NRTIs and NtRTIs. NNRTIs are not incorporated into the viral DNA 
but instead inhibit the movement of protein domains of reverse transcriptase that are 
needed to carry out the process of DNA synthesis. NNRTIs are therefore classified as 
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Fig. 1.21: The structure of Zidovidine/Azothymidine (AZT) a NRTI used in HIV treatment. 
 
Although these reverse transcriptase inhibitors successfully prevent completion of 
synthesis of the viral double stranded DNA, it has proved difficult to develop 
compounds with the ability to entirely eliminate these life-threatening viruses from the 
host genome. Hence, it is for this reason that a number of oligonucleotide-based 
approaches are now being developed such as; antisense oligonucleotides (RNA 
interference, RNAi) and triplex forming oligonucleotides (TFOs), to target gene 
inhibition. 
 
1.5  THE ANTISENSE APPROACH TO REVERSE TRANSCRIPTION 
AND GENE INHIBITION  
 
The survival of viruses and bacteria within a host genome is dependent on the formation 
of their unique proteins. In the human genome, the mRNA sequences that encode these 
essential proteins are absent. Hence, methods that eliminate the foreign mRNA 
molecules without interfering with the mRNA of the host are potentially of great 
therapeutic value. 25 
 
Antisense oligonucleotides are designed to hybridise to specific mRNAs and inhibit 
expression of the particular proteins that are for example, important for the replication 
of a virus, or for the uncontrolled growth of cancer cells. Elimination of the target 
mRNA is the eventual result of antisense. A hybrid duplex is initially formed between 
the mRNA and antisense oligonucleotide; the ribosome of the virus is therefore unable 
to assemble around the viral mRNA and hence cannot direct protein expression, thereby 
inhibiting the synthesis of viral proteins. Ribonuclease-H (RNase-H), which is present 
in normal cells, has endonuclease activity that enhances the antisense effect on mRNA 
molecules hybridised to antisense oligonucleotides, thereby destroying the mRNA 
strand. The antisense effect becomes catalytic. Hence, with the aid of RNase-H, a single 




The successful incorporation of antisense oligonucleotides into cells, without 
degradation by DNA enzymes, requires chemical modification. Modifications are 
normally carried out on the phosphodiester backbone of the antisense oligonucleotides. 
Modifying this moiety inhibits the action of 5’- and 3’-exonucleases, as well as 
endonuclease. DNA enzymes with 5’-exonuclease activity digest oligonucleotides from 
the 5’-end, 3’-exonucleases digest from the 3’-end, and endonucleases digest from 
within the DNA chain. Modifications can also be made to the sugar moiety to prevent 
oligonucleotide degradation by DNase enzymes. Such modifications can be made by 
adding functional groups to the 2’-position of the sugar; 2’-O-methyl; 2’-O-
methoxyethyl; 2’-O-aminoethyl etc. It is possible to combine more than one 
modification in a single oligonucleotide.
39 
 
The antisense approach to gene inhibition is very sophisticated however it is difficult to 
achieve complete inhibition of a specific mRNA when considering the vast numbers of 
mRNA molecules that are present within a cell. Importantly, feedback mechanisms exist 
that can lead to increased mRNA production in response to antisense inhibition of a 
particular message. 
 
A more attractive approach to blocking the synthesis of specific proteins, rather than by 
antisense, is by the direct inhibition of DNA.
40,41 In comparison to the thousands of 
copies of mRNA molecules present when considering the antisense approach, there are 26 
 
only two copies of each DNA target site per diploid cell, hence, a better opportunity for 
the interacting agent to reach its specific target. The direct switching off of genes by an 
external agent in this way is an extremely attractive approach, and can be achieved in 
principle by sterically blocking the double helix so that proteins required for replication 
and transcription can no longer bind. The regions of DNA involved in the regulation of 
gene expression can be a target for inhibition; the formation of intermolecular DNA 
triple helices offers this possibility.  
 




1.6.1  The Discovery of and an Introduction to DNA Triple Helices 
 
Intermolecular DNA triple helices are formed when a third strand oligonucleotide 
(triplex-forming oligonucleotide, TFO) binds in the major groove of DNA, making 
specific contacts with substituents on the exposed faces of the base pairs (fig. 1.22).
43 
The formation of DNA and RNA triple helices was first observed in 1957 by Felsenfeld 
et al.
47,48 using x-ray fibre diffraction studies on mixing polyU and polyA in the ratio 
2:1. Further studies showed that polyC and polyG can generate similar structures under 
conditions of low pH.
49 Triple helices are able to form as a result of the hydrogen 
bonding donors and acceptors located on the exposed faces of the purine bases of DNA 
within the major groove. The two additional hydrogen bonds are able to form between 
the duplex purine residues and the residues in the third strand; these bonds are 
Hoogsteen hydrogen bonds.
40 Duplexes capable of forming triple helices contain purine 
bases on one strand and pyrimidine bases in the complementary strand, hence a pre-




Fig. 1.22: Ribbon model demonstrating the relative position of a TFO (black strand) in the major groove 




The first biological role for triplexes was identified in 1968. Morgan and Wells
50 
showed through an in vitro assay that transcription by an E. coli RNA polymerase could 
be inhibited by the presence of an RNA third strand. However, it was not until 1987 
when it was discovered that the formation of DNA triple helices provided a means for 
designing DNA sequence specific agents.
40 Le Doan et al.
41 demonstrated that a TFO 
containing all α-configured T bases with covalent attachment of an azidoproflavine 
derivative (intercalating mutagenic reagent; fig. 1.23), could form a triple helix with a 
stretch of A·T base pairs within the major groove of the DNA duplex. Hydrogen bonds 
were formed between the thymidine bases of the mutagen-activated TFO to the adenine 
bases within the major groove of the DNA duplex. The azidoproflavine derivate could 
then be excited by light to induce crosslinking reactions to either strand of the target 
duplex. These crosslinked species could then undergo cleavage reactions under alkaline 
conditions, thereby inducing irreversible damage within the target sequence, therefore, 
creating a potential method for controlling gene expression in vivo. Thus, TFOs not only 
have the potential to control biological processes such as transcription, DNA 28 
 





Fig. 1.23: The structure of the azidoproflavine derivative used in the DNA mutagenesis studies conducted 
by Le Doan et al.
41 
 
Naturally occurring intramolecular DNA triple helices exist. H-DNA
46,51-56 forms when 
the third strand is provided by one of the strands of the same duplex DNA molecule at a 
homopurine-homopyrimidine mirror repeat sequence ((dT-dC)n·(dA-dG)n repeats) (fig. 
1.24).
57 The H-DNA intramolecular triple helix is formed by the pyrimidine strand and 
half of the purine strand, leaving the other half of the purine strand single stranded. 
Transition to H-DNA occurs when the DNA is exposed to negative supercoiling 
(twisting of DNA in the opposite direction of the helix) and low pH (half of its C 
residues are protonated). The first polymorph of DNA of this kind was discovered in 
1985 within a sequence (dA-dG)16 in the polypurine strand of a recombinant plasmid 
pEJ4.
58 There exists many different isomeric forms of H-DNA whose structures differ 
depending on base sequence, sequence length, pH, ionic strength and topological stress. 
H-DNA motifs are abundant in the human genome, and it is thought that they have roles 






Fig. 1.24: The structure of the intramolecular triple helical DNA polymorph H-DNA.
57 
 
TFOs can be used in genetic engineering. As a result of their ability to recognise 
sequences within double-helical DNAs with high specificity, TFOs constitute a valuable 
tool for site-directed modification of genomic DNA, and in the use for gene 
manipulation and gene function. Rather than designing molecules (agonists – a 
substance which fully activates the neuronal receptor that it attaches to; and antagonists 
– a substance that attaches to a receptor within a cell but does not activate it) to bind to 
specific receptor sites, TFOs offer an alternative pathway for drug design. Using 
molecules for drug design requires high specificity of the drug molecule with the target 
pharmacological receptor. This requires knowledge of the primary and secondary 
structures of the receptor site itself. The structure of DNA is known in precise molecular 
detail. Hence, the use of TFOs to target a specific region of DNA allows these 
sequence-specific agents to bind with high affinity and efficacy. TFOs are able to bind 
selectively to DNA, they are also able to adopt the same geometry as the helical duplex 
while binding to the major groove, turning through 360 ° every 10 base pairs. This is a 







1.6.2  Triplex motifs and their Structure  
 
Depending on its base composition and binding orientation relative to its DNA target 
site, a TFO can be categorised into either the pyrimidine or purine motif. In the 
pyrimidine motif, the TFO is pyrimidine-rich (consisting mainly of C and T) and runs 
parallel to the duplex purine strand, the triplex is stabilised by the formation of 
Hoogsteen hydrogen base pairs
59, and characterised by T·AT and C
+·GC triplets. These 
triplets are isomorphic (if the C-1’ atoms of the Watson-Crick base pairs are 
superimposed, the positions of the C-1’ atoms of the third strand are almost identical), 
this minimises backbone distortion of both the third strand and duplex between adjacent 
triplets. It is also possible to form a G·GC triplet within this motif, however it is not 
isomorphic with the T·AT and C
+·GC triplets. Protonation at N
3 of cytosine is essential 
for formation of Hoogsteen bonding with N
7 of guanine which occurs only at low pH (< 








Fig. 1.25: The pyrimidine binding motif. Above, binding of a TFO in a parallel orientation to the 
polypurine strand of DNA. Below, structures of the parallel triplets T·AT, C
+·GC and G·GC. 
 
In the purine motif, the TFO is purine-rich (consisting mainly of A and G) and runs 
antiparallel to the duplex purine strand. Reverse-Hoogsteen base pairs enable reasonable 
stacking interactions for the triplex to be stabilised. The purine motif is characterised by 
A·AT, G·GC, and T·AT triplets (fig. 1.26).
60 These triplets are strictly not isomorphous 





Fig. 1.26: The purine binding motif. Above, binding of a TFO to the polypurine strand of DNA in an 
antiparallel orientation. Below, structures of the antiparallel triplets A·AT, G·GC and T·AT. 
 
G·GC and T·AT triplets can be formed in both the parallel and antiparallel motifs, 
hence, GT-containing oligonucleotides have great diversity, in that they can be designed 
to bind in either the parallel or antiparallel orientation. The number of GpT and TpG 
steps influences the stability of the triplex, and hence the binding orientation of the 
TFO. This is a result of backbone distortion imposed by the non-isomorphic nature of 
these triplets.




Each base pair (A·T, T·A, G·C and C·G) has a unique profile in the major groove. It is 
therefore possible to recognise specifically and selectively target any unique DNA 
sequence by probing the major groove through affinity of a base in a TFO, and its 
discrimination of a complementary base pair in the DNA duplex.  
 33 
 
Intermolecular triple helix formation currently suffers from several limitations: (1) at all 
pH, triplexes in general form with lower stability than their duplex counterparts, this is 
partly due to the unfavourable bringing together of three polyanionic DNA strands in 
close proximity; (2) parallel triplexes are thermodynamically stable at room temperature 
below pH 6 in aqueous buffer, however less stable at physiological pH (pH 6.2 and 
above); (3) since there is no simple means of recognising pyrimidine bases, triplex 
formation is generally restricted to homopurine/homopyrimidine tracts.
62,63  
 
1.6.3 Limitations to triple helix formation 
 
1.6.3.1 Triplexes form with lower stability than their duplex counterparts 
 
Triplex formation is governed by several factors including length, base composition, 
divalent cations, and temperature. It is kinetically very slow compared to the rate of 
duplex annealing.
64 In comparison to a duplex, there is a greater negative charge density 
within a triplex, hence greater repulsion between the three negatively charged 
phosphodiester backbones. In addition, the interactions generated by Hoogsteen 
hydrogen bonds are weaker than that generated by Watson-Crick hydrogen bonds. Also, 
triplex formation causes a conformational change in the underlying duplex, and this is 
also thought to contribute to slowing the process of triplex formation.
65  
 
The polyamines; spermine, spermidine, and the diamine putrescine have been found to 
be present in mammalian cells in millimolar concentrations.
66 Their primary and 
secondary amino groups are all protonated at physiological pH and carry four, three and 
two positive charges, respectively. These polyamines are thought to play a key role in 
cell proliferation. They bind strongly to duplex DNA and stabilise its structure, 
neutralising the repulsive forces between the phosphate groups within DNA, and 
directly interacting with the DNA bases.
67-69 At physiological concentration, the 
polyamines are able to interact with triplex DNA through electrostatic forces, and have 
shown to stabilise these structures too in the same way as for duplex DNA.
70 The 
stability arises through screening of the charge interactions between the three negatively 
charged phosphodiester backbones, allowing triplex DNA to form more readily.
70 The 
efficacy to increase triplex stability increases with their charge: spermine > spermidine 
> putrescine.
71  34 
 
The stability of triplexes in the purine motif is pH-independent, however depends on the 
presence of bivalent metal cations.
53 Although, only some bivalent cations are efficient 
in stabilising these triplexes, while others are not, and cation requirements are different 
for different sequences.
72 In addition, physiological concentrations of monovalent 
cations, K
+ and Na
+ in particular, inhibit/destabilise these triplex motifs.
73,74 Another 
requirement within this motif is that the purine TFOs must generally be guanine rich (> 
65 %) to form stable triplexes.
75 However, for some G-rich TFOs, their binding is 
inhibited by the intracellular concentration of K
+. They can be involved in auto-
association processes via guanine-quartets that can compete with triplex formation. 




The requirement for H
+ ions exists for the stability of triplexes in the pyrimidine motif, 
hence they are pH-dependent. These triplexes are also stabilised by the presence of 






1.6.3.2 Parallel triplex formation suffers from the requirement for low pH  
 
Parallel triplex formation generally requires conditions of low pH (< 6.0) necessary for 
protonation of N
3 of the third strand cytosine, to establish two hydrogen bonds with 
guanosine in the C
+·GC triplet (fig. 1.25). However, for the use of TFOs in the 
pyrimidine motif for genetic manipulation, triplex formation is required to occur at 
physiological pH, at which the cytosine base will not be protonated.  
 
The C
+·GC triplet has been reported to provide an increased stability on a triplex 
relative to the T·AT triplet.
77-79 This extra stability is not only attributed to the 
additional hydrogen bond, but also to the existence of stronger hydrogen bonds, 
favourable electrostatic interactions between the positive charge on a protonated 
cytosine and the negatively charged sugar-phosphate backbone, and favourable stacking 
interactions between the charged base and the π-stack.
77,80 Without protonation, the 
C·GC triplet only contains one hydrogen bond between the exocyclic N
4 of cytosine and 
6-keto group of guanine in GC; this triplet exerts a destabilising effect on all triplexes at 
neutral pH.
81  35 
 
The pKa of deoxycytosine is ~ 4.3, although this is increased on triplex formation due to 
the polyanionic environment, and is higher in the centre (pKa ~ 9.5) than the termini 
(pKa ~6.2-7.2) of a triplex,
77 optimum C
+·GC triplet stability still requires acidic 
conditions. Terminal cytosine bases provide an overall less stabilising effect on the 
triplex, and this can be attributed to the poor stacking interactions that are encountered, 
with only one nearest neighbour at the 3’- or 5’-end.
77,81 TFO sequences containing long 
contiguous runs of cytosine bases have shown to destabilise the triplex, this has been 
attributed to the electrostatic repulsion of adjacent protonated cytosines, and hence 
alternate CT base sequences are much preferred.
75,78 
 
Several cytosine base analogues have been designed with the aim of forming Hoogsteen 
hydrogen bonds with guanine at physiological pH, these are discussed in section 1.6.4.2. 
 
1.6.3.3  Triplex formation is restricted to homopurine/homopyrimidine tracts 
 
Triplex formation requires the presence of oligopurine tracts on the target DNA. This 
limitation arises from the fact that within the major groove of duplex DNA, the purine 
bases have two vacant Hoogsteen hydrogen bonding sites (fig. 1.27); they can therefore 
form stable triplets. Pyrimidine bases having only one vacant site within the major 
groove of DNA, cannot form stable triplets, and would therefore not be efficiently 








Fig. 1.27: The vacant Hoogsteen H-bonding sites (donor (d) and acceptor (a)) within the major groove of 
DNA for the Watson-Crick base pairs, A·T and G·C respectively. Purines have distinct binding profiles 
with bidentate vacant Hoogsteen sites whereas pyrimidines have only one.
63 
 
However, within the genome it is often difficult to find sufficiently long uninterrupted 
homopurine sequences. Binding sites containing a single pyrimidine base can lead to 
potentially destabilising mismatches during triplex formation.
75 
 
Along with the limitations discussed above, reagent delivery and cellular uptake are 
problems inherent to all oligonucleotide-based therapies.  
 
1.6.4  Methods to Combat the Limitations to Triple Helix Formation
44,61,63,75,80 
 
1.6.4.1 Increase Triplex Stability by Increasing the Strength of Triplex Binding 
 
Several strategies to improve triple helix formation and increase its stability have been 
introduced and these are described below. They include: modifications to the sugar ring; 







1.6.4.1.1 Sugar  Modifications
82-84 
 
On triplex formation, significant changes to the conformation of the purine strand of the 
underlying duplex occur which is unfavourable as it costs some of the intrinsic binding 
energy. For triplex formation, the optimum conformation of the sugars of the third 
strand is C
3’-endo (N) which imparts little distortion to the duplex purine strand, and 
hence preserves the binding energy.
84 RNA TFOs therefore, have a higher affinity for 
duplex DNA than DNA TFOs. Triplexes formed from DNA TFOs are the least stable 
type of triplex. The sugars within the TFO have a C
2’-endo ( S) conformation, and 
conversion to N-type requires even more of the binding energy, which is unfavourable. 
 
Oligonucleotide modifications in which the sugars are N-type are therefore able to 
produce more stable triplexes. The introduction of electronegative groups to the 2’-
position of the sugar, as in RNA, strongly favours the N-type sugar pucker due to the 
gauche effect.
85,86 The 2’-O-methyl modification has been shown to enhance triplex 
stability.
65,87,88 The presence of this modification causes an increase in the 
hydrophobicity of the triplex, which effectively enhances the Hoogsteen bond stability. 
The modification occupies a narrow groove between the phosphate-sugar backbones of 
the parallel pyrimidine and purine strands that are in close proximity, thereby enhancing 
the rigidity of the triplex.
65 These results were also confirmed in NMR studies; the 2’-
O-methyl group increases triplex stability by reducing the distortion of the duplex 
purine strand.
84 Furthermore, the addition of the methyl group to the 2’-hydroxyl 
significantly inhibits the action of nucleases in degrading the strand.
89 
 
Locked nucleic acid (LNA) monomers (fig. 1.28), also called bridged nucleic acids 
(BNA) are conformationally restricted monomers, and adopt N-type sugar puckers. 
They were first developed by a number of groups between 1996
90 and 1997,
91,92 and 
were called ‘bicyclic nucleosides’. The most extensively reported of these consists of a 
2’-O,4’-C methylene bridge which was developed independently by Singh et al.
93 in 
1998 and Torigoe et al.
94 in 2001. These LNAs, when incorporated into TFOs displayed 
unprecedented hybridisation affinity towards complementary DNA and RNA. It was 
reported
94 that parallel triplex formation of LNA modified TFOs with duplex DNA 
produces a smaller negative (unfavourable) entropy change (ΔS) when compared to the 
entropy change associated with triplex formation of unmodified TFOs with duplex 38 
 
DNA. This is due to a smaller entropic loss on triplex formation with the LNA modified 
TFOs at neutral pH, because these TFOs, in the free state are associated with an 
increased rigidity in comparison to the relatively ‘flexible’ unmodified TFOs in the free 
state. This therefore provides a favourable component to the ΔG (Gibb’s free energy 
change) and leads to an increase in the Ka (association constant). It is important to note 
here that fully modified LNA TFOs do not display binding towards dsDNA. It is 
thought that this is a result of their high rigidity, which is supported by structural studies 
by Gotfredsen et al.
95 There therefore exists a balance between the number of LNA 









Fig. 1.28: The general structure of an LNA (locked nucleic acid) monomer; B represents any nucleo 
heterobase. 
 
1.6.4.1.2 Incorporation of Positive Charges 
 
The stability of triplexes is limited by the charge repulsion that exists between the three 
negatively charged backbones that reside side by side. This is particularly so under 
physiological conditions of low ionic strength. Incorporating positively charged 
moieties into the TFO by either modifying the backbone, sugar or base, can alleviate 
this problem. 
 
Positively charged backbone 
 
The replacement of the phosphodiester linkages of the polyanion DNA with guanidine 
linkers to give the polycation deoxyribonucleic guanidine (DNG) (fig. 1.29) have been 
reported by Bruice
96,97 and co-workers. Double and triple helices were formed between 
pentameric thymidyl DNG and negatively charged poly(dA), which displayed dramatic 39 
 
stability according to their thermal denaturation temperatures.
96 The short DNG 
oligomer strand was reported to bind with unprecedented affinity and base-pair 
specificity.
96 In addition, at low ionic strength, these modified oligomers bound 
irreversibly to the target nucleic acid.
96 The synthesis of the ribose derivative RNG was 
also reported by Bruice
98 and co-workers. The guanidium linkages in RNG are neither 
susceptible to cellular nuclease, nor to chemical degradation under physiological 
conditions. Whereas, the labile nature of the phsophodiester backbone in RNA, causes it 
to be susceptible to nuclease hydrolysis, limiting its application. Hence, RNG is better 
suited as an antisense/antigene agent than RNA. RNG may also combine the favourable 
sugar conformation with the stabilising effect of the additional positive charge; it was 
reported that RNG-DNA forms very stable duplexes.
99 It was predicted that the overall 
structure of RNG is equilibrated as a B-DNA conformation, and the RNG strand adopts 
the general conformation of the DNA backbone. Hence RNG will bind specifically to 
B-DNA. Cationic dimethylaminopropyl phosphoramidate linkages (PNHDMAP), and 
N,N-diethyl-ethylenediamine linkages (DEED) (fig. 1.29) have also been reported
100-102 
for the substitution of the anionic phosphate residues. A fully cationic PNHDMAP α-
TFO was reported to form a highly stable parallel triplex that melts at a higher 
temperature than the duplex target. The recognition of the DNA duplex target with the 





Fig. 1.29: The general structures of polynucleotides with cationic backbone modifications: (from left to 
right) deoxyribonucleic guanidine (DNG), ribonucleic guanidine (RNG), dimethylaminopropyl 






Positively charged sugar 
 
On triplex formation of single stranded RNA with duplex DNA, the 2’-hydroxyl groups 
of the RNA and the phosphate groups of the DNA second strand are in close 
proximity.
103 Cuenoud et al.
103 have reported the attachment of a short amino alkyl 
group (2’-O-aminoethyl) at the 2’ position of thymidine units within a third strand (fig. 
1.30); this allows the protonated amino group to form a specific intermolecular contact 
with a proximal phosphate group of the DNA duplex. Thermal denaturation studies 
showed that the stability of the triplex formed with this modified TFO was enhanced 
significantly in comparison to the triplex formed with the unmodified TFO which was 
displayed by the greater Tm value. This enhanced affinity of the TFO for the double 
stranded DNA could be down to the formation of specific contacts between the 2’-
aminoethoxy side chains and the phosphate backbone of the DNA duplex, which is 
thought to contribute actively to the nucleation-zipping association process. Extension 
of the side chain by an additional methylene group, using a 2’-aminopropoxy group 
caused a significant decrease in triplex stability, suggesting that the 2’-aminoethoxy 








104 reported in 2002 the synthesis of 4’-(α)-C-aminoalkylpyrimidines and 
their incorporation into TFOs along with their triplex binding abilities. They found that 
TFOs containing 4’-α-C-(2-aminoethyl)-2’-deoxythymidine formed thermally stable 
triplexes with the complementary DNA target, in addition these TFOs were more 
resistant to nucleolytic digestion by DNase I endonuclease than unmodified TFOs. 
TFOs containing 4’-α-C-(2-aminoethyl)-2’-deoxy-5-methylcytosine were much more 41 
 
resistant to 3’-exonuclease compared to the unmodified TFOs. Greater stabilisation was 
shown for the 2’-derivative and was attributed to the fact that the protonated 2’-
aminoethoxy side chain is ideally positioned as a result of the gauche effect, to interact 
specifically with the nearby pro-R oxygen of the negatively charged phosphate group of 
the DNA second strand,
105 thereby forming a salt bridge. 
 
Positively charged base 
 
As a result of the positive charge in the C
+·GC triplet, it is more stable than the T·AT 
triplet. Bijapur et al.
106 have replaced thymidines with 5-propargylamino-dU (U
P) (fig. 
1.31) in the third strand TFO and studied its affinity for the duplex target site in 
comparison to the unmodified parent TFO, using UV melting and DNase I footprinting. 
The thermal denaturation studies for the triplex formed from the modified TFO showed 
a single UV-melting transition, which was > 20 °C higher than that of the parent triplex 
containing the unmodified TFO. A single melting temperature was observed at all pH, 
with the Tm decreasing with increasing pH; this is consistent with the requirement for 
protonation of the amino group. DNase I footprinting studies showed that triplexes 
formed with oligonucleotides in which the T was replaced with U
P displayed footprints 
at much lower concentration than their T-containing counterparts. In contrast to 
protonated C, adjacent U
P substitutions are not destabilising; the great the number of U
P 
residues, the greater the stability of the TFO. The alkylyl moiety of U
P also contributes 
to triplex stability by enhancing stacking interactions. Hence, Baijapu et al. 
demonstrated that the stability of DNA triplexes can be dramatically increased by using 
positively charged analogues of thymine, and that placing the charge in the major 








As discussed above triplexes are known to be stabilised by spermine.
70,71 The covalent 
attachment of spermine at the C-5 position of uracil
107 and to the N4 position of 5-
methylcytosine
108 (a naturally occurring cytosine derivative discussed in further detail 
in  section 1.6.4.2.1) (fig. 1.32) both increased triplex stability at physiological pH. 





















dU d5MeC  
 
Fig. 1.32: The structures of the 5-spermine derivative of uracil (left) and the N4-spermine derivative of 5-
methylcytosine (right). Where R = spermine (top).
107,108 
 
It was surprising that the triplexes formed by the TFOs containing the methylcytosine 
derivative were stable at pH 7.3, even though N3 should be unprotonated at this pH. 
This suggests that the lack of the second hydrogen bond in the C
+·GC triplet can be 
compensated by favourable electrostatic interactions between the protonated spermine 
side chain and the phosphate backbone, and possibly hydrogen bonding interactions 
with the duplex bases. These triplexes were less stable at lower pHs. The substitution 
was more effective when placed at either end of the triplex than at the centre and caused 
a slight decrease in Tm with increasing the number of substitutions. These triplexes were 
less dependent on the presence of divalent metal ions such as Mg
2+. 
 
Combining two modifications that individually are known to stabilise triplexes such as 
5-aminopropargyl and 2’-O-aminoethyl should produce stable triplexes across a wide 
range of salt concentrations, particularly under physiological conditions.
109 Bis-amino 
dU (BAU)
110-112 (fig. 1.33) combines these two modifications and contains two positive 43 
 
charges at physiological pH. It dramatically increases triplex stability when 
incorporated into TFOs as thymidine equivalents, with an increase in Tm of 7.7 °C per 
modification at pH 6.5,
111 and the stabilisation is much greater than when either 
modification is used alone. The two positive charges act in different ways to enhance 
triplex stability: the 2’-O-aminoethyl group interacts with a phosphate on the purine 
strand, while the 5-propargylamino group interacts with a third strand phosphate.
110 
This analogue is highly stabilising relative to thymidine and very selective for AT base 
pairs, with enhanced discrimination against pyrimidine inversions.
111 The high stability 
of the BAU·AT triplet permits triplex formation at physiological pH, even for 




Fig. 1.33: The structure of bis-amino dU (BAU).
110,111 
 
1.6.4.1.3 Modifications to the Backbone 
 
Decreasing the charge repulsion between the three polyanionic DNA strands within a 
triplex is an attractive approach to increasing the affinity of a TFO to a duplex target. 
This therefore improves the stability of the triplex formed.  TFOs that contain neutral 
backbones have been developed to do just this, and some examples are discussed below. 
 
Triplex formation using short oligonucleotides containing alternating 
methylphosphonate and phosphodiester linkers (fig. 1.34) have shown to have important 
effects on triplex formation and to serve as substrates for nuclease enzymes.
113 Both the 
phosphonate and phosphodiester linkages within the TFOs that were studied by Miller 
et al.
113 were resistant to hydrolysis by spleen phosphodiesterase and by S1 nuclease. 
The phosphodiester linkages of decamers were however cleaved slowly by snake venom 44 
 
phosphodiesterase and by micrococcal nuclease. The rate of hydrolysis of the modified 
TFOs in comparison to the unmodified TFOs containing all phosphodiester linkages, 
were considerably slower. This difference in rate was thought to be due to the reduction 
of the negative charges which could reduce the affinity of the enzyme for the analogue, 
as well as non-ionic methylphosphonate groups being adjacent to the susceptible 
phosphodiester linkages. However, on using longer oligomers (19-mers) for triplex 
formation, it was reported
114 that no triple helix was detectable by either Tm  or gel 
analysis, when any of the chains A, T, or U was substituted by the corresponding 
methylphosphonate. The addition of a methylphosphonate oligomer strand to a normal 
DNA duplex also gave no detectable triplex. It was reported however, that the inversion 
of the anomeric configuration in the sugar moieties (from β to α) of methylphosphonate 
oligonucleotides can improve their poor binding to their nucleic acid targets.
115 T m 
values for hybrids formed with methylphosphonate α-analogues were obtained, and they 
were compared to those obtained for hybrids of the phosphodiester β- and α-oligomers. 
The non-ionic methylphosphonate α-oligonucleosides have a greater affinity for their 
complementary DNA and RNA strands than their homologues with natural β-anomeric 
configuration. With DNA as the target, the methylphosphonate α-oligomers formed 
duplexes more stable than the corresponding natural phosphodiester β-oligomers. 
Methylphosphonate  α-dT12 bound to its double stranded DNA target at low salt 
concentration of 0.1 M NaCl.
115 
 
Phosphoramidates (fig. 1.34) are 2’-deoxyribooligomers containing N3’→P5’ 
internucleosidic linkages where O3’ of the internucleoside phosphate is replaced by NH. 
They are similar to RNA in that they adopt an N-sugar puckering that favours 
Hoogsteen-type hydrogen bond formation with polypurine tracts in double stranded 
nucleic acids.
116 Thermodynamic and kinetic analyses on triplexes in the pyrimidine 
motif have been carried out by Torigoe et al.
117 Their results have indicated that at 
neutral pH, the phosphoramidate modification significantly increases the thermal 
stability of these triplex motifs (with double-stranded DNA as well as RNA·DNA 
heteroduplexes). In addition, at room temperature and neutral pH, increases in the 
binding constant by nearly two orders of magnitude have been observed for this triplex 
motif. Kinetic studies have demonstrated that the increase in binding constant (Ka) 
results mainly from a decreased dissociation rate constant (Kd).
117 In further studies 
Torigoe et al.
118 have combined this modification with a cationic copolymer. When 45 
 
used on its own the cationic copolymer has been shown to increase the binding constant 
of triplex formation at neutral pH; this results from a considerable increase in the 
association rate constant rather than a decrease in the dissociation rate constant. Hence 
the combination of the two modifications has shown to cooperatively increase the 
binding constant for triplex formation at neutral pH, by four orders of magnitude. 
Kinetic complementarities between increased association rates by the copolymer and 
decreased dissociation rates by the phosphoramidate modification are the cause for the 




Morpholino oligonucleotides are those in which the ribose sugar ring is replaced with a 
six membered morpholino ring and the phosphodiester linkage is replaced by a 
phosphorodiamidate (fig. 1.34). These oligonucleotides when compared to 
phosphodiester and phosphoramidate oligonucleotides form the most stable triplexes in 
the absence of Mg
2+, at a physiological monovalent cation concentration (low ionic 
strength). However, at neutral pH and in the presence of a high Mg
2+ concentration, the 
phosphoramidate oligomers form the most stable triplexes.
119 
 
PNA (peptide nucleic acid) is an oligonucleotide mimic in which the entire deoxyribose 
phosphate backbone of DNA has been replaced by an uncharged backbone made up of 
2-aminoethylglycine repeating units and the nucleobases are attached through a 
methylene carbonyl group (fig. 1.34).
120,121 Mixed sequences of PNA containing all four 
natural nucleobases have been reported to be very potent DNA mimics. They form 
Watson-Crick base-paired duplexes with complementary DNA strands of high 
specificity and thermal stability.
122 Homopyrimidine PNA oligomers form PNA2·DNA 
triplex structures with complementary homopurinic DNA sequences. These oligomers 
have been found to recognise double-stranded DNA targets by a mechanism that 
involves complete displacement of the pyrimidine DNA strand, leaving it looped out as 
a single strand.
121,123 Thus indicating that the PNA2·DNA hybrid is more stable than the 
corresponding DNA triplex; this is a result of a much lower charge repulsion between 
the three strands. It has also been reported
124,125 that a homopurine decamer made up of 
mixed A and G bases can bind to a single target in a double-stranded DNA by strand 
invasion and forming a Watson-Crick base-paired PNA-DNA duplex with the 
complementary DNA strand. The antiparallel duplex (Tm = 69 °C) is approximately 46 
 
10 °C more stable than the parallel duplex (Tm = 57 °C), this result is comparable with 
thermal stability results obtained for PNA2·DNA triplexes.
124 It was also reported that a 
mixed T/G PNA decamer was observed to bind to their Watson-Crick target sequences 
by invasion of the double-stranded DNA and displacing the identical DNA strand, 
forming new PNA-DNA complexes and P-loop formation, requiring two molecules of 
PNA, generating a 2:1 PNA:DNA triplex.
125 Cytosine-rich PNA oligomers form PNA-






Fig. 1.34: Chemical structures of modified DNA backbones. From left to right: (i) phosphodiester, (ii) 
methylphosphonate, (iii) N3’-P5’, (iv) morpholino and (v) PNA.
113-119,121,125 
 
1.6.4.1.4 Improving Base Stacking Interactions 
 
Base stacking (π-π interactions)
22,126,127 involves the interaction between the aromatic 
moieties of the heterocyclic aromatic bases of DNA, and it affects the stability and 
structure of both duplex and triplex DNA.  Extending the aromatic domain within a base 
can potentially increase third strand binding through stacking interactions. There have 
been many reported attempts that have extended the aromatic ring system of pyrimidine 
bases,
128-130 by adding further aromatic rings across the 4-5
128,129 or 5-6
130 positions, 
which should not affect the hydrogen bonding groups used in base pairing. However, 
triplexes containing these modifications did not show enhanced stability, hence the 
modification of pyrimidine nucleosides to form extended ring systems does not 
necessarily result in increased favourable base stacking interactions. The non-natural 
pyrido[2,3-d]pyrimidine F nucleoside can exist in two tautomeric forms F1 and F2 (fig. 47 
 
1.35), and within triple helical complexes F mimics T and recognises AT base pairs (fig. 









Fig. 1.36: The structure of the F·AT triplet.
128 
 
Stacking energies can also be increased by the introduction of a hydrophobic substituent 
at the 5-position of a pyrimidine base, which concomitantly increases hydrophobic 
effects within the major groove. This is supported by the enhanced stability observed 
for the 
MeC
+·GC triplet in comparison to the C
+·GC triplet,
81,131 and the stability of 
T·AT in comparison to U·AT. In the case of 5-methylcytosine, the enhanced triplex 
stability is partly due to an increase in its molecular polarizability with a concomitant 
increase of free energy for stacking, along with a source of positive entropy change due 
to the methyl groups filling a space in the major groove of the DNA duplex, causing a 
release of hydrating water molecules from the double helix to the bulk.
131 It has been 
reported that the incorporation of the modified base 5-(1-propynyl)-2’-deoxyuridine 
(propynylU/pdU) (fig. 1.37) in the third strand of a triplex also leads to enhanced triplex 
stabilisation.
132,133 The incorporation of pdU into TFOs increases the Tm  for triplex 
melting by 2 °C per modification at 1 mM Mg
2+ in comparison to the unmodified TFO. 
This indicates that pdU-modified TFOs are less dependent on Mg
2+ concentration, than 
unmodified TFOs, and are capable of substantial binding even at physiologically low 48 
 
Mg
2+ concentrations that are close to intracellular concentrations.
134 The increased 
stabilisation of this modification is partly down to the extended aromatic cloud of the 
pdU nucleotide stacking well over the 5’-neighbouring nucleotides. Overall, the 
increases in base-stacking interactions and local hydrophobicity caused by the propynyl 
substituent, creates stable triplexes.
133 The incorporation of 5-(1-propynyl)-2’-
deoxycytidine, pdC (fig. 1.37) into TFOs for triple helix formation creates a 



























Fig. 1.37: The structures of pdU (left) and pdC (right).
135 
 
1.6.4.1.4 The Incorporation of Triplex Binding Ligands 
 
The stability of DNA triplexes can be enhanced by the incorporation of small molecules 
that are intercalators which can preferentially bind to triplex DNA over duplex DNA. A 
benzo[e]pyridoindole derivative (BePI) (fig. 1.38), which is composed of aromatic rings 
containing heteroatoms for stacking (intercalation) between the base triplets, and 
incorporates a positive charge to partially alleviate the triplex charge repulsion, has been 
reported to display the preferential triplex binding.
136 Upon irradiation with near-
ultraviolet light, BePI induces covalent modifications of both Watson-Crick strands of 
the triplex, and it increases the thermal stability by more than 20 °C, hence strongly 
stabilising the triplex structure. In the absence of the third oligonucleotide, the strong 
and specific binding sites of the intercalator disappear, and this demonstrates a 
synergistic action of the intercalator and the TFO. The stabilising effect of BePI was 
shown to be much larger than that of the polycation spermine. A requirement for triple 
helix stabilisation by BePI is a long stretch of contiguous T·AT triplets due to the high 49 
 
density of negative charges present at these stretches, whereas the presence of a positive 
charge in a C























Fig. 1.38: The structure of the benzo[e]pyridoindole derivative with OCH3 at the 9-position (BePI).
136 
 
Other DNA binding ligands (acridine
137, triplex binding ligands
138, minor groove 
binding ligands
139 and daunomycin
140) can be covalently attached to a TFO to enhance 
triplex stability. The TFO enables sequence selectivity, while the non-specific DNA 
binding ligand can be used to enhance the affinity of the corresponding TFO. Triplexes 
that are formed at sites containing pyrimidine interruptions can also use this 
methodology to enhance stability.
141 Psoralen (fig. 1.39; see section 1.8 for further 
details on psoralen), a photoreagent can also be added to a TFO to enhance triplex 





Fig. 1.39: The structure and numbering system used for psoralen. 
 
1.6.4.2 Strategies to Combat the Dependency of Parallel Triplex Formation for Low pH. 
 
It can be clearly seen that the recognition of guanine requires a structure presenting two 
hydrogen bond donors to interact with its O6 and N7 (see fig. 1.1). It has been 
previously discussed that several cytosine base analogues have been designed with the 
aim of forming Hoogsteen hydrogen bonds with guanine at physiological pHs and these 
analogues will be discussed here. These analogues can be divided into two classes 50 
 
which are based on either a pyrimidine or a purine ring. These modifications can also be 
used in combination with sugar or backbone modifications. 
 








MeC) (fig. 1.40) is a naturally occurring base and its effect on 
triple-helix formation was first observed in polynucleotide structures.
143 It was found 
that triplex formation was possible at near pH 8 for the triplexes 
(poly(dTd
MeC)·poly(dGdA)·poly(dTd
MeC)) in which all cytosines were substituted with 
MeC. In comparison, the unmodified triplexes containing the unmethylated analogue 
required lower pH for triplex formation.
143 Thermal denaturation studies displayed 
higher thermal midpoint temperatures (Tm) for triplexes containing 5-methyl-2’-
deoxycytosine in comparison to those containing 2’-deoxycytosine at pH 8.0. Hence, 
cytosine methylation strongly enhances triplex stability. These results and those 
obtained in studies by others
131,144 demonstrated that the substitution of 2’-
deoxycytosine with 
MeC extends the pH range at which triple helix formation can occur, 
up to near neutrality. However, not all triplexes containing this base are formed under 
physiological conditions.
145 The differences in the pKa of 2’-deoxycytosine (pKa ~ 4.3) 
and 5-methyl-2’-deoxycytosine (pKa ~ 4.5) is measured to be ≤ 0.2 unit,
147 this slight 
increase in pKa can be used to partly explain the extended pH range for triplex 
formation, however, it cannot affect the protonation at N-3 significantly. Methylation of 
C5 in 
MeC is thought to impart a positive entropic factor that enhances the stability of a 
triplex. The methyl group fills a space in the major groove of a triplex, causing a release 
of hydrating water molecules from the double helix to the bulk, thereby causing a 
positive entropy change.
131 In addition to these effects, another likely source of the 
stabilising influence of the C5-methyl group is from increased base stacking 
interactions; methylation of the stacked bases increases their interaction energies.
146 
Hence, the replacement of cytosine by 
MeC increases the stability of triplexes but does 




























ΨC) (fig. 1.41) is a C-nucleoside (discussed in further depth in 
chapter 2). It is a non-charged cytosine analogue that is able to form Hoogsteen 
hydrogen bondings with guanine at neutral and basic conditions. This is because the N-
3 position of 
ΨC is already bonded to hydrogen, hence being able to form the 
ΨC·GC 
triad, without any pH dependence.  It has been reported that a 2’-methoxy derivative of 
ΨC which was incorporated into a third strand TFO stabilised triplex formation without 
pH-dependence.
148 
ΨC overcomes the limitation presented with duplexes containing 
clusters of guanine residues, due to there being no existence of positive charge-positive 
charge repulsion along the third strand which is experienced when protonated 
MeC or 
dC are present in the third strand.
149 Triplexes containing the 2’-O-methyl derivative are 
more stable than those formed by the corresponding deoxyribooligonucleotides.
149 The 
incorporation of 
ΨC into bis-PNAs (two PNA segments connected in a continuous 
synthesis via a flexible linker) has been reported, they from triple stranded complexes 











6-oxocytidine (fig. 1.42), its 5-methyl derivative and its 2’-O-methyl derivative have 
been incorporated into TFOs and reported to form triplexes, recognising GC base pairs, 52 
 
in a nearly pH independent (6.0-8.0) fashion.
152,153 The methyl derivative encompasses 
slight destabilisation. Both Berresem et al.
152 and Xiang et al.
153 have reported however, 
that at lower pH (< 6.5) cytosine/methylcytosine containing TFOs form more stable 
triplexes than those containing 6-oxocytosine/5-methyl-6-oxocytosine. It is thought that 
more favourable base-stacking interactions occur between the electron-rich 
cytosine/methylcytosine base and the adjacent bases, while the electron-poor 
heterocycles of the 6-oxocytosine and its methyl derivative causes weaker base stacking 
interactions with adjacent bases, and thus, decreases the stability of the triple helix. At 
low pH this effect is not compensated by more stable hydrogen bonds, which are 
present in 6-oxocytidine and its methyl derivative. The acidity at the 3-NH and 4-NH2 
groups is increased due to the presence of the electron-withdrawing oxo group, hence 
stabilising the hydrogen bonds to guanine.
152 It was also thought that as cytosine and 
methylcytosine form one hydrogen bond in the triplex that contains a charged 
hydrogen-bonding partner; this enhances triplex stability, whereas 6-oxocytosine 
residues form only hydrogen bonds involving uncharged partners. At higher pH 
(physiological pH) however, the extent of protonation of cytidine/methylcytidine 
decreases, and triplexes containing 6-oxocytidine/5-methyl-6-oxocytidine, with neutral 
hydrogen bonds dominates in stability; 6-oxocytidine/5-methyl-6-oxocytidine becomes 
superior to cytidine/methylcytidine. Duplexes containing series of contiguous G·C base 
pairs cannot be effectively targeted with TFOs containing 6-oxocytidine/5-methyl-6-
oxocytidine, as a result of ineffective base stacking between the adjacent residues and 
undesirable steric effects, due to the additional carbonyl at the 6 position.
154 Xiang et 
al.
155 reported the use of an acyclic 6-oxocytosine nucleoside derivative in which 
contains an acyclic or ring-opened carbohydrate residue, in TFOs, providing greater 
flexibility to overcome the undesirable steric effects observed when targeting 
contiguous G·C base pairs. However, as the number of acyclic linkers in the TFO was 
increased from two to six, triplex stability was observed to decrease slightly. This 
observation is possibly due to the flexible linker having to adopt the conformation most 
appropriate for triplex formation causing an unfavourable loss in entropy. This cancels 











156-158 (fig. 1.43) is a C-nucleoside 
whose structure is similar to 2’-deoxycytosine, it is however considerably more basic, 
with a pKa of 5.93 (compared with 4.3 for dC), which is closer to physiological pH than 
cytosine or 5-methylcytosine. This analogue was incorporated into 5’-psoralen linked 
oligonucleotides to form triplexes with a target duplex, the oligonucleotides were found 
to have considerably higher binding affinities for the target than the corresponding 
oligonucleotides containing either cytosine or 5-methylcytosine.
156 It has also been 
reported that oligonucleotides containing P bind to their duplex target with significantly 
greater affinity at higher pH than those containing either cytosine or 
MeC, hence 
relieving some of the pH-dependency. This therefore demonstrates that by enhancing 
the degree of N-3 protonation which is obtained through increasing the pKa, the binding 
of cytosine analogues to G·C base pairs is best improved.
157 This increased stability is 
also evident at low pHs. TFOs containing P also form stable complexes with targets 
consisting of contiguous G·C base pairs.
157 The methyl derivative of P; 3-methyl-2-
amino-5-(2’-deoxy-β-D-ribofuranosyl)pyridine (
MeP) (fig. 1.43) and the 2’-O-methyl 
derivative (POMe) (fig. 1.43) have also been reported to be incorporated into TFOs to 
form triplexes with target duplexes.
158 The replacement of cytosine or 
MeC residues with 
MeP, also results in an enhanced affinity of the TFOs to the duplex targets over a pH 
range 6.0-8.0, hence causing an increase in triplex stability and much less expressed pH 
dependence. The replacement of P by 
MeP (which is 0.4 pKa units more basic than P) 
results in no further enhancement of triple helix stability at neutral pH. However, at pH 
values > 8.0, the effect of the pKa difference between 
MeP and P becomes operative. A 
distinct loss of triplex stability has been reported when replacing P by POMe in the third 
strand, although there seems to be no relevant difference in the pKa of these two 54 
 
nucleosides.





Fig. 1.43: The structures and numbering system of 2-aminopyridine (P), 3-methyl-2-aminopyridine (
MeP) 
and 2’-O-methyl-2-aminopyridine (POMe) deoxyribonucleosides.  
 
1.6.4.2.2 Purine  Base  Analogues 
 
Purine analogues can also be used for GC recognition, these are discussed below. The 
triplets that are formed from these analogues however, are not isostructural with T·AT, 
this is because the backbone is in a different position. Hence, equivalent analogues of T 






159 have reported that homopyrimidine TFOs containing the modified purine 
8-oxoadenine are capable of forming stable triplexes with G·C base pairs (fig. 1.44) in 
target duplexes at neutral and basic pH. The keto form of the analogue is required for it 
to exist in the syn conformation. This conformation allows for the formation of two 
hydrogen bonds to G in the target duplex. One hydrogen bond forms between the N-7 
proton of 8-oxoadenine with N-7 of guanine, and the other forms between the 6-amino 
protons of 8-oxoadenine with O-6 of guanine in the G·C base pair. In contrast to 





Fig. 1.44: The structure of the triplet formed between 8-oxo-2’-deoxyadenine and the G·C base pair. 
 
The N
6-methyl derivative of the 8-oxoadenine analogue (fig. 1.45), when incorporated 
into TFOs, has also displayed triplex forming ability to G·C base pairs in target 
duplexes. The triplexes form in a pH-independent fashion within the physiological 
range, without compromising specificity.
160 The increased affinity of this purine 



























Fig. 1.45: The structure of the triplet formed between N
6-methyl-8-oxo-2'-deoxyadenine and the G·C 
base pair. 
 
These analogues recognise G·C and generate triplexes that have the same stability as 
those containing 
MeC at low pH. They can also be used for targeting contiguous 
guanines, which cannot be targeted with cytosine-containing oligonucleotides. 









7-glycosylated purine analogues 
 
It has been reported that an N
7-glycosylated guanine, when incorporated into a 
pyrimidine oligonucleotide, binds with remarkable specificity to the G·C base pairs 
within a duplex forming the N
7-G·GC triplet (fig. 1.46).
161 The third strand orientation 
in the N
7-G·GC triplet is parallel to the purine Watson-Crick strand; this is achieved by 
attaching the deoxyribose moiety to the N
7-position of a guanine base. Hence, the 
Hoogsteen face of the base mimics the arrangement of hydrogen bond donors seen in 
protonated cytosine. At pH 7, N
7-G binds to its target Watson-Crick G·C base pair with 
an affinity equal to that shown by 
MeC. However, at lower pH (5.2) this modified 
nucleoside analogue is not as stabilising as C
+.
162 This comparatively destabilising 
effect of the N
7-G·GC triplet is thought to be due to the localised effect on base stacking 
interactions and the phosphodiester backbone; there exists slight displacements of all 
residues in the Watson-Crick strands. At pH 7, destabilisation as a result of the 
difficulty of protonating the C
+·GC triplet outweighs any destabilisation of the triplex 









7-glycosylated purine analogues include P1
145 (fig. 1.47) and N
7-inosine
163,164 
(fig. 1.48). P1 binds G·C base pairs within a pyrimidine motif triplex similar to cytosine 
in terms of selectivity and strength, however, over an extended pH range. In addition, 
oligonucleotides containing P1 bind G-rich purine tracts in double helical DNA at 
neutral pH. The N
8-glycosylated derivative of P1 generates P2 (fig. 1.47), however no 
triplex formation was observed using this analogue. Hence, the marked difference 
between the isomeric nucleosides P1 and P2 demonstrates the importance of the 57 
 
positioning of the sugar-phosphate backbone along with the glycosidic conformation, 























































Fig. 1.47: The structures of the triplets P1·GC and P2·GC. 
 
Recognition of the G·C base pair has also been demonstrated by N
7-inosine (
7H) and its 
derivatives via only one hydrogen bond between the N-H of inosine and N
7 of guanine 
(fig. 1.48).
164 These analogues were incorporated into TFOs containing 
MeC, and 
displayed binding to a DNA target with equal to slightly increased stability compared to 
a control TFO in which the 
7H residues were replaced by 
MeC. Also, TFO sequences 
containing multiply substituted 
7H residues either in an isolated or in a contiguous 
manner still formed triplexes with their targets of comparable stability as the control 
sequences containing 
MeC, at pH 7.0. Hence, these results show that monodentate 
recognition in the 
7H case to G·C base pairs, is energetically comparable to bidentate 
recognition in the 
MeC or N
7-G cases. Although forming only one hydrogen bond to G·C 
base pairs, the stability of 
7H can be attributed to the additional energetic contribution 
that may arise from enhanced intrastrand stacking around the modified bases alongside 
favourable electrostatic interactions between CH-2 of 
7H and O-6 of guanine.
164 This 
interaction provides a small, positive, direct electrostatic contribution, which is 
energetically beneficial. In addition, this interaction alleviates any destabilising 
interaction that arises if a hydrogen bond acceptor is inactive or involved in secondary 






Fig. 1.48: The structure of the 
7H·GC triplet. 
 




In the major groove of DNA, pyrimidine bases are presented with only one hydrogen 
bonding site on their Hoogsteen face. Hence triplets formed with the pyrimidine bases 
of a target duplex, would form with low affinity and reduced selectivity.
112,165 Third 
strand recognition of cytosine and thymidine bases is therefore hard to achieve, 
restricting triplex formation to homopurine·homopyrimidine tracts. Described below are 
some of the strategies which have been employed for recognising pyrimidine 




The best combinations for recognising T·A and C·G base pairs using natural bases are 
G·TA (fig. 1.49) and T·CG (fig. 1.50).
166,167 However, these triplets are much less stable 
than T·AT and C
+·GC triplets as a result of local changes in the structure of the third 
strand, and multiple inversions are strongly destabilising; a 30-fold decrease in third 
strand affinity is associated with each addition of a pyrimidine residue.
168 The T·CG 
triplet can be accommodated within both parallel and antiparallel triplexes, while G·TA 
is limited to parallel structures. 
 
The hydrogen bond in the G·TA triplet is able to form between the 2-amino proton of 
the third strand guanine and the O-2 group of thymidine within the duplex. For this 
hydrogen bond to exist the guanine base must adopt an anti conformation. The 5-methyl 59 
 
group of thymine in the Watson-Crick base pair is thought to be involved in favourable 
stacking interactions with the third strand guanine, which increases the overall stability 
of the G·TA triplet. If a G·TA triplet has a 3’-adjacent T·AT triplet, an additional 
hydrogen bond can be formed between the unused 2-amino proton of guanine and the 
O-4 of the duplex thymine.
165,169 Hence, G·TA is more stable when flanked by T·AT 
rather than C
+·GC. In order to facilitate the structural changes associated when G is 
incorporated into a pyrimidine-rich TFO, a C
2’-endo  to C
3’-endo sugar pucker 
conversion occurs for the guanine nucleoside, this positions the sugar in a more 





Fig. 1.49: The structure of the G·TA triplet. 
 
Yoon et al.
167 first proposed the parallel triplet, T·CG (fig. 1.50). This triplet contains a 
single hydrogen bond between O-2 of thymine and the exocyclic amino group at C-4 of 
cytosine.
170 Up to three consecutive T·CG triplets can be accommodated within a DNA 
triplex, only if a triplex binding ligand is present, otherwise no footprint is evident.
168 
To minimise backbone distortions, the sugar conformation of thymidine adopts a C
3’-
endo pucker. The T·CG triplet can also be formed within a purine motif antiparallel 
triplex; this is due to the rotatable nature of thymine. The parallel and antiparallel forms 
of the T·CG triplet (fig. 1.50) are nearly superimposable; both possess anti 
conformation of the glycosidic bond, C
3’-endo sugar pucker and a slight 5’ tilt by the 









The abasic linker, 1,2-dideoxy-D-ribose (ϕ) has been incorporated into TFOs to study 
its binding affinity and triplet stabilities when bound to the base pairs A·T, G·C, T·A 
and C·G.
171 The abasic linker is not involved in base pairing or base stacking; it is 
simply present within the TFO to accommodate pyrimidine interruptions in the 
homopurine target strand. Within a pyrimidine third strand, the triplets ϕ·AT, ϕ·GC, 
ϕ·TA and ϕ·CG are significantly less stable than the triplets, T·AT, C
+·GC and G·TA. 
The decrease in binding produced by an abasic site is similar to that observed with 
imperfectly matched natural base triplets. There exists a preference for T·A and C·G 
over A·T and G·C base pairs across the abasic site. Abasic linkers generally destabilise 
a triplex due to loss of base stacking and hydrogen bonding, hence they are unlikely to 






A universal base analogue forms base pairs with each of the natural DNA/RNA bases, 
with little discrimination between them. Most of these analogues stabilise the DNA 
complex by stacking interactions; they are non-hydrogen bonding, hydrophobic, 
aromatic bases.
172 This approach unfortunately has not yielded stable triple helical 61 
 
structures; a loss of specificity is encountered at the universal base position as any base 
can be tolerated here. 
 
Nucleotide Analogues for Recognising Pyrimidine Interruptions: Targeting CG 
 
It has been found that in the antiparallel motif, only thymine shows substantial binding 
to C·G inversions
173 as mentioned above. O-4 of thymine is a major participant in the 
T·CG triplet (fig. 1.50). This was supported by the observation that a TFO containing 
pyridin-4-one deoxyribonucleoside (fig. 1.51) binds to the C·G inversion, while a TFO 
containing pyridine-2-one deoxyribonucleoside (fig. 1.51) does not. Binding of 
pyridine-4-one to C·G inversions is substantially weaker than T (by ~100-fold), hence, 
other interactions, such as hydrophobic and/or stacking effects are additionally 
involved. The importance of the O-4 group provided a starting point in the design of 





Fig. 1.51: The structures of the nucleosides pyrdin-2-one and pyridine-4-one. 
 
It has been reported that the nucleobase 5-methyl-pyrimidine-2-one, 
4HT (fig. 1.52) can 
recognise cytosine of the C·G base pair in the parallel motif as efficiently as T, without 
the compromise in selectivity that is inherent to thymine.
174 The 4-carbonyl and 3-NH 
groups of T are used in the recognition of adenine, by omitting these groups, the 
selectivity for C·G could be increased alongside abolishing the recognition of A. 
Although selectivity was improved, the affinity was at a lower level compared to a 
conventional pu:pu:py triplet. The affinity of third strand binding is tuneable by using 
third strand bases that show enhanced binding to the purine bases (2-aminopyridine for 
recognition of G) and/or by using triplex specific intercalators. Favourable electrostatic 
interactions between the 2-carbonyl group of 
4HT and the 2-CH group at the 5-position 62 
 
of cytosine may also contribute towards the stability of the 
4HT·CG triplet; this 
unconventional hydrogen bond has been mentioned previously in assisting in the 










In order to increase the strength of the 
4HT·CG triplet, Buchini et al.
175 modified the 
sugar with a 2’-O-aminoethyl side chain. This led to an increase in thermal stability of 
the triplex within which it was contained, of about 1.5 °C per modification. At pH 7.0, 
the stability of the 2’-modified triplex was higher than that of the triplex formed with 
the unmodified 
4HT. Duplexes containing up to three C·G interruptions were able to be 
targeted by the corresponding TFOs containing the 2’-modified 
4HT base analogue at pH 
6.5, however, with significantly reduced stability compared to the triplexes formed with 
the duplexes containing single C·G inversions. The formation of a triplex with five C·G 
inversions within the duplex was not observed, even by decreasing the pH to 5.5. 
However, on modifying the % pyrimidine content to 33 % (five C·G inversions) in the 
target duplex and using a TFO containing all 2’-O-aminoethyl ribonucleoside residues, 
Buchini et al.
176 were able to demonstrate recognition of a 15-mer DNA target duplex 
with high selectivity and a third strand affinity which is equal to, or greater than that of 
the two strands of the target duplex for one another. 
 
6-(3-aminopropyl)-7-methyl-3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one (
APP), a derivative 
of 
4HT has also been reported
112,177 to be selective for C·G interruptions in the parallel 
motif, and is ~ 4 °C more stable than T at pH 6.0. The 
APP·CG triplet (fig. 1.53) retains 
the H-bonding pattern of 
4HT·CG. The nucleobase introduces additional aromaticity, 63 
 
and the protonated primary propylamino group can potentially provide extra stability by 
hydrogen bonding with N-7 or O-6 of guanine, or by participating in electrostatic 








178 reported the use of the modified nucleobase, 2-aminopyrimidine (d2APm) 
in TFOs for the selective recognition of C·G inversions (fig. 1.54) in the parallel motif. 
d2APm has a pKa of 3.3, hence providing an unprotonated nitrogen at all physiological 
pH  which acts as the hydrogen bond acceptor site for the recognition of cytosine bases. 
At physiological pH, TFOs containing d2APm give higher triplex Tm values than the 
corresponding triplex formed with dC containing TFOs; ΔTm values between +3 and 




Fig. 1.54: The structure of the 2dAPm·CG triplet. 
 
Obika et al.
179 reported the efficient and selective recognition of the C·G base pair by a 
bridged nucleic acid consisting of the 2-pyridone nucleobase, P
B (fig. 1.55). As a result 64 
 
of the lack of a 3-N atom and a 4-carbonyl or amino group which are crucial for 
hydrogen bonding with other base pairs, P
B has reasonable selectivity for the C·G 
inversion. The 2’,4’-bridged sugar modification produces a great level of stabilisation in 




Fig. 1.55: The structure of the triplet P
B·CG. 
 
Nucleotide Analogues for Recognising Pyrimidine Interruptions: Targeting TA 
 
The presence of the 5-methyl group in thymine presents steric limitations when 
developing analogues to interact with this base. Eldrup et al.
180 developed the PNA 
analogue, 3-oxo-2,3-dihydropyridazine (E) (fig. 1.56) which is connected to the PNA 
backbone  via a β-alanine linker from the 6-position. This linker is long enough to 
potentially circumvent the 5-methyl group of thymine as was indicated by computer 
model building studies. Also, the lack of a hydrogen atom on N-1 greatly reduces any 
steric interference with this group. In comparison with guanine as an interacting base for 
the T·A base pair, the results indicated that the E-base binds stronger than guanine to 
thymine, with ΔTm of +5 °C per modification. The E-base selectively binds to thymine 
over cytosine with ΔTm of +7 °C per modification. However, in thermal stability studies 
conducted to compare uracil in the target in place of thymine, the E-base PNAs were 
shown to bind somewhat stronger to the uracil containing targets (ΔTm of ~ +3 °C per 
modification). This indicated that the design of the E base does not completely solve the 
steric clash problem associated when a nucleobase in a TFO binds to thymine in the 




Fig. 1.56: The structure of the E·TA triplet. 
 
It is thought that the reduced binding of the E-base to thymine compared to uracil was 
due to excessive flexibility of the backbone-nucleobase linker and therefore causing 
steric clash with the 5-methyl group of thymine. Olsen et al.
181,182 addressed the 
flexibility issue by synthesising a new analogue, E
ag (fig. 1.57) which contains a double 
bond. The double bond was introduced to restrict the flexibility in the linker and thereby 
reduce the loss of entropy associated when E incorporated TFOs undergo triplex 
formation. The double bond was additionally thought to yield enthalpic stabilisation 
through stacking interactions with neighbouring base pairs. However, the thermal 
stability results demonstrated that the overall triplex formed with E
ag base is less stable 
than when using the original E-base; ΔTm of -1.5 °C per modification. The recognition 
of uracil was different however; the E-base preferred binding to U over T, while the 
new base E
ag showed a minor preference to T compared to U, with ΔTm of  +0.5 °C per 
modification which suggested absence of significant steric clash between the E
ag-base 
and the 5-methyl group of thymine. In a comparison of the thermodynamic parameters 
of the two different bases, there was no significant difference; the entropy loss in 
particular, was very similar (ΔS° = -2037 KJmol
-1 for E
ag  vs  ΔS° = -2058 for E). 
Therefore, introduction of the more rigid E






Fig. 1.57: The structure of the E
ag·TA triplet. 
 
Nucleotide Analogues for Recognising Both Partners of the Base Pair: CG Recognition 
 
The non-natural deoxyribonucleoside 4-(3-benzamidophenyl)imidazole (D3) (fig. 1.58) 
developed and reported by Griffin et al.
183 was designed to recognise C·G or T·A 
Watson-Crick base pairs, by sterically matching their edges, selectively within the 
parallel triplex motif. It was anticipated that the N-3 within the imidazole moiety, would 
form a single hydrogen bond to the 4-amino group of cytosine, whilst the presence of 
two aromatic rings positioned in the major groove would enable additional stacking 
interactions. The two aromatic rings were connected by a single bond providing a 
rotational degree of freedom, which allowed the non-natural base to adopt a favourable 
geometry for interaction with pyrimidine·purine base pairs. It was found that D3 
recognises both bases within the pyrimidine·purine base pair with preference in 
comparison to the purine·pyrimidine base pairs, within the parallel triplex motif. 
Neighbouring base triplets influence the stabilities of D3·TA and D3·CG by nearest 
neighbour interactions; the triplets are most stable when flanked by T·AT triplets and 
less stable when C
+·GC triplet is on the 3’ side, hence introducing a limitation in that 
there is a need for consideration of the sequence composition of target sites. Another 








Fig. 1.58: The structure of the D3 non-natural deoxyribonucleoside.
183 
 
In fact, it was reported by Koshlap et al.
184 that D3 binds to the T·A and C·G base pairs 
via intercalation at YpA; the binding mode of D3 is unique in that it skips a potential 
base pair in order to intercalate. 
 
Other analogues that share the sequence-selective intercalation as a common binding 
mechanism to C·G and T·A base pairs are L1 and L2 (fig. 1.59) which have been 





Fig. 1.59: The structures of L1 and L2. 
 
Huang et al.
186 reported the recognition of both bases of the C·G inversion, by N-4 
modified cytosine analogues, in triplex formation studies. The side chains of N
4-(3-
acetamidopropyl)cytosine, and N
4-(3-aminopropyl)cytosine interact in a specific 
manner with the C·G base pair of a duplex. For both nucleosides, the 3-acetamide/3-
amino hydrogens, respectively, are able to hydrogen bond to the O-6 carbonyl of 
guanine of the target C·G base pair, as a result of sufficient side chain length. Triplex 
formation of N
4-(3-acetamidopropyl)cytosine is selective for the C·G base pair (Tm = 20 
°C); this modified nucleoside has no affinity for A·T or T·A (Tm < 0 °C); some affinity 
is observed when a G·C base pair was present (Tm = 8 °C). UV melting studies 
demonstrated that the triplet composed of this base with C·G is more stable than C·CG 






























Fig. 1.60: The structure of the triplet formed between N




The N-4(6-aminopyridinyl) derivative (fig. 1.61) has also been reported to form stable 
triplexes with DNA duplexes containing C·G base pair inversions.
187,188 Hydrophobic 
interactions between the pyridinyl ring of N
4-(6-aminopyridinyl)cytosine and 




Fig. 1.61: The structure of the triplet formed between N




Nucleotide Analogues for Recognising Both Partners of the Base Pair: TA Recognition 
 
A novel nucleobase, S (fig. 1.62), was reported by Guianvarc'h et al.
189 to effectively 
circumvent a T·A base pair interruption within a purine·pyrimidine duplex when 
incorporated into a pyrimidine-motif TFO. This nucleoside was achieved through an 
attempt to achieve better triplex stabilisation than the D3 monomer at pyrimidine·purine 
inversions. The S nucleobase consists of two unfused aromatic rings which are linked to 
2’-deoxyribose by an acetamide motif. Three hydrogen bonds are present in the S·TA 69 
 
triplet (fig. 1.62). Thermal denaturation experiments indicated that the Tm value of the 
triplex containing the S·TA triplet (Tm = 50 °C) was very close to those of perfect 
triplexes without any interruptions of the homopurine·homopyrimidine sequences (Tm 
(T·AT) = 51 °C).
189 There does however exist steric hindrance between the 5-methyl 
group of T in the oligopurine-rich target strand and the deoxyribose moiety of S, as was 
demonstrated by the increased Tm/thermal stability obtained by the triplex formed when 
T was replaced by U, featuring the S·UA triplet. Triplexes containing S are most stable 
when the S·TA triplet is flanked by two T·AT triplets, and the stability of the triplexes 
decrease as the number of adjacent C
+·GC triplets around the S·TA triplet is increased. 






Fig. 1.62: The structure of the S·TA triplet. 
 
B
t, a nucleobase analogue featuring a thiazolyl-benzimidazole system, is a derivative of 
the S base. It was anticipated by Guianvarc'h et al.
191 that this modified nucleobase 
would form three selective hydrogen bonds with a T·A inversion (fig. 1.63). B
t has an 
extended aromaticity of the benzimidazole ring, this design was based on the rationale 
that it would achieve greater rigidity of the base, which would hence better stabilise 
triplex formation. Hence, it was expected that B
t would exhibit more efficient triplex 
stabilising properties than S, as a result of the favourable contributing entropic factors. 
However, in contrast to theoretical prediction, thermal denaturation studies gave a Tm 
value for the triplex containing a B
t·TA triplet (Tm = 43 °C) to be lower than that for 
S·TA, and very close to that obtained for a triplex containing a G·TA triplet (Tm = 
45 °C). From these results, it was concluded that B
t did not involve three hydrogen 
bonds as was first thought, this was based on the results obtained for triplexes 70 
 
containing the G·TA triplet that contains only one hydrogen bond and a higher Tm. The 
B
t·TA triplet is thought to involve non-sequence specific interactions such as third 
strand stacking/intercalation. In addition, B
t induced only a moderate discrimination 
between the T·A and C·G base pairs, demonstrating non-specificity of the nucleobase, 
further indicating interactions involved with B








192 prepared the 2’-aminoethoxy derivative of the S nucleoside (SAE) (fig. 
1.64) and reported its incorporation into triplex forming oligonucleotides for recognition 
of T·A interruptions within a target oligopurine tract.
112,192 Biophysical studies indicated 
that SAE had a greater affinity for a single T·A interruption than either G, or S. In the 
presence of eight C
+·GC triplets, stable triplexes were formed at pH 6.0 at an 18-mer 
target site containing two T·A interruptions. In addition to producing stable triplexes at 
T·A interruptions, SAE and S also produce stable triplexes with other base pairs, in 







Fig. 1.64: The structure of the SAE·TA triplet. 
 
Craynest et al.
193 suggested the recognition of the T·A inversion by extended guanine 
analogues, N1, N2, N3 (fig. 1.65), derived from aminobenzimidazole (recognition of the 
thymine base) and thymine or 5-substituted uracil (for recognition of the adenine base) 




Fig. 1.65: The structures of the N1·TA triplet, N2·TA triplet and the N3·TA triplet. 
 
Another important factor to consider when designing antigene oligonucleotides is the 
accessibility of the target sequence within the chromatin structure of the cell nucleus. 
TFOs can encounter many obstacles en route to their genomic target sequence, these 
include; the nuclear chromatin structure/nucleosomal organization; as well as the 
potential trapping of the TFO by nuclear proteins which results in a decrease in the 





1.7  METHODS TO STUDY THE BIOPHYSICAL PROPERTIES OF 
NUCLEIC ACIDS 
 
1.7.1  Ultra-Violet (UV) Melting
195,196 
 
UV-melting analysis is a useful technique to study the biophysical properties of nucleic 
acids, and hence understand their role in biological function. 
 
According to the molecular structure of a substance, light of specific wavelengths can 
be selectively absorbed. The wavelength of light (λ) absorbed is inversely related to the 
energy difference (see eqn. 1) between two allowed states of the valency electrons of 
that particular molecule.  
E = ch/λ 
Equation 1: where c denotes the speed of light, h is Planck’s constant, and λ is the wavelength of light.. 
 
The incident photon of specific energy promotes an electron from the ground state to an 
excited state. The excited electrons eventually return to the ground state, by loss of 
energy via heat radiation.  
 
Spectrophotometry is a method used to quantitatively measure the absorbing species 
(chromophores), and is based on the Beer-Lambert’s Law. Lambert’s law states that ‘the 
fraction of light absorbed by a transparent medium (I/I0) is independent of the incident 
light intensity (which is dependent on the distance the light has had to travel), and each 
successive layer of the medium absorbs an equal fraction of the light passing through 
it’.
195 This is expressed mathematically as follows:   
    
I/I0 = 1/10
kl 
rearranges  to     I0/I = 10
kl 
                 log10(I0/I) = kl 
 
Where I0 is the intensity of the incident light, I is the intensity of transmitted light, l is 
the length of the light-path in the spectrophotometer cuvette, and k is a constant for the 
medium, which is deciphered by Beer’s law.  73 
 
Beer’s Law claims that ‘the amount of light absorbed is proportional to the number of 
molecules of the chromophore through which the light passes’.
195 So, the constant k is 
proportional to the concentration (c) of the chromophore: k = ɛc, where ɛ is the molar 
absorption coefficient, a property of the chromophore itself, it is numerically equal to 
the absorption of a molar (1 molL
-1) solution in a 1 cm light path. Hence, the expression 
of the combined Beer-Lambert law: 
 
log10 (I0/I) = ɛcl 
or A = ɛcl 
 
Where the term log10 (I0/I) is called the absorbance (A). 
 
The purine and pyrimidine nucleobase components of nucleic acids are chromophores; 
they absorb light energy of wavelength between 240-280 nm at neutral pH, with an 
absorption maximum (AbsMax) at around 260 nm. This corresponds to UV light. The 
absorption coefficient of each DNA nucleotide residue is constant; hence the absorption 
at 260 nm can be used to determine the nucleic acid concentration. The absorption of a 
native nucleic acid molecule (oligonucleotide strand) cannot however, be expressed as a 
sum of absorbances of all the component nucleotides. It is actually less than the sum of 
the absorptions of its constituent nucleotides. This is known as the hypochromism of 
nucleic acids,
197,198 and arises from the weak interactions (π-stacking) between the 
neighbouring residues.  
 
When nucleic acids are exposed to high temperatures, extreme pH, low ionic strength, 
or high concentration of urea, they can become denatured. The denaturation process 
involves unwinding of the double helix of the native DNA, the two strands separate as 
random coils, and weak interactions between neighbouring nucleotides are diminished. 
This results in an increase in the molar absorption coefficient, because single stranded 
DNA absorbs UV light more effectively than double stranded DNA, and thus the 
spectra of nucleic acids are associated with a sharp increase in the absorption of UV 
light.
197 Hence, the melting temperature of DNA can be determined by measuring the 
extent of the hyperchromic effect as a function of temperature. 
 74 
 
Stacked bases have a smaller absorption per base than unstacked bases; this is called 
hyperchromicity which is defined as: 
 
% hyperchromicity = 100 (Adenatured-Anative) 
   A native 
 
where Adenature and Anative are the absorbances at high and low temperature, respectively. 
The absorbance versus temperature profile is commonly referred to as a UV absorbance 
melting curve (fig. 1.66).  
 
 
Fig. 1.66: Typical experimental UV melting profile. 
 
As the temperature increases, the UV absorbance/% hyperchromicity increases, this is 
due to an increase in the ratio of molecules in the single stranded version versus native 
state. The melting temperature, Tm, is defined as the temperature at which half of the 
strands are in the native state and half are in the ‘random coil’ state. UV absorbance is a 
highly sensitive technique due to the high molar absorption of the bases.
195 
 
The formation of a DNA triple helix between a triplex-forming oligonucleotide (TFO) 
and double stranded DNA (dsDNA) is a very important process that can be potentially 
exploited for artificial regulation of gene expression. Analysis of DNA-triplex 75 
 
formation in vitro is the first step for any study regarding practical applications of triple 
helices. 
 
Triplex DNA thermal denaturation (fig. 1.67) is based on the hyperchromic effect upon 
the association of the third strand to its target DNA.  
 
Fig. 1.67: A typical UV melting curve showing the biphasic transition of a triplex melt. 
 
Here, the melting temperature (Tm) is the temperature where half of the triplex has 
dissociated into duplex plus third strand. The extinction coefficient of the triple helix is 
lower than that of the dissociated complex, so UV absorbance is increased upon heating 
(dissociation) of the triplex. This increase is cooperative and has a sharp transition that 
permits detection of the melting temperature with quite high precision.
196 
 
Both intrinsic factors such as length and sequence composition, and extrinsic factors 
such as ionic, pH and temperature, influence the stability of DNA triplexes and 
therefore the melting temperature (Tm). Hence these factors need to be taken account of 
when designing sequences and carrying out UV-melting analysis.  
 
Sequences with runs of 3 or more guanines should be avoided, since they tend to form 
G-quartet structures. It is also useful that sequences be designed to have Tm values 
Temperature (°C)





































between 20 °C and 75 °C, to allow upper and lower baselines to be adequately defined. 
With regards to hairpins, to minimize bimolecular self-complementary internal loop 
formation, it has been recommended that a sodium concentration of below 0.1 M is 
used. Self-complementary sequences have a high propensity to form hairpin structures 
that compete with the bimolecular reaction; hence these should also be avoided. If self-
complementary sequences are used, it is recommended that measurements be carried out 
in high salt conditions (e.g 1M NaCl) and to design the middle of the duplex to be G-C 
rich and the ends of the duplex to be A-T rich. The very ends of the duplexes, however, 
should be G-C whenever possible to minimize ‘end-fraying’ artefacts.
195 The ideal 
length of the target sequence is usually between 20 and 45 bp. It has been shown that 
sequences adjacent to a triple helix can influence its stability, hence to be able to fully 
analyse how well a TFO binds to its target, the target should ideally be put in its natural 
context. If the triple helix is very stable, a longer target will be preferred in order to 
clearly differentiate between the melting of the triplex and the dissociation of the 
duplex. The stability of a hairpin duplex can be increased substantially, by the covalent 
linkage of both the strands, the melting temperature is normally achieved at 
temperatures above 90 °C.
196 Choice of buffer with an appropriate pKa to give sufficient 
buffer capacity at the desired pH is important.
195 It is also important that samples are 
pure (typically > 95 % purity), free of dust and degassed, this enables the accurate 
determination of nucleic acid thermodynamics.
195 
 
UV-melting analysis is a widely used method for the determination of triple-helix 






Footprinting is a method used to assess the sequence selectivity of DNA-binding 
ligands, estimate their binding strengths (quantitative footprinting) as well as their 
association and dissociation rate constants for slow binding reactions. The ligands 
include polyamides, triplex-forming oligonucleotides and minor groove binding ligands.  
 
Footprinting utilises cleavage agents such as DNase I or hydroxyl radicals to digest 
double stranded DNA; these agents can modify and/or cleave the phosphodiester 
backbone.
200 When a ligand is bound at specific binding sites within a DNA fragment, 77 
 
digestion is locally inhibited, because the ligand protects the section of the backbone to 
which it is bound, from the cleavage agents.
199  Footprinting is therefore a protection 
assay (see fig. 1.68). 
 
 
Fig. 1.68: Schematic representation of the footprinting experiment. The asterisk represents where the 
DNA fragment is labelled. Here, DNase I is the cleavage agent used to digest the DNA under conditions 
of single-hit kinetics. The ligand protects the DNA fragment from cleavage at its binding site, this is 
evident as a ‘footprint’ when the products of digestion are resolved on a denaturing polyacrylamide gel.
199 
 
A double-stranded DNA fragment is radiolabelled with either 
32P or 
33P, at either the 3’-
end or 5’-end of one strand and is cut by a chemical or enzymatic cleavage agent, on 
average each DNA molecule is cleaved only once (i.e. single-hit kinetics). A random 
distribution of products is produced when the cleavage agent does not possess any 
sequence selectivity, and this can be resolved on a denaturing polyacrylamide gel. In the 
presence of a sequence selective ligand, the cleavage agents cannot cause damage to 
that particular region of the DNA as it is protected. The cleaved DNA strand fragments 
are resolved on the gel according to their length, with the longest fragments residing at 
the top. Sequences that include successive bases from the target site will be missing 
from the reaction and will therefore be evident as a gap (‘‘footprint’’) in the gel.
199  
 
Footprinting can be used to determine the exact binding sites for a ligand, by running 
control and ligand-treated digestion alongside suitable markers (e.g. a Maxam–Gilbert 
chemical sequencing reaction). In addition, a ligand’s binding affinity can be estimated 




DNase I and hydroxyl radicals are the most widely used cleavage reagents in 
footprinting studies. DNase I acts by introducing single strand nicks into the 
phosphodiester backbone, cleaving the O3’–P bond, it is a double-strand-specific 
endonuclease. Cleavage by DNaseI is activated by divalent cations; Mg
2+/Ca
2+ are the 
usual ions of choice (there is a 10-fold more efficiency with magnesium than calcium). 
The cleavage efficiency can be enhanced by manganese, and so it is usually included 
into the reaction buffers. EDTA is used to stop the reaction by chelating these ions. 
Hydroxyl radicals are highly reactive freely diffusible species, they are generated by the 
Fenton reaction between Fe
2+ and H2O2 (Eq. 2).
199  
 
         Fe
2+ + H2O2              Fe
3+ + ˙OH + OH
-    Eq.  2 
 
They are able to cleave close to the bound ligand as a result of their small size, and so 
they more accurately estimate the position of the ligand binding site. The cleavage 
reaction is performed in the presence of EDTA, which chelates the iron as 
[Fe(EDTA)]
2, this is to prevent direct interaction between Fe
2+ and the negatively 
charged DNA substrate. It is thought that the hydroxyl radicals attack at the C4’ or C1’ 




Footprinting substrates are typically restriction fragments that have been obtained from 
appropriate plasmids; they are usually 50–200 base pairs long. It is essential that the 
fragment should contain the preferred binding sites for the ligand under investigation.
199  
 
1.8  AIMS OF THIS PhD RESEARCH 
 
The aims of this PhD research was to firstly develop an efficient, and novel synthetic 
route to the non-naturally occurring cytidine analogue, 3-methyl-2-amino-5-(2’-deoxy-
β-D-ribofuranosyl)pyridine (
MeP). Although synthetic routes to this nucleoside have 
previously been reported
158,201,202 (as discussed above and in chapter 2), these 
procedures are lengthy and have significantly low overall yields. The potential benefits 
of developing a shorter route with greater overall yield include extensive usage of this 
monomer in various TFOs for the study of triplexes in the pyrimidine motif. In 
particular, TFOs that are covalently attached to crosslinking photoreagents such as 79 
 
psoralen (see section 1.9) can be used to target diseases that arise from point mutations, 
such as psoriasis (see section 1.10), for gene silencing therapeutics. The second aim of 
this research was to incorporate 
MeP and psoralen into TFOs that target part of the gfp 
(green fluorescent protein) coding sequence in transgenic Caenorhabditis elegans (C. 
elegans) (see section 1.11), and carry out in vitro biophysical analyses (UV melting, 
footprinting and gel retardation; see chapter 3). If these in vitro studies proved 
successful, in vivo studies would be carried out in the transgenic worms, to observe 
whether the expression of gfp had been inhibited. The third aim of this research was to 
incorporate 
MeP as cytidine equivalents into a TFO that target part of the SLO-1 
promoter gene in C. elegans, and compare the affinity of this TFO with TFOs 





MeCAE), at physiological pH. This was to determine, which 
cytidine analogue out of these four, when incorporated into TFOs, gives the better 
triplex stability, higher binding affinity, and least pH dependency. The final aim of this 
research was to incorporate 
MeP and psoralen into a TFO that targeted part of the UNC-
22 coding gene within C. elegans, and study the in vitro biophysical properties of the 
generated triplex. If the results for these analyses proved successful, this TFO will be 
used in vivo in C. elegans, to study the effect (if any) this TFO has on this organism, 
intracellularly.  
 
Overall, this research will contribute to the area of nucleic acid chemistry, and gene 
silencing therapeutics. Whether the results are positive, or negative, the information 
obtained will enable further research and the development of more robust techniques 





Psoralens are natural products found in plants. They are unique in their ability to freeze 
helical regions of DNA. The reaction of psoralen with DNA occurs by a two-step 
mechanism. The planar psoralen molecule first intercalates within a double helical 
region of DNA. Irradiation into an absorption band of the psoralen molecule controls its 
covalent addition to DNA. Covalent adducts form with the pyrimidine bases of nucleic 
acids, they are stable, but photoreversible. These covalent adducts can form at one or 80 
 
both ends of the psoralen molecule; they are therefore bifunctional photoreagents. In 
using this photoreaction  to form covalent crosslinks with base paired structures, 
psoralens can be used to stabilize DNA triplex structures.
203 
Psoralens are formed by the linear fusion of a furan ring with a coumarin; they are 
tricyclic compounds (fig. 1.39 in section 1.6.4.1.4).
203 
 
When psoralens undergo covalent photocycloaddition, they first intercalate into double-
stranded DNA and then react at either the furan or coumarin end, primarily with 
thymidine, under incident light of wavelength of 320-400 nm. A covalent interstrand 
crosslink forms when both ends of a psoralen molecule bind to thymidines in opposite 
strands of a DNA helix.
203  
 
A conformational change in the DNA backbone is required in order to accommodate a 
diadduct; this is a result of the dihedral angle that exists in a psoralen monoadduct 
between the plane of a psoralen molecule and the plane of a pyrimidine base. Provided 
that the photoreaction between psoralen and DNA is carried out under anoxygenic 
conditions, there is no additional degradation of DNA. During the photochemistry 
reaction, if singlet oxygen is produced, it will degrade all biological molecules with 
which it comes in contact.
203  
 
The degree of psoralen photoreaction/the ratio of monoaddition: crosslinkage can be 
controlled by light dose, by either selecting suitable wavelengths to induce the 
chemistry, or by controlling the duration of light delivered. The photoreaction between 
psoralen and pyrimidines can be reversed using short wavelength ultraviolet light 
(254 nm). The monoadduct and crosslink are chemically stable under various chemical 
conditions, hence, the photochemistry can be carried out under a wide variety of 
conditions including broad ranges of temperature and ionic strength, in the presence or 
absence of divalent cations, and even in some organic solvents.
203 
 
Psoralens are diverse photoreagents; they can be used clinically as 
photochemotherapeutic agents for the treatment of psoriasis (see section 1.10), vitiligo, 
and other skin disorders. Psoralens can also be used to inactivate viruses and other 
pathogens, by irreversible nucleic acid specific crosslinking. Psoralen photochemistry 81 
 
can also be used to inactivate viruses that cannot be otherwise inactivated for vaccine 
production.  
 
Psoralens are ideal probes for nucleic acid structure wherever long wave ultraviolet light 
can be delivered, this is because they are able to penetrate most biological structures and 
are not highly toxic to cells in the absence of actinic light. DNA structure has been 






Psoriasis is a chronic condition, for which the cause is unknown; however, there appears 
to be a genetic predisposition.
204 
 
Psoriasis is principally a T-cell (type of immune cell) mediated disease; epidermal 




The skin is made up of two main layers: the outer (epidermis) and lower (dermis). 
Epidermal cells reproduce at the lowest part of the epidermis and take 28 days to travel 
to the surface. In psoriasis, they divide at a faster rate due to the release of the T-cell 
derived cytokines, and move up to the surface in about four days. Since the cells are not 
fully mature and keratinised, they stick to each other and build up on the skin surface, 
resulting in a scaly appearance. The capillary loops in the dermis become dilated and 




Moderate to severe psoriasis has been successfully treated with a combination of 
psoralen and long-wave ultraviolet radiation (PUVA). Oral psoralen is taken two hours 
before exposure to UV radiation.
206 When the psoralen-treated skin is exposed to UVA 
light, the psoralen binds to thymidine in the DNA of the skin cells and slows DNA 
replication; it induces site-specific chromosomal breaks within the genome (fig. 1.69). 
The resultant DNA damage will stimulate the genomic repair system and thereby 







Fig. 1.69: TFO mediates site-specific delivery of the mutagen, psoralen (turquoise) linked to the 
oligonucleotide. The psoralen intercalates into the adjacent genomic DNA, and when activated by UVA 
irradiation, cross-links the three DNA strands, usually at adjacent thymines. Subsequent repair of the 
lesion via nucleotide excision repair results in base conversion.
75 
 
1.10  CAENORHABDITIS ELEGANS (C. elegans) 
 
The use of DNA triplexes for targeted modification of gene activity is poorly 
understood, and fundamental questions still need to be addressed.  
 
C. elegans are an ideal organism for the study of gene regulation and function. C. 
elegans is a eukaryote, an organism whose cells contain complex structures inside the 
membranes. The genetic material is carried within the nucleus. C. elegans share their 
cellular and molecular structures (membrane bound organelles; DNA complexed into 
chromatin and organized into discreet chromosomes, etc.) and control pathways with 
higher organisms. They are multicellular organisms, which means that they go through 
a complex developmental process, including embryogenesis, morphogenesis, and 
growth to an adult. Thus, biological information that is learnt from C. elegans may be 
directly applicable to more complex organisms, such as humans.
208 About 35 % of C. 
elegans genes have human homologs (a DNA or protein sequence that is similar to 
another DNA or protein sequence because the sequences have common ancestry). Many 
C. elegans genes can function similarly to mammalian genes. They have a fast and 
convenient life cycle. Embryogenesis occurs in approximately 12 hours, development to 
the adult stage occurs in 2.5 days, and the life span is 2-3 weeks.
209 The development of 83 
 
C. elegans is known in great detail because this tiny organism (1 mm in length) is 
transparent and the developmental pattern of all 959 of its somatic cells has been traced. 
 
Surprisingly, the use of TFOs to modulate gene activity in C. elegans has not as yet 
been studied.  
 
It has previously been demonstrated that dsRNA has the ability to act systematically 
within C. elegans, by using a ‘soaking’ method; dsRNA can get access into C.elegans, 
and cause gene interference simply by soaking the animals in solutions (1 to 5 µg/mL) 
of the dsRNA.
210 This gives confidence that TFOs can be designed to gain access to 
cells, following external application (soaking) to the whole animal. Although dsRNA 
and single stranded TFOs may use different uptake mechanisms, modifications can be 
introduced at the 2’-position to make these molecules more RNA-like, as well as 















































2.  SYNTHESIS OF THE C-NUCLEOSIDE CYTIDINE 






The ability to target specific sequences of DNA through oligonucleotide-based triple-
helix formation provides a potentially powerful tool for gene silencing.
75 However, 
within the pyrimidine motif, the requirement for the N3 protonation of the third strand 
cytosine (C
+) is one of the major limitations to using naturally existing bases in TFOs. 
Cytosine protonation requires low pH (due to the relatively low pKa of deoxycytidine, 
pKa = 4.3) to form the two Hoogsteen hydrogen bonds that are required for the 
formation of the C
+.GC triplet (fig. 2.7). For gene silencing, TFOs must be active at 
physiological pH, at which the C



























Fig. 2.1: Structure of the pyrimidine motif C
+.GC triplet. 
 
Several cytosine analogues have therefore been designed with the aim of forming 
Hoogsteen hydrogen bonds with guanines of GC base pairs at physiological pH. These 
have already been discussed in Chapter 1 (section 1.6.4.2). The cytosine analogue under 
investigation in this study is 2-amino-3-methyl-5-(2’-deoxy-β-D-ribofuranosyl)pyridine 
(


























211 and Bates et al.
212 have independently suggested the replacement of 
2’-deoxycytidine, by the structurally closely related C-nucleoside, 2-amino-5-(2’-



















Fig. 2.3: The structure of the cytosine-analogue C-nucleoside, P. 
 
For protonation to occur at higher pH, the basicity of the nucleobase needs to be 
increased. By removing the 2-oxo function, and replacing the N
1 (numbering taken from 
cytosine numbering system) in the pyrimidine ring of cytosine with a carbon, the pKa of 
P is increased to 5.93,
156 which is closer to physiological pH, whereas that for cytosine 
is 4.3. P is structurally analogous to dC; it can still form two Hoogsteen hydrogen bonds 
to guanine bases in duplex DNA. 
 
MeP was derived from P; this idea was based on the fact that 
MeC showed enhanced 
triplex stability results when incorporated into oligonucleotides as deoxycytidine (dC) 
equivalents. Although 
MeC has a slightly higher pKa (4.5) than cytosine, the enhanced 
triplex stability is thought to result from favourable hydrophobic effects generated by 
the formation of a spine of methyl groups in the major groove. This spine of methyl 
groups releases water molecules from the major groove, resulting in a favourable 
increase in the entropy of the surrounding solvent.
131,158 
MeP is ~ 0.4 pKa units more 89 
 
basic than P. In the triplex melting studies carried out by Hildbrand et al.
158, they 
observed no difference in triplex stability between triplexes formed with oligos 
containing P and those containing 
MeP. Hence, this result suggests that the binding of 
cytosine to GC base pairs is best improved by enhancing the degree of N-3 protonation 
(by increasing the pKa), rather than by attaching a hydrophobic methyl group to the C-5 
position.  
 
MeP is able to bind to the GC base pair by the formation of two hydrogen bonds (fig. 
2.4), without perturbing the hydrogen-bonding pattern in neighbouring triplets that are 




Fig. 2.4: Structure of the pyrimidine motif 
MeP.GC triplet. 
 
2.2  C-NUCLEOSIDES 
 
High-affinity, sequence-specific recognition of double-stranded DNA by TFOs is 
important in the selective control of gene expression. Therefore, the replacement of 
natural nucleosides with non-naturally occurring ones is a frequently applied approach. 
This enhances the properties, functions and uses of TFOs.  
 
C-glycosidically linked heteroaryl groups that are present in non-naturally occurring 
nucleosides have incorporated the essential properties of hydrogen bonding and 
stacking, that are required for DNA interaction. Extensive research has been carried out 
on the synthesis of C-nucleosides.
158,201,202,211,213-222  
The analogues should have β-configuration to mimic natural nucleosides. Therefore, a 
crucial consideration in the synthesis of these C-nucleosides is the stereoselective 90 
 
incorporation of the heteroaryl base.
158,211,220,221,223,224 For synthetic procedures that give 
anomeric mixtures of the C-nucleoside,
202 the separation of the anomers can be a very 
challenging step. 
 
2.2.1 Introduction  to  C-nucleosides 
 
C-nucleosides, are a group of nucleosides in which the sugar moiety is linked to a base 
through a carbon-carbon bond.
225 Some C-nucleosides are naturally occurring 
compounds, e.g., pseudouridine (Ψ), which is isolated from yeast t-RNA (certain t-
RNAs deficient in pseudouridine are incapable of participating in protein synthesis)
225; 




Fig. 2.3: Structures of the naturally occurring C-nucleosides Pseudouridine and Showdomycin. 
 
C-nucleosides are much more chemically stable than N-nucleosides (glycosidic linkage 
through a carbon-nitrogen bond), as they possess a hydrolytically and enzymatically 
more robust sugar-base bond.
226 Replacement of the N atom by C often dramatically 
changes the properties of the heterocyclic moiety, i.e. the tautomeric populations and 
acid/base properties of the heterocycles and functional groups (OH, NH2).
227C-
nucleosides have been shown to be suitable candidates for use as building blocks of 
oligonucleotides for use in gene therapy.
221 
 
2.2.2 Synthesis  of  C-Nucleosides
227 
 
Many strategies have been developed for the synthesis of C-nucleosides. They can be 
placed into 5 categories: (1) construction of an aglycon unit on a pre-synthesised 
carbohydrate moiety; (2) construction of a carbohydrate moiety on a pre-synthesised 91 
 
aglycon unit; (3) direct coupling of a carbohydrate moiety with a preformed aglycon 
unit; (4) modification of existing C-nucleosides; and (5) modifications of variable 
modules within the nucleosides. 
 
2.2.2.1 Construction of an Aglycon Unit on a Pre-Synthesised Carbohydrate Moiety 
 
2.2.2.1.1  Introduction of the Nitrile Group and subsequent reactions for 
heterocyclic construction 
 
This approach was the first to introduce a functional group at the anomeric position of 
the carbohydrate, creating a C-C linkage, followed by a multistep assembly of the 
heterocycles onto the C-glycosyl derivative.
225  
 
The synthesis reported by Adamo et al.
214 introduces a nitrile group at the anomeric 
position of a fully protected carbohydrate sugar, 3’,5’-dibenzoyl-1’-methoxy-2’-
deoxyribose 2, using trimethylsilyl cyanide, producing a C-C linkage (scheme. 2.1). A 
heterocyclic base was then constructed through numerous reactions starting at the nitrile 
group in compound 3 to finally give, following cyclisation of 6 with semithiocarbazide, 




Scheme. 2.1: Adamo et al.
214 synthesis to thiazidine nucleoside 7. Reagents and conditions: (i) DCM, 
1.3 eq TMSCN, 3.3 eq BF3Et2O, 0 °C, 1 ½ hrs, 71 %; (ii) dioxane/HCl, 70 °C, 6 hrs, 72 %; (iii) DCM, 
5 eq  α,α-dichloromethyl methyl ether, reflux, 4 hrs, 99 %; (iv) Et2O, 3 eq CH2N2; (v) HCl gas, 30 mins, 




2.2.2.1.2 Wittig-type  reactions 
 
Another approach to aglycon construction utilises Wittig-type chemistry, where reaction 
occurs between a phosphorus ylide and an aldehyde function on the carbohydrate 
moiety.  
 
The first Wittig-type strategy to produce a C-C linkage was demonstrated by Ohrui et 
al.
215, their development of this method involved the reaction of 2’,3’-O-isopropylidene-
5’-O-trityl-D-ribofuranose,  8 with carboxymethoxymethylenetriphenylphosphorane, 9 
(scheme. 2.2). The reaction initially gave 10 which following a Michael-type ring 
closure gave an anomeric mixture of the C-glycosides 11  α,β (with the more polar 
isomer dominating in a 3:1 ratio) in quantitative yield. The C-glycosides can then be 




Scheme. 2.2: Ohrui et al.
215 initial synthetic route towards β-D-ribofuranosyl C-glycosides. Reagents and 




Cycloaddition reactions utilising Diels-Alder
216, 1,3-dipolar
217 and radical species have 




2.2.2.2 Construction of a Carbohydrate Moiety upon an Aglycon Unit 
 
This strategy requires the construction of up to four stereogenic centres, hence it is not 
commonly used.
227 Very complex synthetic procedures are required in order to obtain 
the correct stereochemistry about each individual stereogenic centre in the carbohydrate 
moiety of the nucleosides. 
 
2.2.2.3 Direct Coupling of a Carbohydrate Moiety with a Preformed Aglycon Unit 
 
The most common strategy for the construction of C-nucleosides is the direct coupling 
of a protected sugar moiety with a preformed aglycon nucleophile. There are six 
different approaches, each involving nucleophilic attack at an electrophilic centre: (1) 
nucleophilic addition to ribofuranose derivatives; (2) nucleophilic addition to 1’,2’-
anhydrofuranoses; (3) coupling of nucleophiles with halogenoses; (4) nucleophilic 




2.2.2.3.1  Nucleophilic addition of organometallic reagents to ribofuranose 
derivatives 
 
The addition of organometallic reagents with ribofuranose derivatives leads to a mixture 
of diastereoisomeric diols. Subsequent cyclisation can then proceed in either a non-
diastereoselective fashion or diastereoselectively. Cyclisation can take place under 
acidic conditions,
219,228,229 as was demonstrated in the synthesis of Pseudouridine 
reported by Brown et al.









Scheme. 2.3: Synthesis of Pseudouridine and its α-anomer starting from 2’,3’,5’-tri-O-benzyl-D-ribose 
12. Reagents and conditions: (i) 2,4-di-(tert-butoxy)-5-lithiopyrimidine, -78 °C, THF, 64 %; (ii) HCl, 
MeOH, r.t, 24 hrs, 90 %; (iii) BCl3, -78 °C, DCM, 42 %.
219 
 
The diastereoisomeric diols can also undergo cyclisation under Mitsunobu conditions. 
This was demonstrated by both Reese et al.
202 in the synthesis of Pseudouridine and 2-
aminopyridine C-nucleosides, and by Harusawa et al.
220 in the synthesis of imidazole C-
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Scheme. 2.4: Harusawa et al.
220 Synthesis of 4(5)-(2’-deoxyribofuranosyl)imidazole starting from 2’-
deoxy-3’,5’-di-O-benzyl-D-ribose 14. Reagents and conditions: (i) 2.5 eq 2-(tert-butyldimethylsilyl)-N,N-
dimethylimidazole-1-sulfonamide, 2.5 eq 
nBuLi, -50 °C to r.t, THF, 99 %; (ii) 1.5 M HCl, reflux, 1 hr, 
92 %; (iii) 1.3 eq Bu3P, 1.3 eq TMAD, Benzene, r.t, 14 hrs; (iv) Ethyl chloroformate, pyridine, benzene, 




The synthetic procedure developed by Harusawa et al.
220 was β-stereocontrolled; the 
Mitsunobu reaction produced almost exclusively the desired β-anomer (α:β 1:5) from 
both the R- and S- epimers. This is thought to be accredited to the extra stabilisation 
from intramolecular hydrogen bonding between the nitrogen in the imidazole and 





Fig. 2.4: Mechanistic considerations on β-stereoselective glycosylation on the Mitsunobu cyclisation in 
the synthetic procedure developed by Harusawa et al.
220 
 
The procedure for the 2-aminopyridine C-nucleoside developed by Reese et al.
202 
however, produced an anomeric mixture (α:β 2:3) that required extra steps to enable 
separation (discussed in more detail in section 2.3.1). 
 
2.2.2.3.2  Nucleophilic addition to 1’,2’-anhydrofuranoses 
 
Singh  et al.
218 reported the cis-selective opening of β-configured epoxides in 1,2-
anhydroarabinose by arylaluminium reagents to give polyaromatic C-nucleosides. This 





































Scheme 2.5:  Cis-Selective opening of 1,2-Anhydroarabinose in the synthesis of β-Aryl C-nucleosides by 
Singh  et al.
218  Reagents and conditions: (i) Dimethyldioxirane, CH2Cl2 0 °C; (ii) 1-naphthyllithium, 
AlCl3, THF, CH2Cl2, 50 %; (iii) 1,1-Thiocarbonyl diimidazole, CH2Cl2, 90 %; (iv) 
Tris(trimethylsilyl)silane, Azobisisobutyronitrile, Toluene, 91 %; (v) Tetra-n-butylammonium fluoride, 
THF, 98 %.   
 
Starting with thymidine, the 3’,5’-disiloxane-protected glycal 20 was prepared in two 
steps,
230 which then underwent epoxidation selectively from the β-side. Cis opening of 
the epoxide with trinaphthylaluminium was performed followed by a two-step Barton 
deoxygenation.
231 Removal of the protecting groups at the 3’- and 5’- positions of the 
sugar ring using TBAF in THF afforded the C-nucleoside 25. 
 
2.2.2.3.3  Coupling of nucleophiles with halogenoses 
 
The oldest method for the construction of the C-glycoside bond was reported by Hurd et 
al.
232 They used Grignard reagents to couple with suitably protected α-glycosyl 
chlorides to give anomeric mixtures of the coupling product.  
 
Shapiro et al.
213 were the first to use this approach in the area of C-nucleosides. They 
reported the synthesis of Ψ-uridine (scheme. 2.6) by the coupling of 2,4-
dimethoxypyridine-5-lithium (lithiated 26 at the 5-position) with 2’,3’,5’-tri-O-benzoyl-
D-ribofuranosyl chloride (which was prepared from 1’-O-acetyl-2’,3’,5’-tri-O-benzoyl-
β-ribofuranosyl). The yields however, were very poor (2 % for the natural 
pseudouridine; 3.5 % for all four pseudouridine isomers), which was due to incomplete 
hydrolysis of 27. There was also uncertainty of configuration about the anomeric 





Scheme. 2.6: Synthesis of Pseudouridine by Shapiro et al.
213 Reagents and conditions: (i) n-Butyllithium, 













Fig. 2.5: Hoffer’s α-chlorosugar. 
 
Typically, reactions would involve the coupling of 30 with organometallic reagents 
based on various metals (lithium, zinc, mercury, cadmium, mercury). The yields tended 
to be low in general, and the α-anomer was the dominating product. To obtain the more 
desirable, naturally configured β-anomer, an additional step was normally required 
which involved acid-catalysed epimerisation of the α-anomer.
234,235  
 
Maeba  et al.
235 reported the use of trifluoroacetic acid in dichloromethane for the 
epimerisation of the α-anomer  31, to give the desired β-anomer  32 ( fig. 2.6). The 
combination of protonation of the oxygen within the furan ring, followed by protonation 
of the furanose ring oxygen by acid allows opening and re-closure to take place. Pure 32 
epimerises to 31 under the same conditions, however the rate of epimerisation is 











2.2.2.3.4  Nucleophilic addition to furanolactones 
 
The most frequently used strategy to synthetically construct the C-C glycosidic bond in 
C-nucleosides is via nucleophilic addition of organometallic reagents at low 
temperatures across a lactone functionality 33 (fig. 2.7). This leads to the formation of a 





Fig. 2.7: A general representation of nucleophilic addition of an organometallic reagent, R-X across a 
lactone 33 to give the C-nucleoside, 36. 
 
The hemiacetal is then reduced to the desired C-nucleoside. A popular reaction for the 
reduction of the hemiacetal involves initial deoxygenation by a Lewis acid (normally 
boron trifluoride diethyl etherate), followed by reduction of the oxonium ion 
intermediate, 35 (usually with triethylsilane) to give rise to the C-nucleoside, 36. The 
stereoselectivity normally depends on the nature of the aglycon unit and the protecting 
groups on the sugar moiety. However, the reduction of the oxonium ion using 
triethylsilane is known to proceed with good/excellent stereoselectivity giving rise to 





158,211 and Reese et al.
202 have utilised this method in their synthetic 
routes towards the 2-aminopyridine and 3-methyl-2-aminopyridine C-nucleosides. 
Hildbrand et al. essentially followed the syntheses of C-glycosides by Krohn et al.
223 
and Kraus et al.
236 
 
Alternatively the hemiacetals, 34 can be reduced to the corresponding diols and then 
cyclised under Mitsunobu conditions as was demonstrated by Reese et al.
202 in the 
synthetic route to 2-aminopyridine. Reduction in their case could be carried out by 
using either sodium borohydride, or lithium tri-sec-butyl borohydride  (L-selectride) 




Scheme. 2.7: Synthetic route towards 2-aminopyridine, using nucleophilic addition to a lactone moiety, 
used by Reese et al.
202  Reagents and conditions: (i) 2-[N,N-bis(4-methoxybenzyl)]aminopyridine-5-
lithium, THF, -78 °C, 4 hrs; (ii) NaBH4, MeOH, 0 °C, 2 hrs or L-Selectride, THF, -78 °C to r.t; (iii) 
DEAD or DIAD, Ph3P, THF, 0 °C, 3 hrs.  
 
The hemiacetal can be reduced stereoselectively as was reported by Hanessian et al.
237 
Reported within this literature was the stereo-controlled synthesis of both α- and β-
pseudouridine. Reduction of the hemiacetal, 41 with L-selectride in the presence of 
ZnCl2 gave the altro isomer, 42 which was then cyclised under Mitsunobu conditions to 
afford solely the β-anomer, 43 in 70 % yield (scheme. 2.8). Whereas reduction of the 
hemiacetal, 41 with L-selectride in the absence of ZnCl2 gave the allo isomer, 44 which 
was then cyclised under Mitsunobu conditions to give solely the α-anomer, 45 in 90 % 







Scheme. 2.8: Stereo-controlled synthesis of β-pseudouridine by Hanessian et al.
237  Reagents and 




Scheme. 2.9: Stereo-controlled synthesis of α-pseudouridine by Hanessian et al.
237  Reagents and 
conditions: (i) L-selectride, CH2Cl2/THF, -78 °C to r.t, 88 %; (ii) DIAD, Ph3P, THF, 90 %. 
 
2.2.2.3.5 Heck  Coupling 
 
The Heck reaction is highly regio- and stereoselective. When applied to glycals the 
general reaction proceeds via syn addition of the organopalladium species to the double 
bond followed by syn elimination of the hydridopalladium salt. The addition reaction is 
regiospecific owing to the strong polarization of the enol ether double bond; hence the 
new C-glycosidic bond is formed selectively at the carbon adjacent to the oxygen (the 
anomeric carbon). In addition, the initial attack occurs from the less sterically hindered 
face of the glycal ring. Therefore, the stereoselectivity can be controlled by the use of 
bulky or small groups at the 3’ position of the glycal, along with the use of bulky or 
small ligands in the palladium mediated cross coupling reaction. 
 
The Heck reaction has been important in the construction of the C-C glycosidic bond in 
the synthesis of 2’-deoxy-C-nucleosides; the first reported use of this method was by 
Arai et al.
238 More recently, Raboisson et al.
224 reported the stereocontrolled synthesis 




























Scheme. 2.10:  Stereocontrolled synthesis of the C-nucleoside,  48 starting with the glycal, 46 in a 
palladium mediated cross coupling reaction by Raboisson et al.
224 Reagents and conditions: (i) 8-Iodo-2-
methyl-4-(N-methyl-N-phenylamino)pyrazolo-[1,5-a]-1,3,5-triazine, bis(dibenzylideneacetone)Pd(0), 
Ph3As, TEA, 75%; (ii) sodium triacetoxyborohydride, 92%. 
 
A completely unprotected glycal, 46 was used. However, the use of the bulky palladium 
ligands (triphenylarsine) made the organopalladium reagent (obtained via 
transmetallation) a much hindered complex. Hence, it was probably not able to attack 
the olefinic glycal through the face bearing the 3’-hydroxyl group. Therefore, syn 
addition occurred on the sterically most open face of the glycal (α face) to give the 




Fig. 2.8: The keto-enol tautomerism equilibrium that exists between compound 49 and compound 47.  
 
This adduct is in tautomeric equilibrium with compound 47, which then undergoes 
stereospecific reduction on the 3’-keto group with sodium triacetoxyborohydride to 
yield the 2’-deoxyribofuranosyl C-nucleoside, 48. When K-selectride is used in place of 
the sodium triacetoxyborohydride reagent, reduction is permitted by the less sterically 
hindered face of the sugar ring, forming the stereoisomer of 48, where the 3’-hydroxyl 




2.2.2.3.6  Lewis-acid mediated electrophilic substitutions 
 
A simple route to C-nucleosides is via the coupling of a preformed carbohydrate moiety 
with a (hetero)aryl, the reaction is catalysed by a Lewis acid (Friedel-crafts type 
electrophilic substitution of the aromatic ring by the glycon). Although a simple 
process, it is associated with disadvantages of poor regioselectivity of the aglycon 
attack, and only modest stereoselectivity of the anomeric C-C bond formation. The 
nature of the aglycon controls the regioselectivty of the reaction.  The interaction of the 
protected carbohydrate, the aglycon unit and the Lewis acid affect the 
diastereoselectivity and yield. This Friedel-crafts method is applicable to only some 
electron-rich arenes and heterocycles, in some cases it is accompanied by double 
arylation of the sugar to form the undesired 1,1-diaryl alcohols. 
 
Kalvoda et al
222 used this approach in the initial steps for the synthesis of Showdomycin 
(scheme. 2.11). Condensation of benzylated bromose, 50 with 1,3,5-trimethoxybenzene 
in the presence of the Lewis–acid, zinc oxide gave the C-nucleoside, 51 with α:β C-C 




Scheme. 2.11: Initial steps for the synthesis of Showdomycin by Kalvoda et al.
222 using a Friedel-crafts- 
type approach. Reagents and conditions: (i) 1,3,5-trimethoxybenzene, ZnO, benzene, r.t. 
 
2.2.2.4 Modification of existing C-nucleosides 
 
This approach involves the modifications of the functional groups that exist within 
natural or synthetic C-nucleosides. The modifications are either on the aromatic or the 
sugar moiety, or both; the C-C glycosidic bond is kept intact during all transformations. 
 
This approach involves the stereoselective synthesis of a common intermediate that can, 
through further reactions give a vast range of C-nucleosides with different functions and 103 
 
properties. Walker et al.
239 reported the synthesis of a series of pyrazonic acid C-




Scheme. 2.12: Synthetic route developed by Walker et al.
239 to produce a variety of functionalised 
pyrazine C-nucleosides 55. Reagents and conditions: (i) LTMP, THF, -94 °C; (ii) Ethyl cyanoformate; 
(iii) BCl3, DCM, -70 °C; (iv) Various conditions.
239 
 
The fully protected pyrazine C-nucleoside,  52 was selectively lithiated by lithium 
2,2,6,6-tetramethylpiperidide (LTMP) at low temperature. Electrophilic esterification of 
the lithiated derivative using ethyl cyanoformate, and subsequent debenzylation gave 
the common intermediate, ethyl 3,5-dichloro-6-(β-D-ribofuranosyl)pyrazine-2-
carboxylate, 54. This was then subjected to a variety of reaction conditions to give a 
series of functionalised pyrazine C-nucleosides  55  which were tested for antiviral 
activity. 
 
There exist many synthetic procedures in which the stereoselectivity around the 
glycosidic bond is only moderate; hence controlled epimerisation is highly desirable. 
Jiang et al.
240,241 have reported efficient catalysed epimerisation (α→β and β→α) of C-
nucleosides containing electron donating groups using trifluoroacetic acid in 
dichloromethane. C-nucleosides containing electron withdrawing groups can undergo 
epimerisation in the presence of combination catalysts TFA-benzenesulfonic acid (5:1 
molar ratio), in dichloromethane. Trifluoroacetic acid is non-oxidative; benzenesulfonic 
acid on its own is oxidative and causes substrate decomposition and dehydration. For 
both procedures, no dehydration, carbonisation or decomposition was observed. Hence, 
for synthetic routes that have shown only moderate stereoselectivity for the desired 
anomer, these procedures are useful tools to improve the stereoselectivity and hence the 
overall yield of the C-nucleoside.  
 104 
 
2.2.2.5 Modular approaches to C-nucleoside synthesis 
 
This method can be used in the construction of libraries of C-nucleosides. Once the 
synthetic route to the underlying framework of the nucleoside has been developed, the 
modules that can be varied are: the sugar moiety, the aromatic aglycon and the 
functional groups that exist.  
 
Hocek et al.
242-246 have developed many modular approaches to C-nucleosides. They 
reported the synthesis of 4- and 3- substituted phenyl C-nucleosides based on a facile 
synthesis of protected 4- or 3- bromophenyl C-nucleoside intermediates respectively, 
and their standard palladium mediated cross-coupling reactions with diverse 





Scheme. 2.13: Hocek et al.
242 modular approach towards C-nucleosides. Reagents and conditions: (i) 1,4-
dibromobenzene, Mg, ethylene bromide, THF, 65 °C then r.t; (ii) Benzenesulfonic acid-TFA, DCM, 





Scheme. 2.14: Hocek et al.
242 modular approach towards C-nucleosides. Reagents and conditions: (i) 1,3-
dibromobenzene, Mg, ethylene bromide, THF, 65 °C then r.t; (ii) Benzenesulfonic acid-TFA, DCM, 
40 °C, 24 hrs; (iii) RM (Oragnometallic reagent), Pd(PPh3)4; (iv) NaOMe, MeOH, r.t, overnight. 
 105 
 
1,4- and 1,3-dibromobenzene were converted to mono-Grignard reagents and coupled 
separately with a fully protected halogenose, 30 (Hoffer’s α-chlorosugar).
233 The C-
nucleoside 56/60 was then subjected to a palladium mediated cross-coupling reaction 
with various organometallic reagents (either Suzuki-Miyaura conditions, Stille 
conditions for 56 only, or the use of organozinc or organoaluminium reagents for 56 
only), hence generating a large series of diverse novel C-nucleosides. 
 
In conclusion, there exists a variety of methods for the construction of C-nucleosides. 
These are constantly being improved and altered; there is no generally applicable and 
efficient method. The method of choice normally depends on the nature of the aglycon 
and the glycal. The majority of the earlier methods for synthesising C-nucleosides 
involve many steps and hence resulted in rather low yields and poor stereoselectivity.
221 
The approach of direct attachment of a pre-formed aglycon unit to an appropriate 
carbohydrate overcomes the drawbacks of these initial approaches and hence was the 
strategy of choice in developing the 3-methyl-2-aminopyridine C-nucleoside. However, 
as mentioned above, only a limited range of electron-rich aromatic moieties can be 
used. 
 




2.3.1 Background  work 
 
To date there have been three previously published reports relating to the synthesis of 
MeP (1). Hildbrand et al.
158 (scheme. 2.15) started with the readily available starting 
materials, ribonolactone, 64 (obtained in 3 steps from D-ribose) and the protected 2-
amino-5-bromo-3-methylpyridine, 66 (obtained in 1 step from 65 in scheme 2.15). The 
coupling step followed the syntheses of C-glycosides by Kraus et al.
236 and Krohn et 
al.
223; bromide-lithium exchange in 66 with n-BuLi at -75 °C and in situ reaction with 
lactone 64 afforded a mixture of hemiacetals, 67. The hemiacetals were subsequently 
reduced with excess triethylsilane, borontrifluoride diethyletherate to give exclusively 
the  β-configured nucleoside, 68; the exocyclic amino protection had been cleaved 
during the coupling reaction. Next, protection of the exocyclic amino function with 106 
 
phenoxyacetic anhydride, followed by debenzylation with Lewis acid boron tribromide 
provided the N-protected ribo-C-nucleoside, 70. The 3’ and 5’ hydroxyl groups were 
then selectively protected with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane 
(Markiewicz reagent) to afford 71. A two-step Barton
231 reaction followed; activation of 
the 2’-hydroxyl group with thiocarbonyl diimidazole followed by homolytic reductive 
cleavage of the C-O bond using azoisobutyronitrile (AIBN) and 
tris(trimethylsilyl)silane gave the 2’-deoxy fully protected nucleoside 73. Desilylation 
of  73  with tetra-n-butylammonium fluoride (TBAF) afforded the N-protected  C-
nucleoside, 74. This was then protected at the 5’ position of the sugar ring using 4,4’-
dimethoxytrityl chloride in pyridine, to give 75. This was then subsequently 
phosphitylated at the 3’ position using N,N-diisopropylchlorophosphoramidite and N,N-
diisopropylethylamine to afford the final N-protected monomer, 76. The free nucleoside 
MeP (1) was obtained by treatment of 74 with 25 % aqueous ammonia, in 63 % yield. 
 
The monomer 76 was obtained in 14 steps in ca. 9.7 % overall yield (starting from step 
(ii) in scheme. 2.15). The free nucleoside 
MeP (1) was obtained in 13 steps in ca. 10.1 % 
overall yield (starting from step (ii) in scheme. 2.15). The yield to obtain the protected 
base, 66 was 69 %.  Importantly, the glycosylation step (step (iii)) was β-stereoselective. 
 
One problem encountered by Hildbrand et al.
158, was the partial acetylation of the Pac 
protected amino groups in the residues of 
MeP during the capping step of automated 
oligonucleotide synthesis. These acetyl groups could be removed by methylamine 
treatment (40 % in water, 70 °C, 24 hrs). This initial problem was then overcome by the 
use of phenoxyacetic anhydride as the capping agent instead of acetic anhydride, which 
allowed for efficient post synthetic deprotection under standard ammonolysis conditions 
(25 % NH3, 55 °C, ~ 18 hrs).    
 
This C-nucleoside derivative was incorporated as protonated Cytidine equivalents in 
homopyrimidine oligonucleotides. Tm measurements indicated that over the pH range 
6.0-8.0, the oligonucleotides containing 
MeP had a higher affinity to double-stranded 
DNA than those containing 5-methylcytidine (
MeC). This increased stability was most 
pronounced above pH 7.0. 
MeP containing oligos displayed much lower pH dependence 
and sequence composition effects than those containing 
MeC, in the pH range 6.0-8.0; 




Scheme. 2.15: Hildbrand et al.
158 synthesis to N-protected 
MeP monomer, 76. Reagents and conditions: (i) 
1eq 1,2-bis[(dimethylamino)dimethylsiyl]ethane, 0.7 mol % ZnI2, 140 °C, 15 hrs, 69 %; (ii) 1.5 eq 66, 
1.5 eq n-BuLi, THF, -75 °C, 3 hrs, then 1 eq 64, -75 °C → 0 °C, 4 hrs; (iii) 5 eq Et3SiH, 5 eq BF3·Et2O, 
DCM, - 75 °C → r.t, overnight, 77 % over steps (ii) and (iii); (iv) 3 eq phenoxyacetic anhydride, pyridine, 
r.t, 4 ½ hrs, 67 %; (v) 0.4 M BBr3 in DCM, - 75 °C, 5 hrs, 81 %; (vi) 1.2 eq (Cl(iPr)2Si)2O, pyridine, r.t, 
4 hrs, 84 %; (vii) 2.5 eq (Im)2CS, DMF, 40 °C, 4 hrs, 74 %; (viii) 0.1 eq AIBN, 1.15 eq (Me3Si)3SiH, 
toluene, 80 °C, 5 hrs, 67 %; (ix) 2 eq Bu4NF, THF, r.t, 1 ½ hrs, 93 %; (x) 1.2 eq DMTCl, pyridine, r.t, 
3 ½-8 hrs, 74 %; (xi) 1.5 eq N,N-diisopropyl chlorophophoramidite, 3 eq N,N-diisopropylethylamine, 
THF, r.t, 2 hrs, 81 %. 
 
Reese et al.
202 reported an alternative synthetic route to 
MeP (1), which was based on the 
commercially available starting material 2’-deoxy-D-ribose, 77. This route has not been 
optimised. The fully protected 2’-deoxy lactol 78, which was obtained in three steps 
(scheme. 2.16), was coupled with the dibenzyl protected lithiated pyridine, 79 at low 
temperatures to give a mixture of diols, 80  (scheme. 2.17). Following Mitsunobu 
cyclisation, the fully protected C-nucleoside,  81 ( β:α 3:2) was obtained. The 
chromatographic separation of the α- and β-anomers did not prove feasible at this stage. 
Hence, the mixture had to be converted to the corresponding 3’,5’-diacetate mixture, 82, 
using a two-step process; first treatment with tetraethylammonium fluoride (TEAF) in 108 
 
acetonitrile solution followed by reaction with acetic anhydride in pyridine. The pure β- 
and α-anomers were isolated in this way after chromatographic separation, in 47 % and 
7 % yields respectively. Treatment of the β-diacetate, 82 with ammonium cerium (IV) 
nitrate (CAN) in wet acetonitrile, followed by treatment with alcoholic methylamine, 
gave the free nucleoside 




Scheme. 2.16: The synthetic route to the fully protected 2’-deoxy lactol 78 by Reese et al.
202 Reagents 
and conditions: (i) butan-2-ol, HCl, r.t, 25 mins; (ii) 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane, 


























































Scheme. 2.17: The synthetic route to 
MeP (1) by Reese, et al.
202 Reagents and conditions: (i) Benzyl 
bromide, NaH, N,N-dimethylacetamide (DMA), THF, 91 %; (ii) nBuLi, n-hexane, THF, -78 °C, 40 mins 
then 78, THF, -78 °C, 1 hr then -78 °C→0 °C over 3 hrs; (iii) DIAD, Ph3P, THF, 0 °C, 3 hrs, 41.5 % over 
steps (ii)-(iii); (iv) Et4NF, MeCN, r.t, 90 mins; (v) Ac2O, 1-methylimiazole, pyridine, r.t, 54 % over steps 
(iv)-(v); (vi) CAN, MeCN-H2O (98:2 v/v), r.t, 25 mins; (vii) MeNH2, EtOH, r.t, 16 hrs, 58 %.  
 
To summarise, the route provided by Reese et al. is a 10-step synthesis to the free β C-
nucleoside 
MeP (1) in ca. 7.8 % overall yield (starting from step (ii) in scheme. 2.17). 109 
 
The overall yield to obtain the fully protected lactol 78 was 90 %, and that to obtain the 
protected base 79 was 91 %. The Mitsunobu cyclisation reaction in this case was not 
strongly β-stereoselective. Reese et al. suggested that an anomeric mixture that was 
richer in the β-anomer could possibly be achieved by starting the coupling reaction of 
the glycal with aglycon, from the protected lactone, 83 (scheme. 2.18). Following this, 
reduction of the hydroxy-ketone, 84 with L-Selectride to give the diols 80, and then 




Scheme. 2.18: Alternative route suggested by Reese et al.
202 to improve the β:α ratio of compound 81. 
Reagents and conditions: (i) pyridinium chlorochromate, DCM, r.t, 16 hrs; (ii) nBuLi, n-hexane, THF,     
-78 °C, 40 mins then 83, THF, -78 °C, 1 hr then -78 °C→0 °C over 3 hrs; (iii) L-Selectride, THF, -
78 °C→r.t; (iv) DIAD, Ph3P, THF, 0 °C, 3 hrs. 
 
The third synthesis of 
MeP monomer was documented in the published thesis by Dr. V. 
E. C. Powers.
201 The synthetic scheme developed, essentially followed the work 
reported by Hildbrand et al.
158,211 via the perbenzylated lactone,
247,248 64 and protected 
2-amino-5-bromo-3-methylpyridine,  86  (scheme. 2.15). Unlike Hildbrand et al. 
however, the oxidation step of the perbenzylated lactol, 85 ( scheme. 2.21) did not 
follow that by Timpe et al.
249 This was due to the bad odorous dimethylsulfide being 
formed as a by-product, and the lactone product being contaminated. Instead, the 
oxidising agent, tetrapropylammonium perruthenate (TPAP) was used along with the 
oxidant N-methylmorpholine-N-oxide to yield the lactone in 85 %. Also, 2-amino-5-
bromo-3-methylpyridine was protected with paramethoxy benzyl groups to give 86 in 
78 % yield (scheme. 2.19), as did Reese et al.
202, rather than the disilyl protecting group 
which was used by Hildbrand et al.




Scheme. 2.19: Synthetic route to 5-Bromo-2-[N,N-bis(4-methoxybenzyl)]amino-3-methylpyridine,  86. 
Reagents and conditions: (i) 2.5 eq 4-methoxybenzyl chloride, 2.5 eq NaH, DMF, r.t, 6 hrs, 78 %.
202 
To summarise, the synthetic route developed by Dr. Powers
201 was an adaptation of the 
route developed by Hildbrand et al.
158; a 15-step scheme to the monomer 76, with 
overall yield of ca. 5.6 % (starting from the coupling of the lactone, 64 with the fully 
protected base, 86). The overall yield to obtain the perbenzylated lactone 64 was ca. 
81 % and that to obtain the fully protected base was 78 %. The lower overall yield of 
the synthesis compared to that obtained by Hildbrand et al.
158 was attributed to the low 
yield obtained during the tritylation reaction (39 %), due to the combination of impure 
staring material, and the 4,4’-dimethoxytrityl chloride reagent that was used had 
decomposed. 
 
2.3.2  The approaches towards 
MeP carried out during this PhD 
 




The initial aim of this research was to follow the synthetic route to 
MeP  monomer 
developed by Dr. Powers
201, which was based on the routes developed by Reese et al.
202 
and by Hildbrand et al.
158,211 The final monomer would be incorporated with 
trifluoroacetyl (TFA) protection instead of the phenoxyacetyl, at the exocyclic amino 
moiety. The reason for this was that, trifluoroacetamide is easily cleaved after 
oligonucleotide synthesis, under mildly basic conditions (methanolic ammonia, r.t)
250 in 
comparison to phenoxyacetamide which requires harsher conditions (25 % NH3, 55 °C, 
~ 18 hrs). Capping cannot be used during oligonucleotide synthesis, however. This is 
because the acetic anhydride used would replace the TFA group with an acetyl group 
which is too stable, and requires harsh conditions to be hydrolysed, as was observed by 
Hildbrand et al.
158 The 
MeP monomer would then be incorporated into various TFOs for 
biophysical analysis to investigate the interactions involved with duplex targets. 111 
 
Initially, the TFA group was planned to be incorporated towards the end of the synthetic 
scheme i.e. the phenoxyacetyl protection in 75 from scheme. 2.15 would be cleaved 
after step (x), followed by blocking the 3’ position of the sugar with trimethylsilyl and 
then protection of the exocyclic amino function with TFA. The TMS group would be 




Scheme. 2.20: Potential method to incorporate the required TFA protection into the 
MeP  monomer. 
Reagents and conditions: (i) 25 % NH3, 55 °C, 18 hrs; (ii) TMSCl, Pyridine, r.t; (iii) trifluoroacetic 
anhydride, DCM, 0 °C → r.t.
158,251 
 
By doing this the synthetic route would be increased to 18-steps. In an attempt to keep 
the route as short as possible, it was proposed that the TFA protecting group be added to 
68, post removal of the PMB groups (see scheme. 2.15). However, TFA has been 
known to be hydrolysed under either aqueous or mild acidic/basic conditions
252, hence 
in doing this two potential problems could arise; (i) the TFA group could potentially be 
cleaved by the highly acidic HBr generated during the debenzylation step using the 
Lewis acid BBr3 or; (ii) it could also potentially be cleaved under the highly basic 
conditions of TBAF during the removal of TiPDS. Problems were encountered mid-
scheme, and hence the exocyclic amino protecting group had to be altered (discussed in 
further detail below). 
 
The perbenzylated lactone, 64 was synthesised from D-ribose in three steps (scheme. 
2.21). The initial part of the first step
247,253 involved protection of the anomeric position 
with acidic methanol to form the methyl glycoside, necessary to keep the sugar moiety 
in the furanose conformation. The second part of this step was complete benzylation at 
the 2’-, 3’-, and 5’-positions of the anomeric mixture using benzyl bromide and sodium 
hydride; this one-pot reaction gave the fully protected glycoside, 85 in ca. 90 % yield. 
The methyl group in 85 was then hydrolysed under acidic conditions
201 to give the 
perbenzylated lactol 90 in ca. 66 % yield. Catalytic oxidation
248 of the lactol, using ca. 112 
 
5 mol% of TPAP and 1.6 equivalents N-methlymorpholine-N-oxide with 4 Å powdered 




Scheme. 2.21: Synthetic route to 2’,3’,5’-tri-O-benzyl-D-ribono-1,4-lactone, 64. Reagents and conditions: 
(i) 0.06 eq CH3COCl, MeOH, r.t, 24 hrs, then 6 eq Benzyl Bromide, 6 eq NaH, DMF, 15 hrs, 90 %; (iii) 
AcOH (80 % in water), c.H2SO4, reflux, 120 °C, 30 mins, 66 %; (iv) 5 mol % TPAP, 1.6 eq NMO, 4 Å 
powdered molecular sieves, DCM, 0 °C→r.t, 4 hrs, 83 %.
201,247,248,253 
 
The PMB protected 2-amino-5-bromo-3-methylpyridine,  86 ( scheme. 2.19) was 
afforded in ca. 76 % yield, using an excess of paramethoxybenzyl chloride and sodium 
hydride in DMF at room temperature.
202 
 
Bromide-lithium exchange in 86 with nBuLi at -78 °C and in situ reaction with lactone 
64 furnished a mixture of hemiacetals, 91 which were subsequently reduced with excess 
triethylsilane and boron trifluoride diethyletherate to give the fully protected β- 
configured nucleoside, 92 β (scheme. 2.22).
158 Acidic cleavage of the PMB groups with 
trifluoroacetic acid
201,202 provided 68 β in ca. 59 % over the three steps. The exocyclic 
amino function was then protected with trifluoroacetic anhydride yielding 93  β 
quantitatively.
254 This was then subjected to debenzylation under Lewis acid conditions 
of boron tribromide at low temperature.
158 Unfortunately, the trifluoroacetyl group 
cleaved along with the benzyl groups to afford the free ribo-C-nucleoside, 94 β (fig. 
2.9). The trifluoroacetyl group was thought to have been hydrolysed by the highly 
acidic HBr formed during this reaction. This route was unsatisfactory due to the 






Scheme. 2.22: Attempt 1 for the synthesis of 
MeP monomer. Reagents and conditions: (i) 1.03 eq nBuLi, 
THF, - 78 °C, 1 ½ hrs, then 1.07 eq 64, THF, - 78 °C→0°C, 1 hr; (ii) 6 eq Et3SiH, 6 eq BF3·Et2O, DCM, -
78 °C→r.t, 16 hrs; (iii) DCM, trifluoroacetic acid (1:1), 20 hrs, 59.1 % over steps (i)-(iii); (iv) 1.1 eq 











Fig. 2.9: The structure of the free ribo-C-nucleoside, 94 β. 
 
The nucleoside, 68 β was then protected at the exocyclic amino function using an excess 
of N,N-dimethylformamide dimethylacetal at elevated temperatures to afford 95 β in ca. 
68 % yield
255 (scheme. 2.23). Formamidine protection was introduced as it can be easily 
cleaved under mildly basic conditions (dilute ammonia
256), hence ideal for when 
incorporating the final monomer into an oligonucleotide. 95 β was then subjected to 
Lewis acid conditions of BBr3 at low temperatures,
158 keeping the formamidine 
protection intact, to give the N,N-protected ribo-C-nucleoside, 96 β in quantitative yield. 
The free nucleoside, 94 β obtained during attempt 1, was protected at the exocyclic 
amino function with formamidine protection which also gave 96 β in ca. 77 % yield.
255 
Protection of the 3’- and 5’-hydroxyl groups of 96  β with 1,1,3,3-
tetraisopropyldisiloxane in pyridine afforded 97 β in ca. 57 % yield. Activation of the 
2’- position of 97 β with thiocarbonyl diimidazole in ca. 55 % yield,
158 followed by 114 
 
Barton
231 homolytic reductive cleavage of the C-O bond provided 99 β. 99 β was not 
isolated as decomposition occurred during its purification by column chromatography, 
MS analysis on reaction completion confirmed the correct product. After many attempts 
to improve the yield obtained for the activation of the 2’- position, it remained 
comparatively low, in comparison to those obtained by Hildbrand et al.
158 (74 %) and 
Dr. Powers
201 (80 %), when using the Pac protection. It was therefore thought that the 
dimethylformamidine protection was causing this deficit in yield for this specific 
reaction. It was decided to go back to the original scheme proposed by Dr. Powers,
201 
and incorporate Pac protection onto the exocyclic amino function, even though the 
cleavage of this protecting group after oligonucleotide synthesis requires long duration 




Scheme. 2.23: Attempt 2 for the synthesis of a 
MeP monomer. Reagents and conditions: (i) 10 eq N,N-
dimethylformamide dimethylacetal, MeOH, 80 °C, 22 hrs, 67.8 %; (ii) 4.5 eq BBr3 in DCM, -78 °C→r.t, 
8 hrs, 99 %; (iii) 1.5 eq (Cl(iPr)2Si)2O, pyridine, 0 °C, 1 hr, r.t, 4 hrs, 57 %; (iv) 2.5 eq (Im)2CS, DMF, r.t, 
25 hrs, 55.3 %; (v) 0.2 eq AIBN, 1.15 eq (Me3Si)3SiH, toluene, r.t, 1 hr then 80 °C, 5 hrs.
158,201,255
   
 
Protection of the exocyclic amino function in 68  β  with phenoxyacetic anhydride 
afforded 69 β in ca. 80 % yield
158 (scheme. 2.24). Debenzylation under Lewis acid 
conditions
158 of BBr3 afforded the N-protected ribo-C-nucleoside, 70 β in ca. 22 % 
yield. This low yield was accounted for by the formation of the free ribo-C-nucleoside, 
94 β (fig. 2.9) which was isolated in ca. 46 % yield; 68 % overall yield for this step. The 115 
 
phenoxyacetyl (Pac) group is therefore also susceptible to cleavage under the Lewis 




Scheme. 2.24: Attempt  3 for the synthesis of a 
MeP monomer. Reagents and conditions: (i) 1.7 eq 
(Pac)2O, pyridine, r.t, 4 ½ hrs; 79.5 %; (ii) 4.6 eq BBr3, DCM, -78 °C, 4 hrs, MeOH, -78 °C→r.t, 
overnight, 68 %; (iii) 1.2 eq (Cl(iPr)2Si)2O, pyridine, 0 °C, 1 hr, r.t, 4 hrs, 60.7 %; (iv) 2.5 eq (Im)2CS, 




A popular method to deprotect benzyl ethers is through catalytic hydrogenolysis 
employing various Pd-catalysts. However, all three attempts outlined in scheme. 2.25 
proved unsuccessful (no reaction had occurred); (i) the first attempt to cleave the benzyl 
ethers and keeping the Pac group intact was by palladium catalysed hydrogenolysis 
using H2, Pd/C and sodium bicarbonate; (ii) the second attempt utilised H2, Pd/C in 




Scheme. 2.25: The unsuccessful attempts for debenzylation of 69  β keeping the Pac group intact. 
Reagents and conditions: (i) Pd-C, H2, NaHCO3, EtOH, r.t, 6 hrs; (i) Pd-C, H2 EtOH, r.t, 23 hrs; (i) Pd-C, 




As attempts to improve the debenzylation reaction had proved unsuccessful, both 70 β 
and 94 β were separately protected at the 3’- and 5’-positions, with 1,3-dichloro-1,1,3,3-
tetraisopropyldisiloxane
158 to give 71 β (ca. 61 % yield, see scheme. 2.24) and 100 β 
(ca. 50 %, see scheme. 2.26 ) respectively. 100 β was then protected selectively
259 at the 
exocyclic amino function in the presence of the free 2’-hydroxyl group, with 
pentafluorophenyl-2-phenoxyethanoate,  101 and provided 71  β in ca. 49 % yield 




Scheme. 2.26: The conversion of 94  β  to  71  β.  Reagents and conditions: (i) 1.2 eq (Cl(iPr)2Si)2O, 
pyridine, 0 °C, 1 ½ hrs, r.t, 4 hrs, 50.3 %; (ii) 1.5 eq Et3N, 1.2 eq pentafluorophenyl 2-phenoxyethanoate, 
101, CHCl3, 0 °C, 45 mins, r.t, 21 hrs, 49.2 %.
158,259 
 
71 β was then activated at the 2’ position with 1,1-thiocarbonyl diimidazole to afford 
72 β in ca. 55 % yield which is still comparatively low for reasons unknown. Following 
Barton
231 homolytic reductive cleavage of the C-O bond with AIBN and 
tris(trimethylsilyl)silane in toluene at elevated temperatures,
158 73 β was obtained in ca. 
61% yield (scheme. 2.24). Attempts were made to improve this deoxygenation reaction 
yield; (i) 1,1’-Azobis(cyclohexanecarbonitrile) has been reported
260 t o  b e  a  m o r e  
efficient primary radical initiator than AIBN and has been employed to initiate primary 
radical reactions for C-C bond formation - the attempt that utilised this in the 
deoxygenation reaction, was unsuccessful; (ii) varying quantities of the AIBN initiator, 
(0.5-2.0 equivalents); 73 β was obtained in ca. 61 % yield when using 2.0 eq AIBN; 0.5 
eq gave an incomplete reaction and yield of ca. 66 %; (iii) increasing the amount of 
tris(trimethylsilyl)silane from 1.15 eq stated in the literature
158 to 1.5 eq resulted in the 
breakdown of products and hence a yield of ca. 37 %. It was concluded that the best 
combination was 0.5 eq AIBN and 1.15 eq tris(trimethylsilyl)silane, due to recovering 
the starting material during purification. At this stage there was not enough of 73 β to 
proceed through the three remaining steps of the synthetic route to achieve a suitable 
quantity of the final monomer 76. The route would have to be repeated from the 117 
 
beginning on a large scale with the use of the highly expensive TiPDS reagent, which 
was only required for three steps in this scheme. This led to the development of an 
alternative, short, concise synthetic route to the 
MeP monomer, 76. 
 
A shorter synthetic route was then constructed, based essentially on the literature by 
Harusawa  et  al.
220,221 The route was based on the commercially available starting 
material, 2’-deoxy-D-ribose.  
 
The fully protected 2’-deoxy sugar, 102 was successfully synthesised (scheme. 2.27) in 
ca. 95 % yield in a two-step reaction.
253 The 2’-deoxy-D-ribose, 77 was first
247 
protected as its 1’-O-methyl glycoside using acidic methanol, followed by 
benzylation
253 of the 3’- and 5’-positions using an excess of benzyl bromide and sodium 
hydride in DMF. The 1’-methyl group was then hydrolysed under acidic conditions to 
give the perbenzylated 2’-deoxylactol 14. Initially this acidic hydrolysis was attempted 
with the method used for the D-ribose derivative;
249 80 % acetic acid solution with 
concentrated sulphuric acid at 120 °C for 35 mins,
201 however this resulted in cleavage 
of the benzyl groups. Instead a milder protocol
261,262 of solely 80 % acetic acid solution 




Scheme. 2.27: Route to the perbenzylated lactol, 14. Reagents and conditions: (i) 0.06 eq CH3COCl, 
MeOH, r.t, 1 hr, then 4 eq Benzyl Bromide, 4 eq NaH, DMF, 14 hrs, 95 %; (ii) AcOH (80 % in water), 
reflux, 120 °C, 2 hrs, 60 %.
253,261,262 
 
The reaction of 3’,5’-di-O-benzyl-2’-deoxy-D-ribose, 14 with excess lithium salt of bis-
protected 3-methyl-2-aminopyridine, 86 was initially carried out at the literature 
reported
220 temperature of – 50 °C, to afford the product 103 RS in only 18 % yield. In 
an attempt to improve the yield, the reaction was then attempted at – 78 °C, however, 
surprisingly no reaction occurred on this occasion. Reese et al.
202 reported the coupling 
reaction of the lactol, 78 and the lithium salt of the fully protected base, 79, at - 78 °C to 
afford product in 64.4 % yield. The coupling was also attempted via the use of a 118 
 
Grignard reagent; magnesium powder was added to a solution of 86 in THF and the 
reaction mixture was heated to reflux (70 °C). After two hours, the reaction displayed 
no progression, and the reaction mixture was then cooled to 0 °C for five hours, 
however, no reaction occurred. The coupling reaction was proving to be sensitive to 
temperature; finally, the optimum temperature for this reaction was discovered to be      
- 35 °C. The reaction afforded adduct 103 RS in ca. 92 % yield (scheme. 2.28). 
 
 
Scheme. 2.28: Coupling reaction between the perbenzylated lactol, 14 and the fully protected 2-amino-3-
methylpyridine, 86. Reagents and conditions: (i) 1.0 eq nBuLi, THF, - 35 °C, 30 mins, 0.4 eq 14 in THF, 
- 30 °C, 1 hr then r.t, 4 ½ hrs, 92 %. 
 
Initially, Mitsunobu cyclisation of 103  RS  with  N,N,N’,N’- 
tetramethylazodicarboxamide (TMAD) and tributylphosphine (Bu3P) in benzene as per 
Harusawa et al.
220 afforded the fully protected C-nucleosides 104 α,β in ca. 44.6 %. 
This mixture was separated into its pure anomers by column chromatography (α:β 1:2). 
The low yield was thought to be due to a possible competitive side reaction of TMAD 
taking place
263 (scheme. 2.29); where the betaine, 105 produced in the first step of the 
Mitsunobu reaction cyclises intramolecularly, and hence further reaction cannot occur. 
Tsunoda et al.
264 developed 1,6-dimethyl-1,5,7-hexahydro-1,4,6,7-tetrazocin-2,5-dione 
(DHTD) which is a cyclic Mitsunobu reagent designed to prevent the cyclisation side 
reaction of acyclic azodicarboxamides. Hence the Mitsunobu cyclisation of 103 RS was 
attempted using DHTD and Bu3P in benzene, to afford 104 α,β in ca. 54.3 % (α:β 2:3). 
DHTD is not a commercially available reagent however; hence in an attempt to improve 
the yield further with a commercially available reagent, the cyclisation of the diols was 
attempted using diisopropylazodicarboxylate (DIAD) and Bu3P in THF. This initially 
posed problems in the separation of the anomeric mixture 104 α,β from the reduced 
DIAD by-product, as they both had very similar polarities and the reduced form of 
DIAD is soluble in organic solvents (whereas the reduced TMAD and DHTD was 119 
 
insoluble in organic solvents and hence easily separated by filtration from the anomeric 
mixture). Many methods were attempted to remove the reduced DIAD by-product from 
the anomeric product according to reported procedures
265-267 either during the work-up 
or through precipitation using various solvents, however none of these proved 
successful. Dowex resin 50WX2-200 (H
+) was then employed as a method to trap the 
anomeric product to the resin and separate the by-product, once all by-product had been 
removed, the anomeric product could then be released from the acidic resin with 10 % 






















Scheme. 2.29: Competitive intramolecular side reaction of TMAD during Mitsunobu reactions.
263 
 
This successfully removed the by-product from the anomeric mixture 104  α,β. 
However, the acidic nature of the resin was enough to cause partial (affording the 
anomeric mixture, 106 α,β), and in some cases, complete cleavage of the PMB groups 
from the exocyclic amino moiety of the anomers (affording the anomeric mixture, 107 
α,β), resulting in a complex inseparable anomeric mixture. Attempts were then made to 
separate the anomers by introducing various groups to the exocyclic amino moiety, such 
as trifluoroacetyl, and dimethylformyl. It was thought that by introducing these 
protecting groups, they would impose a greater difference in the polarities of the 
respective α and β anomers. In both cases, separation of the anomers was proven to be 
impossible. Dowex resin activated with pyridinium ions was then utilised in an attempt 
to separate the reduced DIAD from the anomeric product 104 α,β and keeping the PMB 
groups intact. The resin however was too basic to trap the anomeric product, and hence 
no separation between product and by-product was achieved. Finally, the anomers were 
initially separated by column chromatography; this removed some of the reduced DIAD 
from each anomer. The by-product was then separated from the β anomer of 104, by 
submitting the mixture to the next step in the reaction sequence; the removal of the 120 
 
PMB groups under acidic conditions of trifluoroacetic acid giving 107 β. All traces of 
the reduced DIAD were successfully removed by column chromatography due to the 
large difference in the polarities of 107 β and the reduced DIAD. The β-anomer of 107 
was obtained in ca. 32 % over the two steps (i.e. 32 % for the Mitsunobu cyclisation, on 
the assumption that the acidic deprotection step was quantitative). It was now possible 
to obtain the pure anomers with separation from the by-product; however, there was an 
urgent need to improve the yield. Finally, the Mitsunobu cyclisation of 103 RS was 
achieved using TMAD and Bu3P in THF to yield 104 α,β in ca. 88.2 % yield (α:β 
2:3)
220 (scheme. 2.30).  
 
The configurations about the glycosidic bond were determined with the aid of 2-D H
1 
NMR, and NOE studies. It has been reported that the 2’-methylene protons of α- and β-
deoxyribonucleosides have been observed to exhibit characteristic patterns in the 
1H 
NMR.
268 The method can be used to determine the anomeric configuration of C-2’-
deoxyribonucleosides. The signals for the H
2’ protons of 104 β spanned a region of 
0.38 ppm, which is typical of the β-anomer. The larger region of 0.56 ppm for 104 α 
provides evidence for the α-configured anomer. Further to this, in the NOESY spectrum 
of the β-anomer, on the pre-irradiation of the H
4 proton and one of the two H
5’ protons 
separately, a net increase of integrated intensity was experienced by H
2’
β and not H
2’
α 
(fig. 2.10; see chapter 5, section 5.2 for further details). In the NOESY spectrum of the 
α-anomer, on the pre-irradiation of the H
4 proton,
 a net increase of integrated intensity 
was experienced by H
2’
α
 and not H
2’
β; on the pre-irradiation of the H
1’ proton, a net 
increase of integrated intensity was experienced by H
2’
β and not H
2’
α. Most importantly, 
on the pre-irradiation of one of the two H
5’ protons, a net increase of integrated intensity 
was experienced by H
1’, this provides solid evidence for the configuration about the C
1’ 
position in this anomer (fig. 2.11). In addition, it is apparent that H
2’
β resonates at a 
higher field/lower chemical shift than H
2’
α in the β-configured anomer, and that H
2’
α 
resonates at a higher field/lower chemical shift than H
2’
β in the α-configured anomer; 
Reese et al.
202 have also observed this in their NMR studies of the free nucleoside of 




Fig. 2.10: A diagrammatic illustration displaying the through space proton-proton interactions indicated 




Fig. 2.11: A diagrammatic illustration displaying through space proton-proton interactions indicated by 
the NOESY spectra of 104 α. 
 
Cleavage of the PMB groups in 104 β in trifluoroacetic acid: DCM 10:7 afforded 107 β 
in ca. 98.9 % yield.
202 Starting from 103 RS, 107 β was obtained in ca. 52.3 % over the 
two steps. When compared to the previous method using DIAD, TMAD gives the 
optimum yield and easier separation of the reduced azo-reagent, hence the method of 










Scheme. 2.30: Mitsunobu cyclisation of diols 103  RS  followed by cleavage of the PMB groups in 
104 α,β. Reagents and conditions: (i) 1.3 eq Bu3P, 1.3 eq TMAD, Benzene, 0 °C→r.t, 22 hrs, 44.6 %; (i) 
1.5 eq Bu3P, 1.5 eq DHTD, benzene, 0 °C→r.t, 25 hrs, 54.3 %; %; (i) 1.6 eq Bu3P, 1.6 eq DIAD, THF, 
0 °C→r.t, 5 ½ hrs, 32 %; (i) 1.6 eq Bu3P, 1.6 eq TMAD, THF, 0 °C→r.t, 6 ¼ hrs, 88.2 %; (ii) 
Trifluoroacetic acid: DCM 10:7, r.t, 5 ½ hrs, 98.9 %.
202,220,264     
 
The anomeric ratio obtained after Mitsunobu cyclisation was α:β 2:3, whereas in the 
case of Harusawa et al.
220 they obtained an almost exclusive β-configured mixture 
(discussed in more depth in section 2.2.3.3.1) with ratio of α:β 1:5 from a 1:1 mixture of 
the R and S epimers. They gave reasoning for this stereocontrolled synthesis of the C-
nucleoside to the extra stabilisation from the hydrogen bond formed between the 
nitrogen in the imidazole and the 5’-OH group in the sugar (see fig. 2.4) in the 
intermediate. They also encountered exclusively the β-configured nucleoside of the 
ribose derivative from a 1:1 mixture of the epimeric diols. This excellent β-
glycosylation was accounted for by the stabilisation from the hydrogen bonding 
described for the 2’-deoxy version, but also due to the presence of a 2’-O-benzyl 
substituent. The 2’-O-benzyl substituent creates unfavourable sterics and electronic 
repulsion from orbital overlap in the intermediate, when the orientation about the C-1’ 
is in the S-configuration.  Yokoyama  et al.
269 however reported the synthesis of C-
nucleosides having typical aromatic heterocycles as the base moiety, in which the 
coupling reaction of the lithiated salt with the ribofuranose derivative is stereoselective 
depending on the heteroatom within the heterocyclic base. The subsequent Mitsunobu 
cyclisation is then stereospecific; orientation of the glycosidic linkage is controlled by 
the C-1’ configuration of the substrate: one isomer affords the α-anomer and the other 
isomer the β-anomer. It therefore, may have been useful in the case studied here to 
separate the epimeric mixture of diols, 103  RS, and then proceed with Mitsunobu 
cyclisation separately to observe which epimer produced the α-anomer and which the β-123 
 
anomer. This would significantly simplify the Mistunobu cyclisation when using DIAD, 
and the removal of the reduced DIAD by-product by Dowex in the H
+ form would be 
successful. The mixture of cleavage products obtained would no longer be a problem as 
they would all have the same configuration about the C-1’. This may have also 
improved the yield of pure 104 β isolated. The product, 104 β isolated after Mitsunobu 
cyclisation using TMAD was separated by column chromatography from its α-anomer. 
Although separable, the anomers have very similar polarities within the system used for 
separation, hence resulting in some portion of the purified β-product being 
contaminated with its α-anomer. This portion could not be used to for successive steps 
of the scheme, therefore lowering the overall quantity of product obtained at the end of 
the synthesis. Alternatively, as mentioned in section 2.3.1, as Reese et al.
202 suggested; 
the β-stereoselectivity in this case may be increased if the synthesis was started with the 
perbenzylated 2’-deoxy lactone 108 ( scheme. 2.31)  and then reducing the putative 
intermediate hydroxy-ketone, 109 with L-Selectride before carrying out the Mitsunobu 
cyclisation reaction. Reese et al.
202 used this method in the synthesis of 2’-
deoxypseudouridine (scheme. 2.32). The protected lithiopyrimidine of 110 was reacted 
with the corresponding lactone, 83 at -100 °C to give the hydroxy-ketone, 111. This was 
then reduced with L-selectride, the diol mixture, 112 was then cyclised under 
Mitsunobu conditions to give almost entirely the β-anomer of the fully protected 2’-
deoxypseudouridine,  113. They suggested that if it is assumed that the Mitsunobu 
reaction was highly stereospecific, the L-selectride reduction was therefore highly 















































Scheme. 2.31: A potential route to improve the β-glycosylation of the Mitsunobu cyclisation reaction by 
starting the synthetic route with the lactone 108. Reagents and conditions: (i) 5 mol % TPAP, 1.6 eq 
NMO, 4 Å powdered molecular sieves, DCM, 0 °C→r.t; (ii) 1.03 eq nBuLi, THF, - 78 °C, then 1.07 eq 
108, THF, - 78 °C→0 °C; (iii) L-Selectride, THF, -78 °C→r.t; (iv) 1.6 eq Bu3P, 1.6 eq TMAD, THF, 
0 °C→r.t; (iv) 1.6 eq Bu3P, 1.6 eq DIAD, THF, 0 °C→r.t.




Scheme. 2.32: Synthesis of 2’-deoxypseudouridine, 113 by Reese et al.
202 Reagents and conditions: (i) 
1.05 eq nBuLi, THF, hexane, - 100 °C, 30 mins, then 0.8 eq lactone, 83, THF, -100 °C→-78 °C, 3 hrs; 
(ii) 1.2 eq L-Selectride, -78 °C→r.t; (iii) 1.2 eq DIAD, 1.2 eq Ph3P, THF, r.t, 3 hrs, 43.6 % over steps (i)-
(iii).    
 
Alternatively, the use of bulky protecting groups for the 3’- and 5’-hydroxyl groups 
such as tert-butyldiphenylsilyl (TBDPS) may influence the stereoselectivity in the 
coupling reaction of the lithiated base, 86 with the lactol, 14. Hence, producing a greater 125 
 
epimeric ratio bias towards the diol that cyclises under Mitsunobu conditions to give the 
β-anomer. 
 
The suggestions made above may be worth attempting in order to optimise the 
Mitsunobu cyclisation to give better β-glycosylation of compound 104, and hence 
improve the overall yield of the 
MeP monomer. 
 
The exocyclic amino moiety in 107 β was then protected with trifluoroacetic anhydride 
in pyridine at 0 °C to afford 114 β in ca. 70 % (scheme. 2.33).
251,254  Debenzylation by 
hydrogenolysis was then attempted by method of transfer hydrogen
254 using 20 % 
Pd(OH)2-C with cyclohexene in ethanol. This reaction unfortunately caused cleavage of 
the trifluoroacetyl group to afford 107  β. Trifluoroacetamide is an easily cleavable 
amide, previous citations
270 have reported solvolysis in methanol or ethanol at ambient 
temperature with the by-product being the corresponding alkyl trifluoroacetate. Ethyl 
acetate was then employed as the reaction solvent; however the reaction proceeded very 
slowly only to cleave the trifluoroacetyl group. The trifluroacetyl group was proving to 
be too labile to be used for protection of the exocyclic amino function, hence was 
discontinued for the use as a protecting group. It was also concluded that cyclohexene 




Scheme. 2.33: Reagents and conditions: (i) 1.5 eq trifluoroacetic anhydride, pyridine, 0 °C, r.t, 2 ½ hrs, 
70 %; (ii) 20 % Pd(OH)2-C, 1 eq cyclohexene, ethanol, 80 °C, 6 hrs; (ii) 20 % Pd(OH)2-C, 1 eq 
cyclohexene, ethyl acetate, 80 °C.
251,254 
 
In an examination to investigate if dimethylformyl could withstand the conditions of 
debenzylation, dimethylformamidine protection was introduced to the exocyclic amino 
moiety of 107 α,β using N,N-dimethylformamide dimethylacetal in methanol at elevated 
temperature
255 to give 115  α,β. This then underwent hydrogenolysis by transfer 
hydrogen using 20 % Pd(OH)2-C with formic acid in methanol,
271 although 126 
 
debenzylation had occurred as proven by NMR, the dimethylformamidine protection 
had also been cleaved, affording 1  α,β  (scheme. 2.34). The protecting group was 




Scheme. 2.34: Reagents and conditions: (i) 10 eq N,N-dimethylformamide dimethylacetal, MeOH, 70 °C, 
26 hrs; (ii) 20 % Pd(OH)2-C, formic acid, MeOH, 50 °C, 6 hrs.
255,271  
 
Various attempts for the successful cleavage of the benzyl groups in 107 were carried 
out. Using boron tribromide on each of the anomers, 107  α  and  107  β separately 
resulted in complete debenzylation (scheme. 2.35). However, in each case the presence 
of an anomeric mixture, 1 α,β was confirmed by NMR results, indicating ring opening 
and re-closing had occurred. The strong acidity of HBr formed during the reaction was 
thought to be the major cause of this ring-opening, however, it was also thought that 
extra stabilisation within the structure of the molecule was enabling this unfavourable 
ring opening reaction to proceed. The extra stabilisation was thought to come from 
either; (i) the lone pairs on the exocyclic amino function being able to conjugate through 
the nucleobase part of the nucleoside and hence acting essentially as a benzyl group (fig. 
2.12) or; (ii) the 2’-protons are acidic enough to be taken up by a bromide from the 
BBr3 Lewis acid (fig. 2.13). As a result of ring-opening in both cases, and the presence 
of the double bond at the C-1’ position, the C-4’ oxo-anion can attack from either face 
of the double bond (path a gives α, while path b gives β) producing an anomeric 
mixture. Interestingly in both cases, when starting from either α or β, the anomeric ratio 
is in favour of the β-anomer. Lewis acid mediated debenzylation using BBr3 is therefore 
not a suitable method to be used for the β-anomer. However, it could be a potential 
method to increase the β-product when starting with 107  α, providing a suitable 





Scheme. 2.35: Debenzylation of 107 β using BBr3 causing ring-opening and re-closing forming 1 α,β. 








Fig. 2.12: Mechanism 1 for the ring opening of the 2’-deoxy ribose sugar, where the base acts as a benzyl 



































































































Fig. 2.13: Mechanism 2 for the ring opening of the 2’-deoxy ribose sugar, where the acidic 2’-protons are 
taken up by a bromide from the BBr3 Lewis acid. 
 
A convenient method for debenzylation reported in the literatures
272-274 uses 
naphthalene-catalysed lithiation (scheme. 2.36), which is a mild, highly effective 
method for the reduction of benzyl ethers to the corresponding alcohols. This method 
was attempted for the removal of the benzyl groups from 107 β, however proved to be 




Scheme. 2.36: Reductive benzylation with Lithium Naphthalenide.
272 
 
Debenzylation of 107 β was found to occur under hydrogenolysis conditions, using 
Pd(OH)2-C as the catalyst, H2 gas, in ethanol, at elevated temperatures (scheme. 2.37). 
Reaction duration was very slow however (3 days for completion), and afforded 1 β in 
ca. 25 %. The low yield was accounted for by the formation of an open-chain product, 
116, which was the major product, it was formed by a competitive side reaction (see fig. 




Scheme. 2.37: Debenzylation of 107 β using palladium catalysed hydrogenation, to give the desired 
product 1 β and the open-chain side product, 116. Reagents and conditions: (i) Pd(OH)2-C, EtOH, H2, 
60 °C, 80 hrs, 25.1 %. 
 
It was thought that the ring oxygen becomes hydrogenated, along with hydrogenolysis 
of the 3’- and 5’- benzyl ethers, due to the 3-methyl-2-aminopyridine nucleobase acting 












































Fig. 2.14: Possible mechanism for the opening of the sugar ring in 107 β to form the open-chain side 
product 116. 
 
Using MS and NMR analyses, it was observed that the product, 1 β and intermediate, 
117 β (5’-OH, 3’-OBn) formed before the open-chain side product. On stopping the 
hydrogenolysis reaction once 107  β had completely disappeared, the product and 
intermediate could be isolated. The intermediate (117 β) was then put under palladium 130 
 
catalysed hydrogenolysis to allow for product formation. In doing this the overall yield 
to form 1 β was increased to ca. 31 %. This method however, was very time consuming; 
complete disappearance of 107 β was observed after > 21 hrs and that of 117 β was 
observed after 31 hrs. 
 
It was concluded at this stage that the absence of a 2’-modification on the sugar ring 
causes problems under the conditions used for the cleavage of the benzyl groups. 
Hydrogenolysis conditions however are the mildest; hence the debenzylation step was 
not optimised further at this stage.  
 
Protection of the exocyclic amino function in 1  β with N,N-dimethylformamide 
dimethylacetal in methanol at elevated temperatures gave 118 β in ca. 61 % yield.
255 
The 5’-position was then protected with 4,4’-dimethoxytrityl chloride in pyridine to 
afford  119  β in ca. 62.4 % yield
158.  119  β was then subjected to conventional 
phosphitylation conditions of 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and 













Scheme. 2.38: The synthetic route to 
MeP  monomer,  120  β.  Reagents and conditions: (i) 0.06 eq 
CH3COCl, MeOH, r.t, 1 hr, then 4 eq Benzyl Bromide, 4 eq NaH, DMF, 14 hrs, 95 %; (ii) AcOH (80 % 
in water), reflux, 120 °C, 2 hrs, 60 %; (iii) 2.5 eq 4-methoxybenzyl chloride, 2.5 eq NaH, DMF, r.t, 4 hrs 
35 mins, 76.4 %. (iv) 1.0 eq nBuLi, THF, - 35 °C, 30 mins, 0.4 eq 14 in THF, - 30 °C, 1 hr then r.t, 4 ½ 
hrs, 92 %; (v) 1.6 eq Bu3P, 1.6 eq TMAD, THF, 0 °C→r.t, 6 ¼ hrs, 88.2 %; (vi) Trifluoroacetic acid: 
DCM 10:7, r.t, 5 ½ hrs, 98.9 %; (vii) Pd(OH)2-C, EtOH, H2, 60 °C, 80 hrs, 31 %; (viii) Excess N,N-
dimethylformamide dimethylacetal, MeOH, 70 °C, 20 hrs, 61 %; (ix) 1.26 eq DMTCl, pyridine, r.t, 2 hrs 
20 mins, 62.4%; (x) 2 eq DIPEA, 1.3 eq 2-cyanoethyl-N,N-diisopropylchloro phosphoramidite, DCM, r.t, 
1 ¾ hrs, 79.1 %.
158,202,220,253,255,261,262,275 
 
To summarise, the synthetic route developed here (scheme. 2.38) essentially followed 
the works reported by Harusawa et al.
220, Hildbrand et al.
158, Reese et al.
202 and the 
published thesis of Dr Vicki Powers
201; a 10-step scheme towards 
MeP monomer, 120 β 
with overall yield of ca. 4.5 % starting from the coupling reaction (step (iv) in scheme. 
2.38). The free nucleoside, 
MeP, 1 β can be obtained in 7 steps with overall yield of ca. 
14.9 %. The overall yield to obtain the perbenzylated lactol, 14 was ca. 57 % and that to 
obtain the fully protected base, 86 was ca. 76.4 %. The step that pulled the overall yield 
to 120 β down was the low yielding debenzylation (step (vii) in scheme. 2.38), and this 
was accounted for by the formation of the open-chain side product, 116. It can be seen 
that when the overall yield to the free nucleoside, 
MeP  (14.9 %)  obtained  here  is 
compared to that obtained by Hildbrand et al.
158 (10.1 %) and Reese et al.
202 (7.8 %), it 
is the best route. The step that requires urgent optimisation is step (vii) in scheme. 2.38; 132 
 
the debenzylation. If this was optimised, the route would be an efficient, concise 
synthetic procedure to a very useful C-nucleoside and Cytidine-analogue.  
 
This C-nucleoside derivative was incorporated as protonated Cytidine equivalents in a 
homopyrimidine oligonucleotide. Footprinting studies indicated that the 
dimethylformamidine protecting group used for the exocyclic amino moiety had not 
undergone complete cleavage under standard oligonucleotide deprotection conditions 
(concentrated aqueous ammonia at room temperature for 24 hrs) (see chapter 3 for 
further details). Cleavage conditions for 118 β had been determined prior to this and the 
dimethylformamidine protection was shown to be completely removed in 90 % aqueous 
ammonia in ethanol at 55 °C for 10 hrs. Normally the conditions required for cleavage 
become milder when the nucleoside is incorporated within the oligo. However, this was 
not the case as proven by the footprinting results. Therefore, this protecting group was 
proving unsuitable to be used within oligos, especially those containing psoralen 
(discussed further in chapter 3); the search for a new exocyclic amino protecting group 
commenced. 
 
Initially, the aim was to provide the 
MeP monomer with trifluoroacetyl protection at the 
exocyclic position; although capping could not be used during oligonucleotide 
synthesis, the protecting group is very easily cleaved, as mentioned previously. The 
debenzylation step was also in urgent need to be optimised; a more readily cleavable 
protecting group for the 3’- and 5’-hydroxyl group such as paramethoxy benzyl, para-
nitrobenzyl, 2,4-dinitrobenzyl, 2,4-dimethoxybenzyl, benzhydryl etc may be necessary. 
The α-anomer obtained from scheme. 2.38 after step (v) was used for the initial tests and 
optimisations for the new scheme. This was to ensure that the β-anomer was not wasted 
on trial attempts. 
 
Paramethoxy benzyl protection could be used in place of the benzyl protection for the 
3’- and 5’- positions of the 2’-deoxyribose. Hence post Mitsunobu cyclisation, all 
protecting groups could potentially be removed in one step using trifluoroacetic acid in 
DCM. The 2’-deoxy-D-ribose, 77 was first protected as its 1’-O-methyl glycoside using 
acidic methanol, followed by paramethoxybenzylation of the 3’- and 5’-positions using 
an excess of benzyl bromide and sodium hydride in DMF and afforded 121 in ca. 98 % 
yield
202,247,253 (scheme. 2.39). Hydrolysis of the 1’-methyl group was then attempted 133 
 
under acidic conditions of 80 % acetic acid solution,
261,262 the reaction was thought to 
have unfortunately caused partial cleavage of the paramethoxybenzyl groups. Hence, 





Scheme. 2.39: Reagents and conditions: (i) 0.06 eq CH3COCl, MeOH, r.t, 3 hrs 20 mins, then 4 eq p-




Optimisation of the debenzylation step then commenced. Successful removal of the 
PMB groups within 104  α  under acidic conditions of trifluoroacetic acid in DCM 
afforded 107 α in ca. 89 % yield
202 (scheme. 2.40). It was thought that the addition of an 
electron-withdrawing group such as TFA to the exocyclic amino moiety in 107 α would 
prevent the 2-amino-3-methylpyridine ring acting as a benzyl group, and hence prevent 
sugar ring opening during conditions used for debenzylation. Trifluoroacetylation of the 
exocyclic amino function in 107 α was attempted using excess ethyl trifluoroacetate in 
methanol at 0 °C
276 which proved unsuccessful, this method was repeated in DMF 
however no progression was observed. Finally, trifluoroacetylation was successful using 
trifluoroacetic anhydride in pyridine




Scheme. 2.40: Reagents and conditions: (i) Trifluoroacetic acid: DCM 1:1, r.t, 4 ½ hrs, 89 %; (ii) 1.5 eq 
trifluoroacetic anhydride, pyridine, 0 °C→r.t, 2 ¾ hrs, 97 %.
202,251 
 
Debenzylation by hydrogenolysis was attempted with hydrogen gas, Pd(OH)2-C catalyst 
in ethanol at elevated temperatures (60 °C). However, after a total of 82 hrs reaction 
there was still starting material present, and it was thought to contain breakdown 
products. Successful cleavage of the benzyl groups was then achieved using boron 134 
 
trichloride in DCM at – 78 °C
277 (scheme. 2.41), ring opening had not occurred as was 
proven by NMR, however the TFA group had been cleaved. 1 α was afforded in ca. 








It is important to note that care had to be taken with this reaction, as prolonged reaction 
time was observed to cause ring-opening and re-closing forming an anomeric mixture. 
Also, the methanol added to quench the reaction mixture had to be in excess in order to 
efficiently terminate the reaction. It was observed that after 72 hrs, starting with 114 α 
the reaction gave 1 α,β in a 1:1 anomeric mixture in ca. 72 % yield. This would be 
useful in order to improve the yield of β-anomer, starting from the α-configured starting 
material, as mentioned previously when using boron tribromide, and needs to be 
investigated further. 
 
Attempts to protect the exocyclic amino moiety post debenzylation, with TFA using: (i) 
trifluoroacetic anhydride in pyridine
251; (ii) trifluoroacetic anhydride in the presence of 
potassium carbonate in dry 1,4-dioxane at 25 °C
278; (iii) ethyl trifluoroacetate, DMAP in 
pyridine, proved unsuccessful; the group was observed to be too labile as reported by 
Bellamy et al.
270 Attentions turned to the use of Fmoc (Fluorenylmethyloxycarbonyl) as 
a protecting group; it is readily cleaved under mild conditions with base (10 % 
piperidine in DMF).
254 The Fmoc group would therefore be appropriate for use in the 
end monomer, which will be incorporated into oligos and undergo standard 
oligonucleotide deprotection conditions. 
 
Initial attempts to selectively protect the exocyclic amino moiety of 1 α using N-(9-
Fluorenylmethoxycarbonyloxy) succinimide (Fmoc-OSu)
279,280 were not successful 
(scheme. 2.42). When the reaction was carried out with the more reactive Fmoc-Cl in 
pyridine, 122 α was isolated; the 5’-position of the sugar ring had become protected 135 
 
(scheme. 2.42). Hence indicating that the 5’-position required protection prior to Fmoc 




Scheme. 2.42: The failed attempts to protect the exocyclic amino moiety in 1 α with Fmoc protecting 
group. Reagents and conditions: (i) 2 eq NaHCO3, 1.1 eq Fmoc-OSu, 1,4-dioxane, 3 °C, 1 hr 50 mins, 
then r.t, 3 hrs, then 50 °C, 16 hrs; (i) 1.1eq, DIPEA, 1 eq Fmoc-OSu, pyridine, r.t, 1 hr 20 mins, then 
55 °C, 16 hrs; (ii) 5 eq Fmoc-Cl, pyridine, r.t, 7 hrs.
279,280 
 
Protection of the 3’- and 5’-positions of the sugar ring in 1 α was attempted using 
trimethylsilyl chloride (TMS-Cl) in pyridine; however no reaction occurred on this 




Scheme. 2.43: The failed attempt to protect the 3’ and 5’ positions in 1 α. Reagents and conditions: (i) 
15 eq TMS-Cl, pyridine, r.t, 7 hrs, then 45 °C, 17 hrs.  
 
The 5’-position was then tritylated with DMT-Cl in pyridine
158 to afford 123 α in a poor 
yield of ca. 23 %. Attempts were then made to protect the exocyclic amino moiety using 
Fmoc-Cl with DMAP in pyridine at room temperature
281, however these were 









It was apparent that in order to protect the exocyclic amino function, the 3’-position of 
the sugar ring required protection; this was successful using TMS-Cl in pyridine. 
Immediate Fmoc protection of the exocyclic amino moiety could then proceed using an 
excess of Fmoc-Cl, producing a mixture of mono- and bis-Fmoc protected nucleosides, 
124 α and 125 α respectively in ca. 49 % yield, with the majority as 125 α; 125 α was 
the product required (see scheme. 2.45 for the structures of the β equivalents). Many 
attempts were made to cleave the TMS group from the 3’-position; (i) pyridine, water, 
r.t; (ii) sat. NaHCO3, pyridine; (iii) MeOH, pyridine, K2CO3, 0 °C. Cleavage was not 
successful using the first 2 methods, cleavage occurred under conditions of (iii) 
however due to the potassium carbonate being highly basic, this resulted in additionally 
cleaving the Fmoc group. This is as far as optimisation went using the α-anomer. 
 
Successful cleavage of the 3’- and 5’-benzyl groups in 114  β  occurred without 
disruption of the sugar ring, using boron trichloride in DCM at -78 °C,
277 to afford 1 β 
in quantitative yield. Tritylation of the 5’-position of the sugar ring went in ca. 30 % 
yield
158 affording 123 β. This low yield was partly accounted for by the formation of bis 
DMT protected nucleoside, 126 β in ca. 10 %, due to a slight excess of reagent used. 
However, this overall yield of ca. 40 % is still relatively low for the tritylation reaction, 
and may be due to the exocyclic amino moiety being unprotected. The 3’-position of the 
sugar was protected with TMS using TMS-Cl in pyridine. The exocyclic amino moiety 
was then protected using Fmoc-Cl in pyridine, producing a mixture of products; mono-
Fmoc protected nucleoside with TMS at the 3’-position, 124  β, bis-Fmoc protected 
nucleoside with TMS at the 3’-position 125 β, mono-Fmoc protected nucleoside with no 
TMS at the 3’-position, 127 β and bis-Fmoc protected nucleoside with no TMS at the 
3’-position, 128 β. The overall yield for this reaction was ca. 82 %. It was thought that 
during purification by column chromatography, the TMS was partially cleaved. 
Cleavage of the TMS group in 125  β  was successful using an aqueous solution of 
potassium fluoride, affording 128  β  in  ca. 48.6 % yield. This average yield was 
accounted for by the formation of 127 β in ca. 27 % yield, hence overall yield of ca. 
76 %. Cleavage of the TMS group is relatively fast, if the reaction mixture is left for too 
long in aqueous potassium fluoride, the Fmoc groups start to cleave, and hence it was 
crucial to not prolong reaction duration. 128  β was then subjected to conventional 
phosphitylation conditions of 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and 137 
 






Scheme. 2.45: The optimised synthetic route to 
MeP  monomer,  129  β.  Reagents and conditions: (i) 
0.06 eq CH3COCl, MeOH, r.t, 1 hr, then 4 eq Benzyl Bromide, 4 eq NaH, DMF, 14 hrs, 95 %; (ii) AcOH 
(80 % in water), reflux, 120 °C, 2 hrs, 60 %; (iii) 2.5 eq 4-methoxybenzyl chloride, 2.5 eq NaH, DMF, r.t, 
4 ½  hrs, 76.4 %. (iv) 1.0 eq nBuLi, THF, - 35 °C, 30 mins, 0.4 eq 14 in THF, - 30 °C, 1 hr then r.t, 
4 ½ hrs, 92 %; (v) 1.6 eq Bu3P, 1.6 eq TMAD, THF, 0 °C→r.t, 6 ¼ hrs, 88.2 %; (vi) Trifluoroacetic acid: 
DCM 10:7, r.t, 5 ½ hrs, 98.9 %; (vii) 1.5 eq trifluoroacetic anhydride, pyridine, 0 °C, r.t, 2 ½ hrs, 70 %; 
(viii) 3 eq BCl3, DCM, -78 °C, 4 ½ hrs, MeOH, 4 °C, 15 ½ hrs, 98.5 %; (ix) 1.3 eq DMTCl, pyridine, r.t, 
2 hrs, 39.5 %; (x) 15 eq TMS-Cl, pyridine, 4 ½ hrs, 4 eq Fmoc-Cl, pyridine, 1 hr 20 mins, water, 1 hr, 
82.1 %; (xi) 2 eq KF (1.0M), pyridine, r.t, 1 ½ hrs, 76 %; (xii) 2 eq DIPEA, 1.3 eq 2-cyanoethyl-N,N-
diisopropylchloro phosphoramidite, DCM, r.t, 2 ½ hrs, 34 %.
158,202,220,251,253,261,262,275,277   
 
To summarise, the synthetic route developed here (scheme. 2.45) is now a 12-step 
scheme towards 
MeP monomer, 129 β with overall yield of ca. 2.8 % starting from the 
coupling reaction (step (iv)). The free nucleoside, 
MeP, 1 β can be obtained in 8 steps 
with overall yield of ca. 33.3 % starting from the coupling reaction. The overall yield to 
obtain the perbenzylated lactol, 14 was ca. 57 % and that to obtain the fully protected 
base, 86 was ca. 76.4 %. The steps that pulled the overall yield to 129 β down were the 138 
 
low yielding tritylation and phosphitylation (steps (ix) and (xii) respectively); these can 
be improved significantly.  
 
It had come to attention that the Fmoc group is an electron-withdrawing group itself and 
that it may be used in place of TFA in step (vii) during the debenzylation, and be able to 
withstand the Lewis acid conditions.  
 
Successful protection of the exocyclic amino moiety in 107 β with Fmoc-Cl, in pyridine 
and acetonitrile afforded the bis-Fmoc protected nucleoside, 130 β and the mono-Fmoc 
protected nucleoside, 131 β respectively, in overall yield of ca. 96 %. Debenzylation
277 
of 130 β with boron trichloride in DCM at - 78 °C afforded 132 β (with complete 
removal of the benzyl groups from both positions of the sugar ring) and 133 β (3’-O-
benzyl group present) in an overall yield of ca. 79 %. 133 β could then be put on for 
further debenzylation reaction to obtain more product, 132 β. Tritylation
158 at the 5’-
position of 132  β with DMT-Cl in pyridine afforded 128  β, however the use of 
triethylamine to neutralise the reaction mixture caused some cleavage of the Fmoc 
groups. Hence 123 β was also isolated; the overall yield for this reaction was ca. 87 %. 
This cleavage of the Fmoc groups can be avoided by eliminating the use of 
triethylamine; the reaction takes place in pyridine and this should be basic enough to 
mop up the hydrochloric acid produce during the phsphitylation. 123 β had to then 
undergo the TMS and Fmoc protection conditions described in scheme. 2.41. 128 β was 
then subjected to conventional phosphitylation conditions
275 of 2-cyanoethyl N,N-
diisopropylchlorophosphoramidite and N,N-diisopropylethylamine (Hünig’s base) in 













































































Scheme. 2.46: The further optimised synthetic route to 
MeP monomer, 129 β.
282 Reagents and conditions: 
(i) 0.06 eq CH3COCl, MeOH, r.t, 1 hr, then 4 eq Benzyl Bromide, 4 eq NaH, DMF, 14 hrs, 95 %; (ii) 
AcOH (80 % in water), reflux, 110 °C, 2 hrs, 60 %; (iii) 2.5 eq 4-methoxybenzyl chloride, 2.5 eq NaH, 
DMF, r.t, 4 ½ hrs, 76.4 %. (iv) 1.0 eq nBuLi, THF, - 35 °C, 30 mins, 0.4 eq 14 in THF, - 30 °C, 1 hr then 
r.t, 4 ½ hrs, 92 %; (v) 1.6 eq Bu3P, 1.6 eq TMAD, THF, 0 °C→r.t, 6 ¼ hrs, 88.2 %; (vi) Trifluoroacetic 
acid: DCM 10:7, r.t, 5 ½ hrs, 98.9 %; (vii) pyridine, 8 eq Fmoc-Cl, acetonitrile , 0 °C, r.t, 2 hrs, 95.9 %; 
(viii) 3 eq BCl3, DCM, -78 °C, 6 hrs, MeOH, 4 °C, 17 ½ hrs, 78.6 %; (ix) 1.3 eq DMTCl, pyridine, r.t, 3 
½ hrs, 86.8 %; (x) 2 eq DIPEA, 1.21 eq 2-cyanoethyl-N,N-diisopropylchloro phosphoramidite, DCM, r.t, 
2 hrs, 49.5 %.
158,202,220,251,253,261,262,275,277   
 
To summarise, this further optimised synthetic route (scheme. 2.46) is a 10-step scheme 
towards 
MeP monomer, 129 β with overall yield of ca. 15.6 % starting from the coupling 
reaction (step (iv)). The phosphitylation step has much room for improvement, and the 
work-up involved for the DMT protection does not need additional base for neutralising 
the reaction mixture. Introducing the Fmoc protection earlier in the synthetic route 
eliminates both the need to protect the exocyclic amino moiety with TFA protection, 
and the need to protect the 3’-position of the sugar ring with TMS. 
 
The 
MeP monomer, 129 β was incorporated into various oligonucleotides as protonated 






MeCAE)). Successful formation of the putative triplexes was confirmed 
in vitro using biophysical techniques; UV-melting, photo cross linking and footprinting 
studies, which is discussed further in Chapter 3.  
 
To conclude, a concise, efficient route (scheme. 2.46), which has been extensively 
optimised to provide a successfully protected 3-methyl-2-aminopyridine (
MeP) 
monomer, 129 β has been developed. To arrive at this efficient route many different 
approaches had to be explored and some eliminated. 
 
In the future, this synthetic route can be further optimised by attempting to improve β-
































Results and Discussion 
 















3.  BIOPHYSICAL AND BIOLOGICAL STUDIES 
 
3.1  INITIAL STUDIES ON 
MeP 
 
3.1.1  IN VITRO STUDIES 
 
3.1.1.1 FOOTPRINTING  STUDIES 
 
THE EFFECT OF 
MeP ON THE BINDING AFFINITY OF AN OLIGONUCLEOTIDE TO THE GFP 
CODING REGION IN C. ELEGANS AS A FUNCTION OF PH 
 
DNase I footprinting was initially carried out to examine whether 3-methyl-2-amino-5-
(2’-deoxy-β-D-ribofuranosyl)pyridine (
MeP), within the oligo OL1,  can achieve high 
affinity recognition of a target site (fig. 3.1), at pH values up to physiological pH. The 
target site was a 14-base oligopurine tract interrupted by a T; it is part of the gfp coding 
gene, and was obtained from a pUC19 clone.  
 




Fig. 3.1: Sequence of the 14 base-pair target site (underlined) within part of the gfp coding gene, which 
was obtained from a pUC19 clone. TFO OL1 shown in bold; where 5 = 
MeP; 6 = TAE; 7 = SME 
and Pso = Psoralen (see page 280-281 for the respective structures of these base analogues). 
 
Psoralen was also incorporated into the TFO. If footprinting of this oligo proved 
successful at physiological pH, the psoralen cross linking function could then be utilized 
to enhance triplex binding even further.  
 
A restriction fragment labelled at the 3’-end with 
32P, containing the target site (outlined 
in fig. 3.1) was incubated overnight at room temperature with increasing concentrations 
of the triple helix forming oligonucleotide OL1 (ranging from 0.03 µM to 10 µM). 
DNase I generated reaction products were separated by denaturing gel electrophoresis. 
After fixing, drying, and storing the gel overnight in a phosphorimager screen, it was 
scanned for visualisation of the footprint. 144 
 
Figs. 3.2 (A)-(C) show representative footprinting patterns at part of the gfp coding gene 
target site, obtained at pH 5.5, 6.2 and 7.0, respectively. It should be noted, that when 
cloning of the target sequence was carried out, the resultant clone contained a dimer of 
this sequence with the two copies oriented in opposite directions, enabling simultaneous 
visualisation of the purine (upper site) and pyrimidine (lower site) strands. There exists 
a third region which appears to be another footprint; it is in fact part of the second 










Fig. 3.2:  DNase I footprints for the interaction of TFO OL1 with the 14 base-pair target site within part 
of the gfp coding gene. Oligonucleotide concentrations (µM) are indicated at the top of each gel lane. The 
reactions were performed in: (A) 50mM sodium acetate, pH 5.5; (B) 10 mM PIPES, pH 6.2, containing 
50mM NaCl; and (C) 10 mM Tris-HCl, pH 7.0, containing 50 mM NaCl. Tracks labelled “GA” are 
sequencing lanes that are specific for purines (G + A); tracks labelled “CON” represent control where 
there was no TFO present. The solid bars indicate the location of the target site; ‘Pu’ indicates the purine-
rich strand of the target site; ‘Py’ indicates the pyrimidine-rich strand. 
 
At pH 5.5 it can be clearly seen that OL1  prevents DNase I activity down to a 
concentration of 1 µM (fig. 3.2). At pH 6.2 there exists some attenuation of the cleavage 
products for OL1 concentrations of 10 µM and 3 µM, suggesting that the TFO also 
reduces DNase I activity here as well. However, for the lower concentrations of OL1 at 146 
 
pH 6.2, and for all concentrations at pH 7.0, no footprint is evident, which was later 
accounted for (see below).  
 
Analysis by negative mode electrospray mass spectrometry showed that oligonucleotide 
OL1 contained the peak for the approximate expected mass of the oligo of 5199 (M-H)
-. 
However, peaks at 5228, 5256, 5284 etc, were also present, and these corresponded to 
(M-H + n(28))
- where n = 1,2,3 & 4. It was thought that this extra mass of 28 was 
originating from an extra carbonyl group being present. This was likely to have been 
derived from the N,N-dimethylformamidine protecting group used to protect the 
exocyclic amino function at the 2- position in 
MeP. It had been predicted that the 
dimethylformamidine group had undergone incomplete deprotection (hydrolysis) under 
standard oligonucleotide deprotection conditions (concentrated aqueous ammonia, room 
temperature, 24 hours). The formamide derivative is the intermediate formed during 
deprotection of the N,N-dimethylformamidine
283 ( fig. 3.3). For complete cleavage, 
harsher conditions were required. If temperatures had been elevated during the 
deprotection of OL1, the N,N-dimethylformamidine protecting group may have fully 
cleaved. However, heating the ammonia solution to high temperatures such as 55 °C 
would have caused degradation of the Psoralen that had been incorporated into the 
oligo.
284 Hence, these harsher conditions could not be employed during oligonucleotide 
deprotection. Therefore, the use of the formamidine group as protection for the 





Fig. 3.3: Mechanism illustrating the deprotection of the formamidine group affording the formamide 
intermediate and then further reaction producing the free amino product. 
 
As a result of this incomplete cleavage of the exocyclic amino protecting group, some 
insertions of the 
MeP within OL1 did not contain a free amino group at the 2-position of 
the pyridine ring; instead a formyl group was present. Therefore, the necessary 
Hoogsteen hydrogen bond, which is normally formed between the exocyclic 2-amino 
group of 
MeP in the third strand and the 6-oxo group in the guanine (fig. 3.4) of the 
purine strand of the duplex, that is required for triplex formation, is not able to form 
(fig. 3.5). It is also likely that the presence of the amide group at the 2-position has an 
electron withdrawing effect on the pyridine ring, and hence reducing the pKa of the N-1 
in the ring. This was thought to be the reason for the footprinting being observed only at 





MeP·GC triplet shown in 2-D view (left) and as a ball-and-stick 3-D view (right); where red 
represents oxygen, blue represents nitrogen, grey represents carbon, and white represents hydrogen. 
 
 
Fig. 3.5: The disrupted 
MeP·GC triplet that cannot form the appropriate Hoogsteen hydrogen bonds 
required for triplex formation, shown in 2-D view (left) and as a ball-and-stick 3-D view (right); where 
red represents oxygen, blue represents nitrogen, grey represents carbon, and white represents hydrogen. 
 
3.2  COMPARISON OF CYTOSINE-NUCLEOSIDE-ANALOGUES IN TFOS  
 
3.2.1  IN VITRO STUDIES 
 
3.2.1.1  UV-MELTING – THERMAL DENATURATION STUDIES 
 






MeCAE) were incorporated into TFOs OL3,  OL2 and OL5 
respectively (The analogues 
MePOMe and 
MeCAE were synthesised by Mr. C. Lou and 149 
 
Miss M. Shelbourne respectively, School of Chemistry, University of Southampton). 
These TFOs were used to study and compare the thermal stabilities of the triplexes 
formed with a hairpin duplex (OL9) containing the target sequence that is part of the 
SLO-1 promoter gene in C. elegans. The studies were carried out in buffers ranging 
from pH 6.2-8.0 with a buffer concentration of 10 mM Na2HPO4 and 200 mM NaCl. 
These conditions were chosen to approximate to the intracellular environment. The C-
analogues were compared to the control nucleoside, 5-methyldeoxycytidine (
MeC), 
which was incorporated into TFO OL4. Triplex melting data are summarised in table. 
3.1 and representative melting curves are depicted in figs. 3.7-3.11. A schematic 
representation of the sequences is shown in fig. 3.6. 
 
          5’-666665755666665-propyl-3’ 
5’-GACAAAAAGCGGAAAAAGTAG 
     H  
3’-CTGTTTTTCGCCTTTTTCATC 
 





OL3/OL2/OL5/OL4 respectively; 6 = TAE and 7 = SME (see page 280-281 for the respective 
structures of these base analogues). Within the hairpin duplex OL9; H = hexa (ethylene glycol) 
linker, the binding site for the TFO is underlined.   
 
In these experiments, for each C-analogue containing TFO, three insertions of the same 
modified C-analogues (5) interrupted by one 2’-O-methoxyethyl S base (SME, 7), for 
recognition of TA, were placed in the centre of a modified polypyrimidine (poly 2’-O-
aminoethyl thymidine, TAE, 6) TFO. There existed one terminal C-analogue at the 3’ 
end along with a propyl modification, in total there existed four C-analogues within 
each TFO. 
 
For the TFOs studied, the actual temperature for duplex dissociation occurs at a 
temperature higher than the range monitored. It can be seen that this melting transition 
is occurring however, due to the continual increase in absorbance/% hyperchromicity at 
high temperature. 
   
For the majority of the UV melting curves obtained for the TFOs studied in pH 6.2-8.0 
buffer (fig. 3.7-3.12), with the exception of OL3/
MeP and OL4/
MeC  at pH 6.2, a 
biphasic transition was displayed. This is typical of a triple helix; corresponding to an 150 
 
initial triplex to duplex plus TFO transition, followed by duplex dissociation. The 
melting curve which was obtained for OL3/
MeP and OL4/
MeC at pH 6.2, revealed a 
single transition, with Tm value of the triplex in the same range as that of the underlying 
duplex, demonstrating that these triplexes were highly stable at this pH.  
 
COMPARISON OF THE C-NUCLEOSIDE ANALOGUES AND 5-METHYL CYTOSINE 
 
  pH 6.2  pH 6.6  pH 7.0  pH 7.5  pH 8.0 
OL2/
 MePOMe  60.06/60.27  53.79/56.76  45.67/46.08  38.54/38.95  30.20/29.76 
OL3/
MeP  >70.0/>70.0  69.43/69.73  60.69/60.53  52.47/53.13  44.75/44.90 
OL4/
MeC  69.77/69.94  61.71/61.50  53.73/54.05  44.08/44.41  35.04/32.10 
OL5/
MeCAE  64.77/63.43  54.78/55.89  47.24/47.05  36.07/36.39  25.03/25.66 
 
Table. 3.1: UV triplex melting experiments for the C-analogues in 10 mM sodium phosphate, 200 mM 
NaCl, pH 6.2-8.0, using the standard melt program (20-80-20 °C at 0.5 °C/min). Temperature values for 
annealing (Ta) and those for melting (Tm) are given in that order respectively, and quoted in °C. 
Temperature values were determined from a single UV-melting cycle. 
 
  pH 6.2  pH 6.6  pH 7.0  pH 7.5  pH 8.0 
OL2/
 MePOMe  0.21  2.97  0.41  0.41  0.44 
OL3/
MeP  0.00  0.30  0.16  0.66  0.25 
OL4/
MeC  0.17  0.21  0.32  0.33  2.94 
OL5/
MeCAE  1.34  1.11  0.19  0.32  0.63 
 
Table. 3.2: Hysteresis (the difference between the melting (Tm) and annealing temperatures (Ta)) 
observed, in °C. 
 151 
 






























































MeCAE at pH 6.2.  
 
























































MeCAE at pH 6.6. 152 
 






















































MeCAE at pH 7.0. 
 






















































MeCAE at pH 7.5. 153 
 





























































MeCAE at pH 8.0. 
 











































Fig. 3.12: UV-melting curves and the first derivatives for the triplex formed between OL3/
MeP and OL9 
hairpin duplex at pH 6.2-8.0. 154 
 
From the data in table. 3.1, it can be observed that in many cases, the thermal 
dissociation temperatures (Tm) are higher than the association/annealing (Ta) 
temperatures. From the data presented in table. 3.2, in general, hysteresis is dependent 
on pH within the range pH 6.2-8.0. Overall, as the pH increases, so does the hysteresis 
(there exists a few results which do not follow the trend). For all the oligos studied, at 
pH 6.2, with the exception of OL5/
MeCAE, the degree of hysteresis encountered is at its 
lowest. The heating and cooling curves for OL3/
MeP are more or less superimposed at 
pH 6.2. 
 
From the data in table. 3.1, it appears that at all pH, OL3  in which all 
MeC were 
replaced by the C-nucleoside 
MeP,  shows an increase in Tm  relative to OL4/
MeC, 
containing 
MeC. The increase in stability is most pronounced above pH 7.0. The average 
increase in Tm/modification for 
MeP is 2.18 °C at pH 7.5, and 3.2 °C at pH 8.0, relative 
to 
MeC. The results clearly demonstrate that, in the pH range 6.2-8.0, within the TFO 
sequence under examination,  the presence of 
MeP  had a positive effect on triplex 
stability. From the oligos studied here, at all pH, OL3/
MeP gives the highest triplex 
melting temperatures. Hence, by replacing 
MeC in a TFO with 
MeP, which is ~ 2 pKa 
units more basic than 
MeC, results in an enhanced affinity to a double stranded DNA 
target, over the pH range 6.2-8.0.
  
 
The results also conclude that the presence of either a 2’-O-methyl or 2’-O-aminoethyl 
modification is ineffective in enhancing triplex stability, they are actually destabilising, 
as reported previously by Hildbrand et al.
158 (discussed further below). The decrease in 
stability for OL2, containing 
MePOMe, when compared to OL4 containing 
MeC, is most 
pronounced at pH 6.2; the average decrease in Tm/modification is 2.4 °C. Whereas, the 
decrease in stability for OL5, containing 
MeCAE, when compared to OL4/
MeC, is most 
pronounced above pH 7.0; the average decrease in Tm/modification is 2.01 °C at pH 7.5. 
 
This is contrary to the results reported by R. W. Roberts and D. M. Crothers.
285 They 
state that RNA third strands have been recognised to form more stable pyrimidine 
triplexes than the corresponding DNA third strands; this observed variability must lie in 




MeCAE contain Cytosine analogues in which their sugar resembles an RNA-like 
sugar conformation.  155 
 
For all pH buffers 6.2-8.0, the general trend observed in terms of thermal triplex 







It was expected that the thermal stability of OL3/
MeP would be greater than that of 
OL4/
MeC, which is displayed in the results. However, it was also expected that the trend 







A DNA single strand alone usually adopts a C
2’-endo conformation. NMR studies
287,288 
and polynucleotide fibre diffraction analyses
289 of DNA triplexes show that the sugars 




MePOMe was designed to improve the effectiveness and 
strength of binding of the TFO in which it was incorporated, in comparison to the deoxy 
version. This 2’-OMe ribose modification has been reported
286 to impart a C
3’-endo 
conformation, which is optimal for triplex formation by pyrimidine oligonucleotides, 
imposing a lower degree of distortion on the underlying duplex than third strands 
containing deoxyribose based nucleosides. This has the salutary effect of reducing some 
of the entropic barriers to triplex formation.
286 The methoxy groups enhance the rigidity 
of the triple stranded structure,
65 and van der Waals interactions exist between the 
methyl groups and the i-1 purine residues in the duplex.
286  
 
The results obtained in this study agree to some extent with that reported by Hildbrand 
et al.
158 In comparison to the deoxy nucleoside, 
MeP, the ribose nucleoside, 
MePOMe does 
not enhance triplex stability. The TFO sequence studied by Hildbrand et al. contained 
five 
MePOMe, and for conditions above pH 6.5, no affinity to the target duplex was 
observed. For the TFO sequence containing OL2/
MePOMe, affinity is observed above pH 




MeC. The difference between the two studies; in this case the TFO under 
investigation contains a uniform ribose backbone, whereas the TFOs studied by 
Hildbrand et al.
158 had a heterogeneous backbone composition (composed of both 2’-
deoxy and 2’-O-methyl ribose units). As suggested by Hildbrand et al.
158 the 156 
 
heterogeneous oligonucleotides behave differently from their pure ribo and deoxyribo 
sequences, and this could be due to differences in preferred conformation of the third 
strand or the triplex itself.
158 In both this study and that carried out by Hildbrand et 
al.,
158 the replacement of 
MeP with 
MePOMe results in a distinct loss in triplex stability, 
although there is no relevant difference in the pKa of these two nucleosides.  
 
The 2’-O-aminoethyl modified base analogues are designed for dual recognition. These 
analogues are able to recognise duplex DNA through base–base contacts, as well as by 
the formation of a salt bridge between the protonated amino function of the 
oligonucleotide and an oxygen of the negatively charged phosphodiester unit of the 
target purine strand (fig. 3.14).
290 The presence of the 2'-O-aminoethyl side chains also 
contributes actively to the nucleation-zipping association process. Specific contacts 
between the 2'-O-aminoethyl and the phosphate backbone of the DNA duplex are able 
to form, and this provides for a dramatic increase in the binding affinity as well as in the 
association rate constant.
291 The sugar conformation is C3’-endo-2’-exo, and the 






Fig. 3.14: The structure of the 
MeCAE, showing the region where Hoogsteen hydrogen bonds form and 




Due to the combination of its positive charge and RNA-like sugar conformation, 
MeCAE 
was expected to have the most profound effect on the kinetics of triplex formation for 
the TFO in which it was incorporated. It was also expected that the resultant complex 
would have a greater stability at physiological pH and low Mg
2+ concentration, than any 157 
 
of the other three Cytosine analogues. Hence, it was a surprise when the results obtained 
did not reflect this. 
 
It was later determined that the 2’-O-aminoethyl group was being acetylated during the 
synthesis of 
MeCAE. This was evident by the presence of the peak in the oligonucleotide 
MS at 5851 (see page 278), corresponding to the mass of the oligo plus four additional 
acetyl groups (+172); one per 
MeCAE. A peak at 5678 was that expected in the absence 
of acetyl migration.  
 
It was determined from 2-D NMR studies that the acetyl protecting group was migrating 
from the exocyclic amino function during the Staudinger reaction,
292 in which the 2’-O-
azidoethyl group was reduced to 2’-O-aminoethyl (scheme. 3.15). The COSY NMR 
displays correlation between the protons of one of the CH2 in the 2’-O-aminoethyl 




Scheme. 3.15: The Staudinger reaction. Reagents and conditions: (i) 2 eq Triphenyl phosphine, 5 eq 
Water, THF, 45 °C, 14 hrs.
292  
 
It was thought that for the acetyl migration to occur, the exocyclic amino group and the 
2’-O-aminoethyl chain would have to be in close proximity in space. Once the azide 
functional group had been reduced to amine functionality to give a primary alkyl amine, 
this region of the molecule was highly nucleophillic and therefore more reactive, in 
comparison to the exocyclic amine attached at the C-4 position of the aromatic ring in 
the 5-methylcytosine base. The trigonal pyramidal arrangement of bonds around 
nitrogen is shallower in aryl amines vs. alkyl amines. This is a result of resonance 158 
 
delocalisation of the lone pair into the aromatic  system; it is this delocalisation that is 
responsible for the decreased nucleophilicity of aryl vs. alkyl amines. The acetyl 




Fig. 3.16: The mechanism of the Staudinger reaction and the rapid acetyl migration that follows. 
 
Once the 2’-O-aminoethyl group had been acetylated, it was inert to aqueous ammonia 
which was used in oligonucleotide deprotection. The ammonia required to deprotect the 
acetyl group from the exocyclic amino group was not nucleophilic enough to cleave the 
acetyl from the 2’-O-aminoethyl, harsher conditions were required.  
 
Due to this problem being unforeseen at the start of the synthesis, the synthetic 
development of the 
MeCAE monomer was monitored each step by 1D NMR and MS. The 159 
 
molecular analytical results were misleading due to the presence of two amino 
functionalities; it was difficult to differentiate using 1D NMR, which position had been 
acetylated. On discovering that acetyl migration is possible, more precise monitoring 
methods need to be put in place to determine exactly the position of the acetyl group 
(e.g. detailed NMR studies or x-ray crystallography). 
MeCAE monomer synthesis is 
currently being modified to prevent this unwanted acetyl migration from occurring. 
 
Pyrimidine motif triplexes are known for their sensitivity to increase in pH. The decline 
in stability of triplexes in the pyrimidine motif as the pH is increased is ascribed to the 
loss of protonation at the nitrogen within the base of the C-analogues. Although there is 
also an accompanying loss of a hydrogen bond, it has been shown that the loss of the 
positive charge is the more critical factor.
286  
 
Analysis of the triplexes formed by OL2-5 as a function of pH (6.2-8.0) (fig. 3.17; see 
also  fig. 3.12 for the melting curves and first derivatives of OL3/
MeP) showed the 




MeP showed a more pronounced decline in Tm between pH 
6.6-7.0; -10.68 °C for OL2/
MePOMe and -9.20 °C for OL3/
MeP. Whereas, between pH 
7.0 and 8.0, the decline in Tm was more gradual as the pH increased. This was 
illustrated by the shallower Tm differential in this section of the profiles; OL2/
MePOMe:  
-7.13 °C between pH 7.0-7.5 and -9.19 °C between pH 7.5-8.0; OL3/
MeP : -7.4 °C 
between pH 7.0-7.5 and -8.23 °C between pH 7.5-8.0. Hence, these two 
oligonucleotides are at their most sensitive within the pH range 6.6-7.0, while above pH 
7.0, the sensitivity decreases somewhat. This was expected; the pKas of 
MeP and its 2’-
O-methyl derivative, 
MePOMe is ~ 6.33 (pKa range 6.0-7.0). Hence, the pH sensitivity of 
triplex melting will be most pronounced in this pH range (pH 6.2-7.0). This is because 
exactly half of the nucleosides are protonated and the other half unprotonated. On 
moving away from the pKa range of these bases to higher pH, these bases will be fully 
deprotonated, and therefore the triplex Tm will be much less sensitive to changes in pH. 160 
 






































Fig. 3.17: Tm vs. pH profile, representing the drop in Tm as a function of pH for the triplexes formed 






A shallower Tm differential was observed for OL4/
MeC and OL5/
MeCAE between pH 
6.6-7.0; -7.45 °C for OL4/
MeC, and -8.84 °C for OL5/
MeCAE. Over the pH range 7.0-
8.0, a slightly larger Tm differential was observed than that for OL2/
MePOMe  and 
OL3/
MeP. For OL4/
MeC, -9.64 °C Tm differential was observed between pH 7.0-7.5, and 
-12.31 °C between pH 7.5-8.0. For OL5/
MeCAE, -10.66 °C Tm differential was observed 
between pH 7.0-7.5, and -10.73 °C between pH 7.5-8.0. Hence, OL4/
MeC  and 
OL5/
MeCAE are at their most sensitive in the pH range 7.0-8.0. 
 
Overall, when the pH was increased from 6.6-8.0, the Tm differential was: -27.00 °C for 
OL2/
MePOMe; -24.83 °C for OL3/
MeP; -29.40 °C for OL4/
MeC;  and -30.23 °C for 
OL5/
MeCAE. Thus, from these results, it can be stated that, an oligo containing 
MeP 
encounters the least sensitivity to increase in pH, whereas an oligo containing 
MeCAE 
encounters the most sensitivity to increase in pH. Hence, the presence of 
MeP in a TFO, 
in comparison to the other three C-analogues, partially ameliorates the destabilising 
effects of pH in the physiological range. This lower pH dependence of the Tm values for 
MeP containing oligo in comparison to 
MeC containing oligo is a direct consequence of 161 
 
the higher pKa. The observation that 
MeCAE encounters the most sensitivity to pH is a 
confirmation that the 2’-O-aminoethyl group was acetylated as described above; the pKa 
of this amino group is 8.5-9.0. Hence it would still be protonated at physiological pH 
and higher, and this positive charge would partially compensate for the loss of the 
charge on the base of the C-analogue, as the pH moves to the physiological range. 
Therefore, the TFO with 
MeCAE (OL5) should not encounter the most sensitivity to 
increase in pH. 
 
3.2.1.2 FOOTPRINTING  STUDIES 
 








respectively, would enable the TFO within which it is incorporated to have the greatest 
affinity at physiological pH, to the target site, a 15 base-pair oligopurine tract 
interrupted by a cytosine. The target site is part of the slo-1 promoter gene in C. elegans 
(fig. 3.18). 
 




Fig. 3.18: DNase I footprinting reaction; Sequence of the 15 base-pair target site (underlined) part of the 
slo-1 promoter gene. TFO shown in bold; 5 = 
MeP/
MePOMe/
MeC (OL3/OL2/OL4 respectively); 6 
= TAE; and 7 = SME (see page 280-281 for the respective structures of these base analogues). 
 
A  restriction fragment labelled at the 3’-end with 
32P, containing the target site outlined 




MeC  (increasing concentrations 
ranging from 0.01/0.03 µM to 10 µM). DNase I generated reaction products were 
separated by denaturing gel electrophoresis, and after fixing, drying, and storing 
overnight in a phosphorimager screen, the footprint was visualised by scanning. 
 
Figs. 3.19-3.21 show representative footprinting patterns at a region of the slo-1 
promoter gene target site, obtained at pH 5.0, 7.0 & 7.5 respectively. As previously 
stated, it should also be noted here, that when cloning of the target sequence was carried 
out, the resultant clone contained a dimer of this sequence with the two copies oriented 162 
 
in opposite directions, enabling simultaneous visualisation of the purine (upper site) and 
pyrimidine (lower site) strands. There exists a third region which appears to be another 








Fig. 3.19: DNase I cleavage patterns produced by OL3/
MeP (right) and OL4/
MeC (left) with the 15 base-
pair oligopurine target site interrupted by a cytosine, that exists within the slo-1 promoter gene region. 
Oligonucleotide concentrations (µM) are indicated at the top of each gel lane. The reaction was 
performed in 50mM sodium acetate, pH 5.0. Track labelled “GA” is the sequencing lane that is specific 
for purines (G + A). The solid bars indicate the location of the target site; ‘Pu’ indicates the purine-rich 




Fig. 3.20: DNase I cleavage patterns produced by OL3/
MeP, OL4/
MeC and OL2/
MePOMe with the 15 base-
pair oligopurine target site interrupted by a cytosine, that exists within the slo-1 promoter gene region. 
Oligonucleotide concentrations (µM) are indicated at the top of each gel lane. The reaction was 
performed in 10 mM Tris-HCl, pH 7.0. Track labelled “GA” is the sequencing lane that is specific for 
purines (G + A). The solid bars indicate the location of the target site; ‘Pu’ indicates the purine-rich 





Fig. 3.21: DNase I cleavage patterns produced by OL3/
MeP (right) and OL4/
MeC (left) with the 15 base-
pair oligopurine target site interrupted by a cytosine, that exists within the slo-1 promoter gene region. 
Oligonucleotide concentrations (µM) are indicated at the top of each gel lane. The reaction was 
performed in 10 mM Tris-HCl, 50 mM NaCl pH 7.5. Track labelled “GA” is the sequencing lane that is 
specific for purines (G + A). The solid bars indicate the location of the target site; ‘Pu’ indicates the 
purine-rich strand of the target site; ‘Py’ indicates the pyrimidine-rich strand. 166 
 
From  fig. 3.19 it is clear to see that both OL3/
MeP  and  OL4/
MeC generate good 
footprints at pH 5.0 as expected. For both TFOs, there exists enhanced cleavage at the 
3’-(lower) end of the upper target site (purine-rich strand) at the triplex-duplex junction; 
this is a good indicator that the TFOs are binding (evidence for local oligonucleotide-
induced DNA structural change).
106,199 It cannot however, be determined for the TFO 
concentrations used at this pH, which gives the better protection of the target site from 
cleavage by DNase I.  
 
At pH 7.0, the DNase I cleavage patterns (fig. 3.20) show that OL3/
MeP and OL4/
MeC 
prevent cleavage of the target site by DNase I efficiently, down to a concentration of 
0.3 µM.  OL3/
MeP  binds with a slightly higher affinity than OL4/
MeC at this 
concentration, while OL2/
MePOMe provides effective protection from cleavage down to 
a concentration of only 1.0 µM. Hence, both OL3/
MeP and OL4/
MeC have a binding 
affinity, and in theory, an association rate constant (Ka, this was not determined during 
this study) that is approximately three-fold greater than that for OL2/
MePOMe. At pH 7.5 
(fig. 3.21), OL3/
MeP provides the better protection from cleavage of the target site by 
DNase I, compared to OL4/
MeC. At a concentration of 0.3 µM, OL3/
MeP displays high 
binding affinity to the target site, whereas OL4/
MeC has a similar binding affinity at a 
concentration (1.0 µM) that is three times that of OL3/
MeP. Hence, the theoretical Ka for 
OL3/
MeP would be approximately three-fold greater than that for OL4/
MeC.  
 
From these results, it can be stated that at physiological pH, OL3/
MeP provides the best 
protection of the target site from cleavage by DNase I and hence has the greatest 
binding affinity (theoretical Ka)  when compared to OL2/
MePOMe  and  OL4/
MeC. 
Therefore, incorporation of 
MeP  into triplex-forming oligonucleotides has a positive 
effect on the stability of the triplex which it forms with its target duplex, and hence an 
enhanced binding affinity at physiological pH.  
 
DNase I footprinting to determine the effectiveness of TFO OL5/
MeCAE, was not carried 
out as the 2’-O-aminoethyl group was found to be acetylated (discussed above). In the 
future a footprinting comparison needs to be made between 
MeP and 
MeCAE, when the 
MeCAE monomer has been synthesised without acetylation of the 2’-O-aminoethyl 





The utilisation of TFOs for genomic manipulation requires the development of 
oligonucleotides that can form stable triplexes in the nuclear environment. Base and 
sugar modifications have the potential to overcome the classical limitations imposed by 




In the experiments described above, the objective has been to identify which modified 
Cytosine-analogue when incorporated into a TFO of interest, is best able to enhance the 
stability of the triplex at physiological pH. From the footprinting results presented here, 
at pH 7.5, 
MeP, when incorporated into the TFO of interest, enhances the stability of the 
triplex formed by three-fold relative to 
MeC, this is due to its enhanced basicity. From 
both the UV melting and footprinting results, this TFO (OL3) has a higher affinity to 
double-stranded DNA over the pH range of 6.2-8.0 and a greater pH-independence in 
comparison with the other TFOs studied. Hence, 
MeP is an excellent replacement for 
MeC in recognition of double stranded DNA at physiological pH. However, due to the 
acetylation of the 2’-O-aminoethyl in 
MeCAE, this conclusion needs to be revisited when 
this TFO has been synthesised.  
 
It is important to note at this stage that the effective delivery of oligonucleotides to their 
respective sites of action in the nucleus or cytoplasm has been an issue of concern.
293 
Although OL2/
MePOMe showed a lower stabilising effect on the triplex formed when 
compared to OL4/
MeC and OL3/
MeP, nucleosides with 2’-modifictaions are known to 
have high resistance to degradation by nucleases in vivo, whereas 2’-
deoxyribonucleosides are highly susceptible to this degradation, and are very unstable 
in vivo.
294,295 Hence, although the in vitro studies show low stability by the triplex 
formed by OL2/
MePOMe at physiological pH when compared to those triplexes formed 
with OL3/
MeP and OL4/
MeC, the Tm is reasonable considering the high resistance this 
oligonucleotide should experience against nuclease cleavage when used in biological 
systems. 
 
It was essential that the above thermal stability studies were carried out; only then was it 
realised, by making a comparison to results reported by Cuenoud et al.
291 and Puri et 
al.,
286 that the 
MeCAE was acetylated.  168 
 
The footprinting studies prove that by incorporating 
MeP into an oligo, the stability of 
the triplex formed is enhanced in comparison to an oligo containing either the naturally 
occurring 
MeC  or the synthetic 
MePOMe, and hence this TFO efficiently protects the 
triplex from DNase I cleavage at physiological pH. 
 
It is expected that once the synthesis of a suitable 
MeCAE monomer has been established, 
the stability of the triplex formed with the respective TFOs will be profoundly 
enhanced. Also, due to the presence of the 2’-modification, in vivo experiments are 
expected to produce promising results due to the monomer’s ability to inhibit TFO 
degradation by nuclease cleavage. 
 
3.3  PSORALEN PHOTO- CROSSLINKING REACTIONS 
 
3.3.1  IN VITRO STUDIES 
 
3.3.1.1 UV-MELTING STUDIES - Psoralen-conjugated TFO containing 
MeP 
 
Psoralen is a linear furocoumarin which reacts via a [2+2] cycloaddition, in concert with 
long wave UV light (UVA), to form photoadducts primarily with thymidines at 5’-TpA-
3’ sites in double stranded DNA. This reaction is highly regio- and stereospecific, 
forming an interstrand cross-link as the major product under the conditions employed in 




A 30-mer duplex (7·8), being made up of the complementary strands, OL7 and OL8 
(fig. 3.21 in which the 22-base pair TFO binding site is underlined), was used as the 
target for the 5’-end psoralen-linked TFO (OL6), and is a region of the UNC-22 coding 
gene in C. elegans. 3-methyl-2-amino-5(2’-deoxy-β-D-ribofuranosyl)pyridine (
MeP) and 
Psoralen C6 (Pso) were incorporated into the TFO, OL6. Studies were carried out to 
compare using ultraviolet melting, the difference in the triplex thermal stability at 
different pH; pre and post UV photo-crosslinking of the Psoralen. A schematic 





            5’-Pso-6557566566566576566566–propyl-3’ OL6 
            5’-ACTTAGGTGAAGAAGAAGCAGAAGAAGAAG  7 
            3’-TGAATCCACTTCTTCTTCGTCTTCTTCTTC  8  
 
Fig. 3.22: Triplex UV melting experiment. TFO OL6 shown in bold; 6 = TAE; 5 = 
MeP, 7 = SME 
and Pso =  Psoralen (see page 280-281 for the respective structures of these base analogues). 
Oligonucleotides 7·8 form the duplex that contains the target site for the TFO, which is underlined. 
 
The objective here was to demonstrate that by incorporating psoralen into the TFO OL6 
and carrying out photo-crosslinking reactions under long wavelength ultraviolet light, 
the thermal stability of the triplex would be enhanced significantly at pH values up to 
physiological pH, in comparison to that prior to photo cross-linking. Therefore the 









Table 3.3: Thermal stabilities, Tm (ºC) of the triplexes formed at varying pH, between the psoralen-linked 
oligonucleotide and duplex 7·8 (Tm ~ 70 °C), pre- and post- UV induced photo-crosslinking reactions.  
 170 
 









































Fig. 3.23: UV-melting profiles and first derivatives for the complexes formed between TFO OL6 and 
duplex 7·8 pre photo-crosslinking. The reactions were performed in 10 mM sodium phosphate, 200 mM 










































Fig. 3.24: UV-melting profiles and first derivatives for the complexes formed between TFO OL6 and 
duplex 7·8 post photo-crosslinking. The reactions were performed in 10 mM sodium phosphate, 200 mM 

















































Fig. 3.25: UV-melting profiles and first derivatives for the complexes formed between TFO OL6 and 
duplex 7·8 post photo-crosslinking. The reactions were performed in 10 mM sodium phosphate, 200 mM 
NaCl, pH 7.5-8.0. The duplex concentration was 1 μM and the TFO concentration was 3 μM. 
 
The interaction of the Psoralen linked TFO OL6 with the duplex DNA target 7·8 was 
initially studied by ultraviolet melting in the pH range 6.6-8.0 prior to photo-
crosslinking. The results are displayed in the first column of table. 3.3, and in fig. 3.23. 
Significantly high thermal stabilities were observed within the pH range examined. The 
high Tm encountered can be attributed to 5’-Psoralen intercalating at the duplex-triplex 
junction, hence providing a powerful cooperative enhancement of binding to this target. 
As expected, the thermal stability of the triplex decreased with an increase in pH; 
~ 10 ºC decrease in Tm was observed as pH was increased by 0.4-0.5 units. 
 
The triplexes were then irradiated with UV light (365 nm for 20 mins) and subjected to 
further melting studies. In all cases, as expected, the melting curves were totally 
transformed (see figs. 3.24-3.25), in agreement with that reported by Li et al.
296 After 
irradiation, at pH 7.0 and 7.5 there existed only one high-temperature melting transition, 
the transition owing to the dissociation of the TFO from the triplex structure had 
disappeared. The duplex and cross-linked TFO were melting at similar temperatures 173 
 
~  70 °C. Post irradiation at pH 8.0, two melting transitions were observed. The 
transition corresponding to the melting of the cross-linked triplex had shifted 
significantly to higher temperatures. At all pH studied, a shift in the triplex Tm of ~ + 26 
°C was observed on forming the cross-linked triple helical complex from the pre-
crosslinked triplex.  
 
In conclusion, by using psoralen in combination with nucleotide analogues, and 
allowing triplex-directed double strand psoralen photoadduct formation, highly stable 
cross-linked structures are able to form under physiological conditions. The crosslinking 
studies substantiate the use of psoralen and UVA phototherapy in vivo as a conventional 
treatment for psoriasis. In addition, the studies demonstrate that diseases with a similar 
pathophysiology to psoriasis can be treated in a similar way. 
 
3.3.1.2 FOOTPRINTING STUDIES- Psoralen-conjugated TFO containing 
MeP 
 
DNase I footprinting was carried out to examine how the incorporation of 
MeP and 
psoralen within the TFO, OL6 affects the recognition affinity and stability of the triple 
helix formed at a particular target site, at pH values up to physiological pH. The target 
site was a 22-base pair DNA fragment, part of the UNC-22 coding gene within 
C.elegans (figure. 3.26).  
 




Fig. 3.26: Sequence of the 22 base-pair target site (underlined) within part of the unc-22 coding gene 
which had been cloned into the pUC19 plasmid. TFO OL6 shown in bold; 5 = 
MeP; 6 = TAE; 7 = 
SME and Pso  = Psoralen (see page 280-281 for the respective structures of these base 
analogues). 
                 
A restriction fragment (pyrimidine rich strand) labelled at the 3’-end with 
32P, 
containing the target site outlined in fig. 3.26, was incubated at room temperature 
overnight with increasing concentrations of the triple helix forming oligonucleotide 
OL6  (0.03 µM-10 µM). DNase I generated reaction products were separated by 174 
 
denaturing gel electrophoresis, and after fixing, drying, and storing overnight in a 
phosphorimager screen, the footprint was visualised by scanning. 
 
From fig. 3.27 it can be seen that protection of the target site from DNase I cleavage by 
OL6 occurs at a concentration of 10 µM; between 10-1.0 µM OL6 has attenuated 
DNase I cleavage, it is slightly better at pH 7.0 than at pH 7.5. Therefore the triplex 
formed at pH 7.0 has a slightly higher stability than that at pH 7.5. The results 
demonstrate that the stability of the triplex decreases with increasing pH. At a 10 µM 
concentration of the TFO a stable triplex is formed at physiological pH, the TFO is able 





Fig. 3.27: DNase I cleavage patterns produced by the interaction of TFO OL6 with the 22 base-pair target 
site within the UNC-22 coding region in C. elegans; the pyrimidine strand is visualised here. 
Oligonucleotide concentrations (µM) are indicated at the top of each gel lane. The reactions were 
performed in: (A) 10 mM Tris-HCl, pH 7.0, containing 50 mM NaCl and (B) 10 mM Tris-HCl, 50 mM 
NaCl  pH 7.5. Tracks labelled “GA” are sequencing lanes that are specific for purines (G + A); tracks 
labelled “CON” represent control where there was no TFO present. These were obtained without any UV-
irradiation. The solid bars indicate the location of the pyrimidine-rich target site and the asterisk 
corresponds to the TpA step where the psoralen will bind. 176 
 
3.3.1.3 GEL ELECTROPHORESIS 
 
Gel-retardation analysis was utilised to determine the ability of the psoralen labelled 
TFO OL6 to form double-stranded cross-links with its target duplex, a 22-base pair 
DNA fragment, part of the UNC-22 coding sequence within C.elegans (fig. 3.26). One 
strand of the duplex was labelled at the 3’-end with [
32P] phosphate. The TFO, OL6 was 
equilibrated with the duplex overnight at 20 °C before irradiating. After ultraviolet 
irradiation at 365 nm, the samples were denatured, and the reaction products analysed 
by gel electrophoresis (5 % polyacrylamide gel, fig. 3.28).  
 
Fig. 3.28: Gel electrophoresis depiction of the UV-induced crosslinking of the psoralen-linked TFO OL6 
to the target duplex, the 22-base pair tract, part of the unc-22 coding sequence in C.elegans. The reactions 
were performed in (A) 10 mM Tris-HCl, pH 7.0, containing 50 mM NaCl, and (B) 10 mM Tris-HCl, 50 
mM NaCl  pH 7.5. Oligonucleotide concentrations (µM) are indicated at the top of each gel lane. “free”, 
“mono-adduct”, and “cross-linked” indicate the presence of a single DNA strand, the formation of 
covalent attachment between the TFO OL6 and one strand of the duplex, and the covalent attachment 
between the TFO OL6 and both strands of the duplex, respectively; illustrated in the diagrams.    177 
 
At both pH, a pattern of retarded bands is produced; the lower retarded species 
corresponds to the mono-adduct, while the upper (slower) retarded band corresponds to 
the bis adduct in which the TFO is linked to both strands of the duplex (fig. 3.28). The 
slower, bis-adduct is the predominant species after 20 mins UV irradiation, while a 
small amount of mono-adduct is still present. This mono-adduct could represent; (1) 
where the first reaction of psoralen with a thymidine in the target site involved the 
pyrone 3,4-double bond, this mono-adduct does not then go on to absorb light above 
300 nm and cannot be converted to the bis adduct; or (2) it could represent incomplete 
cross linking where only the initial cross linking of the furan moiety of psoralen to the 
pyrimidine strand has occurred, which would then if the reaction went to completion, be 
followed by cross-linking of the pyrone moiety to the purine strand. The bis-adduct 
represents where the initial reaction of psoralen involved the 4’,5’-double bond of the 
furan ring to form the mono-adduct with the 5,6-double bond of the thymidine in the 
purine strand of the duplex target site. This then goes on further to absorb light above 
310 nm, in order to engage in the second reaction involving the 3,4-double bond on the 




The UV-induced crosslinking is more efficient at pH 7.0 than at pH 7.5. At pH 7.0, 
some cross-linking is evident down to a concentration of 0.03 µM. At pH 7.5 no cross-
links are produced below a concentration of 0.3 µM. Hence, crosslinking at pH 7.0 is 
possible at a concentration ten-fold less than that at pH 7.5. 
 
From these results it can be stated that, incorporating 
MeP and psoralen into TFOs, 
enables high affinity recognition of the TFO to the target site, hence formation of stable 
triplexes at physiological pH. The additional feature of crosslinking two strands of DNA 
at specific sites via UV irradiation enables the formation of covalent attachments 
between the psoralen, TFO and duplex target site. Biological processes that require an 
opening of the double helix such as replication and transcription can therefore be 
blocked. Inside cells it is likely that these cross-links will be recognised by repair 
enzymes. This could lead to mutations at the specific sites where the oligonucleotide 
has targeted the cross-linking reaction.
297 Hence, psoralen-containing TFO conjugates 
have the potential to be good probes for demonstrating the formation of triple helices 178 
 
within living cells. This was investigated via the in vivo methods described below in C. 
elegans. 
 





210 was administered as the method of delivery of TFO, OL6 to the C. elegans 
by external application (worms are soaked in a solution of the TFO OL6, this is the 
method of delivery). It has the disadvantage that it may have low efficiency in terms of 
penetrance of effects, but has the tremendous advantage that it is amenable to large, 
automated genome wide-screens. It was thought to be the most suitable method to test 
for the effects of TFO mediated regulation of gene expression in adult animals. 
 
Experiments were carried out, with and without the aid of nanoparticles, in vivo-
jetPEI
TM; a delivery reagent used to aid the delivery and improve the uptake of OL6 by 
the cells. In vivo-jetPEI
TM was developed to deliver DNA and oligonucleotides in order 
to mediate gene expression in various tissues upon in vivo administration. It does not 
induce any significant pro-inflammatory response after application. Unfortunately, in 
both cases, whether or not the delivery reagent was administered, no effect was 
observed. 
 
UNC-22 provides a sensitive and specific assay for genetic interference, as it is the only 
gene in C. elegans genome that can mutate by loss-of-function, to give a twitching 
phenotype.
298 Hence, it was expected that OL6 would induce a decrease in UNC-22 
gene expression and therefore produce twitching phenotypes in the C. elegans that were 
soaked. However this was not observed. 
 
An alternative delivery route should be attempted in the future. It is possible that 
injection into syncytial tissue (C. elegans gonad) for incorporation into germ cells could 
provide efficient uptake of the TFO. When generating transgenic animals, this is the 
route of access for plasmid DNA. It is anticipated that TFOs will gain intracellular 
access to the germ cells when delivered by this route. This method of delivery however, 
has the disadvantage that the effect of the TFO is likely to be diluted out following cell 179 
 
division, so the highest penetrance of effect might be expected only at the earliest stages 
of development. Alternatively, the TFOs can be administered by injection into the 
intestine of C. elegans. This method has the unfortunate disadvantage that it is relatively 
slow and not suitable for targeting large numbers of genes. These two delivery methods 
are worth attempting in the future. If proved successful, this research can progress 














































4.1  THE ACHIEVEMENTS OF THIS RESEARCH 
The initial aims set out for this PhD research have all been met successfully. A novel, 
concise synthetic route to the 
MeP  monomer has been developed. The overall yield 
obtained for this monomer (starting from the coupling reaction of the carbohydrate 
moiety with the aglycon) is significantly higher than those reported (15.5 % vs. 9.7 %
158 
and 5.6 %
201; see graph. 1 below). The number of steps required to obtain the final 






















Graph. 1: A comparison between the yields obtained for the 
MeP monomer by others, and that achieved 
during this PhD research. 
In addition, the overall yield to the free nucleoside is significantly higher than that 
reported (33.3 % vs. 10.1 %
158 and 7.8 %
202; see graph. 2 below). The synthetic scheme 
developed here to obtain the 
MeP monomer is efficient, and it makes a good contribution 
towards nucleic acids chemistry. Others needing to develop this cytidine analogue for 
use in biological studies/applications can use the route developed here. 
However, during the second attempt at optimising the synthetic route, there was a drop 
in the overall yield of the final monomer (graph. 3). This was due to the low yielding 
tritylation (40 %) and phosphytilation (34 %) reactions. All other steps for this synthetic 




















Graph. 2: A comparison between the yields obtained for the free 
MeP nucleoside by others, and that 
achieved during this PhD research.  
In conclusion, the exocyclic amino moiety of 
MeP needs to be blocked prior to the 
tritylation reaction in order to obtain a tritylation yield of ≥ 60 %. The tritylation step in 
the first attempt (see scheme. 2.38, page 129) was ~ 62 %; the exocyclic amino moiety 
in the precursor for this step was protected. In the second attempt (see scheme. 2.45, 
page 135), tritylation was carried out on the free nucleoside, 1 β. Although the exocyclic 
amino moiety did not partake in the tritylation reaction, it may interfere, causing a 
reduction in this yield. Hildbrand et al.
158 obtained a tritylation yield of 74 %; the 
precursor to this reaction was protected at the exocyclic amino moiety with 
















Graph. 3: The progression of the overall yield of 
MeP after optimisations of the synthetic route. 185 
 
The greatest overall yield for 
MeP was achieved during the third attempt (see graph. 3). 
However, there is still room for improvement. The phosphitylation reaction yield can be 
improved using reagents with a greater purity. In addition, the mistunobu reaction needs 
further optimisation; the β:α ratio for this step was 3:2. As discussed in Chapter 2, 
methods that can increase the ratio of β-glycosylation need to be investigated, and this is 
an area that this research can be extended. Increasing the β:α ratio can significantly 
increase the overall yield of the 
MeP  monomer. As mentioned in Chapter 2, using 
bulkier protecting groups, such as tert-butyldiphenylsilyl (TBDPS), at the 3’- and 5’-
positions of the 2’-deoxy-β-D-ribose ring, may help to increase β-glycosylation. During 
the coupling reaction of lactol, 14 with the protected base, 86, the TBDPS group at the 
3’ position should increase steric hindrance at the exo face of the sugar ring, and can 
therefore potentially induce an increase in the diastereoselectivity towards the epimer 
that then cyclises under mistunobu conditions to give the β-product. Alternatively, 
attempting scheme. 2.31 in chapter 2 (page 122), is another way that could increase β-
glycosylation. This would involve oxidation of lactol, 14 to the 2’-deoxy lactone, 108, 
and following coupling, the stereoselective reduction of the hydroxyl ketone, 109 with 
L-Selectride to the diols, 103 RS. As a result of its steric nature, L-Selectride (a hydride 
reagent), can stereoselectively reduce carbonyl groups. The scheme would therefore be 
increased by two steps, which would take the total to 12 steps. However, if these steps 
are high yielding, and the percentage of β-glycosylation is increased, it would be 
worthwhile. 
In addition to the development of a concise, high yielding route to the monomer 
MeP, in 
vitro and in vivo studies of 
MeP containing pyrimidine motif TFOs have been carried 
out. No footprints were detected for TFO OL1 at physiological pH. This was a result of 
the dimethylformamidine group not being suitable for the protection of the exocyclic 
amino moiety. This protecting group converts to the inert formyl group during 
conditions of standard oligonucleotide deprotection.   
MeP can be used in place of cytidine in TFOs in the pyrimidine motif to give stable 
triplexes. Footprinting and UV melting studies comparing the 
MeP containing pyrmidine 
motif TFO, OL3 with other cytidine analogue substituted pyrimidine motif TFOs 
(
MeC/OL4 and 
MePOMe/OL2), demonstrated that for achieving stable triplexes at 
physiological pH, 
MeP is superior to both 
MeC and 
MePOMe. The poor biophysical results 186 
 
displayed by the 
MeCAE incorporated TFO, OL5, indicated the need for further 
optimisation of the synthetic route to this monomer. In particular, it was discovered that 
during the Staudinger reaction, an unwanted acetyl migration was occurring from the 
exocyclic amino moiety on the base of 
MeCAE, to the 2’-O-aminoethyl moiety. Hence, 
the comparison of 
MeP  vs 
MeCAE biophysical results needs revision. The synthetic 
scheme for 
MeCAE has been optimised (by Miss M. Shelbourne) to avoid the unwanted 
side reaction, hence for future studies the same TFO sequence incorporating the newly 
synthesised 
MeCAE OL5 needs to be compared to OL3.  
The simultaneous incorporation of 
MeP and psoralen into a pyrimidine motif TFO, OL6 
enabled the formation of stable triplexes to its target site at physiological pH. Following 
UV irradiation, the TFO demonstrated the ability to form crosslinked triplexes at its 
target site with high stability at physiological pH. In vivo studies of this TFO did not 
unfortunately demonstrate the formation of triplexes with a target site in C. elegans. 
This result however, does not imply that the TFO is not able to form stable triplexes in 
vivo, more so, it could be that the delivery method that was not effective. “Soaking” was 
the method of delivery of the TFO, and due to time constraints other delivery methods 
(via intramuscular, subcutaneous, intravenous, and intraperitoneal injection) were not 
attempted. Particle bombardment using gold particles has been shown to be able to 
deliver genes successfully into cells,
299 and this is a method that should be explored for 
the delivery of TFO OL6. In addition, using electric pulses to introduce this TFO into 
cells may also be a successful approach. Electric pulses enable cell membranes to be 
transiently permeable.
300 These are areas that need to be investigated further (see 
Chapter 3 for additional delivery method suggestions).  
4.2 RESEARCH  CONTINUED 
Following on from the biophysical studies carried out to compare cytidine analogues, 
during this PhD research, further studies have been carried out, and reported after the 
duration of this PhD, by Mr. C. Lou
282 in this research group. A comparison between 
oligos containing dC, 
MeP, and 
MePOMe in terms of their selectivity towards duplex DNA 
over single stranded DNA, and their resistance to nuclease degradation has been made. 
Overall, incorporating four additions of the cytidine analogues, 
MeP, and 
MePOMe 
separately into two different polyT TFOs, both TFOs had greater selectivity towards 
duplex DNA than single stranded DNA. This was demonstrated by the negative ΔTm 187 
 
(the difference between that particular TFO and the TFO containing dC) displayed on 
graph. 4. In particular, the TFO containing 
MePOMe  had greater selectivity towards 
double stranded DNA than the TFO containing 
MeP. When 
MeC was incorporated into a 
TFO of this nature, the TFO had preference to the complementary antiparallel single 
strand of DNA than the duplex DNA (Graph. 4). This result demonstrates that in vivo, 
pyrimidine motif TFOs with a uniform ribose backbone containing either 
MeP or 





















Graph. 4: The difference in UV melting temperatures (Tm) between the duplex formed from the TFO 
containing the respective cytidine analogue (indicated on graph) and its antiparallel complementary single 
DNA strand, and the duplex formed from the same single stranded DNA with the TFO containing dC.
282 
In addition, a homopyrimidine TFO containing 
MePOMe encounters greater resistance to 
degradation by serum nuclease than when 
MeP was incorporated. After 24 hours the 
TFO containing 




4.3 APPLICATIONS  FOR GENE THERAPY? 
From the biophysical comparison of the cytidine analogues described within this thesis, 
it can be hypothesised that 
MeP incorporated TFOs will be successful in vivo for future 
gene silencing therapeutics. Gene inhibition can be achieved by the highly selective and 
stable triplex formation at a promoter site, this has the potential to block the binding of 
various transcription factors, hence inhibiting transcription.
75 However it is well known 






293-295,301 hence the likeliness of the oligo to be at its target site for a 
substantial amount of time to enable an effect is quite low. Therefore, further 
modifications to the 
MeP monomer, such as to the phosphodiester backbone (see 
Chapter 1; section 1.6.4.1.3) may be required to enable greater resistance to degradation 
by nucleases, and allow for wider applications in vivo. 
4.4 BIOLOGICAL  BARRIERS TO GENE THERAPY
293,302  
For antigene TFOs to be successful for therapeutic value, they must be able to enter 
cells with minimal toxicity.
302 In addition, they must be able to overcome biological 
barriers, antigene TFOs are presented with many biological barriers that stand between 
their initial administration and their site of action. As discussed above, nuclease activity 
in the plasma and tissues, by exonucleases and endonucleases cause degradation to 
TFOs that are not sufficiently modified. TFOs can also encounter uptake by the kidney 
or liver which can cause rapid excretion. In addition to this, the reticuloendothelial 
system can clear the body of any foreign TFOs. Endothelial cells control the integrity of 
the vasculature and these are also a barrier to TFOs reaching their target site.
293 Progress 
is being made to overcome these biological barriers to gene therapy, so that in the future 
these therapeutics can be widely available for the management of diseases at the 
transcriptional level. This will affect the medical industry in a positive manner, and 
change the way that healthcare is practised.  
4.5 MOVING  FORWARD
122,125 
As discussed in chapter 1, PNA is an oligonucleotide mimic where the deoxyribose 
phosphate backbone of DNA has been replaced by a backbone composed of 2-
aminoethylglycine units. This is an area that can be expanded for the 3-methyl-2-
aminopyridine base. Developing a synthetic route to the PNA equivalent of 
MeP, and 
carrying out biophysical analyses on triplexes formed with respective DNA targets, 
would be an area where this PhD research could be extended. Pyrimidine motif PNA 
oligos containing natural nucleosides are able to form highly stable (PNA)2·DNA 
triplexes that are much more stable than the corresponding DNA·DNA duplexes.
122 
From the biophysical results obtained during this PhD research, in terms of providing 
triplex stability, the following trend is observed: 
MeP > 
MeC > dC,  when these 
nucelosides are incorporated into TFOs. Hence,  pyrimidine motif PNA oligos 
containing 
MeP would be expected to create (PNA)2·DNA triplexes with even greater 189 
 
stability than those containing natural nucleosides. It would be interesting to carry out 
the biophysical analyses, and if proved successful, test the PNA TFOs in vivo. They 

































5.   EXPERIMENTAL 
5.1   SYNTHESIS 
5.1.1   GENERAL  EXPERIMENTAL 
5.1.1.1   REAGENTS AND SOLVENTS 
All reagents were purchased from Aldrich, Avocado, Fluka and TCI Europe and used 
without purification with the exception of the following solvents, which were purified 
by distillation: Ethanol/Methanol (over iodine and magnesium); DCM/TEA/DIPEA 
(over calcium hydride); Pyridine (over potassium hydroxide); THF (over sodium wire 
and benzophenone). All reactions were carried out under an argon atmosphere using 
oven-dried glassware with purified and distilled solvents. Separation and purification by 
ion exchange was performed using Dowex resin 50WX2-200 (H
+). 
5.1.1.2   CHROMATOGRAPHY 
Column chromatography was carried out under pressure using Fisher scientific 
DAVISIL 60A (35-70 micron) silica.   
Thin layer chromatography was performed using Merck Kieselgel 60 F24 (0.22mm 
thickness, aluminium backed). Compounds were visualised by irradiation at 365/254 
nm, and/or staining with the following stains:  
A’ - Anisaldehyde (p-anisaldehyde 13.8 mL, glacial acetic acid 5.7 mL, conc. Sulphuric 
acid 18.75 mL, 95 % ethanol 507 mL (9.3:3.8:12.5:338 v/v)). Compounds containing a 
sugar component would produce blue/black  colour after staining and heating. 
Compounds containing DMT component produced a strong orange colour after staining 
and heating. 
B’ – Ninhydrin (Ninhydrin 0.3 g, n-butanol 97 mL, glacial acetic acid 3 mL). 
Compounds containing a primary amine group would produce a pink colour after 
staining and heating. 194 
 
The solvent system for TLC referred to as H-1 is the following; EA: Acetone: EtOH: 
H2O 4:1:1:1. 
5.1.1.3   MELTING POINT ANALYSIS 
Melting points were measured using a Gallenkamp electrothermal device and values 
have been quoted as a range of temperature (ºC). 
5.1.1.4   INFRARED SPECTROSCOPY 
Infrared spectra were recorded on a BIORAD FT-IR using a Golden Gate adapter and 
BIORAD WIN-IR software or a Satellite FT-IR using a Golden Gate adapter and WIN 
FIRST-lite software.  Absorptions are described as strong (s), medium (m), broad (b) or 
weak (w).   
5.1.1.5   MASS SPECTROMETRY 
Low-resolution mass spectra were recorded using electrospray technique on a Fisons 
VG platform instrument or a Waters ZMD quadrupole mass spectrometer in 
acetonitrile, water or methanol (HPLC grade). High-resolution mass spectra were 
recorded in acetonitrile, water or methanol (HPLC grade) using electrospray ionization 
on a Bruker APEX III FT-ICR mass spectrometer.  
5.1.1.6   NMR SPECTROSCOPY 
1H NMR spectra were measured at 300 MHz on a Bruker AC300 spectrometer and 400 
MHz on a Bruker DPX400 spectrometer.  
13C NMR spectra were measured at 75 MHz 
and 100 MHz on the same spectrometers respectively.  Chemical shifts are given in ppm 
relative to tetramethylsilane, and J values are given in Hz and are correct to within 
0.5 Hz.  All spectra were internally referenced to the appropriate residual undeuterated 
solvent signal.






31P NMR spectra were recorded on a Bruker AV300 spectrometer 
at 121 MHz and were externally referenced to 85 % phosphoric acid in D2O. 
Multiplicities are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet 
(m), double doublet (dd), double triplet (dt), triple doublet (td), double double doublet 
(ddd), broad (br). 195 
 
5.2   COMPOUNDS  SYNTHESISED 
No. Compound  Page 
1 α,β  2-Amino-3-methyl-5-(2’-deoxy-D-ribofuranosyl)pyridine 243 
1 α  2-Amino-3-methyl-5-(2’-deoxy-α-D-ribofuranosyl)-pyridine 256 
1 β  2-Amino-3-methyl-5-(2’-deoxy-β-D-ribofuranosyl)pyridine 245, 
247, 261 
14  3’,5’-di-O-benzyl-2’-deoxy-D-ribono-1,4-lactol 228 
64  2’,3’,5’-Tri-O-benzyl-D-ribono-1,4-lactone 202 
68 β  2-Amino-3-methyl-5-(2’,3’,5’-tri-O-benzyl-β-D-
ribofuranosyl)pyridine 
207 
69 β  3-Methyl-2-[N-(phenoxyacetyl)amino]-5-(2’,3’,5’-tri-O-benzyl-β-
D-ribofuranosyl)pyridine 
217 
70 β  3-Methyl-2-[N-(phenoxyacetyl)amino]-5-(β-D-
ribofuranosyl)pyridine 
218 
71 β  3-Methyl-2-[N-(phenoxyacetyl)amino]-5-[3’,5’-O-(1,1,3,3,-
tetraisopropyl disiloxane-1,3-diyl)-β-D-ribofuranosyl]pyridine 
222 








85  Methyl- 2’,3’,5’-tri-O-benzyl-D-ribose 199 
86  5-Bromo-2-[N,N-bis(4-methoxybenzyl)]amino-3-methylpyridine 203 




92 β  2-[N,N-bis(4-methoxybenzyl)]amino-3-methyl-5-(2’,3’,5’-tri-O-
benzyl-β-D-ribofuranosyl)pyridine 
206 
93 β  3-Methyl-2-trifluoroacetamide-5-(2’,3’,5’-tri-O-benzyl-β-D-
ribofuranosyl)pyridine 
208 
94 β  2-Amino-3-methyl-5-(β-D-ribofuranosyl)pyridine 209,  218 196 
 
95 β  2-N,N-[(dimethylamino)methylidene]-3-methyl-5-(2’,3’,5’-tri-O-
benzyl-β-D-ribofuranosyl)pyridine 
210 
96 β  2-N,N-[(dimethylamino)methylidene]-3-methyl-5-(β-D-
ribofuranosyl)pyridine 
211 












100 β  2-Amino-3-Methyl-5-[3’,5’-O-(1,1,3,3,-tetraisopropyldisiloxane-
1,3-diyl)-β-D-ribofuranosyl]pyridine 
220 
101  Pentafluorophenyl 2-phenoxyethanote  221 
102  Methyl-3’,5’-di-O-benzyl-2’-deoxy-D-ribose 226 
103 RS  2-[N,N-bis(4-methoxybenzyl)]amino-3-methyl-5-(3’,5’-di-O-
benzyl-2’-deoxy-D-ribofuranosyl)pyridine 
229 
104 α,β  2-[N,N-bis(4-methoxybenzyl)]amino-3-methyl-5-(3’,5’-di-O-
benzyl-2’-deoxy-D-ribofuranosyl)pyridine 
232 
106 α,β  2-[N-(4-methoxybenzyl)]amino-3-methyl-5-(3’,5’-di-O-benzyl-2’-
deoxy-D-ribofuranosyl)pyridine 
236 
107 α,β  2-Amino-3-methyl-5-(3’,5’-di-O-benzyl-2’-deoxy-D-
ribofuranosyl)pyridine 
237 
107 α  2-Amino-3-methyl-5-(3’,5’-di-O-benzyl-2’-deoxy-α-D-
ribofuranosyl)-pyridine 
254 
107 β  2-Amino-3-methyl-5-(3’,5’-di-O-benzyl-2’-deoxy-β-D-
ribofuranosyl)pyridine 
239 
114 α,β  3-Methyl-2-trifluoroacetamide-5-(3’,5’-di-O-benzyl-2’-deoxy-D-
ribofuranosyl)pyridine 
241 




114 β  3-Methyl-2-trifluoroacetamide-5-(3’,5’-di-O-benzyl-2’-deoxy-β-
D-ribofuranosyl)-pyridine 
242 
115 α,β  2-N,N-[(dimethylamino)methylidene]-3-methyl-5-(3’,5’-di-O-
benzyl-2’-deoxy-D-ribofuranosyl)pyridine 
243 
116  2-Amino-3-methyl-5-(1’,2’-deoxy-D-ribofuranosyl)pyridine 245 
117 β  2-Amino-3-methyl-5-(3’-O-benzyl-2’-deoxy-β-D-
ribofuranosyl)pyridine 
247 
118 α  2-N,N-[(dimethylamino)methylidene]-3-methyl-5-(2’-deoxy-α-D-
ribofuranosyl)pyridine 
252 
118 β  2-N,N-[(dimethylamino)methylidene]-3-methyl-5-(2’-deoxy-β-D-
ribofuranosyl)pyridine 
248 
119 β  2-N,N-[(dimethylamino)methylidene]-3-methyl-5-(5’-O-(4,4’-
dimethoxytrityl)- 2’-deoxy-β-D-ribofuranosyl)pyridine 
249 




121   Methyl-3’,5’-di-O-paramethoxybenzyl-2’-deoxy-D-ribose 253 
122 α  2-Amino-3-methyl-5-(5’-O-(fluorenylmethyloxycarbonyl)-2’-
deoxy-α-D-ribofuranosyl)pyridine 
258 
123 α  2-Amino-3-methyl-5-(5’-O-(4,4’-dimethoxytrityl)-2’-deoxy-α-D-
ribofuranosyl)pyridine 
259 
123 β  2-Amino-3-methyl-5-(5’-O-(4,4’-dimethoxytrityl)-2’-deoxy-β-D-
ribofuranosyl)pyridine 
250, 275 
















126 β  2-Amino-3-methyl-5-(3’,5’-di-O-(4,4’-dimethoxytrityl)-2’-deoxy-
β-D-ribofuranosyl)pyridine 
262 
127 β  2-[N-(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(5’-O-
(4,4’-dimethoxytrityl)- 2’-deoxy-β-D-ribofuranosyl)pyridine 
264, 267 








130 β  2-[N,N-bis-(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-
(3’,5’-di-O-benzyl-2’-deoxy-β-D-ribofuranosyl)pyridine 
271 
131 β  2-[N-(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(3’,5’-di-
O-benzyl-2’-deoxy-β-D-ribofuranosyl)pyridine 
271 
132 β  2-[N,N-bis-(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(2’-
deoxy-β-D-ribofuranosyl)pyridine 
273 
133 β  2-[N-(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(3’-O-
benzyl-2’-deoxy-β-D-ribofuranosyl)pyridine 
273 
134 β  2-Amino-3-methyl-5-(3’,5’-O-[1,1,3,3-tetraisopropyldisiloxane-
1,3-diyl]-β-D-ribofuranosyl)pyridine 
213 
135  3’,5’-Di-O-paramethoxybenzyl-2’-deoxy-D-ribose 254 









In all cases where the same reactions have been carried out more than once, the best 

















A solution of hydrochloric acid in methanol (60.85 mL) [made from acetyl chloride 
(0.85 mL, 12 mmol) in methanol (60 mL, 1484 mmol)] was added dropwise to a 
solution of D-ribose (30.0 g, 200 mmol) in methanol (230 mL). The mixture was stirred 
at r.t for 24 hrs. Upon completion sodium bicarbonate (17.0 g, 202 mmol) was added. 
The mixture was filtered, concentrated in vacuo, co-evaporated with toluene, and then 
redissolved in anhydrous DMF (230 mL). Benzyl bromide (143 mL, 1200 mmol) was 
added and the reaction mixture cooled to 0 C before portion wise addition of sodium 
hydride (60 % dispersion in mineral oil, 48.0 g, 1200 mmol). The reaction was then left 
to stir at r.t for 15 hrs and methanol (175 mL) was added cautiously. The mixture was 
reduced in vacuo, and then partitioned between DCM and water. The organic layers 
were combined and dried over anhydrous sodium sulphate, and the solvent removed in 
vacuo. Purification by column chromatography (Hex: EA 9:1, 8:1, 7:1, 0:1 v/v) afforded 
85 (78.33 g, 90.1 %) as yellow oils. 
 
Data for α anomer:  
 
Rf (Hex: EA 7:3, A’): 0.49 
 
LRMS: [ES
+, MeOH] m/z (%): 457 ((M+Na)
+, 37), 452 ((M+NH4)
+, 100).  
 
HRMS: [ES
+] found 457.1977 Da (M+Na
+) calculated 457.1985 Da. 
 200 
 
1H NMR (300 MHz, CDCl3): δ 7.34-7.15 (15H, m, H
Ar), 4.84 (1H, d, J = 1.1 Hz, H
1’), 
4.59 (1H, d, J = 11.7 Hz, Bn-CH), 4.54 (1H, d, J = 12.1 Hz, Bn-CH), 4.50 (1H, d, J = 
12.1 Hz, Bn-CH), 4.48 (1H, d, J = 12.1 Bn-CH), 4.46 (1H, d, J = 12.1 Hz, Bn-CH), 
4.38 (1H, d, J = 12.1 Bn-CH), 4.26 (1H, ddd, J = 7.0, 5.5, 3.7 Hz, H
4’), 3.94 (1H, dd, J 
= 7.0, 4.7 Hz, H
3’), 3.76 (1H, dd, J = 4.7, 1.1 Hz, H
2’), 3.54 (1H, dd, J = 10.6, 4.0 Hz, 
H
5’), 3.44 (1H, dd, J = 10.6, 5.9 Hz, H
5’), 3.24 (3H, s, OCH3).  
 
13C NMR (75 MHz, CDCl3): δ 138.5, 138.1 (C
Ar), 128.5, 128.5, 128.4, 128.1, 128.0, 





3’), 73.4, 72.6, 
72.5 (Bn-CH2), 71.5 (C
5’), 55.2 (OCH3).  
 
IR:  νmax/cm
-1 (neat) 3062 (w, aromatic C-H), 3029 (w, aromatic C-H), 1496 (w, 
aromatic C=C), 1453 (m, aromatic C=C), 1103 (m, C-O), 1065 (m, C-O), 1026 (s, C-O). 
 
Data for β anomer:  
 
Rf (Hex: EA 7:3, A’): 0.20 
 
LRMS: [ES
+, MeOH] m/z  (%): 458 ((M(
13C)+Na)
+, 27), 457 ((M+Na)





+] found 457.1985 Da (M+Na
+) calculated 457.1985 Da. 
 
1H NMR (300 MHz, CDCl3): δ 7.40-7.22 (15H, m, H
Ar), 4.89 (1H, d, J = 4.0 Hz, H
1’), 
4.71 (1H, d, J = 12.8 Hz, Bn-CH), 4.67 (1H, d, J = 13.1 Hz, Bn-CH), 4.62 (1H, d, J = 
12.5 Hz, Bn-CH), 4.59 (1H, d, J = 12.4 Hz, Bn-CH), 4.51 (1H, d, J = 12.1 Hz, Bn-CH), 
4.45 (1H, d, J = 12.1, Bn-CH), 4.27 (1H, dd, J = 6.9, 4.0 Hz, H
4’), 3.85 (1H, dd, J = 6.9, 
3.3 Hz, H
3’), 3.80 (1H, dd, J = 6.6, 4.0 Hz, H
2’), 3.49 (3H, s, OCH3), 3.45 (1H, dd, J = 
10.6, 4.4 Hz, H
5’), 3.39 (1H, dd, J = 10.6, 4.4 Hz, H
5’).  
 
13C NMR (75 MHz, CDCl3): δ 138.2, 138.1, 138.0 (C






3’), 73.6, 72.7, 72.5 (Bn-CH2), 
70.4 (C
5’), 55.7 (OCH3). 201 
 
IR:  νmax/cm
-1 (neat) 3062 (w, aromatic C-H), 3029 (w, aromatic C-H), 1496 (w, 
aromatic C=C), 1453 (m, aromatic C=C), 1104 (m, C-O), 1038 (s, C-O), 1026 (s, C-O). 
 



















85 (78.33 g, 180.3 mmol) was stirred in acetic acid solution (80 % in water, 355 mL). 
Concentrated sulphuric acid (11.3 mL) was added and the mixture heated to reflux 
(120 °C) for 30 mins. The acetic acid was then removed in vacuo. DCM (355 mL) was 
added to the reaction mixture after it was cooled to r.t, neutralisation (pH 7-8) by 
sodium bicarbonate followed. The reaction mixture was then partitioned between DCM 
and water. The organic layers were combined and dried over anhydrous sodium 
sulphate. The solvent was then removed in vacuo to give a red-brown oil (75.8 g). The 
crude mixture was initially purified by filtration through a silica plug (EA: Hexane 2:3) 
to remove acidic and salt impurities. Further purification by column chromatography 
(Hex: EA 4:1, 3:1, 1:1 v/v) afforded the lactol intermediate, 90 (50.0 g, 65.9 %) as an 
orange-brown oil. 
 
Data for α anomer:  
 
Rf (Hex: EA 7:3, A’): 0.18 
 
Data for β anomer:  
 
Rf (Hex: EA 7:3, A’): 0.03 
 
Data for anomeric mixture: 202 
 
LRMS: [ES
+, CH3OH]  m/z (%): 863 ((2M+Na)
+, 6), 444 ((M(
13C)+Na)
+, 27), 443 
((M+Na)




+] found 443.1824 Da (M+Na
+) calculated 443.1829 Da. 
 
IR: νmax/cm
-1 (neat); 3415 (w br, O-H), 3030 (w, aromatic C-H), 2864 (w br, O-H), 
1496 (w, aromatic C=C), 1453 (m, aromatic C=C), 1240 (w, C-O), 1206 (w, C-O), 1075 


















90 (47.0 g, 111.7 mmol ) was dissolved in anhydrous DCM (250 mL), molecular sieves 
were added, followed by addition of N-methylmorpholine-N-oxide (20.9 g, 
178.3  mmol). The reaction mixture was then cooled to 0 °C before adding tetra-n-
propylammonium perruthenate (VII) (2.1 g, 5.95 mmol). The reaction mixture was left 
to warm to r.t and stirred for 4 hrs, after which it was initially purified through a silica 
plug eluting with hexane. The filtrate was concentrated in vacuo, and upon purification 
by column chromatography (Hex: EA 8:1, 6:1, 4:1, 3:1 v/v) 64 was isolated as a light 
yellow solid (39.0 g, 83.4 %). 
 
Rf (Hex: EA 7:3, A’): 0.41  
 
mp: 57-59 °C , lit
249 54-55 °C (diisopropyl ether). 
 
LRMS: [ES
+, MeOH] m/z (%): 859 ((2M+Na)
+, 33), 854 ((2M+NH4)
+, 48), 441 
((M+Na)
+, 46), 436 ((M+NH4)





+] found 441.1675 Da (M+Na
+) calculated 441.1672 Da. 
 
1H NMR (300 MHz, CDCl3): δ 7.41-7.28 (15H, m, H
Ar), 4.97 (1H, d, J = 12.1 Hz, Bn-
CH), 4.76 (1H, d, J = 12.1 Hz, Bn-CH), 4.72 (1H, d, J = 11.0 Hz, Bn-CH), 4.58-4.54 
(2H, m, H
4’ plus Bn-CH), 4.52 (IH, d, J = 13.2 Hz, Bn-CH), 4.43 (1H, d, J = 11.7 Hz, 
Bn-CH), 4.40 (1H, d, J = 5.9 Hz, H
2’), 4.12 (1H, dd, J = 5.5, 1.8 Hz, H
3’), 3.68 (1H, dd, 
J = 11.0, 2.9 Hz, H
5’), 3.57 (1H, dd, J = 11.0, 2.9 Hz, H
5’).  
 









-1 (neat) 3061 (w, aromatic C-H ), 3032 (w, aromatic C-H), 2913 (w, alkane 
C-H), 2867 (w, alkane C-H), 1779 (s, C=O), 1453 (m, aromatic C=C), 1360 (m, C-O), 
1101 (m, C-O), 1047 (s, C-O), 1026 (s, C-O). 
 








To a solution of 2-Amino-5-bromo-3-methylpyridine (20 g, 107.5 mmol) in anhydrous 
DMF (430 mL) was added 4-methoxybenzyl chloride (36.4 mL, 268.7 mmol) and the 
solution cooled to 0 °C for 30 mins before careful portion wise addition of sodium 
hydride (60 % dispersion in mineral oil, 10.7 g, 268.7 mmol). The reaction mixture was 
then left to stir at r.t for 4 hrs 35 mins. Upon completion water (5 mL) was added 
dropwise until the release of H2 gas ceased. Solvent was then removed under high 
vacuum. The residue was redissolved in DCM and quenched with water. The organic 204 
 
phases were combined, dried over anhydrous sodium sulphate and solvent removed in 
vacuo. Recrystallisation proceeded using the following method. The residue was 
redissolved in 95 % ethanol/water (450 mL), activated charcoal was added (4.6 g) and 
the mixture stirred at 105 °C for ~1 hr. The mixture was then filtered over celite 
(glassware had been kept in the oven for over 2 hrs). The filtrate was allowed to cool to 
r.t and crystallisation followed after leaving overnight at 4 °C. The crystals were filtered 
and washed with ice cold ethanol, and left to dry under high vacuum to give 86 (> 35 g, 
> 76.4 %) as white crystals. 
 
Rf (Hex: EA 1:1, A’): 0.62 
 
mp: 83-85 °C  
 
LRMS: [ES








+, 21), 429 ((M(
81Br)+H)
+, 99), 428 ((M(
13C)(
79Br)+H)






+] Found 427.1018 Da (M(Br
79)+H)
+ calculated 427.1016 Da. 
    Found 429.1018 Da (M(Br
81)+H)
+ calculated 429.1021 Da. 
 
1H NMR (300 MHz, CDCl3): δ 8.16 (1H, d, J = 2.0 Hz, H
6); 7.51 (1H, d, J = 2.0 Hz, 
H
4); 7.14 (4H, d, J = 8.5 Hz, H
9); 6.81 (4H, d, J = 8.6 Hz, H
10); 4.21 (4H, s, H
7); 3.78 
(6H, s, OCH3), 2.36 (3H, s, CH3). 
 









10), 55.3 (OCH3), 53.8 (C
7), 18.8 (CH3). 
 
IR: νmax/cm
-1 (neat) 3000 (w, C-H aromatic), 2954 (w, C-H), 2929 (w, C-H), 2834 (w, 
C-H), 1509 (s, C=C aromatic), 1463 (m, C=C aromatic), 1448 (m, C=C aromatic), 1364 
(m, C-N), 1244 (s, C-N), 1167 (s, C-N), 1033 (s, C-O). 
 











86 (36.0 g, 84.2 mmol) was dissolved in anhydrous THF  (180  mL)  and  cooled  to           
– 78 °C under an argon atmosphere before adding n-butyllithium (1.6 M solution in 
hexanes, 54.0 mL, 86.7 mmol). The mixture changed colour from yellow to orange-
yellow. The reaction mixture was stirred for 1 hr 30 mins at - 78 °C before adding 64 
(38.0 g, 90.3 mmol) dropwise via cannular as a solution in THF (135 mL). The reaction 
mixture was stirred for a further 30 mins at - 78 °C before allowing to warm to 0 °C, the 
reaction mixture was left to stir for 1 hr. Saturated sodium bicarbonate (750 mL) was 
added and the mixture extracted with diethyl ether. The organic layers were combined, 
dried over anhydrous sodium sulphate and the solvent removed in vacuo to give an 
orange-brown oil, 91. 91 was left to dry under high vacuum overnight. 
 









































Note: Equivalents of reagents are with respect to 86. 
 
91 was dissolved in anhydrous DCM (240 mL) and cooled to - 78 C under an argon 
atmosphere before adding triethylsilane (81 mL, 504 mmol) and boron trifluoride 
diethyl etherate (63 mL, 504 mmol). The mixture was left to stir at - 78 C for 4 hrs, 
0 C for 2 hrs, before leaving to warm to r.t overnight (16 hrs). Saturated sodium 
bicarbonate solution (120 mL) was added to the reaction mixture, and left to stir for 
1  hr. The reaction mixture was then extracted with DCM. The organic layers were 
combined, dried over anhydrous sodium sulphate and solvent removed in vacuo to give 
a brown oil, 92 β. 
 

































Note: Equivalents of reagents are with respect to 86. 
 
92 β was dissolved in DCM (150 mL) and to this trifluoroacetic acid (150 mL) was 
added, the reaction mixture was left to stir at r.t for 20 hrs. On completion the mixture 
was evaporated to dryness and the residue dissolved in DCM (900 mL) and washed 
extensively with sat. NaHCO3 (aq) (1500 mL). The organic layers were combined, dried 
over anhydrous sodium sulphate and solvent removed in vacuo to give a brown oil. 
Purification by column chromatography (Hex: EA 1:1, 2:8, 0:1 v/v) afforded 68 β as an 
orange-brown oil (25.4 g, 49.8 mmol, 59.1 %). 
 
Note: Final percentage yield is with respect to the starting material 86 i.e. over the 3- 
step synthesis. 
 
Rf (EA, B’): 0.21 
 
LRMS: [ES
+, CH3CN]  m/z (%): 533 ((M+Na)
+, 5), 512 ((M(
13C)+H)




1H NMR (300 MHz, CDCl3): δ 7.93 (1H, d, J = 1.8 Hz, H
6), 7.38-7.17 (16H, m, H
4 
plus H
Ar), 4.89 (1H, d, J = 7.3 Hz, H
1’), 4.67 (1H, d, J = 12.1 Hz, Bn-CH), 4.62 (1H, d, 
J = 12.1 Hz, Bn-CH), 4.60 (1H, d, J = 12.1 Hz, Bn-CH), 4.55 (1H, d, J = 11.7 Hz, Bn-
CH), 4.53 (1H, d, J = 12.1 Hz, Bn-CH), 4.48 (2H, br s, NH2), 4.44 (1H, d, J = 12.1 Hz, 
Bn-CH), 4.31 (1H, dd, J = 7.3, 3.7 Hz, H
4’), 4.04 (1H, dd, J = 5.1, 3.3 Hz, H
3’), 3.82 208 
 
(1H, dd, J = 7.3, 4.4 Hz, H
2’), 3.66 (1H, dd, J = 10.6, 4.0 Hz, H
5’), 3.61 (1H, dd, J = 
10.3, 3.7 Hz, H
5’),  2.18 (3H, s, CH3).  
 
13C NMR (75 MHz, CDCl3): δ 156.9 (C
2), 145.2 (C
5), 143.8 (C
6), 138.3, 138.1, 137.8 
(C
Ar), 136.5 (C









































A solution of 68 β (1.6 g, 3.13 mmol) in anhydrous pyridine (5.8 mL, 71.7 mmol), was 
cooled to 0 °C under an argon atmosphere, before dropwise addition of trifluoroacetic 
anhydride (0.5 mL, 3.45 mmol). The reaction mixture was left to warm to r.t and stirred 
for 17 hrs. Upon completion, the reaction mixture was quenched with saturated 
potassium chloride (100 mL) and extracted with DCM (300 mL). The organic layers 
were combined and dried over anhydrous sodium sulphate; solvent was reduced in 
vacuo to give a red-brown oil. Purification by column chromatography 
(Hex: EA 1:0, 3:1, 2:1, 1:1 v/v) afforded 93 β (2.05 g, quantitative yield) as a yellow-
green oil. 
 
Rf (DCM: MeOH 97:3, B’): 0.47 209 
 
LRMS: [ES
+, CH3CN] m/z (%): 630 ((M(
13C)+Na)
+, 37), 629 ((M+Na)



























A solution of 93 β (2.0 g, 3.30 mmol) in anhydrous DCM (20 mL) was cooled to           
– 78 °C under an argon atmosphere; boron tribromide (1.0 M solution in DCM, 14.85 
mL, 14.85 mmol) was added dropwise. The reaction mixture was left to stir at – 78 °C 
for 4 hrs. Methanol (10 mL) was added cautiously and the reaction mixture left to warm 
to r.t and stirred overnight. The solvent was removed in  vacuo and the residue 
redissolved in methanol (2 mL). DCM (300 mL) was added portion-wise and a 
precipitate, 94 β started to form. The solvent was removed via syringe and the white-
grey solid, 94 β (0.79 g, quantitative) fully formed after storage in freezer overnight.  
 
Rf (DCM: MeOH 9:1, A’): 0.25 
 
LRMS: [ES
+, CH3CN] m/z (%): 242 ((M(
13C)+H)




+] found 241.1187 Da (M+H
+) calculated 241.1183 Da. 
 
1H NMR (300 MHz, CD3OD): δ 7.89 (1H, s, H
6), 7.83 (1H, s, H
4), 4.62 (1H, d, J = 7.3 
Hz, H
1’), 4.11 (1H, dd, J = 5.1, 3.3 Hz, H
3’), 4.00 (1H, dd, J = 7.7, 4.0 Hz, H
4’), 3.89 
(1H, dd, J = 7.3, 5.5 Hz, H
2’), 3.79 (1H, dd, J = 12.1, 3.7, H
5’), 3.72 (1H, dd, J = 12.1, 
4.4, H
5’), 2.27 (3H, s, CH3). 
 210 
 
13C NMR (75 MHz, CD3OD): δ 155.2 (C










5’), 16.8 (CH3). 
 
IR: νmax/cm
-1 (neat) 3180 (s, br, O-H and N-H), 3210 (s, br, O-H and N-H), 3120 (s, br, 
O-H and N-H), 3075 (s, br, O-H and N-H), 3000 (w, aromatic C-H), 1668 (s, aromatic 
C=C), 1625 (s, aromatic C=C), 1574 (m, aromatic C=C), 1469 (w, aromatic C=C), 1454 



























To a solution of 68 β (12.0 g, 23.5 mmol) in anhydrous methanol (50 mL), was added 
N,N-dimethylformamide dimethyl acetal (15.6 mL, 117.6 mmol) and the reaction 
mixture heated to reflux (80 °C) for 4 hrs after which, another addition of N,N-
dimethylformamide dimethyl acetal (15.6 mL, 117.6 mmol) was added. Completion 
occurred after 18 hrs reflux as confirmed by MS; the solvent was removed in vacuo. 
Purification by column chromatography (DCM: MeOH 1:0, 99:1, 98:2, 97:3 v/v) 
afforded 95 β (9.0 g, 67.8 %) as a yellow oil. 
 
Rf (EA): 0.41 
 
LRMS: [ES
+, CH3CN] m/z (%): 568 ((M(2 
13C)+H)
+, 6), 567 ((M(
13C)+H)






+] found 566.3003 Da (M+H
+) calculated 566.3013 Da. 
 
1H NMR (400 MHz, CDCl3): δ 8.27 (1H, s, H




Ar), 4.85 (1H, d, J = 7.6 Hz, H
1’), 4.57 (1H, d, J = 12.0 Hz, Bn-CH), 
4.51 (1H, d, J = 12.0 Hz, Bn-CH), 4.46 (1H, d, J = 12.0 Hz, Bn-CH), 4.40 (1H, d, J = 
12.1 Hz, Bn-CH), 4.36 (1H, d, J = 12.0 Hz, Bn-CH), 4.23 (1H, dd, J = 7.6, 3.5 Hz, H
4’), 
3.93 (1H, dd, J = 5.5, 3.5 Hz, H
3’), 3.74 (1H, dd, J = 7.5, 5.5 Hz, H
2’), 3.57 (1H, dd, J = 
10.5, 4.0 Hz, H
5’), 3.52 (1H, dd, J = 10.6, 4.0 Hz, H
5’), 3.00 (6H, s,  NCH3), 2.13 (3H, 
s, CH3).  
 






Ar), 128.9, 128.3, 128.2, 128.2, 128.1, 127.9, 127.7, 127.6, 127.6, 127.5, 





3’), 73.3, 72.1, 71.8 
(Bn-CH2), 70.4 (C
5’), 40.3, 34.2 (NCH3), 17.5 (CH3). 
 
Analytical data was consistent with that reported in the literature.
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A solution of 95 β (9.09 g, 16.1 mmol) in anhydrous DCM (70 mL) was cool - 78 °C 
under an argon atmosphere, before the careful addition of BBr3 (1.0 M in DCM, 72 mL, 212 
 
72.0 mmol). The reaction mixture was left to stir at - 78 °C for 3 hrs before the careful 
addition of methanol (70 mL). The reaction mixture was left to warm to - 68 °C for 
2 hrs and then r.t for 3 hrs before the removal of solvent in vacuo. The residue was 
redissolved in water (100 mL) and extracted with DCM (50 mL). The aqueous layer 
was isolated and co-evaporated with anhydrous pyridine. The residue was dried under 





A solution of 94 β (0.58 g, 2.40 mmol) in anhydrous methanol (6 mL) was heated to 
45 °C,  N,N-dimethylformamide dimethyl acetal (3.2 mL, 24 mmol) was added (the 
reaction mixture changed from a colourless solution to a yellow solution). The reaction 
mixture was heated to reflux (80 °C) for 5 mins. Solvent was removed in  vacuo. 
Purification by column chromatography (DCM: MeOH 97:3, 9:1, 85:15 v/v) afforded 
96 β (0.55 g, 77.1 %) as a light yellow residue. 
 
Rf (DCM: MeOH 8:2, B’): 0.38 
 
LRMS: [ES
+, CH3CN] m/z (%): 297 ((M(
13C)+H)




+] found 296.1604 Da (M+H
+) calculated 296.1605 Da. 
 
1H NMR (300 MHz, DMSO): δ 8.53 (1H, s, H
7), 8.09 (1H, s, H
6), 7.66 (1H, d, J = 1.5 
Hz, H
4), 4.95 (3H, br s, OH
2’, OH
3’ plus OH
5’), 4.54 (1H, d, J = 7.3 Hz, H
1’), 3.92 (1H, 
dd, J = 5.1, 3.3 Hz, H
3’), 3.81 (1H, dd, J = 7.7, 4.0 Hz, H
4’), 3.74 (1H, br t, J = 6.6 Hz, 
H
2’), 3.57 (1H, dd, J = 12.4, 4.7 Hz, H
5’), 3.51 (1H, dd, J = 12.1, 4.8 Hz, H
5’), 3.21 
(3H, s, NCH3), 3.13 (3H, s, NCH3), 2.28 (3H, s, CH3).  
 











5’), 35.4 (NCH3), 34.2 
(NCH3), 17.1 (CH3). 
 
Analytical data was consistent with that reported in the literature.
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2-N,N-[(dimethylamino)methylidene]-3-methyl-5-(3’,5’-O-[1,1,3,3-

















































A solution of 96 β (4.7 g, 15.9 mmol) in anhydrous pyridine (100 mL) was cooled to 
0  °C before the dropwise addition of 1,3-dichloro-1,1,3,3-tetraisopropyl disiloxane 
(7.6 mL, 23.9 mmol). The reaction mixture was left to stir at 0 °C for 1 hr, followed by 
r.t for 4 hrs. Solvent was then removed under high vacuum and the residue redissolved 
in DCM (100 mL) and washed with sat. NaHCO3 (aq) (50 mL). The aqueous layer was 
further extracted with DCM. The organic layers were combined and dried over 
anhydrous sodium sulphate. Solvent was removed in  vacuo to give a brown oil. 
Purification by column chromatography (Hex: EA 3:1, 2:1, 1:1, 1:2, 1:3 v/v) afforded 
97 β (trans: cis 4:1, 4.86 g, 9.04 mmol) and 134 β (0.223 g, 0.46 mmol) as light yellow 
oils (59.7 % overall yield). 
 
Data for isomeric mixture 97 β: 
 
Rf (Hex: EA 1:1): 0.23 
 
LRMS:¨[ES
+, CH3CΝ] m/z  (%): 539 ((Μ(
13C)+Η)





+] found 538.3121 Da (M+H
+) calculated 538.3127 Da. 
 
Data for major isomer (trans): 
 
1H NMR (400 MHz, CDCl3): δ 8.32 (1H, s, H
7), 8.07 (1H, d, J = 2.0 Hz, H
6), 7.40 (1H, 
d, J = 1.5 Hz, H
4), 4.72 (1H, d, J = 4.0 Hz, H
1’), 4.39-4.35 (1H, m, H




5’), 3.07 (6H, s, NCH3), 2.97 (1H, br s, OH
2’), 2.28 (3H, s, CH3), 1.09-
1.03 (28H, m, CH3 plus CH from TiPDS).  
 











5’), 40.6, 34.6  (NCH3),  
17.8, 17.6, 17.6, 17.5, 17.3, 17.2, 17.1 (CH3 plus TiPDS-CH3), 13.6, 13.4, 13.0, 12.8 
(TiPDS-CH). 
 
Data for minor isomer (cis): 
 
1H NMR (300MHz, CDCl3): δ 8.33 (0.26H, s, H
7), 7.95 (0.26H, s, H
6), 7.30 (0.26H, s, 
H
4), 4.66 (0.26H, d, J = 4.5 Hz, H
1’), 4.39-4.35 (0.26H, m, H




5’), 3.07 (1.56H, s, NCH3), 2.97 (0.26H, br s, OH
2’), 2.29 (0.78H, s, 
CH3), 1.09-1.03 (7.28H, m, CH3 plus CH from TiPDS). 
 











5’), 40.6, 34.6  (NCH3), 
17.8, 17.6, 17.6, 17.5, 17.3, 17.2, 17.1 (CH3 plus TiPDS-CH3), 13.6, 13.4, 13.0, 12.8 
(TiPDS-CH). 
 











































To a solution of 97 β (0.349 g, 0.65 mmol) in anhydrous DMF (3 mL) was added 1,1-
thiocarbonyl diimidazole (0.3 g, 1.62 mmol) and the reaction mixture stirred at r.t under 
an argon atmosphere for 25 hrs.  Solvent was removed under high vacuum. The residue 
was quenched with saturated sodium chloride solution (30 mL) and extracted with 
DCM (3 x 50 mL). The organic layers were combined and dried over anhydrous sodium 
sulphate. Solvent was removed in vacuo to give a yellow oil. Purification by column 
chromatography (DCM: MeOH 1:0, 99:1, 98:2, 97:3 v/v) afforded 98  β (0.233 g, 
55.3 %) as a light-yellow solid. 
 
Rf (EA: NH3: MeOH 5:1:1): 0.67 
 
LRMS: [ES
+, CH3CN]  m/z (%): 671 ((M(
13C)+Na)
+, 5), 670 ((M+Na)
+, 11), 649 
((M(
13C)+H)




+] found 648.3060 Da (M+H
+) calculated 648.3066 Da. 
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1H NMR (300 MHz, CDCl3): δ 8.32 (1H, s, H
7/H
10), 8.30 (1H, s, H
7/H
10), 8.12 (1H, d, 
J = 2.2 Hz, H
6), 7.61 (1H, t, J = 1.5 Hz, H
9), 7.46 (1H, d, J = 2.2 Hz, H
4), 6.99 (1H, m,  
H
8), 5.66 (1H, dd, J = 4.7, 1.4 Hz, H
2’), 5.10 (1H, d, J = 1.5 Hz, H
1’), 4.57 (1H, dd, J = 
8.8, 5.1, H
3’), 4.15 (1H, dd, J = 12.8, 2.6, H
5’), 4.05-4.00 (2H, m, H
4’plus H
5’), 3.02 
(6H, s, NCH3), 2.23 (3H, s, CH3), 1.03-0.87 (28H, m, CH3 plus CH from TiPDS).  
 















5’), 40.6, 34.6 (NCH3), 17.9, 17.6, 17.5, 17.4, 17.2, 17.1, 17.0 
(CH3 plus TiPDS-CH3), 13.5, 13.2, 12.9, 12.8 (TiPDS-CH). 
 































To a solution of 98 β (0.192 g, 0.297 mmol) in anhydrous toluene (3 mL) was added 
azobisisobutyronitrile, AIBN (0.01 g, 0.059 mmol) and tris(trimethylsilyl)silane 
(0.11 mL, 0.342 mmol), under an argon atmosphere. The reaction mixture was left to 
stir at r.t for 1 hr while purging under argon, after which it was heated to 80 °C for 
5 hrs. The reaction mixture was cooled to r.t before adding NaOH (1.0 M, 15 mL).  The 
mixture was extracted with ethyl acetate.  The organic layers were combined, dried over 217 
 
sodium sulphate and the solvent removed in vacuo. Purification by column 
chromatography (Hex: EA 1:1, 0:1 v/v) caused decomposition of 99 β. Reaction had 
proceeded successfully as was shown by MS monitoring throughout the reaction, 
producing the peak for the correct mass of the product. 
 
LRMS: [ES
+, CH3CN] m/z (%): 1044 ((2M(
13C)+H)
+, 14), 1043 ((2M+H)
+, 18), 523 
((M(
13C)+H)

































To a solution of 68 β (4.77 g, 9.35 mmol) in anhydrous pyridine (30 mL) was added  
phenoxyacetic anhydride (4.55 g, 15.9 mmol) portion wise, and the reaction mixture left 
to stir at r.t under an argon atmosphere for 4 hrs 30 mins. Water (13 mL) was added to 
the reaction mixture and solvent removed under high vacuum. The residue was 
redissolved in ethyl acetate (150 mL) and quenched with sodium carbonate (1.0 M, 
100  mL). The organic phases were combined and dried over anhydrous sodium 
sulphate. Solvent was removed in  vacuo.  Purification by column chromatography 
(DCM: EA 99:1, 98:2, 97:3, 96:4, 95:5, 9:1, 85:15, 8:2, 7:3 v/v) afforded 69 β (4.80 g, 
79.5 %) as a light-brown oil. 
 




+, CH3CN] m/z (%): 669 ((M(2 
13C)+Na)






1H NMR (300 MHz, CDCl3): δ 8.58 (1H, br s, NH), 8.31 (1H, d, J = 2.2 Hz, H
6), 7.60 
(1H, d, J = 2.2 Hz, H
4), 7.40-7.20 (17H, m, H
Ar plus H
10), 7.07 (1H, t, J = 7.5 Hz, H
11);  
7.02 (2H, d, J = 6.0 Hz, H
9), 5.03 (1H, d, J = 7.0 Hz, H
1’), 4.70-4.43 (8H, m, Bn-CH2 
plus H
7), 4.37 (1H, dd, J = 7.3, 3.7 Hz, H
4’), 4.06 (1H, dd, J = 5.1, 4.0 Hz, H
3’), 3.83 
(1H, dd, J = 6.6, 5.1 Hz, H
2’), 3.70 (1H, dd, J = 10.6, 4.0, H
5’), 3.62 (1H, dd, J = 10.2, 
3.7, H
5’), 2.16 (3H, s, CH3).  
 





4), 138.1, 137.9, 137.8 (C
Ar), 137.5 (C
5), 134.6 (C
3), 130.0, 128.5, 128.5, 128.4, 










3’) 73.6 (Bn-CH2), 72.6 (C
5’), 72.1 (Bn-
CH2), 70.4 (C
7), 67.5 (Bn-CH2), 18.0 (CH3). 
 




3-Methyl-2-[N-(phenoxyacetyl)amino]-5-(β-D-ribofuranosyl)pyridine,  (70  β); 2- 




A solution of 69 β (6.65 g, 10.3 mmol) in anhydrous DCM (60 mL) was cooled to         
– 78 °C before addition of boron tribromide (47 mL, 47 mmol) cautiously under an 
argon atmosphere. (On addition of BBr3, the reaction mixture changed colour from light 219 
 
brown to milky brown). The reaction mixture was left to stir at - 78 °C for 4 hrs after 
which methanol (23 mL) was added and the reaction mixture was left to stir overnight at 
r.t. Solvent was then removed in vacuo. The residue was quenched with DCM (60 mL) 
and extracted with water (120 mL). The aqueous layers were combined and neutralised 
with NaOH (2.0 M). Solvent was removed slightly to give an optimum concentration to 
allow for precipitation. Precipitation occurred after 48 hrs storage at 4  °C. The 
precipitate was filtered under vacuum, and then dried under high vacuum to afford 70 β 
(0.837 g, 2.24 mmol) as a white solid. The filtrate was reduced in vacuo, and pre-
adsorbed onto silica with methanol, water and acetone. The solvents were then co-
evaporated with toluene. Purification by column chromatography (DCM: MeOH 9:1, 
8:2, 6:4, 55:45 v/v) afforded 94 β (1.14 g, 4.74 mmol) as a pale peach solid. The overall 
yield for the reaction was 67.8 %. 
 
Data for compound 70 β: 
 
Rf (DCM: MeOH 9:1, A’): 0.24 
 
LRMS: [ES
+, MeOH] m/z (%): 772 ((2M+Na)
+, 70), 398 ((M(
13C)+Na)
+, 22), 397 
((M+Na)
+, 100), 376 ((M(
13C)+H)
+, 15), 375 ((M+H)
+, 63). 
     [ES
-, MeOH] m/z (%): 373 ((M+Na)
+, 100). 
 
1H NMR (400 MHz, Pyr-d5): δ 11.1 (1H, s, NH), 8.88 (1H, d, J = 1.5 Hz, H
6); 8.02 
(1H, d, J = 1.5 Hz, H
4), 7.33 (2H, t, J = 8.5 Hz, H
10), 7.16 (2H, d, J = 7.5 Hz, H
9),  7.03 
(1H, t, J = 7.0 Hz, H
11), 5.36 (1H, d, J = 7.5 Hz, H
1’), 5.05 (2H, s, H
7), 4.84 (1H, dd, J 
= 5.5, 3.5 Hz, H
3’), 4.73 (1H, dd, J = 7.5, 4.0 Hz, H
4’), 4.54 (1H, dd, J = 7.0, 5.5 Hz, 
H
2’), 4.29 (1H, dd, J = 11.5, 4.0, H
5’), 4.23 (1H, dd, J = 11.6, 4.0, H
5’), 2.29 (3H, s, 
CH3). 
 














5’), 18.5 (CH3). 
 
































A solution of 94 β (1.14 g, 4.75 mmol) in anhydrous pyridine (16 mL) was cooled to 
0 °C before dropwise addition of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (1.8 mL, 
5.68 mmol) under an argon atmosphere. The reaction mixture was left to stir at 0 °C for 
1 hr 30 mins, then r.t for 4 hrs. The solvent was co-evaporated with ethanol in vacuo. 
The residue was quenched with NaOH (1.0 M, 7 mL), and extracted with DCM 
(14 mL). The aqueous layer was further extracted with DCM. The organic layers were 
combined, dried over anhydrous sodium sulphate and the solvent removed in vacuo to 
give crude as a peach oil. Purification by column chromatography (DCM: MeOH 1:0, 
99:1, 3:97 v/v) afforded 100 β (1.152 g, 50.3 %) as a peach foam. 
 
Rf (DCM: MeOH 9:1, B’): 0.09 
 
LRMS: [ES
+, MeOH] m/z (%): 484 ((M(
13C)+H)
+, 36), 483 ((M+H)
+, 100). 
 
1H NMR (400 MHz, CDCl3): δ 7.84 (1H, s, H
6), 7.43 (1H, s, H
4), 4.63 (1H, d, J = 4.5 
Hz, H
1’), 4.33 (1H, t, J = 6.0 Hz, H




5’), 3.87 (1H, dd, J = 6.0, 4.5 Hz, H
2’), 2.18 (3H, s, CH3), 1.08-1.02 
(28H, m, CH3 and CH from TIPDS). 221 
 
13C NMR (100 MHz, CDCl3): δ 155.7 (C
2), 138.3 (C
6), 137.7 (C







5’), 17.6 (CH3), 17.5, 17.4, 17.2, 






























N,N’-dicyclohexylcarbodiimide, DCC (7.46 g, 36.1 mmol) was slowly added to a stirred 
solution of phenoxyacetic acid (5.00 g, 32.9 mmol) in DCM (50 mL) at r.t. The 
resulting solution was stirred for 15 mins. A solution of pentafluorophenol (6.05 g, 
32.9 mmol) in DCM (50 mL) was slowly added, and the solution was stirred at r.t for a 
further 5 hrs. The resulting precipitate (dicyclohexylurea) was removed through 
filtration. The filtrate was quenched with water and extracted with DCM (3 x 100mL). 
The combined organic layers were dried over anhydrous sodium sulphate and solvent 
removed  in  vacuo. Purification by column chromatography (Hex: Et2O 9:1 v/v) 
afforded 101 (7.58 g, 72.5 %) as a white solid. 
 
Rf (Pet ether: Et2O 9:1, A’): 0.53 
 
1H NMR (400 MHz, CDCl3): δ 7.34 (2H, t, J = 8.6 Hz, H
8), 7.06 (1H, t, J = 6.5 Hz, 
H
9), 6.98 (2H, d, J = 9.0 Hz, H
7), 5.00 (2H, s, H
5). 
 
13C NMR (100 MHz, CDCl3): δ 165.4 (C=O), 157.1 (C
6), 141.2 (142.5 and 139.9, 2C, 
ddt, 
1JC,F = 255.3 Hz, 
2JC,F = 8.7 Hz, 
2JC,F = 4.8 Hz, C
2-F), 139.9 (141.2 and 138.7, 1C, 
dtt, 
1JC,F = 255.8 Hz, 
2JC,F = 13.5 Hz, 
3JC,F = 9.7Hz, C
1-F), 138.1 (139.3 and 136.9, 2C, 
dtd, 
1JC,F = 245.4 Hz, C
3-F), 129.9 (C






  222 
 
19F NMR (300 MHz, CDCl3): δ -152.5 (2F, d, 
3JF,F = 18.3, Fortho), -157.2 (1F, t, 
3JF,F = 
22.8, Fpara), -162.0 (2F, t,
 3JF,F = 22.8, Fmeta). 
 












A solution of 70 β (0.837 g, 2.24 mmol) in anhydrous pyridine (8 mL) was cooled to 
0  °C before addition of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (0.84 mL, 
2.69 mmol) dropwise under an argon atmosphere. The reaction mixture was left to stir 
at 0 °C for 1 hr, then r.t for 4 hrs. The solvent was removed in vacuo and the residue 
quenched with NaOH (1.0 M, 4 mL), and extracted with DCM (10 mL). The aqueous 
layer was further extracted with DCM. The organic layers were combined, dried over 
anhydrous sodium sulphate and the solvent removed in vacuo to give a mustard yellow 
oil. Purification by column chromatography (Hex: EA 3:1, 3:2 v/v) afforded 71  β 









To a solution of 100 β (1.02 g, 2.12 mmol) in anhydrous chloroform (4 mL), was added 
TEA (0.4 mL, 3.17 mmol). To this, a solution of pentafluorophenyl 2-phenoxyethanote, 
101 (0.81 g, 2.54 mmol) in anhydrous chloroform (3 mL) was added, and the resulting 
reaction mixture stirred at 0 C for 45 mins, then r.t for 21 hrs. Solvent was then 
removed in vacuo. Purification by column chromatography (Hex: EA 8:2, 7:3, 6:4 v/v) 
afforded 71 β (0.643 g, 49.2 %) as a white foam. 
Rf (Hex: EA 1:1, B’): 0.29 
 
LRMS: [ES
+, MeOH] m/z (%): 640 ((M(
13C)+Na)
+, 5), 639 ((M+Na)
+, 48), 618 
((M(
13C)+H)
+, 2), 617 ((M+H)
+, 17). 
     
1H NMR (400 MHz, CDCl3): δ 8.59 (1H, br s, NH), 8.32 (1H, s, H
6), 7.63 (1H, d, J = 
1.5 Hz, H
4), 7.33 (2H, dd, J = 9.0, 7.5 Hz, H
10), 7.04 (1H, t, J = 7.5 Hz, H
11),  6.98 (2H, 
d, J = 8.0 Hz, H
9), 4.82 (1H, d, J = 4.0 Hz, H
1’), 4.67 (2H, s, H
7), 4.35 (1H, t, J = 6.5 
Hz, H
3’), 4.13-4.00 (3H, m, H
4’ plus H
5’), 3.92 (1H, m, H
2’),
 3.01 (1H, br s, OH
2’), 2.27 
(3H, s, CH3), 1.07-0.97 (28H, m, CH plus CH3 from TIPDS). 
 

















5’), 18.2 (CH3), 17.6, 17.6, 17.5, 17.3, 
17.2, 17.1 (TiPDS-CH3), 13.6, 13.3, 13.2, 13.0, 12.8 (TiPDS-CH). 
 



















































To a solution of 71 β (0.840 g, 1.36 mmol) in anhydrous DMF (8 mL) was added 1,1-
thiocarbonyl diimidazole (0.616 g, 3.41 mmol) and the reaction mixture was left to stir 
at r.t under an argon atmosphere for 29 hrs. Solvent was removed in vacuo. The reaction 
mixture was quenched with water (15 mL) and extracted with ethyl acetate (25 mL); the 
aqueous layers were further extracted with ethyl acetate (3 x 25 mL). The combined 
organic layers were dried over anhydrous sodium sulphate. Solvent was removed in 
vacuo to give crude as a yellow oil. Purification by column chromatography (Hex: EA 
3:1, 2:1, 1:1 v/v) afforded 72 β (0.551 g, 55.1 %) as a yellow foam. 
 
Rf (Hex: EA 1:1, B’): 0.24 
 
LRMS: [ES
+, MeOH] m/z (%): 751 ((M(
13C) +Na)
+, 45), 750 ((M+Na)
+, 95), 729 
((M(
13C)+H)
+, 22), 728 ((M+H)
+, 100). 
 
1H NMR (400 MHz, CDCl3): δ 8.58 (1H, br s, NH), 8.50 (1H, d, J = 2.0, H
6), 8.39 (1H, 
s, H
12), 7.79 (1H, d, J = 1.5 Hz, H
4), 7.68 (1H, s, H
13), 7.35 (2H, t, J = 8.5 Hz, H
10), 
7.07 (1H, d, J = 1.0 Hz, H
14), 7.04 (1H, d, J = 7.5Hz, H
11), 6.99 (2H, d, J = 8.5 Hz, H
9), 
5.73 (1H, d, J = 5.0 Hz, H
2’), 5.26 (1H, s, H
1’), 4.70 (2H, s, H
7), 4.61 (1H, dd, J = 9.0, 225 
 
5.0 Hz, H
3’), 4.27-4.24 (1H, m, H
5’), 4.12-4.08 (2H, m, H
4’ plus H
5’), 2.30 (3H, s, CH3), 
1.11 –0.99 (28H, m, CH plus CH3 from TiPDS). 
 




















5’), 18.2 (CH3), 17.6, 17.5, 17.4, 17.2, 17.1, 17.0 (TiPDS-CH3), 13.5, 13.1, 12.9, 12.8 
(TiPDS-CH). 
 




































To a solution of 72 β (0.306 g, 0.421 mmol) in anhydrous toluene (6.0 mL) was added 
azobisisobutyronitrile, AIBN (0.14 g, 0.844 mmol) followed by tris(trimethylsilyl)silane 
(0.15 mL, 0.485 mmol). The reaction mixture was purged under argon and stirred at r.t 
for 1 hr, after which it was heated to 80 ºC for 5 hrs 30 mins. The reaction mixture was 
left to cool to r.t and solvent was removed in vacuo. The crude was then quenched with 
NaOH (1.0 M, 6 mL), and extracted with ethyl acetate (12 mL x 3). The organic layers 
were combined and dried over anhydrous sodium sulphate. Solvent was removed in 
vacuo to give following purification by column chromatography (Hex: EA 1:1 v/v) 73 β 
(0.15 g, 61.4 %) as a yellow oil. 226 
 
Rf (Hex: EA 1:1, A’): 0.34 
 
LRMS: [ES
+, MeOH] m/z (%): 602 ((M(
13C)+H)
+, 36), 601 ((M+H)
+, 100). 
 
1H NMR (400 MHz, CDCl3): δ 8.53 (1H, br s, NH), 8.24 (1H, d, J = 2.0 Hz, H
6), 7.57 
(1H, d, J = 2.0 Hz, H
4), 7.36-7.32 (2H, m, H
10), 7.05 (1H, t, J = 7.5 Hz, H
11), 6.99 (2H, 
dd, J = 8.5, 1.0 Hz, H
9), 5.10 (1H, t, J = 7.5 Hz, H
1’), 4.68 (2H, s, H
7), 4.53 (1H, dt, J = 
7.5, 4.5 Hz, H
3’), 4.12 (1H, dd, J = 10.5, 2.0 Hz, H
5’), 3.93-3.85 (2H, m, H
4’ plus H
5’), 
2.39 (1H, ddd, J = 12.5, 7.0, 4.5 Hz, H
2’), 2.27 (3H, s, CH3), 2.04 (1H, dt, J =13.0, 7.5 
Hz, H
2’), 1.09-1.03 (28H, m, CH plus CH3 from TiPDS). 
 

















2’), 18.1 (CH3), 17.7, 17.6, 17.5, 





   
To a solution of 2’-deoxy-D-ribose (15.0 g, 111.8 mmol) in anhydrous methanol 
(560 mL), a solution of acetyl chloride (0.5 mL, 6.71 mmol) in anhydrous methanol 
(33.6 mL. 829.8 mmol) was added dropwise and the reaction mixture left to stir at r.t for 
1 hr. Upon completion, NaHCO3 (13.0 g, 155 mmol) was added until pH 7.0. The 
reaction mixture was then filtered. Solvent was removed in vacuo. The residue was co-
evaporated with toluene. The residue was then redissolved in anhydrous DMF 
(560 mL), benzyl bromide (53.2 mL, 447.3 mmol) was added and the reaction mixture 
cooled to 0 ˚C before portion wise addition of NaH (60 % in mineral oil, 18.0 g, 
447.3 mmol). The reaction mixture was then left to warm to r.t and left for 14 hrs. On 227 
 
completion, the reaction mixture was cooled to 0 ˚C over an ice bath before careful 
addition of anhydrous methanol (400 mL) and the mixture evaporated to dryness 
followed by co-evaporation with toluene. The residue was then quenched with water 
and extracted with DCM (500 mL). The organic phases were combined and dried over 
anhydrous sodium sulphate. Solvent was removed in vacuo. Column chromatography 
(DCM: EA 1:0, 99:1, 95:5, 9:1, 8:2, 7:3 and 6:4 v/v) afforded 102 (> 34.84 g, > 95 %) 
as a faint yellow oil.  
Data for α anomer: 
 
Rf (Hex: EA 7:3, A’): 0.37 
 
LRMS: [ES
+, MeOH] m/z (%): 680 ((2M(
13C)+Na)
+, 9), 679 ((2M+Na)
+, 33), 352 
((M(
13C)+Na)
+, 25), 351 ((M+Na)
+, 100). 
 
1 NMR (400 MHz, CDCl3): δ 7.33-7.28 (10H, m, H
Ar), 5.07 (1H, dd, J = 5.5, 1.0, H
1’), 
4.58-4.47 (4H, m, Bn-CH2), 4.24 (1H, dd, J = 8.5, 4.0, H
4’), 3.97 (1H, ddd, J = 8.0, 4.5, 
3.0, H
3’), 3.54 (1H, dd, J =10.0, 4.0, H
5’), 3.50 (1H, dd, J = 10.5, 4.5, H
5’), 3.40 (3H, s, 
OCH3), 2.22 (1H, ddd, J = 14.1, 8.0, 5.5, H
2’), 2.02 (1H, ddd, J =14.0, 2.5, 1.0, H
2’). 
 
13C NMR (100 MHz, CDCl3): δ 138.3, 138.3 (C





3’), 73.6, 71.7 (Bn-CH2), 70.3 (C
5’), 55.3 (OCH3), 39.1 
(C
2’). 
     
Data for β anomer: 
 
Rf (Hex: EA 7:3, A’): 0.46 
 
LRMS: [ES
+, MeOH] m/z (%): 680 ((2M(
13C)+Na)
+, 9), 679 ((2M+Na)
+, 33), 352 
((M(
13C)+Na)
+, 25), 351 ((M+Na)
+, 100). 
1H NMR (400 MHz, CDCl3): δ 7.42-7.34 (10H, m, H
Ar), 5.17 (1H, dd, J = 5.5, 2.5, 
H
1’), 4.68-4.54 (4H, m, Bn-CH2), 4.35 (1H, td, J = 6.0, 3.5, H
4’), 4.22 (1H, td, J = 6.5, 
3.5, H
3’), 3.63 (1H, dd, J = 9.5, 6.0, H
5’), 3.57 (1H, dd, J = 9.6, 6.0, H
5’), 3.36 (3H, s, 
OCH3), 2.30 (1H, ddd, J = 13.1, 6.6, 2.0, H
2’), 2.20 (1H, dt, J = 13.6, 5.5, H
2’). 228 
 
13C NMR (100 MHz, CDCl3): δ 138.3, 138.1 (C





3’), 73.4 (Bn-CH2), 72.1 (C
5’), 71.7 
(Bn-CH2), 55.0 (OCH3), 39.5 (C
2’). 
 


















A solution of 102 (17.82 g, 54.3 mmol) in acetic acid solution (80 % acetic acid in 
water, 232 mL) was heated to 110 C for 2 hrs after which the solution changed colour 
from faint yellow to mustard yellow. On completion, solvent was removed in vacuo 
before neutralization by sat. NaHCO3 (aq). The reaction mixture was then extracted 
with DCM (3 x 500 mL). The organic phases were combined and dried over anhydrous 
sodium sulphate. Solvent was removed in vacuo to give the crude as a mustard-yellow 
oil (15.2 g). Column chromatography (DCM: EA 1:0, 99.5:0.5, 99:1, 98:2, 97:3, 96:4, 
95:5, 94:6, 93:7, 92:8, 91:9, 9:1, 88:15, 7:3 v/v) afforded 14 (10.25 g, 60 %) as a pale 
yellow oil. 
Data for α anomer: 
Rf (Pet ether: EA 7:3, A’): 0.27 
Data for β anomer: 
Rf (Pet ether: EA 7:3, A’): 0.43 
Data for the anomeric mixture: 
LRMS: [ES
+, MeOH] m/z (%): 652 ((2M(
13C)+Na)
+, 2), 651 ((M+Na)
+, 9), 338 
((M(
13C)+Na)
+, 19), 337 ((M+Na)
+, 100). 229 
 
HRMS: [ES
+] Found 337.1415 Da (M+Na)
+, calculated 337.1410 Da. 
 
1H NMR (400 MHz, CDCl3): δ 7.37-7.32 (20H, m, H
Ar), 5.58 (1H, br t, J = 3.5 Hz, 
H
1’α), 5.50 (1H, d, J = 9.5 Hz, H





4’α), 4.13-4.11 (1H, m, H
3’ β), 4.01 (1H, d, J = 8.0 Hz, OHα), 3.80 
(1H, d, J = 9.5 Hz, OH β), 3.65 (1H, dd, J = 10.0, 3.5 Hz, H
5’ α), 3.57 (1H, dd, J = 10.0, 
3.5 Hz, H
5’ α), 3.53 (1H, dd, J = 10.0, 4.5 Hz, H
5’ β), 3.40 (1H, dd, J = 10.0, 5.5 Hz, H
5’ 
β), 2.22 (2H, m, H
2’ α), 2.14 (2H, t, J = 3.0, H
2’ β). 
 
13C NMR (100 MHz, CDCl3): δ 138.0, 137.9, 137.5, 137.4 (C
Arα,β), 128.6, 128.5, 
















































Coupling reaction Method 1
220 
 
A solution of 86 (1.0 g, 2.35 mmol) in anhydrous THF (6.5 mL) was cooled to - 50 °C 
before dropwise addition of butyllithium (1.6 M solution in hexanes, 1.5 mL, 
2.35 mmol). The reaction mixture was left to stir for 2 hrs 30 mins, before dropwise 
addition of a solution of 14 (0.3 g, 0.94 mmol) in anhydrous THF. The reaction mixture 
was then left to warm to r.t, after 2 hrs 30 mins reaction had not completed hence 
another addition of 14 (0.27 g, 0.86 mmol) in anhydrous THF to the reaction mixture. 
After overnight stirring the reaction was still incomplete. The reaction was stopped 230 
 
however, and solvent removed in vacuo. The brown-orange residue was quenched with 
water and extracted with ethyl acetate. The organic phases were combined and dried 
over anhydrous sodium sulphate. Solvent was removed in  vacuo and column 
chromatography (Hex: EA 8:2, 7:3, 6:4, 1:1 v/v) afforded 103 R and 103 S (0.11 g, 
18 %) as orange-brown oils. 
 
Coupling reaction Method 2
220 
 
A solution of 86 (53.8 g, 126.1 mmol) in anhydrous THF (180 mL) was cooled to          
– 35  °C before dropwise addition of n-butyllithium (1.6 M solution in hexanes, 
79.0 mL, 126.1 mmol), the reaction mixture changed colour from yellow to dark brown. 
The reaction mixture was left to stir at - 35 °C for 30 mins, before dropwise addition of 
a solution of 14 (15.84 g, 50.4 mmol) in anhydrous THF (50 mL), the reaction mixture 
became a light red-brown colour. The reaction mixture was then left to stir at - 30 °C for 
1 hr, after which it was allowed to warm to r.t for 4 hrs 30 mins. Solvent was removed 
in vacuo. The brown-orange residue was quenched with water and extracted with EA. 
The organic phases were combined and dried over anhydrous sodium sulphate. Solvent 
was removed in vacuo and column chromatography (DCM: EA 1:0, 95:5, 93:7, 9:1, 1:1, 
EA:MeOH 8:2, 7:3 v/v) afforded the epimeric mixture, 103 RS (30.74 g, 92.0 %) as a 
brown foam. 
Data for the epimeric mixture: 
Rf (DCM: EA 8:2, A’): 0.55 
HRMS: [ES
+] Found 663.3421 Da (M+H)
+, calculated 663.3429 Da. 
Data for less polar epimer: 
 
Rf (Hex: EA 1:1, A’): 0.35 
 
LRMS: [ES
+, MeOH] m/z (%): 685 ((M+Na)
+, 12), 664 ((M(
13C) +H)
+, 40), 663 
((M+H)
+, 100) 
      [ES







1H NMR (400 MHz, CDCl3): δ 8.11 (1H, d, J = 2.0 Hz, H
6), 7.43 (1H, d, J = 2.0 Hz, 
H
4), 7.37-7.29 (10H, m, H
Ar), 7.17 (4H, d, J = 8.5 Hz, H
9), 6.80 (4H, d, J = 8.5 Hz, 
H
10), 4.88 (1H, br t, J = 6.5 Hz, H
1’), 4.63-4.59 (2H, m, Bn-CH2), 4.56 (2H, s, BnCH2), 
4.23 (4H, s, H
7), 4.03-3.98 (1H, m, H
4’), 3.81 (1H, dd, J = 11.0, 5.5 Hz, H
3’), 3.76 (6H, 
s, OCH3), 3.65 (1H, dd, J = 9.5, 3.5 Hz, H
5’), 3.60 (1H, dd, J = 9.5, 6.5 Hz, H
5’), 3.17 
(1H, br s, OH
1’), 2.86 (1H, br s, OH




13C NMR (100 MHz, CDCl3): δ 160.9 (C
2), 158.5 (C
11), 142.9 (C
6) 138.0, 137.9 (C
Ar), 
137.3 (C
4), 134.2, 131.2, 130.9 (C
Ar), 129.6 (C









1’), 55.2 (OCH3), 53.8 (C
7), 39.5 (C
2’), 18.8 (CH3). 
 
Data for more polar epimer: 
 
Rf (Hex: EA 1:1, A’): 0.25 
 
LRMS: [ES
+, MeOH] m/z (%): 685 ((M+Na)
+, 12), 664 ((M(
13C) +H)
+, 40), 663 
((M+H)
+, 100) 
      [ES






1H NMR (400 MHz, CDCl3): δ 8.12 (1H, d, J = 2.5, H
6), 7.43 (1H, d, J = 2.0, H
4), 
7.36-7.28 (10H, m, H
Ar), 7.17 (4H, d, J = 8.5, H
9), 6.81 (4H, d, J = 8.6, H
10), 4.89 (1H, 
dd, J = 8.5, 3.0, H
1’), 4.61-4.51 (4H, m, Bn-CH2), 4.23 (4H, s, H
7), 4.05 (1H, dd, J = 
10.6, 5.5, H
4’), 3.76 (7H, br s, OCH3 plus H
3’), 3.61-3.58 (2H, m, H
5’), 2.38 (3H, s, 
CH3), 2.13 (1H, br dt, J = 15.1, 8.5, H
2’), 1.92 (1H, dt, J = 15.0, 3.5, H
2’). 
 
13C NMR (100 MHz, CDCl3): δ 161.0 (C
2), 158.5 (C
11), 143.1 (C
6), 137.8, 137.8 (C
Ar), 
137.8 (C
4), 134.2, 134.0, 131.1, 130.9 (C
Ar), 129.6 (C









1’), 55.2 (OCH3), 53.8 (C
7), 39.0 (C
2’), 18.8 (CH3). 
 


































Mitsunobu Cyclisation Method 1 
 
A solution of 103 RS (0.173 g, 0.261 mmol) in anhydrous benzene (5 mL) was cooled 
to 0 C, Bu3P (0.08 mL, 0.34 mmol) was added followed by TMAD (0.06 g, 
0.34  mmol). The reaction mixture was left to stir at r.t for 22 hrs, after which the 
insoluble material was filtered and the filtrate concentrated in  vacuo. The resulting 
crude oil was quenched with water and extracted with ethyl acetate. The organic layers 
were combined and dried over anhydrous sodium sulphate, solvent was removed in 
vacuo. Column chromatography (Hex: EA 1:0, 95:5, 9:1, 8:2 v/v) afforded 104 
(0.075 g, 44.6 %) as 2 anomers (: 1:2) as light yellow oils. 
 
Mitsunobu Cyclisation Method 2 
 
A solution of 103 RS (0.180 g, 0.27 mmol) in anhydrous benzene (1 mL) was cooled to 
0 C, Bu3P (0.10 mL, 0.41 mmol) was added followed by DHTD (0.07 g, 0.41 mmol). 
The reaction mixture was left to stir at r.t for 25 hrs, after which the insoluble material 
was filtered and the filtrate concentrated in vacuo. The resulting crude oil was quenched 
with water and extracted with ethyl acetate. The organic layers were combined and 
dried over anhydrous sodium sulphate, solvent was removed in vacuo. Column 233 
 
chromatography (Hex: EA 1:0, 95:5, 9:1 v/v) afforded 104  α  and  104  β ( α:β 2:3, 
0.0945 g, 54.3 %) as yellow oils. 
 
Mitsunobu Cyclisation Method 3 
 
A solution of 103 RS (0.215 g, 0.32 mmol) in anhydrous THF (2.0 mL) was cooled to 
0 C, Bu3P (0.13 mL, 0.52 mmol) was added followed by DIAD (0.1 mL, 0.52 mmol). 
The reaction mixture was left to stir at r.t for 15 hrs 30 mins, after which solvent was 
removed in vacuo. The resulting crude oil in methanol was loaded onto a pyridinium 
activated dowex column (the dowex had been washed with 10 % pyridine in MeOH: 
H2O 1:1). First the reduced DIAD by-product was removed in methanol (300 mL), 
followed by water (300 mL). The anomeric product 104 α,β was released from the resin 
using 10 % NH3 in MeOH: H2O 1:1 (3.0 L). The pyridinium form dowex was used to 
avoid removal of paramethoxy benzyl groups by the acidic dowex, however the 
compound is not basic enough to exchange with the pyridinium ions, hence there was 
no separation of the reduced DIAD from the anomeric product. 
 
Mitsunobu Cyclisation Method 4 
 
A solution of 103 RS (3.1832 g, 4.8 mmol) in anhydrous THF (24.0 mL) was cooled to 
0 C, Bu3P (2.0 mL, 7.68 mmol) was added followed by DIAD (1.5 mL, 7.68 mmol). 
The reaction mixture was left to stir at r.t for 5 hrs 30 mins, after which solvent was 
removed in vacuo. Column chromatography (Hex: EA 1:0, 95:5, 9:1 v/v) afforded 104 
as 2 anomers α (1.21 g) and β (2.04 g) as yellow oils; both containing the reduced 
DIAD by-product. 
 
Mitsunobu Cyclisation Method 5 
 
A solution of 103 RS (12.49 g, 18.84 mmol) in anhydrous THF (86.0 mL) was cooled to 
0 C, before addition of Bu3P (7.44 mL, 30.15 mmol) followed by TMAD (5.19 g, 
30.15 mmol). The reaction mixture was left to stir at r.t for 6 hrs 15 mins, after which 
the reaction mixture was filtered and the filtrate concentrated in vacuo. The residue was 
quenched with water and extracted with ethyl acetate. The organic phases were 234 
 
combined and dried over anhydrous sodium sulphate. Solvent was removed in vacuo to 
afford the crude (23.11 g) as a brown oil. Column chromatography (Pet ether: EA 5:1, 
4:1, 3:1 v/v) afforded 104 α and 104 β (α:β 2:3, 10.77 g, 88.2 %) as yellow oils. 
 
Data for the anomeric mixture: 
 
HRMS: [ES
+] Found 645.3324 Da (M+H)
+, calculated 645.3323 Da. 
 
Data for α anomer: 
 
Rf (Hex: EA 1:1, A’): 0.58 
 
1H NMR (400 MHz, CDCl3): δ 8.09 (1H, d, J = 2.0 Hz, H
6), 7.59 (1H, s, H
4), 7.36-7.28 
(10H, m, H
Ar), 7.15 (4H, d, J = 8.5 Hz, H
9), 6.80 (4H, d, J = 8.5 Hz, H
10), 5.02 (1H, t, J 
= 8.0 Hz, H
1’), 4.63-4.52 (4H, m, Bn-CH2), 4.36 (1H, dd, J = 9.0, 4.5 Hz, H
4’), 4.26 
(1H, dd, J = 10.6, 6.5 Hz, H
3’) 4.22 (4H, s, H
7), 3.78 (6H, s, OCH3), 3.61 (2H, m, H
5’), 
2.61 (1H, dt, J = 13.0, 6.5 Hz, H
2’










137.9, 131.8, 131.1 (C
Ar), 129.6 (C







1’), 73.6, 71.9 (Bn-CH2), 71.0 (C
5’), 55.3 (OCH3), 53.7 
(C
7), 40.7 (C
2’), 18.9 (CH3). 
 
NOE (400 MHz, CDCl3): irradiation at δ 8.09 (H-C(6)) produced NOE enhancement at 
δ 5.02 (H-C(1’)); irradiation at δ 7.59 (H-C(4)) produced NOE enhancements at δ 5.02 
(H-C(1’)), 2.36 (H-C(CH3)), 2.05 (H-C(2’α)), the cross-peak between the H
4 and the 
higher field H
2’
α resonance signals is stronger than that between H
4 and H
1’; irradiation 
at δ 5.02 (H-C(1’)) produced NOE enhancements at δ 8.09 (H-C(6)), 7.59 (H-C(4)), 
3.61 (H-C(5’)), 2.61 (H-C(2’β)), the cross-peak between the H
1’ and lower field H
2’
β 
resonance signals is very strong, and the cross-peak between H
1’ and H
6 resonance 
signals is stronger than that between H
1’ and H
4; irradiation at δ 3.61 (H-C(5’)) 
produced NOE enhancements at δ 5.02 (H-C(1’)), 4.60 (H-C(Bn 5’)), 4.36 (H-C(4’)). 
 235 
 
Data for β anomer: 
 
Rf (Hex: EA 1:1, A’): 0.61 
LRMS: [ES
+, MeOH] m/z (%): 647 ((M(2 
13C)+H)
+, 9), 646 ((M(
13C)+H)
+, 41), 645 
((M+H)
+, 100). 
1H NMR (400 MHz, CDCl3): δ 8.06 (1H, d, J = 2.0 Hz, H
6), 7.40 (1H, s, H
4), 7.29-7.21 
(10H, m, H
Ar), 7.10 (4H, d, J = 8.5 Hz, H
9), 6.74 (4H, d, J = 9.0 Hz, H
10), 5.02 (1H, dd, 
J = 10.5, 4.5 Hz, H
1’), 4.53 (2H, s, Bn-CH2), 4.50 (2H, s, Bn-CH2), 4.23 (1H, m, H
4’), 
4.16-4.12 (5H, m, H
3’ plus H
7), 3.68 (6H, s, OCH3), 3.60 (1H, dd, J = 10.0, 4.0 Hz, 
H
5’), 3.53 (1H, dd, J = 10.0, 5.0 Hz, H
5’), 2.27 (4H, m, H
2’
α plus CH3), 1.89 (1H, ddd, J 




13C NMR (100 MHz, CDCl3): δ 161.3 (C
2), 158.5 (C
11), 143.6 (C




5), 130.6, 129.5 (C
Ar), 128.5, 128.4 (C








1’), 73.5, 71.2 
(Bn-CH2), 71.1 (C
5’), 55.2 (OCH3), 53.7 (C
7), 40.8 (C
2’), 18.8 (CH3). 
 
NOE (400 MHz, CDCl3): irradiation at δ 8.06 (H-C(6)) produced NOE enhancement at 
δ 5.02 (H-C(1’)); irradiation at δ 7.40 (H-C(4)) produced NOE enhancements at δ 5.02 
(H-C(1’)), 2.27 (H-C(CH3)), 1.89 (H-C(2’β)), the cross-peak between H
4 and higher 
field H
2’
β resonance signals is stronger than that between H
4 and H
1’; irradiation at δ 
5.02 (H-C(1’)) produced NOE enhancements at δ 8.06 (H-C(6)), 7.40 (H-C(4)), 2.27 
(H-C(2’α)), 1.89 (H-C(2’β)), the cross peak between H
1’ and H
6 resonance signals is 
stronger than that between H
1’ and H




resonance signals is stronger than that between H
1’ and H
2’
β; irradiation at δ 3.60 (H-
C(5’)) produced NOE enhancements at δ 4.53 (H-C(Bn 5’)), 3.53 (H-C(5’)), the cross-
peak between H
5’ and H
5’ resonance signals is stronger than that between H
5’ and Bn-
CH2; irradiation at δ 3.53 (H-C(5’)) produced NOE enhancements at δ 3.60 (H-C(5’)), 
1.89 (H-C(2’β)), the cross-peak between H
5’ and H
5’ resonance signals is stronger than 
that between H




Analytical data consistent with that reported in the literature.








A solution of 103 RS (0.79 g, 1.19 mmol) in anhydrous THF (5 mL) was cooled to 
0 C, Bu3P (0.5 mL, 1.96 mmol) was added followed by DIAD (0.4 mL, 1.96 mmol). 
The reaction mixture was left to stir at r.t for 17 hrs, after which solvent was removed in 
vacuo. The resulting crude oil in methanol was loaded onto a dowex column. First the 
reduced DIAD by-product was removed in methanol (500 mL), followed by water 
(500 mL). The anomeric product was then released from the resin using 10 % NH3 in 
MeOH: H2O 1:1 (4.0 L). The crude, 106 α,β was taken on to the next step. 
Data for α anomer: 
LRMS: [ES
+, MeOH] m/z (%): 525 ((M+H)
+, 100). 
Data for β anomer: 
LRMS: [ES
+, MeOH] m/z (%): 526 ((M(
13C)+H)
+, 38), 525 ((M+H)
+, 100). 
1H NMR (400 MHz, CDCl3): δ 8.01 (1H, d, J = 2.5 Hz, H




4), 6.88 (2H, d, J = 8.5 Hz, H
10), 5.04 (1H, dd, J = 11.0, 5.0 Hz, H
1’), 4.61-
4.57 (6H, m, Bn-CH2 plus H
7), 4.36 (1H, br s, NH), 4.27 (1H, td, J = 5.0, 2.0 Hz, H
4’), 
4.19 (1H, d, J = 6.0 Hz, H
3’), 3.81 (3H, s, OCH3), 3.66 (1H, dd, J = 10.0, 4.5 Hz, H
5’), 
3.59 (1H, dd, J = 10.0, 5.0 Hz, H
5’), 2.28 (1H, dd, J = 12.6, 5.0 Hz, H
2’
α), 2.02 (3H, s, 
CH3), 1.96 (1H, ddd, J = 13.6, 11.0, 6.0 Hz, H
2’
β).  
13C NMR (100 MHz, CDCl3): δ 159.3 (C
2), 156.8 (C
11), 143.8 (C













1’), 73.9 (Bn-CH2), 71.7 
(C
5’), 71.5 (Bn-CH2), 55.7 (OCH3), 45.9 (C
7), 40.9 (C
2’), 17.4 (CH3).  

























Acidic Cleavage of PMB groups Method 1 
 
To a solution of 106 α,β (0.608 g, 1.16 mmol) in anhydrous DCM (4.0 mL) was added 
trifluoroacetic acid (4.0 mL) and the solution left to stir for 23 hrs after which solvent 
was removed in  vacuo. The residue was redissolved in DCM and quenched with 
sat. NaHCO3 (aq). The organic layers were combined and dried over anhydrous sodium 
sulphate. Column chromatography (DCM: MeOH 1:0, 99:1, 98:2, 97:3 v/v) afforded the 
mixture 107 α,β with no separation of the anomers. 
 
Acidic Cleavage of PMB groups Method 2 
 
The crude 104 α,β (0.055 g, 0.085 mmol) was dissolved in anhydrous DCM (0.5 mL) 
and trifluoroacetic acid (0.5 mL) was added. The reaction mixture was left to stir at r.t 
for 19 hrs. On completion, the reaction mixture was quenched with NaHCO3 (aq) and 
extracted with DCM. The organic layers were combined and dried over anhydrous 





Data for α anomer: 
 
Rf (DCM: MeOH 8:2, A’): 0.83 
 
Data for β anomer: 
 
Rf (DCM: MeOH 8:2, A’): 0.91 
 
Data for anomeric mixture:  
 
LRMS: [ES
+, MeOH] m/z (%): 809 ((2M+H)
+, 7), 406 ((M(
13C)+H)




1H NMR (400 MHz, CDCl3): δ 7.91 (1H, s, H
6 α/), 7.89 (1H, d, H
6 /β), 7.44 (1H, s, 
H
4 α/), 7.35-7.28 (21H, m, H
Ar α, plus H
4 /β), 5.02 (1H, dd, J = 11.0, 5.0 Hz, H
1’ 
), 4.96 (1H, br t, J = 7.0 Hz, H
1’ ), 4.62-4.52 (8H, m, BnCH2 α,), 4.40 (4H, br s, 
NH2 α,), 4.34 (1H, dd, J = 8.5, 4.0 Hz, H
4’ ), 4.28-4.23 (2H, m, H
3’  plus H
4’ ), 
4.17 (1H, br d, J = 5.5 Hz, H
3’ ), 3.65 (1H, dd, J = 10.5, 4.5 Hz, H
5’ ), 3.61-3.57 (3H, 
m, H
5’  plus H
5’ ), 2.57 (1H, dt, J = 12.6, 7.0 Hz, H
2’
β ), 2.28 (1H, dd, J = 13.6, 5.5 
Hz, H
2’
α ), 2.10 (3H, s, CH3 / ), 2.06 (3H, s, CH3 /) 2.03-2.00 (1H, m, H
2’
α ), 




13C NMR (100 MHz, CDCl3): δ 157.1, 156.9 (C
2 ), 144.1, 144.0 (C
6 ), 138.4, 
138.2 (C
Ar ), 136.4, 136.3 (C
4 ), 128.5, 128.5, 128.5, 127.8, 127.8, 127.7 (CH
Ar 
), 83.9 (C
4’ ), 82.9 (C
4’ ), 81.8 (C
3’ ), 80.9 (C
3’ ), 78.5, 78.3 (C
1’ ), 73.6, 
73.5, 71.9 (Bn-CH2
 ), 71.3, 71.2 (C
5’ ), 71.0 (Bn-CH2
 ), 40.8, 40.7 (C
2’ ), 


































To a solution of 104  β containing reduced DIAD (2.04 g) in anhydrous DCM 
(14.0 mL), was added trifluoroacetic acid (14.0 mL), and the reaction mixture stirred at 
r.t for 3 hrs 30 mins. On completion, solvent was removed in vacuo. The residue was 
redissolved in DCM and quenched with sat. NaHCO3
 (aq). At this stage the organic 
phase changed from maroon-brown to green. The organic phases were combined and 
dried over anhydrous sodium sulphate. Solvent was removed in vacuo to give a mustard 
coloured oil (1.9699 g). Column chromatography (Hex: EA 1:1, 0:1 v/v) afforded 28 β 




To a solution of 104 β (4.71 g, 7.30 mmol) in anhydrous DCM (17.0 mL) was added 
trifluoroacetic acid (17.0 mL) and the reaction mixture changed colour from yellow to 
deep pink-purple, it was left to stir at r.t for 5 hrs 30 mins, before more trifluoroacetic 
acid (8.0 mL) was added and the reaction mixture left to stir for a further 1 hr 20 mins 
after which solvent was removed in vacuo. The residue was redissolved in water and 
NaHCO3 was added until > pH 8.0, extraction with DCM followed. The organic layers 
were combined and dried over anhydrous sodium sulphate. Solvent was removed in 
vacuo to afford the crude (5.1750 g) as a mustard yellow oil. Column chromatography 240 
 
(Hex: EA 6:4, 1:1, 4:6, 3:7, EA: MeOH 9:1, 8:2 v/v) afforded 107 β (2.92 g, 98.9 %) as 
a mustard yellow oil. 
 
Method 3  
 
To a solution of 114 β (0.008 g, 0.016 mmol) in anhydrous ethanol (0.6 mL) was added 
20 % Pd(OH)2-C (0.004 g), followed by cyclohexene (0.0002 mL. 0.0016 mmol). The 
reaction mixture was refluxed (80 °C) for 6 hrs. The reaction mixture was then filtered 
over celite, and the filtrate was reduced in vacuo to give 107 β as a crude residue. (MS 
confirmed removal of TFA while the benzyl groups remained intact). 
 
Rf (EA: MeOH 95:5, A’): 0.43 
 
LRMS: [ES
+, MeOH] m/z (%): 831 ((2M+Na)
+, 10), 427 ((M+Na)
+, 12), 406 
((M(C
13)+H)




+] Found 405.2175 Da (M+H)
+, calculated 405.2173 Da. 
 
1H NMR (400 MHz, CDCl3): δ 7.81 (1H, s, H
6), 7.41 (1H, s, H
4), 7.35-7.29 (10H, m, 
H
Ar), 5.50 (2H, br s, NH2), 5.00 (1H, dd, J = 10.6, 5.0 Hz, H
1’),
 4.58 (2H, s, Bn-CH2), 
4.56 (2H, s, Bn-CH2), 4.28-4.25 (1H, m, H
4’), 4.18 (1H, d, J = 6.0 Hz, H
3’),
 3.64 (1H, 
dd, J = 10.0, 4.0 Hz, H
5’), 3.58 (1H, dd, J = 10.0, 5.0 Hz, H
5’), 2.29 (1H, dd, J = 13.0, 
5.0 Hz, H
2’




13C NMR (100 MHz, CDCl3): δ 156.2 (C
2), 139.8 (C
6) 138.2, 138.1 (C
Ar), 137.8 (C
4), 







1’), 73.6 (Bn-CH2), 71.2 (Bn-CH2), 71.2 (C
5’), 40.7 (C
2’), 16.9 (CH3). 
 













107 α,β (0.2967 g, 0.733 mmol) was dissolved in anhydrous pyridine (3 mL) and cooled 
to 0 °C. Trifluoroacetic anhydride (0.21 mL) was then added and the reaction mixture 
left to stir at r.t for 72 hrs. Solvent was removed in vacuo. The residue was quenched 
with sat. KCl and extracted with DCM. The organic phases were combined and dried 
over anhydrous sodium sulphate. Solvent was removed in  vacuo. Column 
chromatography (Hex: EA 1:0, 9:1, 8:2, 7:3 v/v) afforded the starting material 107 α,β 
(0.2117 g) and an insignificant quantity of product 114 α,β.  
 
Data for both anomers: 
 
Data for α anomer: 
 
Rf (Hex: EA 1:1, A’): 0.37 
 
Data for β anomer: 
 












A solution of 107 β (1.58 g, 3.91 mmol) in anhydrous pyridine (17.0 mL) was cooled to 
0 °C before dropwise addition of trifluoroacetic anhydride (0.81 mL, 5.86 mmol). The 
reaction mixture was then left to stir at r.t for 2 hrs 30 mins, after which the solvent 
volume was reduced to half under high vacuum and the reaction mixture was partitioned 
between sat. NaHCO3 (aq) and DCM. The organic phases were combined and dried 
over anhydrous sodium sulphate; solvent was removed in vacuo to afford 114 β (1.36 g, 
70 %) as a yellow oil.  
 
LRMS: [ES
+, MeOH] m/z (%): 1024 ((2M(
13C)+Na), 4), 1023 ((2M(
13C)+Na), 28), 523 
((M + Na)
+, 100), 501 ((M + H)
+, 22). 
 
1H NMR (400 MHz, CDCl3): δ 8.02 (1H, s, H
6), 7.71 (1H, s, H
4), 7.37-7.30 (10H, m, 
CH
Ar), 5.12 (1H, dd, J = 10.5, 5.0 Hz, H
1’),
 4.58-4.56 (4H, m, Bn-CH2), 4.31 (1H, td, J 
= 4.0, 2.0 Hz, H
4’), 4.20 (1H, br d, J = 6.0 Hz, H
3’),
 3.64 (1H, dd, J = 10.0, 6.0 Hz, H
5’), 
3.62 (1H, dd, J = 10.0, 5.5 Hz, H
5’), 2.38 (1H, ddd, J = 13.0, 5.0, 1.0 Hz, H
2’
α), 2.26 
















1’), 73.7 (Bn-CH2), 71.4 (Bn-CH2), 71.1 (C
5’), 41.3 (C
2’), 17.7 (CH3). 


























To a solution of 107 α,β (0.2117 g, 0.523 mmol) in anhydrous methanol (2.0 mL), was 
added N,N-dimethylformamide dimethylacetal (0.7 mL, 5.23 mmol) and the reaction 
mixture stirred at 70 °C for 26 hrs. After which solvent was removed in vacuo. The 
crude, 115 α,β (0.2492 g) was taken onto the next step. 
 
Data for anomeric mixture: 
 
Rf (DCM: MeOH 95:5, A’): 0.52 
 
LRMS: [ES
+, MeOH] m/z (%): 461 ((M(
13C)+H)
+, 30), 460 ((M+H)
+, 100). 
 























To a solution of 115 α,β (0.2492 g, 0.54 mmol) in anhydrous methanol (1.5 mL) was 
added 20 % Pd(OH)2-C (0.4227 g), followed by formic acid (1.5 mL). The reaction 
mixture was heated to 50 °C for 6 hrs. The reaction mixture was then filtered over 244 
 
celite, the filtrate was reduced in vacuo. The residue was quenched with water and 
NaOH and solvent removed in vacuo. The residue was stirred in ammonia solution at r.t 
overnight. Solvent was then removed in vacuo.  The crude was loaded onto dowex 
using methanol to remove the salt formed. The dowex was washed with methanol then 
water, to remove the salt. The anomeric product was released from the dowex using 
10 % NH3 in MeOH: H2O 1:1, solvent was reduced in vacuo and under high vacuum to 
give crude (0.1231 g). Column chromatography (EA: MeOH 7:3 v/v) was attempted, 
however, no separation of the anomers was achieved. NMR confirmed amidine 





A solution of 107 β (0.305 g, 0.75 mmol) in anhydrous DCM (4.0 mL) was cooled to      
– 78 °C, before careful addition of boron tribromide solution (1.0 M in DCM, 2.64 mL, 
2.64 mmol). The dark brown reaction mixture was left to stir at - 78 °C for 1 hr 30 mins 
after which anhydrous methanol (4.5 mL) was added and the reaction mixture was left 
to stir at - 60 °C for 1 hr 30 mins. The reaction mixture was then left to warm to r.t for 
1 hr 30 mins. Solvent was then removed in vacuo and the residue redissolved in DCM 
and extracted with water. The aqueous layers were combined and neutralised with 
ammonia solution until pH 7.0. Some solvent was removed in vacuo and the aqueous 
phase was stored at 4 °C to allow for precipitation. Precipitation did not occur; hence, 
solvent was completely removed in vacuo and the crude purified on dowex to remove 






A solution of 107 α (0.3478 g, 0.86 mmol) in anhydrous DCM (4.0 mL) was cooled to    
- 78 °C before dropwise addition of boron trichloride (1.0 M in DCM, 4.3 mL, 
4.3 mmol). The reaction mixture was left to stir at - 78 °C for 3 hrs 30 mins after which 
methanol (3.7 mL) was added and the reaction mixture left to warm to r.t over 3 hrs 
after which NaHCO3 was added until pH 7.0 and water added. Partition between DCM 
and water followed. The aqueous phases were combined and reduced in vacuo to give 
the crude as a white solid plus salt. NMR and MS analyses showed that the benzyl 245 
 
groups had been removed, however, the ring had opened and re-closed to form an 
anomeric mixture of the nucleoside 1 α,β (α:β 1:2). 
 
Rf (DCM: MeOH 8:2, A’): 0.35 
 
LRMS: [ES
+, MeOH] m/z (%): 226 ((M(C
13)+H)
+, 12), 225 ((M+H)
+, 100). 
 





To a solution of 107 β (0.6283 g, 1.553 mmol) in anhydrous ethanol (1.5 mL) was 
added Pd(OH)2-C (0.20 g). The reaction mixture was put under high vacuum followed 
by H2 purge (x 3); it was left to stir under H2 gas and heated to 60 °C for 80 hrs. The 
reaction mixture was allowed to cool to r.t and then filtered over celite. Solvent from the 
filtrate was removed in  vacuo to give a faint orange oil (0.4056 g). Column 
chromatography (EA:MeOH 98:2, 97:3, 96:4, 95:5 v/v) afforded 1 β (0.088g, 25.1 %) 
as a clear oil, and an open chain by-product, 116, as was confirmed by NMR and MS. 
 
Data for 1 β: 
 
Rf (EA: MeOH 8:2, A’): 0.16 
LRMS: [ES
+, MeOH] m/z (%): 471 ((2M+Na)
+, 14), 247 ((M+Na)
+, 28), 226 
((M(C
13)+H)
+, 12), 225 ((M+H)
+, 100). 
HRMS: [ES
+] Found 225.1232 Da (M+H)
+, calculated 225.1234 Da. 246 
 
1H NMR (400 MHz, DMSO): δ 7.72 (1H, d, J = 2.0 Hz, H
6), 7.24 (1H, s, H
4), 5.68 
(2H, br s, NH2), 4.98 (1H, d, J = 4.0 Hz, OH
3’), 4.81 (1H, dd, J = 10.5, 5.5 Hz, H
1’),
 
4.69 (1H, br t, J = 5.5 Hz, OH
5’), 4.15 (1H, m, H
3’), 3.69 (1H, td, J = 5.5, 2.0 Hz, H
4’), 
3.41 (2H, m, H
5’), 2.03 (3H, s, CH3), 1.91 (1H, dd, J = 12.6, 5.0 Hz, H
2’
α), 1.80 (1H, td, 















2’), 16.9 (CH3). 
 
Analytical data consistent with that stated in the literature.
202 
Data for 116: 
Rf (EA: MeOH 8:2, A’): 0.04 
LRMS: [ES
+, MeOH] m/z (%): 228 ((M(
13C)+H)
+, 12), 227 ((M+H)
+, 100). 
HRMS: [ES
+] Found 227.1392 Da (M+H)
+, calculated 227.1390 Da. 
1H NMR (400 MHz, DMSO): δ 7.61 (1H, s, H
6), 7.11 (1H, s, H
4), 5.51 (2H, br s, NH2), 
4.48 (3H, br s, OH), 3.52 (1H, dd, J = 11.0, 3.5 Hz, H
11),
 3.33 (1H, dd, J = 10.5, 6.0 Hz, 
H
11), 3.30-3.22 (2H, m, H
9 plus H
10), 2.56 (1H, ddd, J = 14.0, 10.0, 4.5 Hz, H
7), 2.36 
(1H, ddd, J = 16.6, 9.5, 7.0 Hz, H
7), 2.02 (3H, s, CH3), 1.80-1.73 (1H, m, H
8), 1.47 (1H, 
tt, J = 13.5, 5.0 Hz, H
8). 




















2-Amino-3-methyl-5-(2’-deoxy-β-D-ribofuranosyl)pyridine, (1 β); 2-Amino-3-







































To a solution of 107 β (0.827 g, 2.04 mmol) in anhydrous ethanol (13.0 mL) was added 
Pd(OH)2-C (0.25 g). The reaction mixture was put under high vacuum followed by H2 
purge (x 3); it was left under H2 gas and heated to 60 °C for 21 hrs 30 mins. After which 
all starting material had disappeared, product and intermediate were present. The 
reaction mixture was allowed to cool to r.t and then filtered over celite. Solvent from the 
filtrate was removed in  vacuo to give a faint pink foam (0.5884 g). Column 
chromatography (EA:MeOH 98:2, 97:3, 96:4, 95:5 v/v) afforded 1  β  (0.095 g, 
0.423 mmol) as a white foam. The intermediate, 117 β (0.22 g, 0.7 mmol) was also 
isolated and put on for further hydrogenolysis reaction (31 hrs) to yield 1 β (0.045 g, 
0.201 mmol). Overall 1 β (0.14 g, 31 %) was afforded as a white foam. 
 









































To a solution of 1 α,β (0.184 g, 0.808 mmol) in anhydrous methanol (4.0 mL), was 
added N,N-dimethylformamide dimethyl acetal (3.0 mL, excess) and the solution stirred 
at reflux (70 °C) for 4 hrs 30 mins, after which reaction mixture was cooled to r.t and 
solvent removed in vacuo. The crude (0.2684 g) still contained a little of the starting 
material. Initially, column chromatography (DCM: MeOH 1:0, 99:1, 97:3, 95:5 v/v) 
separated the starting material from the anomeric product. Another column was 
attempted to separate the anomers (EA: H-1 95:5, 9:1 v/v), however separation was not 
achieved. A third column (EA: H-1 1:0, 99:1, 98:2 v/v) afforded 118 β (0.02 g) as a 
light yellow oil and anomeric mixture 118 α,β (0.0327 g) as a mustard yellow oil. 





To a solution of 1 β (0.095 g, 0.42 mmol) in anhydrous methanol (1.5 mL) was added 
N,N-dimethylformamide dimethyl acetal (1.5 mL, excess) and the reaction mixture 
stirred at reflux (70 °C) for 20 hrs. On completion, solvent was removed in vacuo to 
give a yellow residue. Column chromatography (DCM: MeOH 1:0, 95:5, 9:1, 85:15 
v/v) afforded 118 β (> 0.071 g, > 61 %) as a yellow oil. 
 249 
 
Rf (DCM: MeOH 8:2, A’): 0.47 
LRMS: [ES
+, MeOH] m/z (%): 281 ((M(C
13)+H)
+, 17), 280 ((M+H)
+, 100). 
HRMS: [ES
+] Found 280.1650 Da (M+H)
+, calculated 280.1656 Da. 
1H NMR (400 MHz, MeOD): δ 7.90 (1H, s, H
7), 7.85 (1H, d, J = 2.0 Hz, H
6), 7.42 (1H, 
d, J = 1.5 Hz, H
4), 4.91 (1H, dd, J = 10.5, 5.5 Hz, H
1’), 4.19 (1H, m, H
3’), 3.77 (1H, td, 
J = 5.0, 2.5 Hz, H
4’), 3.51 (2H, m,  H
5’), 2.97 (3H, s, NCH3), 2.93 (3H, s, NCH3), 2.12 
(3H, s, CH3), 2.01 (1H, dd, J = 13.0, 5.5 Hz, H
2’

















2’), 40.8, 34.8 
(NCH3), 17.9 (CH3). 
 






































To a solution of 118  β (0.3336g, 1.20 mmol; which had been co-evaporated with 
anhydrous pyridine (2 mL x 3) under high vacuum and left to dry overnight under high 
vacuum) in anhydrous pyridine (2 mL) was added a solution of 4,4’-dimethoxytrityl 
chloride (0.51 g, 1.51 mmol) in anhydrous pyridine (3 mL) dropwise over 20 mins. The 250 
 
reaction mixture was left to stir at r.t for 2 hrs 20 mins after which solvent was reduced 
to half under high vacuum. TEA (0.5 mL) and methanol (1 mL) were added, the colour 
of the reaction mixture changed from bright orange to green. The reaction mixture was 
partitioned between NaHCO3 and DCM. The aqueous layer was further extracted with 
DCM (x 2). The organic phases were combined and dried over anhydrous sodium 
sulphate. Solvent was removed in vacuo to give crude (0.7874 g) as a yellow foam. 
Column chromatography (DCM: MeOH 1:0, 95.5:0.5, 99:1, 98.5:1.5, 98:2, 97.5:2.5, 
97:3, 96.5:3.5, 96:4 v/v (all pre-equilibrated with 0.5 % pyridine)) afforded 119  β 
(0.435 g, 62.4 %) as a white foam. 
 
Rf (DCM: MeOH 9:1, A’): 0.46  
LRMS: [ES
+, MeOH] m/z (%): 583 ((M(C
13)+H)
+, 28), 582 ((M+H)
+, 100). 
HRMS: [ES
+] Found 582.2966 Da (M+H)
+, calculated 582.2962 Da. 
 
1H NMR (400 MHz, CDCl3): δ 8.29 (1H, s, H
7), 7.99 (1H, d, J = 2.0 Hz, H
6), 7.43 (1H, 
d, J = 1.5 Hz, H
4), 7.41 (2H, br s, H
16), 7.31 (4H, dd, J = 9.0, 2.0 Hz, H
11), 7.23 (2H, br 
s, H
17), 7.17 (1H, br t, J = 7.5 Hz, H
18), 6.78 (4H, d, J = 9.0 Hz, H
12), 5.05 (1H, dd, J = 
10.0, 5.5 Hz, H
1’), 4.41 (1H, m, H
3’), 3.99 (1H, td, J = 5.5, 2.5 Hz, H
4’), 3.79 (6H, s, 
OCH3), 3.31 (1H, dd, J = 10.0, 4.5 Hz, H
5’), 3.22 (1H, dd, J = 10.0, 5.5 Hz, H
5’), 3.04 
(6H, s, NCH3), 2.20 (3H, s, CH3), 2.15 (1H, ddd, J = 13.6, 6.0, 2.0 Hz, H
2’
α), 2.04 (1H, 


























55.4 (OCH3), 43.7 (C
2’), 40.6, 34.6 (NCH3) 17.9 (CH3). 
 















































To a solution of 119 β (0.380 g, 0.65 mmol) in anhydrous DCM (3 mL) was added N,N-
diisopropylethylamine (0.23 mL, 1.31 mmol) followed by dropwise addition of  2-
cyanoethyl  N,N-diisopropylchlorophosphoramidite (0.19 mL, 0.85 mmol) under an 
argon atmosphere and the reaction mixture left to stir at r.t for 1 hr 45 mins. The 
reaction mixture was transferred via needle and syringe to a separating funnel 
containing anhydrous DCM. The reaction mixture was washed with saturated KCl 
(10 mL) and the organic phase was dried over anhydrous sodium sulphate. Solvent was 
removed  in  vacuo  under argon, to give following purification by column 
chromatography (EA: DCM 8:2 (0.5 % pyridine)) under argon pressure, 120 β, as a 
white foam (diastereoisomers 1:1, 0.4014 g, 79.1 %). 
  
Rf (EA (0.5 % pyridine), A’): 0.40, 0.31. 
LRMS: [ES
+, MeOH] m/z (%): 784 ((M(2 
13C)+H)
+, 10), 783 ((M(
13C)+H)




+] Found 782.4044 Da (M+H)
+, calculated 782.4041 Da. 
1H NMR (400 MHz, CDCl3): δ 8.31 (2H, s, H
7), 8.05 (2H, br t, J = 3.0 Hz, H
6), 7.48-
7.45 (6H, m, H
4 plus H
16/H
17), 7.34 (8H, dt, J = 9.0, 3.0 Hz, H




17), 7.21-7.17 (2H, m, H
18), 6.81-6.78 (8H, m, H
12), 5.07 (2H, dd, J = 10.5, 5.0 
Hz,  H
1‘), 4.55-4.51 (2H, m, H
3‘), 4.23-4.15 (2H, m, H
4‘), 3.87-3.79 (2H, m, 
OCH2CH2CN), 3.77 (12H, s, OCH3), 3.73-3.65 (2H, m, OCH2CH2CN), 3.64-3.53 (4H, 
m, iPr-CH), 3.32-3.20 (4H, m, H
5’), 3.05 (12H, s, NCH3), 2.61 (2H, t, J = 8.0 Hz, 
OCH2CH2CN), 2.46 (2H, t, J = 8.0 Hz, OCH2CH2CN), 2.31 (2H, ddd, J = 32.0, 12.0, 
4.0 Hz, H
2’
α), 2.22 (6H, s, CH3), 2.11-2.03 (2H, m, H
2’
β), 1.29-1.08 (24H, m, iPr-CH3). 
 
13C NMR (100 MHz, CDCl3): δ 158.6 (C
2), 154.4 (C




5), 130.3, 130.3 (C








9),  78.6 (C
1’), 76.3 (C
3’), 64.4 (C
5’), 58.6, 58.4 
(OCH2CH2CN), 55.4 (OCH3), 45.5, 43.5, 43.4, 43.3, (iPr-CH), 43.2 (C
2’), 38.0, 35.5 
(NCH3), 24.7, 24.6, 24.6, 23.1 (iPr-CH3), 20.5 (OCH2CH2CN), 17.8 (CH3). 
 
31P NMR (121 MHz, CDCl3) δ 148.69 (s, 1P, P), 148.49 (s, 1P, P). 
 









To a solution of 1 α (0.0787 g, 0.35 mmol) in anhydrous methanol (1.6 mL) was added 
N,N-dimethylformamide dimethylacetal (1.6 mL) and the reaction mixture stirred at 
70 °C for 25 hrs 30 mins. On completion, solvent was removed in vacuo to give crude 
118 α (0.1984 g) as a yellow residue. 
 
Rf (DCM: MeOH 8:2, A’): 0.35 
LRMS: [ES
+, MeOH] m/z (%): 281 ((M(
13C)+H)
+, 19), 280 ((M+H)
+, 100). 253 
 
1H NMR (300 MHz, MeOD): δ 8.01 (1H, s, H
7), 7.96 (1H, s, H
6), 7.54 (1H, s, H
4), 4.97 
(1H, dd, J = 8.7, 6.4 Hz, H
1’),
 4.32 (1H, m, H
3’), 3.95 (1H, m, H
4’),
 3.65 (2H, m, H
5’), 
3.08 (3H, s, NCH3),  3.03 (3H, s, NCH3), 2.59 (1H, dt, J = 12.4, 6.8 Hz, H
2’
β), 2.24 (3H, 















To a solution of 2’-deoxy-D-ribose (1.0 g, 7.46 mmol) in anhydrous methanol (37 mL), 
a solution of acetyl chloride (0.03 mL, 0.45 mmol) in anhydrous methanol (2.24 mL) 
was added dropwise and the reaction mixture left to stir at r.t for 3 hrs 20 mins after 
which sat. NaHCO3 aq. was added until pH 7.0. The reaction mixture was filtered and 
solvent removed in  vacuo. The residue was co-evaporated with toluene (x 2). The 
residue was redissolved in anhydrous DMF (37 mL), p-methoxybenzyl chloride (4 mL, 
29.8 mmol) was added and the reaction mixture cooled to 0 °C before portion wise 
addition of NaH (60 %, 1.2 g, 29.8 mmol). The reaction mixture was left to warm to r.t 
and stirred for 15 hrs. On completion, the reaction mixture was cooled to 0 °C before 
careful addition of methanol (27 mL). Solvent was removed in vacuo and co-evaporated 
with toluene. The residue was then quenched with water and extracted with DCM. The 
organic phases were combined and dried over anhydrous sodium sulphate. Solvent was 
removed in vacuo. Purification by column chromatography (DCM: EA 1:0, 98:2, 9:1, 
8:2, 7:3, 6:4 v/v) afforded 121 α,β (2.7387 g, 98 %) as a faint yellow oil. 
 
Rf (DCM: EA 99:1, A’): 0.10. 
 
1H NMR (400 MHz, CDCl3): δ 7.37-7.25 (8H, m, H
Ar α,β), 6.94-6.88 (8H, m, H
Ar α,β), 
5.13 (1H, dd, J = 5.0, 2.0, H
1’ α/β), 5.10 (1H, dd, J = 5.5, 1.0, H
1’ α/β), 4.56-4.44 (8H, 
m, PMB-CH2
 α,β), 4.30-4.24 (2H, m, H
4’ α,β), 4.18-4.14 (1H, m, H
3’ α/β), 4.01-3.97 
(1H, m, H
3’ α/β), 3.85 (6H, s, PMB-OCH3 α/β), 3.84 (6H, s, PMB-OCH3 α/β), 3.59-254 
 
3.50 (4H, m, H
5’ α,β), 3.45 (3H, s, OCH3 α/β), 3.35 (3H, s, OCH3 α/β), 2.29-2.22 (2H, 
m, H
2‘ α,β), 2.15 (1H, dt, J = 13.5, 5.5, H
2’ α/β), 2.03 (1H, m, H
2’ α/β). 
 
13C NMR (100 MHz, CDCl3): δ 159.3, 159.2 (C
Ar α,β), 129.5, 129.4, 129.3, 113.8, 
113.8, 113.7 (CH
Ar α,β), 105.5, 105.2 (C
1’), 82.9, 82.2 (C
4’), 86.1 (C
9), 79.7, 78.2 (C
3’), 
73.1, 73.0 (PMB-CH2 α,β), 71.8 (C
5’ α/β), 71.3, 71.2 (PMB-CH2 α,β), 69.9 (C
5’ α/β), 
55.4 (PMB-OCH3
 α,β), 55.1, 55.0 (OCH3















A solution of 121 α,β (2.6559, 7.09 mmol) in 80 % acetic acid solution (24 mL acetic 
acid, 6 mL water) was heated to 110 °C for 1 hr 30 mins after which reaction mixture 
was allowed to cool to r.t. sat.NaHCO3 was added until pH 7.0, extraction with DCM 
followed. The organic phases were combined and dried over anhydrous sodium 








To a solution of 104 α (2.71 g, 4.20 mmol) in anhydrous DCM (10 mL) was added 
trifluoroacetic acid (10 mL) over 5 mins (the reaction mixture changed colour from 
yellow to deep pink-purple), it was left to stir at r.t for 4 hrs 45 mins after which solvent 255 
 
was removed in vacuo. The residue was redissolved in water and sodium carbonate was 
added until pH 9.0, extraction with DCM followed. The organic layers were combined 
and dried over anhydrous sodium sulphate. Solvent was removed in vacuo to afford the 
crude (2.66 g) as a mustard yellow oil. Purification by column chromatography 
(Hex: EA 6:4, 1:1, 0:1, EA: MeOH 8:2 v/v) afforded 107 α (1.51 g, 89 %) as a yellow 
oil. 
 
Rf (DCM: MeOH 95:5, B’): 0.19. 
 
LRMS: [ES
+, MeOH] m/z (%): 832 ((2M(
13C)+Na)
+, 7), 831 ((2M+Na)
+, 12), 810 
((2M(C
13)+H)
+, 9), 809 ((2M+H)
+, 19), 427 ((M+Na)
+, 12), 406 ((M(C
13)+H)





+] Found 405.2175 Da (M+H)
+, calculated 405.2173 Da. 
 
1H NMR (400 MHz, CDCl3): δ 7.89 (1H, s, H
6), 7.44 (1H, d, J = 1.0 Hz, H
4), 7.35-7.28 
(10H, m, H
Ar), 4.96 (1H, dd, J = 8.6, 7.0 Hz, H
1’), 4.62-4.47 (4H, m, Bn-CH2), 4.45 
(2H, br s, NH2), 4.34 (1H, dd, J = 8.5, 4.5 Hz, H
4’), 4.25 (1H, dd, J = 10.5, 6.5 Hz, H
3’), 
3.60 (2H, m, H
5’), 2.57 (1H, dt, J = 12.6, 7.0 Hz, H
2’















1’), 73.6, 71.8 (Bn-CH2), 
70.9 (C
5’), 40.7 (C

















A solution of 107 α (1.04 g, 2.57 mmol) in anhydrous pyridine (11.0 mL) was cooled to 
0 °C before dropwise addition of trifluoroacetic anhydride (0.53 mL, 3.85 mmol). The 
reaction mixture was then left to stir at r.t for 2 hrs 45 mins, after which the reaction 
mixture was partitioned between sat. NaHCO3 (aq) and DCM. The organic layers were 
combined and dried over anhydrous sodium sulphate; solvent was reduced in vacuo to 
afford 114 α (1.25 g, 97 %) as a mustard-yellow oil.  
 
Rf (DCM: MeOH 95:5, A’): 0.77. 
LRMS: [ES
+, MeOH] m/z (%): 1024 ((2M(
13C) + Na)





+, 5), 523 ((M + Na)
+, 100), 502 ((M(
13C) + H)
+, 20), 501 ((M + H)
+, 
75). 




A solution of 114 α (1.25 g, 2.5 mmol) in anhydrous DCM (7.0 mL) was cooled to          
– 78  °C before dropwise addition of boron trichloride (1.0 M in DCM, 7.5 mL, 
7.5  mmol). The reaction mixture was left to stir at - 78 °C for 7 hrs after which 
methanol (30 mL) was added and the reaction mixture left to stand at 4 °C for 18 hrs. 257 
 
NaOH (aq, 2M) was added until pH 7.0. Solvent was removed in vacuo. The crude was 
partitioned between water and DCM. The aqueous phases were combined and solvent 
reduced in vacuo and high vacuum, to give crude (1.88 g) as a cream-yellow solid. 
Column chromatography (DCM: MeOH 85:15, 8:2 v/v) afforded 1 α (0.54 g, 96 %) as a 
cream-white solid. 
Rf (DCM: MeOH 8:2, B’): 0.14 
LRMS: [ES
+, MeOH] m/z (%): 225 ((M + H)
+, 100). 
1H NMR (400 MHz, DMSO): δ 7.74 (1H, d, J = 2.0 Hz, H
6), 7.57 (1H, s, H
4), 6.74 
(2H, br s, NH2), 5.06 (1H, br s, OH
3’), 4.82 (1H, t, J = 7.5 Hz, H
1’),
 4.70 (1H, br s, 
OH
5’), 4.18 (1H, m, H
3’), 3.80 (1H, dd, J = 9.5, 5.0 Hz, H
4’), 3.48 (1H, dd, J = 11.6, 4.0 
Hz, H
5’), 3.40 (1H, dd, J = 11.6, 5.0 Hz, H
5’), 2.44 (1H, dt, J = 12.6, 7.0 Hz, H
2’
β), 2.11 



















A solution of 1 α (0.307 g, 1.371 mmol) in anhydrous pyridine (5.7 mL) was cooled to 
0 °C before dropwise addition of trifluoroacetic anhydride (0.3 mL, 2.16 mmol). The 
reaction mixture was left to stir at r.t for 3 hrs after which the reaction mixture was 
partitioned between DCM and NaHCO3. The organic phases were combined and dried 
over anhydrous sodium sulphate. Solvent was then removed in vacuo and high vacuum. 
The residue was dried under high vacuum. The product, 136 α was present in a mixture 
with 1 α. 
Rf (DCM: MeOH 8:2, A’): 0.54 258 
 
LRMS: [ES
+, MeOH] m/z (%): 664 ((2M(C
13) + Na)
+, 21), 663 ((M(C
13) + Na)
+, 95), 
343 ((M + Na)
+, 100). 
1H NMR (400 MHz, MeOD): δ 8.78 (1H, br s, NH), 7.89 (1H, s, H
6), 7.72 (1H, s, H
4), 
5.03 (1H, t, J = 7.0 Hz, H
1’),
 4.40-4.35 (1H, m, H
3’), 4.01 (1H, dd, J = 8.5, 4.0 Hz, H
4’), 
3.75-3.58 (2H, m, H
5’), 2.65 (1H, dt, J = 13.0, 6.5 Hz, H
2’
β), 2.27 (3H, s, CH3), 1.89 
(1H, dt, J = 13.0, 6.5 Hz, H
2’
α). 
19F NMR (300 MHz, MeOD): δ -78.2, -78.1, -77.9, -77.8 (s, CF3). 
2-Amino-3-methyl-5-(5’-O-(fluorenylmethyloxycarbonyl)-2’-deoxy-α-D-




To a solution of 1 α (0.1 g, 0.45 mmol) in anhydrous pyridine (1.0 mL) was added a 
solution of Fmoc-Cl (0.583 g, 2.25 mmol) in anhydrous pyridine (1.0 mL). The reaction 
mixture was left to stir at r.t for 7 hrs after which the reaction mixture was partitioned 
between EA and water. The organic phases were combined and dried over anhydrous 
sodium sulphate. Solvent was removed in vacuo to give crude (0.2792 g) as a white 
solid. Column chromatography (DCM: MeOH 1:0, 98:2, 95:5, 9:1 v/v) afforded 122 α. 
Rf (DCM: MeOH 8:2, A’): 0.71 
LRMS: [ES
+, MeOH] m/z (%): 893 ((2M+H)
+, 4), 470 ((M(
13C) + Na)
+, 7), 269 ((M + 
Na)
+, 24), 448 ((M(
13C) + H)
+, 29), 447 ((M+H)
+, 100). 
1H NMR (400 MHz, DMSO): δ 7.89 (2H, d, J = 7.6 Hz, Fmoc H
Ar), 7.71 (1H, s, H
6), 
7.66 (2H, d, J = 7.5 Hz, Fmoc H
Ar), 7.43-7.31 (5H, m, Fmoc H
Ar plus H
4), 6.04 (2H, br 259 
 
s, NH), 5.28 (1H, br s, OH
3’), 4.76 (1H, dd, J = 9.5, 6.5 Hz, H
1’),
 4.54 (2H, d, J = 6.0 
Hz, H
7), 4.31 (1H, t, J = 6.0 Hz, H




3’), 3.94 (1H, td, J = 7.0, 3.5 Hz, H
4’), 2.42 (1H, dt, J = 12.5, 6.5 Hz, 
H
2’




13C NMR (100 MHz, DMSO): δ 157.1 (Fmoc C=O), 154.5 (C
2), 143.3, 143.3 (Fmoc 
C
Ar), 141.2 (C
6), 140.8 (Fmoc C
Ar), 136.5 (C




Ar), 121.4 (Fmoc C
Ar), 120.2 (Fmoc CH
















To a solution of 1 α (0.24 g, 1.10 mmol) in anhydrous pyridine (5.0 mL) was added a 
solution of 4,4’-dimethoxytrityl chloride (0.47 g, 1.39 mmol) in anhydrous pyridine 
(5.0 mL) and the reaction mixture left to stir at r.t for 3 hrs before solvent volume was 
reduced to half under high vacuum. TEA (0.5 mL) and methanol (1mL) were added and 
the reaction mixture partitioned between DCM and sat. NaHCO3 (aq). The organic 
phases were combined and dried over anhydrous sodium sulphate. Solvent was removed 
in vacuo and under high vacuum to give crude as a yellow foam (0.4293 g). Column 
chromatography (DCM: MeOH (0.5 % pyridine) 1:0, 99:1, 98:2, 97:3, 96:4, 95:5 v/v) 
afforded 123 α (0.1347 g, 23 %) as a pale yellow foam. 
LRMS: [ES
+, MeOH] m/z (%): 1054 ((2M(
13C) + H)
+, 8), 1053 ((2M + H)
+, 19), 528 
((M(
13C) + H)
+, 28), 527 ((M + H)
+, 100). 260 
 
1H NMR (400 MHz, DMSO): δ 7.80-7.74 (1H, m, H




7.30-7.27 (6H, m, H
9 plus H
13/H
14), 7.22 (1H, m, H
15), 6.88 (4H, d, J = 9.0 Hz, H
10), 
5.66 (2H, br s, NH2), 5.07 (1H, d, J = 5.0 Hz, OH
3’), 4.78 (1H, dd, J = 9.6, 6.0 Hz, H
1’),
 
4.17-4.14 (1H, m, H
3’), 3.95 (1H, dd, J = 9.0, 5.5 Hz, H
4’), 3.74 (6H, s, OCH3), 3.06 
(1H, dd, J = 10.0, 4.0 Hz, H
5’), 3.02 (1H, dd, J = 11.0, 5.5 Hz, H
5’), 2.41 (1H, dt, J = 
12.0, 6.6 Hz, H
2’











8), 135.8, 135.5 (C











5’), 55.0 (OCH3),  42.8 
(C
2’), 17.1 (CH3). 
2-[N,N-bis-(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(3’-trimethylsilyl-5’-
O-(4,4’-dimethoxytrityl)-2’-deoxy-α-D-ribofuranosyl)pyridine, (125 α) and 2-[N-
(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(3’-trimethylsilyl-5’-O-(4,4’-
dimethoxytrityl)-2’-deoxy-α-D-ribofuranosyl)pyridine, (124 α) 
 
 
To a solution of 123 α (0.06 g, 0.114 mmol) in anhydrous pyridine (1.0 mL) was added 
TMS-Cl (0.1 mL, 0.798 mmol) and the reaction mixture left to stir at r.t for 1 hr 50 mins 
after which another 7 eq TMS-Cl (0.1 mL, 0.798 mmol) was added and the reaction 
mixture left to stir at r.t for 40 mins. Fmoc-Cl (0.15 g, 0.57 mmol) was then added, and 
the reaction mixture went from a clear yellow solution to opaque. The reaction mixture 
was left to stir at r.t for 30 mins after which water was added and the reaction mixture 
left to stir at r.t for 1 hr 30 mins, extraction with DCM followed. The organic phases 
were combined and dried over anhydrous sodium sulphate. Solvent was removed in 
vacuo and high vacuum to give crude as a yellow oil (0.1544 g). Column 261 
 
chromatography (Pet ether: EA (0.5 % Pyridine) 9:1, 85:15, 8:2, 7:3, 6:4 v/v) afforded a 
mixture of 125 α and 124 α (0.0458, 48.7 %) as a white solid. 
 
Data for 125 α: 
 
LRMS: [ES
+, MeOH] m/z (%): 1067 ((M(
13C) + Na
+, 22), 1066 ((M + Na)
+, 80). 
 
Data for 124 α: 
 
LRMS: [ES
+, MeOH] m/z (%): 845 ((M(C
13)+Na)
+, 12), 844 ((M+Na)



























A solution of 114 β (1.36 g, 2.72 mmol) in anhydrous DCM (8.0 mL) was cooled to        
– 78  °C before dropwise addition of boron trichloride (1.0 M in DCM, 8.2 mL, 
8.2 mmol). The reaction mixture was left to stir at - 78 °C for 4 hrs 30 mins after which 
excess methanol (30 mL) was added and the reaction mixture left to stand at 4 °C for 
15 hrs 30 mins after which NaOH (aq, 2.0 M) was added until pH 8.0. Solvent was 
reduced in vacuo. The residue was partitioned between water and DCM. The aqueous 
phases were combined and solvent removed in vacuo, to give crude as a cream-yellow 
solid. Column chromatography (DCM: MeOH 85:15, 8:2 v/v) afforded 1 β (> 0.60 g, > 
98.5 %) as a cream-white solid. 
Rf (DCM: MeOH 8:2, A’): 0.25 
 262 
 







































































To a solution of 1 β (0.66 g, 2.95 mmol) in anhydrous pyridine (6.0 mL) was added a 
solution of 4,4’-dimethoxytrityl chloride (1.30 g, 3.83 mmol) in anhydrous pyridine 
(7.0 mL) drop wise over 15 mins and the reaction mixture left to stir at r.t for 2 hrs after 
which solvent volume was reduced to half in vacuo. TEA (1.0 mL) and MeOH (2.0 mL) 
were added, the reaction mixture became a lime green colour from bright orange. The 
reaction mixture was partitioned between DCM and sat. NaHCO3 (aq). The aqueous 
layers were further extracted with DCM. The organic phases were combined and dried 
over anhydrous sodium sulphate. Solvent was removed in vacuo and high vacuum to 
give crude (1.63 g) as a yellow foam. Column chromatography (DCM: MeOH (0.5 % 
Pyridine) 1:0, 99:1, 97:3, 95:5 v/v) afforded 123 β (0.4596 g) and 126 β (0.2451 g) as 
white foams (39.5 % overall yield). 
 
Data for 123 β: 
 
Rf (DCM: MeOH 8:2, A’): 0.43 263 
 
LRMS: [ES
+, MeOH] m/z (%): 1054 ((2M(
13C) + H)
+, 8), 1053 ((2M + H)
+, 18), 528 
((M(
13C) + H)
+, 28), 527 ((M + H)
+, 100). 
HRMS: [ES
+] Found 527.2539 Da (M+H)
+, calculated 527.2540 Da. 
 
1H NMR (400 MHz, DMSO): δ 7.77 (1H, s, H
6), 7.42 (2H, d, J = 7.5 Hz, H
13/H
14), 




14), 7.16 (1H, m, H
15), 6.87 (4H, d, J = 9.0 Hz, H
10), 
5.64 (2H, br s, NH2), 5.06 (1H, d, J = 4.0 Hz, OH
3’), 4.88 (1H, dd, J = 10.0, 5.0 Hz, 
H
1’),
 4.15 (1H, m, H
3’), 3.86 (1H, dd, J = 7.0, 4.5 Hz, H
4’), 3.73 (6H, s, OCH3), 3.06 
(2H, m, H
5’), 1.99 (1H, ddd, J = 13.0, 5.5, 1.5 Hz, H
2’
α), 1.96 (3H, s, CH3), 1.88 (1H, 











4), 129.7, 128.9 (C














5’), 55.0 (OCH3),  43.2 (C
2’), 17.0 (CH3). 
 
Data for 126 β: 
 
Rf (DCM: MeOH 8:2, A’): 0.89 
LRMS: [ES
+, MeOH] m/z (%): 1182 ((2M + H)
+, 4), 830 ((M(C
13) + H)




+] Found 829.3847 Da (M+H)
+, calculated 829.3847 Da. 
1H NMR (400 MHz, DMSO): δ 7.73 (1H, s, H
6), 7.37-7.35 (2H, m, H
Ar), 7.29-7.13 
(17H, m, H
Ar), 6.83-6.75 (8H, m, H
10), 5.67 (2H, s, NH2), 4.88 (1H, dd, J = 11.0, 5.0 
Hz, H
1’),
 4.16 (1H, d, J = 5.0 Hz, H
3’), 3.91 (1H, s, H
4’), 3.73 (6H, s, OCH3), 3.71 (6H, 
s, OCH3), 2.94-2.91 (1H, m, H
5’),2.78 (1H, dd, J = 10.0, 4.5 Hz, H
5’), 1.90 (3H, s, 
CH3), 1.59-1.51 (1H, m, H
2’
α), 1.37 (1H, dd, J = 12.6, 5.0 Hz, H
2’
β). 
13C NMR (100 MHz, DMSO): δ 158.0 (C
2), 158.0 (C





Ar), 135.5, 135.5, 135.2, 129.8, 129.7, 129.6, 129.5, 
127.8, 127.8, 127.6, 127.6, 126.7, 126.5 (CH
Ar), 113.1, 113.0 (C
10),  86.2 (C





5’), 54.9 (OCH3),  42.0 (C
2’), 16.9 (CH3). 264 
 
2-[N,N-bis-(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(3’-trimethylsilyl-5’-
O-(4,4’-dimethoxytrityl)-2’-deoxy-β-D-ribofuranosyl)pyridine, (125 β); 2-[N,N-bis-
(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(5’-O-(4,4’-dimethoxytrityl)-2’-
deoxy-β-D-ribofuranosyl)pyridine, (128 β); 2-[N-
(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(3’-trimethylsilyl-5’-O-(4,4’-
dimethoxytrityl)-2’-deoxy-β-D-ribofuranosyl)pyridine, (124 β) and 2-[N-
(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(5’-O-(4,4’-dimethoxytrityl)-2’-

































































































































































To a solution of 123 β (0.3972 g, 0.755 mmol) in anhydrous pyridine (4.0 mL) was 
added TMS-Cl (0.57 g, 4.53 mmol) and the reaction mixture left to stir at r.t for 2 hrs 
after which another 3 eq TMS-Cl (0.3 mL, 2.36 mmol) was added and the reaction 
mixture left to stir at r.t for 1 hr. Another 3 eq TMS-Cl (0.3 mL, 2.36 mmol) was added 
and the reaction mixture left to stir at r.t for 45 mins after which another 3 eq TMS-Cl 
(0.3 mL, 2.36 mmol) added and the reaction mixture left to stir at r.t for 45 mins, 
solvent was then removed in high vacuum. The residue was resuspended in anhydrous 
pyridine (4.0 mL) and Fmoc-Cl (0.78 g, 3.02 mmol) added portion wise after which 
white solid precipitated. The reaction mixture was left to stir at r.t for 1 hr 20 mins after 
which water (excess) was added and the reaction mixture left to stir at r.t for 1 hr. 
Partition between DCM and water followed. The organic phases were combined and 
dried over anhydrous sodium sulphate. Solvent was removed in vacuo and high vacuum 
to give crude (0.9532 g) as a peach foam. Column chromatography (Pet ether: EA 
(0.5 % Pyridine) 1:0, 95:5, 9:1, 85:15, 8:2, 7:3, 6:4, 1:1, EA:MeOH (0.5 % Pyridine) 9:1 
v/v) afforded 125 β (0.2056 g, 0.2 mmol), 128 β (0.147 g, 0.18 mmol), 124 β (0.125 g, 
0.13 mmol) and 127 β (0.083 g, 0.11 mmol); all as white foams (overall yield 82.1 %). 
 
Data for 125 β: 
 
Rf (Pet ether: EA 6:4, A’): 0.73 
 
LRMS: [ES
+, MeOH] m/z (%): 1069 ((M(3 
13C) + Na)





+, 80), 1066 ((M + Na)
+, 100). 
 
1H NMR (400 MHz, DMSO): δ 8.17 (1H, d, J = 2.0 Hz, H
6), 7.74 (4H, d, J = 7.0 Hz,  
H
Ar), 7.59 ( 1H, d, J = 2.0 Hz, H
4), 7.46-7.40 (2H, m, H
Ar), 7.32-7.13 (19H, m, H
Ar), 
6.84 (4H, d, J = 9.0 Hz, H
10), 5.19 (1H, dd, J = 10.0, 6.0 Hz, H
1’),
 4.50-4.37 (5H, m, H
17 
plus H
3’), 4.07 (2H, t, J = 6.0 Hz, H
18), 4.01 (1H, dd, J = 7.5, 5.0 Hz, H
4’), 3.67 (6H, s, 
OCH3), 3.27-3.20 (2H, m, H
5’), 2.27-2.24 (1H, m, H
2’
α), 1.96 (1H, ddd, J = 14.0, 10.0, 
6.0 Hz, H
2’
β), 1.68 (3H, s, CH3), 0.08 (9H, s, TMS-CH3). 
 
13C NMR (100 MHz, DMSO): δ 158.1, 150.6, 148.2, 144.8 (C
Ar), 144.2 (C
6), 143.7, 
143.1, 140.6, 138.3 (C
Ar), 137.4 (C
4), 135.6, 130.5 (C











5’), 55.0 (OCH3), 45.9 (C
18), 43.4 (C
2’), 16.0 (CH3), 0.0 (TMS-CH3). 
 
Data for 128 β: 
 
Rf (Pet ether: EA 6:4, A’): 0.27 
LRMS: [ES
+, MeOH] m/z (%): 995 ((M(2 
13C) + Na)
+, 3), 994 ((M(
13C) + Na)
+, 60), 
993 ((M + Na)
+, 100). 
HRMS: [ES
+] Found 993.3737 Da (M+Na)
+, calculated 993.3722 Da. 
 
1H NMR (400 MHz, DMSO): δ 8.15 (1H, d, J = 2.0 Hz, H
6), 7.74 (4H, d, J = 7.5 Hz,  
H
Ar), 7.58 ( 1H, d, J = 2.0 Hz, H
4), 7.46-7.44 (2H, m, H
Ar), 7.35-7.13 (19H, m, H
Ar), 
6.83 (4H, d, J = 8.5 Hz, H
10), 5.27 (1H, d, J = 4.0 Hz, OH
3’), 5.20 (1H, dd, J = 10.0, 5.5 
Hz, H
1’),
 4.43 (4H, m, H
17), 4.26 (1H, m, H
3’), 4.08-4.05 (3H, m, H
18 plus H
4’), 3.66 
(6H, s, OCH3), 3.20 (2H, m, H
5’), 2.30 (1H, m, H
2’
α), 1.91 (1H, m, H
2’
β), 1.66 (3H, s, 
CH3. 
 
13C NMR (100 MHz, DMSO): δ 158.1, 150.6, 148.1, 145.0 (C
Ar), 144.2 (C
6), 143.7, 
143.1, 140.7, 138.5 (C
Ar), 137.4 (C
4), 137.2, 135.7, 135.6 (C
Ar), 130.4, 129.7, 127.8, 









5’), 55.0, 55.0 (OCH3), 45.9 (C
18), 43.6 
(C
2’), 16.0 (CH3). 
 
Data for 124 β: 
 
Rf (Pet ether: EA 6:4, A’): 0.67 
 
Data for 127 β: 
 





dimethoxytrityl)-2’-deoxy-β-D-ribofuranosyl)pyridine, (128 β) and 2-[N-
(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(5’-O-(4,4’-dimethoxytrityl)-2’-




To a solution of 125 β (0.0495 g, 0.0473 mmol) in anhydrous pyridine (0.5 mL) was 
added a solution of KF (aq, 1.0 M, 0.1 mL, 0.0946 mmol) and the reaction mixture left 
to stir at r.t for 1 hr 30 mins after which reaction mixture was partitioned between DCM 
and water. The organic phases were combined and dried over anhydrous sodium 
sulphate. Solvent was removed in vacuo. Column chromatography (Hex: DCM (0.5 % 
Pyridine) 2:8, 0:1, DCM: EA 9:1, 8:2, 7:3, 1:1, 0:1 v/v) afforded 128  β  (0.022 g, 
0.023 mmol) and 127 β (0.0094 g, 0.013 mmol) as white foams (76 % overall yield). 
 
Data for 128 β: 
 
Rf (DCM: Hex 8:2, A’): 0.30 
 
Data for 127 β: 
 
Rf (DCM: Hex 8:2, A’): 0.05 
LRMS: [ES
+, MeOH] m/z (%): 772 ((M(
13C) + Na)
+, 45), 771 ((M + Na)
+, 90), 750 
((M(
13C) + H)
+, 12), 749 ((M + H)
+, 100). 268 
 
HRMS: [ES
+] Found 749.3220 Da (M+H)
+, calculated 749.3221 Da. 
 
1H NMR (400 MHz, DMSO): δ 9.58 (1H, s, NH), 8.26 (1H, d, J = 2.0 Hz, H
6), 7.88 
(2H, d, J = 7.5 Hz,  H
Ar), 7.71 (2H, d, J = 6.5 Hz, H
Ar), 7.66 ( 1H, d, J = 1.5 Hz, H
4), 
7.43-7.14 (13H, m, H
Ar), 6.87 (4H, d, J = 8.6 Hz, H
10), 5.17 (1H, d, J = 3.5 Hz, OH
3’), 
5.11 (1H, dd, J = 10.0, 5.5 Hz, H
1’),
 4.39 (4H, d, J = 7.0 Hz, H
17), 4.27 (1H, t,  J = 7.0 
Hz, H
18), 4.20 (1H, m, H
3’), 3.96 (1H, m, H
4’), 3.72 (6H, s, OCH3), 3.15 (1H, dd, J = 
10.5, 4.0 Hz, H
5‘), 3.11 (1H, dd, J = 10.5, 5.0 Hz, H
5’), 2.18 (1H, m, H
2’
α), 2.09 (3H, s, 


























5’), 55.0 (OCH3), 46.6 
(C
18), 43.7 (C





































































To a solution of 128 β (0.1637 g, 0.169 mmol) in anhydrous DCM (0.5 mL) was added 
N,N-diisopropylethylamine (0.06 mL, 0.337 mmol) followed by dropwise addition of  
2-cyanoethyl  N,N-diisopropylchlorophosphoramidite (0.37 M in DCM, 0.5 mL, 
0.185 mmol) under an argon atmosphere, and the reaction mixture left to stir at r.t for 
1  hr 55 mins, after which another 0.2 eq (0.0075 mL, 0.034 mmol) phosphitilating 
reagent was added and reaction mixture was left to stir at r.t for another 35 mins. The 
reaction mixture was then transferred via needle and syringe to a separating funnel 
containing anhydrous DCM. The reaction mixture was washed with saturated KCl 
(5 mL) and the organic phase was dried over anhydrous sodium sulphate. Solvent was 
removed  in  vacuo  under argon, to give following purification by column 
chromatography (Hex: EA 7:3 (0.5 % pyridine)) under argon pressure, 129  β, a 
diastereoisomeric mixture (1:1) as a white foam (0.0674 g, 34 %). 
 
Data for the diastereoisomeric mixture: 
 
Rf (Hex: EA 1:1 (0.5 % pyridine), A’): 0.47, 0.28. 270 
 
LRMS: [ES
+, MeOH] m/z (%): 1196 ((M(2 
13C) + Na)
+, 25), 1195 ((M(
13C) + Na)
+, 
78), 1194 ((M + Na)
+, 100), 1172 ((M + H)
+, 18). 
 
31P NMR (121 MHz, CD3CN) δ 148.90 (s, 1P, P), 148.75 (s, 1P, P). 
 
1H NMR (400 MHz, CD3CN): δ 8.04 (2H, s, H
6), 7.66 (8H, d, J = 8.0 Hz, H
Ar), 7.51-
7.48 (4H, m, H
Ar), 7.45 (2H, m, H
4), 7.37-7.19 (38H, m, H
Ar), 6.82-6.79 (8H, m, H
10), 
5.19 (2H, dd, J = 8.0, 4.0 Hz, H
1’), 4.57 (2H, m, H
3’), 4.46 (8H, m, H
17), 4.29-4.26 (2H, 
m, H
4’), 4.03 (4H, t, J = 8.0 Hz, H
18), 3.91-3.78 (2H, m, OCH2CH2CN), 3.76-3.73 (2H, 
m, OCH2CH2CN), 3.69-3.59 (16H, s, OCH3 plus iPr-CH), 3.32 (2H, t, J = 4.0 Hz, H
5’), 
3.28 (2H, d, J = 4.0 Hz, H
5’), 2.68 (2H, t, J = 8.0 Hz, OCH2CH2CN), 2.58 (2H, t, J = 
8.0 Hz, OCH2CH2CN), 2.53-2.52 (1H, m, H
2’
α), 2.45 (1H, dd, J = 16.0, 8.0 Hz, H
2’
α), 
2.09-2.01 (2H, m, H
2’
β), 1.55 (6H, s, CH3), 1.22-1.13 (24H, m, iPr-CH3). 
 





145.1, 144.2, 141.8 (Fmoc-C
Ar), 138.7, 138.1 (C
4), 136.8, 136.8 (DMT-C
Ar), 131.7, 





1’), 76.3, 76.2 (C
3’), 68.5 (C
17), 65.1, 65.1 (C
5’), 59.4, 59.2 (OCH2CH2CN), 
55.6 (OCH3), 47.1 (C
18), 43.9 (iPr-CH), 43.8, 43.5 (C
2’), 24.8, 24.7 (iPr-CH3), 20.9 
















deoxy-β-D-ribofuranosyl)pyridine, (130 β) and 2-[N- 
(fluorenylmethyloxycarbonyl)]amino-3-methyl-5-(3’,5’-di-O-benzyl-2’-deoxy-β-D-

























































A solution of 107 β (1.0777 g, 2.66 mmol) in anhydrous pyridine (7.0 mL) was cooled 
to 0 °C before careful addition of Fmoc-Cl (5.514 g, 21.3 mmol) in anhydrous 
acetonitrile (5.0 mL). The reaction mixture was left to stir at 0 °C for 2 hrs (reaction 
mixture had turned dark brown from mustard yellow) after which solvent was reduced 
under high vacuum. The residue was then partitioned between water and DCM. The 
organic phases were combined and dried over anhydrous sodium sulphate. Solvent was 
removed in vacuo and high vacuum to give crude (5.8508 g) as a mustard yellow oil. 
Column chromatography (Hex: EA 9:1, 8:2, 7:3, 6:4, 1:1, 0:1, EA: MeOH 8:2 v/v) 
afforded 130 β (0.6123 g, 0.722 mmol), and a mixture of 130 β and 131 β (3:7 ratio 
respectively, 1.26 g), as cream white foams. The mixture was put for further reaction to 
convert 130 β into 131 β using this same method, and then purification by column 
chromatography (Hex: EA 9:1, 8:2, 7:3, 6:4, 1:1, 0:1, EA: MeOH 8:2 v/v) afforded 
130 β (0.5448 g, 0.642 mmol) and 131 β (0.7433 g, 1.186 mmol) as cream white foams. 





Data for 130 β: 
 
Rf (Hex: EA 1:1; A’): 0.39. 
 
LRMS: [ES
+, MeOH] m/z (%): 850 ((M(
13C) + H)




+] Found 871.3367 Da (M + Na)
+, calculated 871.3354 Da. 
 
1H NMR (400 MHz, CDCl3): δ 8.21 (1H, d, J = 2.0 Hz, H
6), 7.66 (4H, d, J = 7.6 Hz, 
H
Ar), 7.56 (1H, d, J = 2.0 Hz, H
4), 7.43-7.28 (17H, m, H
Ar), 7.20 (5H, m, H
Ar), 5.23 
(1H, dd, J = 10.5, 5.0 Hz, H
1’), 4.64 (2H, s, Bn-CH2), 4.63 (2H, s, Bn-CH2), 4.49-4.40 
(5H, m, H
8 plus H
4’), 4.25 (1H, d, J = 5.5 Hz, H
3‘), 4.09-4.06 (2H, m, H
9), 3.73 (1H, dd, 
J = 10.0, 4.0 Hz, H
5’), 3.67 (1H, dd, J = 10.0, 5.0 Hz, H
5’), 2.45 (1H, dd, J = 12.0, 5.5 
Hz, H
2’
α), 1.96 (1H, ddd, J = 13.5, 11.0, 6.0 Hz, H
2’
β), 1.83 (3H, s, CH3). 
 
13C NMR (100 MHz, CDCl3):  δ 151.6 (C
Ar), 148.9 (C
2), 144.9 (C
6), 144.5, 143.4 
(Fmoc-C
Ar), 141.7, 141.3, 138.4 (C









1’), 73.8, 71.4 (Bn-CH2), 71.3 (C
5’), 68.8 (C
8), 46.7 (C













































































A solution of 130 β (1.0382 g, 1.22 mmol) in anhydrous DCM (3.7 mL) was cooled to     
- 78 °C before careful dropwise addition of boron trichloride (1.0 M in DCM, 3.7 mL, 
3.7 mmol). The reaction mixture changed colour from mustard yellow to dark brown. 
The reaction mixture was left to stir at - 78 °C for 6 hrs after which methanol (HPLC 
grade, ~ 100 mL) was added and the reaction mixture was left to stir at – 75 °C for 
30 mins after which it was left to stand at 4 °C for 17 hrs 30 mins. Sat. NaHCO3 was 
added until pH 7.0 obtained. Solvent was removed in vacuo and the residue partitioned 
between DCM and water. The organic phases were combined and dried over anhydrous 
Na2SO4. Solvent was removed in  vacuo to give crude as a cream foam. Column 
chromatography (DCM: MeOH 1:0, 98:2, 96:4, 94:6, 92:8, 9:1 v/v) afforded 132 β 
(0.542 g) and 133 β (0.1162 g) as cream foams (overall yield 78.6 %). 
 
Data for 132 β: 
 




+, MeOH] m/z (%): 692 ((M(
13C) + Na)
+, 42), 691 ((M + Na)
+, 100), 669 
((M + H)
+, 12).  
 
HRMS: [ES
+] Found 691.2407 Da (M + Na)
+, calculated 691.2415 Da. 
 
1H NMR (400 MHz, DMSO): δ 8.17 (1H, s, H
6), 7.77 (3H, d, J = 7.0 Hz, Fmoc-H
Ar), 
7.62 (1H, s, H
4), 7.35 (4H, m, Fmoc-H




1’), 4.85 (1H, t, J = 5.5 Hz, OH
5’), 4.44 (4H, m, H
8), 4.31 (1H, m, 
H
3’), 4.10-4.07 (2H, m, H
9), 3.92-3.91 (1H, m, H
4’), 3.61-3.51 (2H, m, H
5’), 2.23 (1H, 
dd, J = 11.5, 5.0 Hz, H
2’
α), 1.89 (1H, td, J = 12.6, 5.5 Hz, H
2’
β), 1.73 (3H, s, CH3). 
 
13C NMR (100 MHz, DMSO): δ 150.7 (C
Ar), 148.0 (C
2), 144.3 (C





3), 128.9, 128.6, 128.4, 128.2, 
127.6, 127.3 (Fmoc-CH
Ar), 126.9 (Fmoc-C
Ar), 125.9, 125.2 (Fmoc-CH
Ar), 124.7 
(Fmoc-C








9),  43.4 (C
2’), 16.0 (CH3). 
 
Data for 133 β: 
 
Rf (DCM: MeOH 9:1; A’): 0.69. 
 
LRMS: [ES
+, MeOH] m/z (%): 781 ((M + Na)





















Co-evaporation of 132 β (0.70 g, 1.048 mmol) with anhydrous pyridine (3 x 3 mL) was 
carried out under high vacuum and then left to dry overnight under high vacuum. To a 
solution of 132 β (0.70 g, 1.048 mmol) in anhydrous pyridine (2.5 mL) was added a 
solution of 4,4’-dimethoxytrityl chloride (0.40 g, 1.18 mmol) in anhydrous pyridine 
(2.5 mL) dropwise and the reaction mixture was left to stir at r.t for 2 hrs after which 
0.1  eq 4,4’-dimethoxytrityl chloride (0.035 g, 0.105 mmol) in anhydrous pyridine 
(0.3 mL) was added and the reaction mixture left to stir at r.t for 1 hr. Another 0.15 eq 
4,4’-dimethoxytrityl chloride (0.053 g, 0.156 mmol) in anhydrous pyridine (0.3 mL) 
was added and the reaction mixture left to stir at r.t for 30 mins. Solvent was reduced to 
half under high vacuum, methanol (2 mL) and TEA (1 mL) were added, and the 
reaction mixture partitioned between DCM and a 1:1 mixture of H2O: sat. NaHCO3 aq. 
The organic phases were combined and dried over anhydrous sodium sulphate. Solvent 
was removed in vacuo and high vacuum to give crude as a pale orange foam. Column 
chromatography (Hex: EA (0.5 % Pyridine) 1:1, 4:6, EA: MeOH 9:1 v/v) afforded 




Data for 128 β: 
 
Rf (Hex: EA 1:1(0.5 % Pyridine); A’): 0.15. 
 
LRMS: [ES
+, MeOH] m/z (%): 994 ((M(
13C) + Na)
+, 62), 993 ((M + Na)
+, 100), 973 
((M(
13C) + H)




+] Found 971.3898 Da (M + H)
+, calculated 971.3902 Da. 
 
1H NMR (400 MHz, DMSO): δ 8.15 (1H, d, J = 2.0 Hz, H
6), 7.74 (4H, d, J = 7.5 Hz, 
H
Ar), 7.57 (1H, d, J = 1.5 Hz, H
4), 7.45 (4H, d, J = 7.0 Hz, H
Ar), 7.32-7.19 (19H, m, 
H
18 plus H
Ar), 6.83 (4H, d, J = 8.5 Hz, H
19), 5.26 (1H, d, J = 4.5 Hz, OH
3’), 5.20 (1H, 
dd, J = 10.0, 5.5 Hz, H
1’), 4.44 (4H, m, H
8), 4.26 (1H, m, H
3’), 4.08-4.05 (3H, m, H
9 
plus H
4’), 3.67 (6H, s, OCH3), 3.20 (2H, d, J = 4.5 Hz, H
5’), 2.31-2.27 (1H, m, H
2’
α), 
2.00-1.90 (1H, m, H
2’
β), 1.66 (3H, s, CH3). 
 






6), 143.1, 140.6 (Fmoc-C
Ar), 138.5 (C
Ar), 137.2 (C
4), 135.7, 135.6 
(C
Ar), 130.4 (C












5’), 54.9, 54.9 (OCH3), 45.9 (C
9),  43.6 (C
2’), 16.0 (CH3). 
 
Data for 123 β: 
 
Rf (Hex: EA 1:1(0.5 % Pyridine); A’): 0.08. 
























































To a solution of 128 β (0.387 g, 0.3985 mmol) in anhydrous DCM (2.3 mL) was added 
anhydrous N,N-diisopropylethylamine (0.14 mL, 0.797 mmol) followed by dropwise 
addition of  2-cyanoethyl N,N-diisopropylchlorophosphoramidite (0.1 mL, 
0.4383 mmol) under an argon atmosphere, and the reaction mixture left to stir at r.t for 
1  hr 25 mins after which another 0.11 eq (0.01 mL, 0.0448 mmol) phosphitilating 
reagent was added and reaction mixture was left to stir at r.t for another 35 mins. The 
reaction mixture was transferred via needle and syringe to a separating funnel 
containing anhydrous DCM. The reaction mixture was washed with saturated KCl 
(10 mL) and the organic phase was dried over anhydrous sodium sulphate. Solvent was 
removed  in  vacuo  under argon, to give following purification by column 
chromatography (Hex: EA 1:1 (0.5 % pyridine) v/v) under argon pressure, 129 β, as a 
white foam (0.231 g, 49.5 %, diastereoisomers 1:1). 
 
Data for the diastereoisomeric mixture: 
 
Rf (Hex: EA 1:1 (0.5 % pyridine), A’): 0.27; UV positive; Stains red-orange. 278 
 
LRMS: [ES
+, MeOH] m/z (%): 1194 ((M(
13C) + Na)
+, 30), 1193 ((M + Na)
+, 48), 1174 
((M (3 
13C) + H)
+, 5), 1173 ((M (2 
13C) + H)
+, 18), 1172 ((M (
13C) + H)




31P NMR (121 MHz, CD3CN) δ 148.90 (s, 1P, P), 148.75 (s, 1P, P). 
 
1H NMR (400 MHz, CD3CN): δ 8.04 (2H, s, H
6), 7.66 (8H, d, J = 7.5 Hz, H
Ar), 7.51-
7.45 (6H, m, H
Ar plus H
4), 7.38-7.19 (38H, m, H
Ar plus H
18), 6.83-6.80 (8H, m, H
19), 
5.20 (2H, dd, J = 9.0, 4.0 Hz, H
1’), 4.59-4.56 (2H, m, H
3’), 4.47 (8H, m, H
8), 4.29-4.26 
(2H, m, H
4’), 4.05-4.02 (4H, m, H
9), 3.87-3.84 (2H, m, OCH2CH2CN), 3.75-3.74 (2H, 
m, OCH2CH2CN), 3.69 (16H, m, OCH3 plus iPr-CH), 3.33 (2H, t, J = 4.5 Hz, H
5’), 3.30 
(2H, d, J = 4.5 Hz, H
5’), 2.68 (2H, t, J = 6.0 Hz, OCH2CH2CN), 2.58 (2H, t, J = 6.0 Hz, 
OCH2CH2CN), 2.55-2.43 (2H, m, H
2’
α), 2.10-2.04 (2H, m, H
2’
β), 1.58 (6H, s, CH3), 
1.23-1.13 (24H, m, iPr-CH3). 
 
13C NMR (100 MHz, CD3CN): δ 159.7 (C
20), 151.9 (C




Ar), 142.1, 139.0, 139.0 (C
Ar), 138.3 (C
4), 131.9 (C
3), 131.1, 129.1, 




4’), 78.6, 78.5 (C
1’), 77.0, 76.4 (C
3’), 68.8 (C
8), 65.4, 65.3 (C
5’), 59.5 
(OCH2CH2CN), 55.9 (OCH3), 47.3 (C
9), 44.1 (iPr-CH), 44.0, 43.7 (C
2’), 24.9 (iPr-














5.3     OLIGONUCLEOTIDE  SYNTHESIS 
 
All phosphoramidites synthesised were incorporated into various oligonucleotides 
sequences and then analysed by negative mode electrospray MS analysis. 
 
5.3.1     SYNTHESIS OF OLIGONUCLEOTIDES 
 
The synthesised monomers were treated as follows: After purification by column 
chromatography the monomer was dissolved in freshly distilled DCM. Aliquots 
corresponding to between ~60-100 moles (depending on the phosphitilation yields) 
were transferred to ABI monomer reagent bottles and dried in a desiccator overnight 
under high vacuum before being stored under a positive pressure of argon at – 20 C. 
 
Standard DNA phosphoramidites, solid supports, and additional reagents were 
purchased from Link Technologies or Applied Biosystems, Ltd. The psoralen C6 
phosphoramidite was purchased from Glen Research, Inc. All oligonucleotides were 
synthesized on an Applied Biosystems 394 automated DNA/RNA synthesizer using a 
1.0 µmol phosphoramidite cycle of acid-catalyzed detritylation, coupling, capping, and 
iodine oxidation. Normal monomers (A, G, C, and T) were allowed to couple for 25 
seconds and all other monomers for an additional 300 seconds. Stepwise coupling 
efficiencies and overall yields of monomers with DMT protection were determined by 
measuring trityl cation conductivity and in all cases were > 98.0 %. All -cyanoethyl 
phosphoramidite monomers were dissolved in anhydrous acetonitrile to a concentration 
of 0.1 M immediately prior to use. To all psoralen C6 containing oligonucleotides, the 
oligo was synthesised first, after which psoralen was incorporated as a phosphoramidite 
and deprotection followed. 
 
The oligonucleotides attached to the synthesis columns were treated with 20 % 
diethylamine in acetonitrile for 20 mins before cleavage from the support. This 
procedure removes cyanoethyl groups from the phosphotriesters and scavenges the 
resultant acrylonitrile; preventing cyanoethyl adducts being formed at the primary 
amine sites of the modified nucleosides. 280 
 
Cleavage of the oligonucleotides containing modified nucleosides, from the solid 
support and deprotection was achieved by exposure to concentrated aq. ammonia for 
24 hrs at r.t (1 hr at r.t cleaved the oligos from the resin, the ammonia solution was then 
left at r.t for an additional 23 hrs to allow for deprotection). Cleavage of the 
oligonucleotides containing non-modified nucleosides, from the solid support and 
deprotection was achieved quantitatively by treatment with concentrated aqueous 
ammonia at 55 ºC for 5 hrs. 
 
5.3.2   OLIGONUCLEOTIDE  PURIFICATION 
 
Purification of oligonucleotides was carried out by reversed-phase HPLC by using a 
Gilson system with a Brownlee Aquapore column (C8, 8 mm x 250 mm, 300 Å pore) 
with a gradient of CH3CN in NH4OAc increasing from 0 to 50 % buffer B over 30 mins 
with a flow rate of 4 mLmin
-1 (elution buffer A: 0.1 M NH4OAc, pH 7.0; buffer B: 
0.1 M NH4OAc with 50 % CH3CN, pH 7.0). Elution of oligonucleotides was monitored 
by ultraviolet absorption at 295 nm. After HPLC purification, oligonucleotides were 
desalted by using NAP-10 Sephadex columns (GE Healthcare) according to the 
manufacturer’s instructions.  
 
The eluted oligonucleotides were analysed by UV-Visible absorption spectroscopy 
(295  nm) and the concentrations of each oligonucleotide were calculated from the 
standard molar extinction coefficients of the four natural bases (ε = mol
-1 L cm
-1 for the 
oligonucleotide) = (A 15.4) + (G 11.5) + (C 7.4) + (T 8.7) × 0.91)
305. The 
oligonucleotides were then stored under argon permanently at - 20 C or temporarily at 
5 C. 
 
5.3.3   OLIGONUCLEOTIDE  ANALYSIS 
 
Oligonucleotide analysis was carried out by capillary gel electrophoresis (CE) and mass 
spectrometry. Each sample (0.4 OD per 100 µL) was injected on to an ssDNA 100-R 
gel by using a Tris-borate urea (7 M) buffer (kit N° 477480) on a Beckman coulter 
P/ACE
TM MDQ capillary gel electrophoresis system controlled by 32 Karat software. 
The injection voltage was 10.0 kV and separation voltage was 9.0 kV. The 281 
 
electropheregram was run for 45.0 mins and peaks were monitored by UV absorbance at 
254 nm.  
 
TFOs were analysed by negative mode electrospray MS by using a Fisons VG platform 
spectrometer in water with triisopropylamine (2 µL of a 1 % solution in MeOH).  
 
Hairpin duplexes were analysed by MALDI-TOF using a ThermoBioAnalysis Dynamo 
MALDI-TOF spectrometer in positive ion mode with internal standard calibration (Tn) 
(experimental error of ± 0.1 % for the total mass of the oligonucleotide).
306 
 
5.3.4   OLIGONUCLEOSTIDES  SYNTHESISED 
 




































































































































































5.3.4.4   KEY TO MODIFIED NUCLEOSIDES AND OLIGONUCLEOTIDE  
  MODIFICATIONS 
 
Code Name  Structure 


























































Pso  Psoralen C6   
 
H  hexa(ethylene glycol)   
 
 
5.4     BIOPHYSICAL  STUDIES 
 
5.4.1   ULTRAVIOLET-MELTING ANALYSIS 
 
UV melting experiments were performed on a Varian Cary 400 Scan UV-visible 
spectrophotometer, in Hellma SUPRASIL synthetic quartz, 10mm path length cuvettes, 
monitoring at 280 nm, with a DNA duplex concentration of 1.0 µM and a volume of 
1.2  mL. The sample chamber was flushed with air pumped through a desiccant to 285 
 
prevent condensation of atmospheric water on the cells. Samples were prepared as 
follows: The third strand and duplex were mixed in a 3:1 ratio respectively in 2 mL 
Eppendorf tubes, then lyophilized before resuspending in 1.2 mL of the appropriate 
buffer solution (10 mM sodium phosphate at pH 6.2, 6.6, 7.0, 7.5 and 8.0, containing 
200 mM NaCl). The samples were then filtered into the cuvettes with Kinesis 
regenerated cellulose 17 mm, 0.45 µM syringe filters. The UV melting protocol (carried 
out pre-crosslinking for pH 6.2-8.0; post crosslinking for pH 7.0-8.0 only) involved 
initial denaturation by heating to 80 °C at 10 °C/min followed by annealing by cooling 
to 20 °C at 0.5 °C/min, then maintaining at 20 °C for 20 min before starting the melting 
experiment which involved heating from 20 °C to 80 °C at 0.5 °C/min, holding at 80 °C 
for two mins then cooling to 20 °C at 0.5 °C/min. Two successive melting curves were 
measured before fast annealing from 80 °C to 20 °C at 10 °C/min. Melting temperatures 
(Tm) were determined by the maximum of the first derivative plot of the second heating 
curve using OriginLab software. 
 
5.4.1.1   BUFFER PREPARATIONS 
 
Buffers at various pH were made according to the methods reported.
307 
 
5.4.1.1.1  Buffer pH 5.0 
 
To a solution of acetic acid (0.12 g) in deionised water (180 mL) was added NaCl 
(2.238 g). The solution was then titrated to pH 5.5 at 20 °C with monovalent NaOH 
(0.1 M) and then made up to 200 mL with deionised water. 
 
5.4.1.1.2  Buffer pH 6.2 
 
To a solution of NaH2PO4 (0.24 g) in deionised water (180 mL) was added NaCl 
(2.178 g). The solution was then titrated to pH 6.19 with NaOH (0.1 M) and then made 






5.4.1.1.3  Buffer pH 6.6 
 
To a solution of NaH2PO4 (0.24 g) in deionised water (180 mL) was added NaCl 
(2.134 g). The solution was then titrated to pH 6.59 with NaOH (0.1 M) and then made 
up to 200 mL with deionised water. 
 
5.4.1.1.4  Buffer pH 7.0 
 
To a solution of NaH2PO4 (0.24 g) in deionised water (180 mL) was added NaCl 
(2.081 g). The solution was then titrated to pH 7.0 with NaOH (0.1 M) and then made 
up to 200 mL with deionised water. 
 
5.4.1.1.5  Buffer pH 7.5 
 
To a solution of NaH2PO4 (0.24 g) in deionised water (180 mL) was added NaCl 
(2.029 g). The solution was then titrated to pH 7.5 with NaOH (0.1 M) and then made 
up to 200 mL with deionised water. 
 
5.4.1.1.6  Buffer pH 8.0 
 
To a solution of NaH2PO4 (0.24 g) in deionised water (180 mL) was added NaCl 
(2.004 g). The solution was then titrated to pH 8.0 with NaOH (0.1 M) and then made 
up to 200 mL with deionised water. 
 
5.4.1.2   CROSS-LINKING 
 
Triplexes were prepared as stated above (pH 7.0, 7.5 and 8.0 only) and each cuvette was 
suspended into an ice bath and irradiated with UV light (UVGL-58 handheld UV lamp, 
365 nm) at a distance of 4 cm for 20 mins. The UV-melting method described above 






5.4.2     FOOTPRINTING EXPERIMENTS 
 
Footprinting studies were performed by Professor Keith Fox, Dr Nuria Vergara (School 
of Biological Sciences, University of Southampton) and me (School of Chemistry, 





5.4.2.1.1  GA track marker 
 
The GA track marker was prepared as follows; 1.5 µL 
32P 3’-end radiolabelled DNA 
was mixed with 20 µL sterile water and 5 µL DNase I stop solution (10 mM EDTA, 
1  mM NaOH, 0.2 % bromophenol blue, 80 % formamide). The sample was then 
incubated at 100 °C for 45 mins with the microcentrifuge tube cap open to allow 
evaporation. 
 
5.4.2.1.2  DNase I footprinting 
 
The footprinting buffers were prepared (50 mM sodium acetate, pH 5.5; 10 mM Tris-
HCl, pH 7.0; 10 mM Tris-HCl, 50 mM NaCl, pH 7.5). 15 µL of the TFO of interest 
(OL1, 128.77 µM; OL2, 98.66 µM; OL3, 104.86 µM; OL4, 74.01 µM) was taken for 
each different pH footprint and dried in a speed vacuum for ~ 20 mins until the pellet 
was completely dry. The pellet was then resuspended in the appropriate buffer to give a 
final concentration of 15 µM; ~ 129 µL for OL1; ~ 99 µL for OL2; ~ 105 µL for OL3 
and~ 74 µL for OL4 (NOTE: in the final reaction, when the TFO is mixed with the 
DNA, the TFO will be at a final concentration of 10 µM). From the 10 µM TFO stock 
solution, serial dilutions were prepared to give 3.0 µM, 1.0 µM, 0.3 µM, 0.1 µM, 
0.03  µM etc. In new Eppendorf tubes, 1.5 µL of 
32P 3’-end radiolabelled
  DNA 
(dissolved in TE2 buffer; 10 mM Tris, 0.1 mM EDTA, pH 7.5) was mixed with 3.0 µL 
TFO (dissolved in the appropriate buffer). An extra tube was prepared with just 1.5 µL 
radiolabelled DNA duplex and 3 µL footprinting buffer (negative control). The tubes 
including the GA track were left overnight at room temperature. After equilibration of 
the ligand–DNA complexes the mixtures were then digested; by adding to each 288 
 
Eppendorf tube 2 µL DNase I enzyme solution (4 µL DNase I enzyme was diluted in 
1 mL DNase I buffer (20 mM NaCl, 2 mM MgCl2, 2 mM MnCl2), 4 µL of this initial 
diluted solution was then diluted again in 1 mL DNase I buffer). DNase I was purchased 
from Sigma and stored at -20 °C at a stock concentration of 7200 U/mL in 0.15 M NaCl 
containing 1 mM MgCl2. After 1 min the digestion reaction was stopped by adding 4 µL 
DNase I stop solution (10 mM EDTA, 1 mM NaOH, 0.1 % bromophenol blue, 80 % 
formamide) to each Eppendorf tube. Before loading onto the gel the DNA was 
denatured by incubating at 100 °C for 3 min and quickly cooled on ice. 6 µL of each 
sample was then loaded onto the gel (8 % denaturing polyacrylamide gels containing 
8 M urea, prepared in 1 x TBE buffer). Gels (40 cm long, 0.3 mm thick) were run at 
1500 V for approximately 2 hrs until the dye reached the bottom of the plates. The gel 
plates were then separated, the gel was fixed by immersing in 10 % (v/v) acetic acid, 
transferred to Whatmann 3MM paper and dried under vacuum at 80 °C. The dried gel 
was then exposed to a phosphorimager screen overnight before scanning with a Storm 
phosphorimager using ImageQuant software. Bands were assigned by comparison with 
Maxam-Gilbert lanes specific for G and A. 
 
5.4.2.2 PHOTODDUCT FORMATION AND GEL ELECTROPHORESIS
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Samples were prepared in the same way as for footprinting. Triplexes were prepared 
with the radiolabelled duplex and TFO, OL6 (varying concentrations; 10, 3, 1, 0.3, 0.1, 
0.03 µM) in either 10 mM Tris-HCl, pH 7.0 or 10 mM Tris-HCl, 50 mM NaCl pH 7.5, 
and were incubated at 20 °C in the dark overnight. The samples were then placed in a 
microtitre plate on ice and irradiated with UV light (6W UVGL-58 Mineralight lamp, 
365 nm) at a distance of 2 cm for 20 minutes. The reaction was stopped by adding 4 µL 
DNase I stop solution (10 mM EDTA, 1 mM NaOH, 0.1 % bromophenol blue, 80 % 
formamide). Samples were then heated to 100 °C for 3 minutes before rapidly cooling 
on ice, and loading onto a low percentage denaturing polyacrylamide gel (5 %). The 
polyacrylamide gel was run at 1500 V for ~ 2 hrs and then fixed in 10 % (v/v) acetic 
acid. The gel was then transferred to Whatman 3MM paper and dried under vacuum at 
80 °C for 1 hr. The dried gel was then exposed to a phosphorimager screen overnight 
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